{
    "filename": "pdf.pdf",
    "content_type": "application/pdf",
    "file_size": 3766065,
    "metadata": {
        "identifiers": {
            "doi": "10.3389/fmicb.2020.00298",
            "url": "https://www.frontiersin.org/articles/10.3389/fmicb.2020.00298/pdf"
        },
        "title": "Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses",
        "keywords": [
            "human coronaviruses",
            "pathogenesis",
            "SARS-CoV",
            "MERS-CoV",
            "2019-nCoV",
            "subunit vaccines"
        ],
        "author": "Ning Wang, Jian Shang, Shibo Jiang, Lanying Du",
        "date": 2020,
        "affiliations": [
            "Kimball Research Institute, New York Blood Center, New York, NY, United States,",
            "Department of Veterinary and Biomedical Sciences, College of Veterinary Medicine, University of Minnesota, Saint Paul, MN, United States,",
            "Key Laboratory of Medical Molecular Virology (MOE/NHC/CAMS), School of Basic Medical Sciences, Shanghai Medical College, Fudan University, Shanghai, China",
            "The University of Illinois at Chicago, United States",
            "Ahmed Mohamed Kandeil, National Research Centre, Egypt",
            "Loyola University Chicago,"
        ],
        "journal": "Frontiers in Microbiology",
        "volume": "11",
        "abstract": "Seven coronaviruses (CoVs) have been isolated from humans so far. Among them, three emerging pathogenic CoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and a newly identified CoV (2019-nCoV), once caused or continue to cause severe infections in humans, posing significant threats to global public health. SARS-CoV infection in humans (with about 10% case fatality rate) was first reported from China in 2002, while MERS-CoV infection in humans (with about 34.4% case fatality rate) was first reported from Saudi Arabia in June 2012. 2019-nCoV was first reported from China in December 2019, and is currently infecting more than 70000 people (with about 2.7% case fatality rate). Both SARS-CoV and MERS-CoV are zoonotic viruses, using bats as their natural reservoirs, and then transmitting through intermediate hosts, leading to human infections. Nevertheless, the intermediate host for 2019-nCoV is still under investigation and the vaccines against this new CoV have not been available. Although a variety of vaccines have been developed against infections of SARS-CoV and MERS-CoV, none of them has been approved for use in humans. In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs. These subunit vaccines are introduced on the basis of full-length spike (S) protein, receptorbinding domain (RBD), non-RBD S protein fragments, and non-S structural proteins, and the potential factors affecting these subunit vaccines are also illustrated. Overall, this review will be helpful for rapid design and development of vaccines against the new 2019-nCoV and any future CoVs with pandemic potential. This review was written for the topic of Antivirals for Emerging Viruses: Vaccines and Therapeutics in the Virology section of Frontiers in Microbiology.",
        "references": "@misc{he2006a,\n  author = {He},\n  date = {2006},\n  more-authors = {true}\n}\n@article{kam2007a,\n  author = {Kam},\n  date = {2007},\n  title = {Jaume},\n  journal = {et al},\n  more-authors = {true},\n  language = {}\n}\n@article{he2004a,\n  author = {He},\n  date = {2004},\n  title = {Du},\n  journal = {et al},\n  more-authors = {true},\n  language = {}\n}\n@misc{du2009a,\n  author = {Du},\n  date = {2009},\n  more-authors = {true}\n}\n@misc{du2009b,\n  author = {Du},\n  date = {2009},\n  more-authors = {true}\n}\n@misc{zakhartchouk2007a,\n  author = {Zakhartchouk},\n  date = {2007},\n  more-authors = {true}\n}\n@article{li2013a,\n  author = {Li},\n  date = {2013},\n  title = {Guo},\n  journal = {et al},\n  more-authors = {true},\n  language = {}\n}\n@incollection{zheng2009a,\n  author = {Zheng},\n  date = {2009},\n  title = {aAbs, antibodies; ADE, antibody-dependent enhancement; Alum hydro, aluminum hydroxide; CHO, Chinese hamster},\n  volume = {Interleukin},\n  unmatched-author = {Liu et al., He et al., ovary; CpG, cysteine-phosphate-guanine; I. D., intradermal; I. M., 10; I. P.,},\n  more-authors = {true},\n  source = {intramuscular; IFN-\u03b3, interferon gamma; IL-2, interleukin 2; IL-4, interleukin},\n  language = {}\n}\n@misc{rabbits2005a,\n  author = {rabbits (He},\n  date = {2005},\n  title = {In spite of their immunogenicity, it appears that these N- and M-based SARS subunit vaccines have not been investigated for their protective efficacy against SARS-CoV infection. Thus, it is unclear whether these nonS structural protein-based SARS subunit vaccines can prevent SARS-CoV infection},\n  more-authors = {true},\n  language = {}\n}\n@incollection{unknown2006a,\n  title = {The expression of recombinant protein-based SARS subunit vaccines may be changed by the following factors. First, addition of an intron splicing enhancer to the truncated SARS-CoV S protein fragments results in better enhancement of protein expression in mammalian cells than the exon splicing enhancers, and different cells may result in different fold increase of protein expression},\n  publisher = {Chang et al},\n  date = {2006},\n  source = {Second, inclusion of a post-transcriptional gene silencing suppressor p19 protein from tomato bushy stunt virus to a SARS-CoV N protein may significantly increase its transient expression in tobacco},\n  unmatched-publisher = {(Zheng et al.,},\n  language = {}\n}\n@article{unknown2007a,\n  title = {Other factors that potentially affect the immunogenicity of SARS subunit vaccines include immunization routes and adjuvants (Zakhartchouk},\n  journal = {et al},\n  date = {2007},\n  author = {},\n  publisher = {Li et al},\n  source = {Significantly high-titer antibodies were induced by monomeric or trimeric SARS-CoV S and S1 proteins through the intramuscular (I. M.) route compared to the subcutaneous (S. C.) route},\n  more-authors = {true},\n  unmatched-publisher = {(Zakhartchouk et al.,},\n  language = {}\n}\n@incollection{unknown2013a,\n  title = {MERS-CoV Subunit Vaccines Based on RBD Numerous MERS-CoV RBD-based subunit vaccines have been developed and extensively evaluated in available animal models since the emergence of MERS-CoV},\n  publisher = {Table},\n  date = {2013},\n  author = {},\n  source = {In general, these subunit vaccines have strong immunogenicity and are capable of inducing high neutralizing antibodies and/or protection against MERSCoV infection (Ma et al},\n  unmatched-publisher = {(Zhou et al.,},\n  unmatched-author = {Tai et al., Zhou et al., Zhang et al., et al., Wang Y. et al.,},\n  more-authors = {true},\n  language = {}\n}\n@incollection{lu2013a,\n  title = {Co-crystallographic analyses of MERS-CoV RBD and/or RBD/DPP4 complexes have confirmed that the RBD is attributed to residues 367\u2013588},\n  publisher = {Chen et al},\n  date = {2013},\n  pages = {367\u2013606},\n  author = {Lu},\n  unknown = {NHPs) (Lan et al},\n  note = {However, it only partially protects},\n  source = {in the MERS-CoV S1 subunit. Indeed, a recombinant MERS-CoV RBD (rRBD) fragment (residues 367\u2013606) elicits RBD-specific antibody and cellular immune responses and neutralizing antibodies in mice and/or non-human primates},\n  more-authors = {true},\n  language = {}\n}\n@misc{pallesen2017a,\n  author = {Pallesen},\n  date = {2017},\n  more-authors = {true}\n}\n@misc{lan2014a,\n  author = {Lan},\n  date = {2014},\n  more-authors = {true}\n}\n@misc{du2013a,\n  author = {Du},\n  date = {2013},\n  title = {Ma et al},\n  more-authors = {true},\n  language = {}\n}\n@article{du2013b,\n  author = {Du},\n  date = {2013},\n  title = {Zhang},\n  journal = {et al},\n  unmatched-author = {Ma et al., 2014b; Tang et al.,},\n  more-authors = {true},\n  source = {Nyon et},\n  language = {},\n  address = {al}\n}\n@misc{tai2016a,\n  author = {Tai},\n  date = {2016},\n  more-authors = {true}\n}\n@incollection{du2016a,\n  author = {Du},\n  date = {2016},\n  note = {Jiaming},\n  title = {Yang et al., 2014a aaa, amino acid; Abs, antibodies; Ad5, adenovirus serotype 5; Ad5-hDPP4 mice, Ad5-hDPP4-transuced mice; Alum hydro, aluminum hydroxide; Alum pho, Aluminum phosphate; hDPP4, human dipeptidyl peptidase},\n  publisher = {TNF)-alpha},\n  unmatched-author = {Wang et al., Adney et al., et al., adjuvant; I. M., intramuscular; I. N.,},\n  more-authors = {true},\n  source = {hDPP4-Tg mice, transgenic mice expressing MERS-CoV receptor human DPP4; IFA, incomplete Freund\u2019s},\n  language = {}\n}\n@article{unknown2015a,\n  title = {NHPs from MERS-CoV infection by alleviating pneumonia and clinical manifestations, as well as decreasing viral load},\n  publisher = {Lan et al},\n  date = {2015},\n  journal = {et al},\n  source = {In addition, an RBD protein fragment containing MERSCoV S residues 377\u2013622 fused with the Fc tag of human IgG can induce MERS-CoV S1- and/or RBD-specific humoral and cellular immune responses in the immunized mice with neutralizing activity against MERS-CoV infection},\n  unmatched-publisher = {(Du et al., et al.,},\n  language = {},\n  address = {Ma}\n}\n@article{unknown2018a,\n  title = {MERS-CoV Subunit Vaccines Based on Non-S Structural Proteins Unlike SARS subunit vaccines which have been designed based on viral N and M proteins, it appears that very few subunit vaccines have been developed based on the non-S structural protein(s) of MERS-CoV. One study reports the induction of specific antibodies by MERS-CoV N peptides (Yang et al., 2014a), and another report shows that N protein is used for development of vaccines based on viral vector Vaccinia virus, modified Vaccinia Ankara (MVA) (Veit},\n  journal = {et al},\n  date = {2018},\n  source = {This may be potentially a consequence of the weak immunogenicity and/or protective efficacy of non-S structural proteins, further confirming the role of MERS-CoV S protein as the key target for the development of MERS vaccines, including subunit vaccines},\n  language = {}\n}\n@book{unknown2015b,\n  title = {As described above, MERS-CoV subunit vaccines containing different antigens or fragment lengths, particularly those based on the RBD, have apparently variable immunogenicity and/or protective efficacy, and a critical neutralizing domain that contains an RBD fragment corresponding to residues 377\u2013588 of S protein elicits the highest neutralizing antibodies among several fragments tested},\n  publisher = {et al., 2014b; Zhang et al},\n  date = {2015},\n  language = {},\n  address = {Ma}\n}\n@incollection{unknown2014a,\n  title = {Vaccination pathways are important in inducing efficient immune responses, and different immunization routes may elicit different immune responses to the same protein antigens. For example, immunization of mice with a MERS-CoV subunit vaccine (RBD-Fc) via the intranasal route induced higher levels of cellular immune responses and stronger local mucosal neutralizing antibody responses against MERS-CoV infection than those induced by the same vaccine via the S. C. pathway (Ma et al},\n  date = {2014},\n  publisher = {route (Lan et al},\n  source = {In addition, while Freund\u2019s and CpG-adjuvanted rRBD protein elicited higher-level systematic and local IFN\u03b3-producing T cells via the S. C. route, this protein adjuvanted with Alum and CpG induced higher-level tumor necrosis factoralpha (TNF-\u03b1) and interleukin 4 (IL-4)-secreting T cells via the I. M},\n  language = {}\n}\n@article{unknown2015c,\n  title = {Antigen dosage, immunization doses, and intervals may significantly affect the immunogenicity of MERS-CoV subunit vaccines. Notably, a MERS-CoV RBD (S377-588-Fc) subunit vaccine immunized at 1 \u03bcg elicited strong humoral and cellular immune responses and neutralizing antibodies in mice although the one immunized at 5 and 20 \u03bcg elicited a higher level of S1-specific antibodies},\n  publisher = {Tang et al},\n  date = {2015},\n  journal = {et al},\n  source = {In addition, among the regimens at one dose and two doses at 1-, 2-, and 3-week intervals, 2 doses of this protein boosted at 4 weeks resulted in the highest antibodies and neutralizing antibodies against MERS-CoV infection (Wang Y},\n  language = {}\n}\n@incollection{currently2020a,\n  author = {Currently},\n  title = {the newly identified 2019-nCoV is spreading to infect people, resulting in significant global concerns. It is critical to rapidly design and develop effective vaccines to prevent infection of this new coronavirus. Since S protein and its fragments, such as RBD, of SARS-CoV, and MERS-CoV are prime targets for developing subunit vaccines against these two highly pathogenic human CoVs, it is expected that similar regions of 2019-nCoV can also be used as key targets for developing vaccines against},\n  publisher = {this new coronavirus (Jiang et al},\n  date = {2020},\n  source = {Similarly, other regions of 2019-nCoV, including S1 and S2 subunits of S protein and N protein, can be applied as alternative targets for vaccine development. Taken together, the approaches and strategies in the development of subunit vaccines against SARS and MERS described in this review will provide important information for the rapid design and development of safe and effective subunit vaccines against 2019-nCoV infection},\n  language = {}\n}\n@book{adney2019a,\n  author = {Adney, D.R. and Wang, L. and van Doremalen, N. and Shi, W. and Zhang, Y. and Kong, W.P.},\n  date = {2019},\n  title = {Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas},\n  publisher = {Viruses 11: E212},\n  doi = {doi: 10.3390/v11030212},\n  more-authors = {true},\n  language = {}\n}\n@article{al-amri2017a,\n  author = {Al-Amri, S.S. and Abbas, A.T. and Siddiq, L.A. and Alghamdi, A. and Sanki, M.A. and AlMuhanna, M.K.},\n  date = {2017},\n  title = {Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein},\n  journal = {Sci. Rep},\n  volume = {7},\n  pages = {44875},\n  doi = {doi: 10.1038/srep 44875},\n  more-authors = {true},\n  language = {}\n}\n@article{annan2013a,\n  author = {Annan, A. and Baldwin, H.J. and Corman, V.M. and Klose, S.M. and Owusu, M. and Nkrumah, E.},\n  journal = {E., et al},\n  date = {2013},\n  title = {Human betacoronavirus 2c EMC/2012-related viruses in Bats, Ghana and Europe},\n  volume = {19},\n  pages = {456\u2013459},\n  doi = {doi: 10.3201/eid1903.121503},\n  unmatched-journal = {Emerg. Infect. Dis.},\n  language = {}\n}\n@article{arbour2000a,\n  author = {Arbour, N. and Day, R. and Newcombe, J. and Talbot, P.J.},\n  date = {2000},\n  title = {Neuroinvasion by human respiratory coronaviruses},\n  journal = {J. Virol},\n  volume = {74},\n  pages = {8913\u20138921},\n  doi = {doi: 10.1128/jvi.74.19.8913-8921.2000},\n  language = {}\n}\n@article{azhar2014a,\n  author = {Azhar, E.I. and El-Kafrawy, S.A. and Farraj, S.A. and Hassan, A.M. and Al-Saeed, M.S. and Hashem, A.M.},\n  date = {2014},\n  title = {Evidence for camel-to-human transmission of MERS coronavirus},\n  journal = {N. Engl. J. Med},\n  volume = {370},\n  pages = {2499\u20132505},\n  doi = {doi: 10.1056/NEJMoa1401505},\n  more-authors = {true},\n  language = {}\n}\n@article{bailey-elkin2014a,\n  author = {Bailey-Elkin, B.A. and Knaap, R.C. and Johnson, G.G. and Dalebout, T.J. and Ninaber, D.K. and van Kasteren, P.B.},\n  date = {2014},\n  title = {Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression},\n  journal = {J. Biol. Chem},\n  volume = {289},\n  pages = {34667\u201334682},\n  doi = {doi: 10.1074/jbc. M114.609644},\n  more-authors = {true},\n  language = {}\n}\n@article{bisht2004a,\n  author = {Bisht, H. and Roberts, A. and Vogel, L. and Bukreyev, A. and Collins, P.L. and Murphy, B.R.},\n  date = {2004},\n  title = {Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice},\n  journal = {Proc. Natl. Acad. Sci. U. S. A},\n  volume = {101},\n  pages = {6641\u20136646},\n  doi = {doi: 10.1073/pnas.0401939101},\n  more-authors = {true},\n  language = {}\n}\n@article{buchholz2004a,\n  author = {Buchholz, U.J. and Bukreyev, A. and Yang, L.J. and Lamirande, E.W. and Murphy, B.R. and Subbarao, K.},\n  date = {2004},\n  title = {Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity},\n  journal = {Proc. Natl. Acad. Sci. U. S. A},\n  volume = {101},\n  pages = {9804\u20139809},\n  doi = {doi: 10.1073/pnas.0403492101},\n  more-authors = {true},\n  language = {}\n}\n@article{bukreyev2004a,\n  author = {Bukreyev, A. and Lamirande, E.W. and Buchholz, U.J. and Vogel, L.N. and Elkins, W.R. and St Claire, M.},\n  date = {2004},\n  title = {Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS},\n  journal = {Lancet},\n  volume = {363},\n  pages = {2122\u20132127},\n  doi = {doi: 10.1016/s0140-6736(04)16501-x},\n  more-authors = {true},\n  language = {}\n}\n@article{chan2011a,\n  author = {Chan, P.K. and Ma, S. and Ngai, S.M.},\n  date = {2011},\n  title = {Identification of T-cell epitopes of SARS-coronavirus for development of peptide-based vaccines and cellular immunity assessment methods},\n  journal = {Hong Kong Med. J},\n  volume = {17},\n  pages = {26\u201330},\n  number = {6},\n  language = {}\n}\n@article{chang2006a,\n  author = {Chang, C.Y. and Hong, W.W. and Chong, P. and Wu, S.C.},\n  date = {2006},\n  title = {Influence of intron and exon splicing enhancers on mammalian cell expression of a truncated spike protein of SARS-CoV and its implication for subunit vaccine development},\n  journal = {Vaccine},\n  volume = {24},\n  pages = {1132\u20131141},\n  doi = {doi: 10.1016/j.vaccine.2005.09.011},\n  language = {}\n}\n@article{channappanavar2017a,\n  author = {Channappanavar, R. and Perlman, S.},\n  date = {2017},\n  title = {Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology},\n  journal = {Semin. Immunopathol},\n  volume = {39},\n  pages = {529\u2013539},\n  doi = {doi: 10.1007/s00281-017-0629-x},\n  language = {}\n}\n@article{chen2014a,\n  author = {Chen, W.H. and Du, L. and Chag, S.M. and Ma, C. and Tricoche, N. and Tao, X.},\n  date = {2014},\n  title = {Yeastexpressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate},\n  journal = {Hum. Vaccin. Immunother},\n  volume = {10},\n  pages = {648\u2013658},\n  doi = {doi: 10.4161/hv.27464},\n  more-authors = {true},\n  language = {}\n}\n@article{chen2013a,\n  author = {Chen, Y. and Rajashankar, K.R. and Yang, Y. and Agnihothram, S.S. and Liu, C. and Lin, Y.L.},\n  date = {2013},\n  title = {Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus},\n  journal = {J. Virol},\n  volume = {87},\n  pages = {10777\u201310783},\n  doi = {doi: 10.1128/jvi.01756-13},\n  more-authors = {true},\n  language = {}\n}\n@article{chiu2005a,\n  author = {Chiu, S.S. and Chan, K.H. and Chu, K.W. and Kwan, S.W. and Guan, Y. and Poon, L.L.},\n  date = {2005},\n  title = {Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China},\n  journal = {Clin. Infect. Dis},\n  volume = {40},\n  pages = {1721\u20131729},\n  doi = {doi: 10.1086/430301},\n  more-authors = {true},\n  language = {}\n}\n@article{cho2018a,\n  author = {Cho, H. and Excler, J.L. and Kim, J.H. and Yoon, I.K.},\n  date = {2018},\n  title = {Development of Middle East respiratory syndrome coronavirus vaccines - advances and challenges},\n  journal = {Hum. Vaccin. Immunother},\n  volume = {14},\n  pages = {304\u2013313},\n  doi = {doi: 10.1080/21645515.2017.138 9362},\n  language = {}\n}\n@article{cui2019a,\n  author = {Cui, J. and Li, F. and Shi, Z.L.},\n  date = {2019},\n  title = {Origin and evolution of pathogenic coronaviruses},\n  journal = {Nat. Rev. Microbiol},\n  volume = {17},\n  pages = {181\u2013192},\n  doi = {doi: 10.1038/s41579-0180118-9},\n  language = {}\n}\n@incollection{de2011a,\n  editor = {King, A.M.Q. and Adams, M.J. and Carstens, E.B. and Lefkowitz, E.J.},\n  date = {2011},\n  title = {Family Coronaviridae, virus taxomomy: classification and nomenclature of viruses,},\n  booktitle = {Ninth Report of the International Committee on Taxonomy of Viruses},\n  publisher = {Elsevier Academic Press},\n  pages = {806\u2013826},\n  author = {De Groot, R.J. and Baker, S. and Baric, R. and Enjuanes, L. and Gorbalenya, A. and Holmes, K.V.},\n  more-authors = {true},\n  language = {},\n  address = {Amsterdam}\n}\n@article{dediego2014a,\n  author = {DeDiego, M.L. and Nieto-Torres, J.L. and Jimenez-Guardeno, J.M. and Regla-Nava, J.A. and Castano-Rodriguez, C. and Fernandez-Delgado, R.},\n  date = {2014},\n  title = {Coronavirus virulence genes with main focus on SARS-CoV envelope gene},\n  journal = {Virus. Res},\n  volume = {194},\n  pages = {124\u2013137},\n  doi = {doi: 10.1016/j.virusres.2014.07.024},\n  more-authors = {true},\n  language = {}\n}\n@article{deng2012a,\n  author = {Deng, M.P. and Hu, Z.H. and Wang, H.L. and Deng, F.},\n  date = {2012},\n  title = {Developments of subunit and VLP vaccines against influenza A virus},\n  journal = {Virol. Sin},\n  volume = {27},\n  pages = {145\u2013153},\n  doi = {doi: 10.1007/s12250-012-3241-1},\n  language = {}\n}\n@article{desforges2013a,\n  author = {Desforges, M. and Desjardins, J. and Zhang, C. and Talbot, P.J.},\n  date = {2013},\n  title = {The acetyl-esterase activity of the hemagglutinin-esterase protein of human coronavirus OC43 strongly enhances the production of infectious virus},\n  journal = {J. Virol},\n  volume = {87},\n  pages = {3097\u20133107},\n  doi = {doi: 10.1128/jvi.02699-12},\n  language = {}\n}\n@article{desforges2014a,\n  author = {Desforges, M. and Le Coupanec, A. and Brison, E. and Meessen-Pinard, M. and Talbot, P.J.},\n  date = {2014},\n  title = {Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans},\n  journal = {Adv. Exp. Med. Biol},\n  volume = {807},\n  pages = {75\u201396},\n  doi = {doi: 10.1007/978-81-322-1777-0_6},\n  language = {}\n}\n@article{drexler2014a,\n  author = {Drexler, J.F. and Corman, V.M. and Drosten, C.},\n  date = {2014},\n  title = {Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS},\n  journal = {Antiviral Res},\n  volume = {101},\n  pages = {45\u201356},\n  doi = {doi: 10.1016/j.antiviral.2013.10.013},\n  language = {}\n}\n@article{drosten2003a,\n  author = {Drosten, C. and Gunther, S. and Preiser, W. and van der Werf, S. and Brodt, H.R. and Becker, S.},\n  date = {2003},\n  title = {Identification of a novel coronavirus in patients with severe acute respiratory syndrome},\n  journal = {N. Engl. J. Med},\n  volume = {348},\n  pages = {1967\u20131976},\n  doi = {doi: 10.1056/NEJMoa030747},\n  more-authors = {true},\n  language = {}\n}\n@article{du2008a,\n  author = {Du, L. and He, Y. and Jiang, S. and Zheng, B.J.},\n  date = {2008},\n  title = {Development of subunit vaccines against severe acute respiratory syndrome},\n  journal = {Drugs Today},\n  volume = {44},\n  pages = {63\u201373},\n  doi = {doi: 10.1358/dot.2008.44.1.1131830},\n  language = {}\n}\n@article{du2009c,\n  author = {Du, L. and He, Y. and Zhou, Y. and Liu, S. and Zheng, B.J. and Jiang, S.},\n  date = {2009},\n  title = {The spike protein of SARS-CoV - a target for vaccine and therapeutic development},\n  journal = {Nat. Rev. Microbiol},\n  volume = {7},\n  pages = {226\u2013236},\n  doi = {doi: 10.1038/nrmicro2090},\n  language = {}\n}\n@article{du2015a,\n  author = {Du, L. and Jiang, S.},\n  date = {2015},\n  title = {Middle East respiratory syndrome: current status and future prospects for vaccine development},\n  journal = {Expert Opin. Biol. Ther},\n  volume = {15},\n  pages = {1647\u20131651},\n  doi = {doi: 10.1517/14712598.2015.1092518},\n  language = {}\n}\n@article{du2013c,\n  author = {Du, L. and Kou, Z. and Ma, C. and Tao, X. and Wang, L. and Zhao, G.},\n  date = {2013},\n  title = {A truncated receptor-binding domain of MERS-CoV Spike protein potently inhibits MERSCoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines},\n  journal = {PLoS One},\n  volume = {8},\n  pages = {81587},\n  doi = {doi: 10.1371/journal.pone.0081587},\n  more-authors = {true},\n  language = {}\n}\n@article{du2013d,\n  author = {Du, L. and Ma, C. and Jiang, S.},\n  date = {2013},\n  title = {Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC},\n  journal = {J. Infect},\n  volume = {67},\n  pages = {348\u2013350},\n  doi = {doi: 10.1016/j.jinf.2013.05.002},\n  language = {}\n}\n@article{du2016b,\n  author = {Du, L. and Tai, W. and Yang, Y. and Zhao, G. and Zhu, Q. and Sun, S.},\n  date = {2016},\n  title = {Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines},\n  journal = {Nat. Commun},\n  publisher = {7: 13473},\n  doi = {doi: 10.1038/ncomms 13473},\n  more-authors = {true},\n  language = {}\n}\n@article{du2016c,\n  author = {Du, L. and Tai, W. and Zhou, Y. and Jiang, S.},\n  date = {2016},\n  title = {Vaccines for the prevention against the threat of MERS-CoV},\n  journal = {Expert Rev. Vaccines},\n  volume = {15},\n  pages = {1123\u20131134},\n  doi = {doi: 10.1586/14760584.2016.1167603},\n  language = {}\n}\n@article{du2017a,\n  author = {Du, L. and Yang, Y. and Zhou, Y. and Lu, L. and Li, F. and Jiang, S.},\n  date = {2017},\n  title = {MERS-CoV spike protein: a key target for antivirals. Expert Opin},\n  journal = {Ther. Targets},\n  volume = {21},\n  pages = {131\u2013143},\n  doi = {doi: 10.1080/14728222.2017.1271415},\n  language = {}\n}\n@article{du2010a,\n  author = {Du, L. and Zhao, G. and Chan, C.C. and Li, L. and He, Y. and Zhou, Y.},\n  date = {2010},\n  title = {A 219-mer CHOexpressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity},\n  journal = {Viral. Immunol},\n  volume = {23},\n  pages = {211\u2013219},\n  doi = {doi: 10.1089/vim.2009.0090},\n  more-authors = {true},\n  language = {}\n}\n@article{du2009d,\n  author = {Du, L. and Zhao, G. and Chan, C.C. and Sun, S. and Chen, M. and Liu, Z.},\n  date = {2009},\n  title = {Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity},\n  journal = {Virology},\n  volume = {393},\n  pages = {144\u2013150},\n  doi = {doi: 10.1016/j.virol.2009.07.018},\n  more-authors = {true},\n  language = {}\n}\n@article{du2007a,\n  author = {Du, L. and Zhao, G. and He, Y. and Guo, Y. and Zheng, B.J. and Jiang, S.},\n  date = {2007},\n  title = {Receptorbinding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model},\n  journal = {Vaccine},\n  volume = {25},\n  pages = {2832\u20132838},\n  doi = {doi: 10.1016/j.vaccine.2006.10.031},\n  more-authors = {true},\n  language = {}\n}\n@misc{du2013e,\n  author = {Du, L. and Zhao, G. and Kou, Z. and Ma, C. and Sun, S. and Poon, V.K.},\n  date = {2013},\n  title = {Identification of a receptor-binding domain in the S protein of the novel human coronavirus},\n  more-authors = {true},\n  language = {}\n}\n@article{unknown-a,\n  title = {Middle East Respiratory Syndrome coronavirus as an essential target for vaccine development},\n  journal = {J. Virol},\n  volume = {87},\n  pages = {9939\u20139942},\n  doi = {doi: 10.1128/jvi.01048-13},\n  language = {}\n}\n@article{du2009e,\n  author = {Du, L. and Zhao, G. and Li, L. and He, Y. and Zhou, Y. and Zheng, B.J.},\n  date = {2009},\n  title = {Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells},\n  journal = {Biochem. Biophys. Res. Commun},\n  volume = {384},\n  pages = {486\u2013490},\n  doi = {doi: 10.1016/j.bbre.2009.05.003},\n  more-authors = {true},\n  language = {}\n}\n@book{elshabrawy2012a,\n  author = {Elshabrawy, H.A. and Coughlin, M.M. and Baker, S.C. and Prabhakar, B.S.},\n  date = {2012},\n  title = {Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing},\n  publisher = {PLoS One 7: e50366},\n  doi = {doi: 10.1371/journal.pone.0050366},\n  language = {}\n}\n@article{esper2006a,\n  author = {Esper, F. and Weibel, C. and Ferguson, D. and Landry, M.L. and Kahn, J.S.},\n  date = {2006},\n  title = {Coronavirus HKU1 infection in the United States},\n  journal = {Emerg. Infect. Dis},\n  volume = {12},\n  pages = {775\u2013779},\n  doi = {doi: 10.3201/eid1205.051316},\n  language = {}\n}\n@article{falsey2002a,\n  author = {Falsey, A.R. and Walsh, E.E. and Hayden, F.G.},\n  date = {2002},\n  title = {Rhinovirus and coronavirus infection-associated hospitalizations among older adults},\n  journal = {J. Infect. Dis},\n  volume = {185},\n  pages = {1338\u20131341},\n  doi = {doi: 10.1086/339881},\n  language = {}\n}\n@article{fehr2015a,\n  author = {Fehr, A.R. and Perlman, S.},\n  date = {2015},\n  title = {Coronaviruses: an overview of their replication and pathogenesis},\n  journal = {Methods Mol. Biol},\n  volume = {1282},\n  pages = {1\u201323},\n  doi = {doi: 10.1007/978-1-49392438-7_1},\n  language = {}\n}\n@article{fouchier2004a,\n  author = {Fouchier, R.A.M. and Hartwig, N.G. and Bestebroer, T.M. and Niemeyer, B. and de Jong, J.C. and Simon, J.H.},\n  date = {2004},\n  title = {A previously undescribed coronavirus associated with respiratory disease in humans},\n  journal = {Proc. Natl. Acad. Sci. U. S. A},\n  volume = {101},\n  pages = {6212\u20136216},\n  doi = {doi: 10.1073/pnas.0400762101},\n  more-authors = {true},\n  language = {}\n}\n@article{ge2013a,\n  author = {Ge, X.Y. and Li, J.L. and Yang, X.L. and Chmura, A.A. and Zhu, G. and Epstein, J.H.},\n  date = {2013},\n  title = {Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor},\n  journal = {Nature},\n  volume = {503},\n  pages = {535\u2013538},\n  doi = {doi: 10.1038/nature12711},\n  more-authors = {true},\n  language = {}\n}\n@article{gerna2006a,\n  author = {Gerna, G. and Campanini, G. and Rovida, F. and Percivalle, E. and Sarasini, A. and Marchi, A.},\n  date = {2006},\n  title = {Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients},\n  journal = {J. Med. Virol},\n  volume = {78},\n  pages = {938\u2013949},\n  doi = {doi: 10.1002/jmv.20645},\n  more-authors = {true},\n  language = {}\n}\n@article{he2006b,\n  author = {He, Y. and Li, J. and Jiang, S.},\n  date = {2006},\n  title = {A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity},\n  journal = {Biochem. Biophys. Res. Commun},\n  volume = {344},\n  pages = {106\u2013113},\n  doi = {doi: 10.1016/j.bbrc.2006.03.139},\n  language = {}\n}\n@article{he2006c,\n  author = {He, Y. and Li, J. and Li, W. and Lustigman, S. and Farzan, M. and Jiang, S.},\n  date = {2006},\n  title = {Crossneutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein},\n  journal = {J. Immunol},\n  volume = {176},\n  pages = {6085\u20136092},\n  doi = {doi: 10.4049/jimmunol.176.10.6085},\n  language = {}\n}\n@article{he2005a,\n  author = {He, Y. and Lu, H. and Siddiqui, P. and Zhou, Y. and Jiang, S.},\n  date = {2005},\n  title = {Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies},\n  journal = {J. Immunol},\n  volume = {174},\n  pages = \"4908\u20134915.\" # \"10.1016/j.bbrc.2004.09.106\",\n  doi = {doi: 10.4049/jimmunol.174.8.4908},\n  unmatched-author = {He, Y., Zhou, Y., Liu, S., Kou, Z., Li, W., Farzan, M., et al.},\n  source = {Receptorbinding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine},\n  unmatched-journal = {Biochem. Biophys. Res. Commun.324,},\n  unmatched-volume = {773\u2013781.doi:},\n  unmatched-pages = {10.1016/j.bbrc.2004.09.106},\n  language = {}\n}\n@article{he2005b,\n  author = {He, Y. and Zhou, Y. and Siddiqui, P. and Niu, J. and Jiang, S.},\n  date = {2005},\n  title = {Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus},\n  journal = {J. Clin. Microbiol},\n  volume = {43},\n  pages = {3718\u20133726},\n  doi = {doi: 10.1128/jcm.43.8.3718-3726.2005},\n  language = {}\n}\n@article{hofmann2005a,\n  author = {Hofmann, H. and Pyrc, K. and van der Hoek, L. and Geier, M. and Berkhout, B. and Pohlmann, S.},\n  date = {2005},\n  title = {Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry},\n  journal = {Proc. Natl. Acad. Sci. U. S. A},\n  volume = {102},\n  pages = {7988\u20137993},\n  doi = {doi: 10.1073/pnas.0409465102},\n  language = {}\n}\n@article{jaume2012a,\n  author = {Jaume, M. and Yip, M.S. and Kam, Y.W. and Cheung, C.Y. and Kien, F. and Roberts, A.},\n  date = {2012},\n  title = {SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement},\n  journal = {Hong Kong Med. J},\n  volume = {18},\n  pages = {31\u201336},\n  more-authors = {true},\n  number = {2},\n  language = {}\n}\n@article{jiaming2017a,\n  author = {Jiaming, L. and Yanfeng, Y. and Yao, D. and Yawei, H. and Linlin, B. and Baoying, H.},\n  date = {2017},\n  title = {The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection},\n  journal = {Vaccine},\n  volume = {35},\n  pages = {10\u201318},\n  doi = {doi: 10.1016/j.vaccine.2016.11.064},\n  more-authors = {true},\n  language = {}\n}\n@article{jiang2012a,\n  author = {Jiang, S. and Bottazzi, M.E. and Du, L. and Lustigman, S. and Tseng, C.T. and Curti, E.},\n  date = {2012},\n  title = {Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome},\n  journal = {Expert Rev. Vaccines},\n  volume = {11},\n  pages = {1405\u20131413},\n  doi = {doi: 10.1586/erv.12.126},\n  more-authors = {true},\n  language = {}\n}\n@article{jiang2020a,\n  author = {Jiang, S. and Du, L. and Shi, Z.},\n  date = {2020},\n  title = {An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies},\n  journal = {Emerg Microbes Infect},\n  volume = {9},\n  pages = \"275\u2013277.\" # \"10.3201/1107.050219\",\n  doi = {doi: 10.1080/22221751.2020.1723441},\n  unmatched-author = {Jiang, S., He, Y., and Liu, S.},\n  source = {SARS vaccine development},\n  unmatched-journal = {Emerg. Infect. Dis.11,},\n  unmatched-volume = {1016\u20131020.doi:},\n  unmatched-pages = {10.3201/1107.050219},\n  language = {}\n}\n@article{jiang2013a,\n  author = {Jiang, S. and Lu, L. and Du, L. and Debnath, A.K.},\n  date = {2013},\n  title = {A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC},\n  journal = {J. Infect},\n  volume = {66},\n  pages = {464\u2013466},\n  doi = {doi: 10.1016/j.jinf.2012.12.003},\n  language = {}\n}\n@article{kam2007b,\n  author = {Kam, Y.W. and Kien, F. and Roberts, A. and Cheung, Y.C. and Lamirande, E.W. and Vogel, L.},\n  date = {2007},\n  title = {Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro},\n  journal = {Vaccine},\n  volume = {25},\n  pages = \"729\u2013740.\" # \"10.1093/infdis/119.3.282\",\n  doi = {doi: 10.1016/j.vaccine.2006.08.011},\n  unmatched-author = {Kapikian, A. Z., James, H. D., Kelly, S. J., Dees, J. H., Turner, H. C., McIntosh, K., et al.},\n  more-authors = {true},\n  source = {Isolation from man of avian infectious bronchitis virus-like viruses (coronavirus) similar to 229E virus with some epidemiological observations},\n  unmatched-journal = {J. Infect. Dis.119,},\n  unmatched-volume = {282\u2013290.doi:},\n  unmatched-pages = {10.1093/infdis/119.3.282},\n  language = {}\n}\n@article{killerby2018a,\n  author = {Killerby, M.E. and Biggs, H.M. and Haynes, A. and Dahl, R.M. and Mustaquim, D. and Gerber, S.I.},\n  date = {2018},\n  title = {Human coronavirus circulation in the United States 2014-2017},\n  journal = {J. Clin. Virol},\n  volume = {101},\n  pages = {52\u201356},\n  doi = {doi: 10.1016/j.jcv.2018.01.019},\n  more-authors = {true},\n  language = {}\n}\n@article{kim2017a,\n  author = {Kim, K.Y. and Han, S.Y. and Kim, H.S. and Cheong, H.M. and Kim, S.S. and Kim, D.S.},\n  date = {2017},\n  title = {Human coronavirus in the 2014 winter season as a cause of lower respiratory tract infection},\n  journal = {Yonsei Med. J},\n  volume = {58},\n  pages = {174\u2013179},\n  doi = {doi: 10.3349/ymj.2017.58.1.174},\n  language = {}\n}\n@article{king2018a,\n  author = {King, A.M.Q. and Lefkowitz, E.J. and Mushegian, A.R. and Adams, M.J. and Dutilh, B.E. and Gorbalenya, A.E.},\n  date = {2018},\n  title = {Changes to taxonomy and the international code of virus classification and nomenclature ratified by the international committee on taxonomy of viruses},\n  journal = {Virol},\n  volume = {163},\n  pages = {2601\u20132631},\n  doi = {doi: 10.1007/s00705-018-3847-1},\n  more-authors = {true},\n  source = {Arch},\n  language = {}\n}\n@article{ksiazek2003a,\n  author = {Ksiazek, T.G. and Erdman, D. and Goldsmith, C.S. and Zaki, S.R. and Peret, T. and Emery, S.},\n  date = {2003},\n  title = {A novel coronavirus associated with severe acute respiratory syndrome},\n  journal = {N. Engl. J. Med},\n  volume = {348},\n  pages = {1953\u20131966},\n  doi = {doi: 10.1056/NEJMoa030781},\n  more-authors = {true},\n  language = {}\n}\n@article{kudelova2015a,\n  author = {Kudelova, M. and Belvoncikova, P. and Vrbova, M. and Kovalova, A. and Stibraniova, I. and Kocakova, P.},\n  date = {2015},\n  title = {Detection of murine herpesvirus 68 (MHV-68) in dermacentor reticulatus ticks},\n  journal = {Microb. Ecol},\n  volume = {70},\n  pages = {785\u2013794},\n  doi = {doi: 10.1007/s00248015-0622-7},\n  more-authors = {true},\n  language = {}\n}\n@article{kusanagi1992a,\n  author = {Kusanagi, K. and Kuwahara, H. and Katoh, T. and Nunoya, T. and Ishikawa, Y. and Samejima, T.},\n  date = {1992},\n  title = {Isolation and serial propagation of porcine epidemic diarrhhea virus in cell-cultures and partial characterization of the isolate},\n  journal = {J. Vet. Med. Sci},\n  volume = {54},\n  pages = {313\u2013318},\n  doi = {doi: 10.1292/jvms.54.313},\n  more-authors = {true},\n  language = {}\n}\n@book{lan2014b,\n  author = {Lan, J. and Deng, Y. and Chen, H. and Lu, G. and Wang, W. and Guo, X.},\n  date = {2014},\n  title = {Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen},\n  publisher = {PLoS One 9: e112602},\n  doi = {doi: 10.1371/journal.pone.011 2602},\n  more-authors = {true},\n  language = {}\n}\n@article{lan2015a,\n  author = {Lan, J. and Yao, Y. and Deng, Y. and Chen, H. and Lu, G. and Wang, W.},\n  date = {2015},\n  title = {Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge},\n  journal = {EBioMedicine},\n  volume = {2},\n  pages = {1438\u20131446},\n  doi = {doi: 10.1016/j.ebiom.2015.08.031},\n  more-authors = {true},\n  language = {}\n}\n@article{lau2006a,\n  author = {Lau, S.K. and Woo, P.C. and Yip, C.C. and Tse, H. and Tsoi, H.W. and Cheng, V.C.},\n  date = {2006},\n  title = {Coronavirus HKU1 and other coronavirus infections in Hong Kong},\n  journal = {J. Clin. Microbiol},\n  volume = {44},\n  pages = {2063\u20132071},\n  doi = {doi: 10.1128/jcm.02614-05},\n  more-authors = {true},\n  language = {}\n}\n@article{lau2018a,\n  author = {Lau, S.K.P. and Zhang, L. and Luk, H.K.H. and Xiong, L. and Peng, X. and Li, K.S.M.},\n  date = {2018},\n  title = {Receptor usage of a novel bat lineage C betacoronavirus reveals evolution of Middle East respiratory syndrome-related coronavirus spike proteins for human dipeptidyl peptidase 4 binding},\n  journal = {J. Infect. Dis},\n  volume = {218},\n  pages = {197\u2013207},\n  doi = {doi: 10.1093/infdis/jiy018},\n  more-authors = {true},\n  language = {}\n}\n@article{lehmann2008a,\n  author = {Lehmann, C. and Wolf, H. and Xu, J.G. and Zhao, Q.B. and Shao, Y.M. and Motz, M.},\n  date = {2008},\n  title = {A line immunoassay utilizing recombinant nucleocapsid proteins for detection of antibodies to human coronaviruses},\n  journal = {Diagn. Microbiol. Infect. Dis},\n  volume = {61},\n  pages = {40\u201348},\n  doi = {doi: 10.1016/j.diagmicrobio.2007.12.002},\n  more-authors = {true},\n  language = {}\n}\n@article{lelli2013a,\n  author = {Lelli, D. and Papetti, A. and Sabelli, C. and Rosti, E. and Moreno, A. and Boniotti, M.B.},\n  date = {2013},\n  title = {Detection of coronaviruses in bats of various species in Italy},\n  journal = {Viruses},\n  volume = {5},\n  pages = {2679\u20132689},\n  doi = {doi: 10.3390/v5112679},\n  language = {}\n}\n@article{li2008a,\n  author = {Li, F.},\n  date = {2008},\n  title = {Structural analysis of major species barriers between humans and palm civets for severe acute respiratory syndrome coronavirus infections},\n  journal = {J. Virol},\n  volume = {82},\n  pages = {6984\u20136991},\n  doi = {doi: 10.1128/jvi.00442-08},\n  language = {}\n}\n@article{li2015a,\n  author = {Li, F.},\n  date = {2015},\n  title = {Receptor recognition mechanisms of coronaviruses: a decade of structural studies},\n  journal = {J. Virol},\n  volume = {89},\n  pages = {1954\u20131964},\n  doi = {doi: 10.1128/jvi.02615-14},\n  language = {}\n}\n@article{li2016a,\n  author = {Li, F.},\n  date = {2016},\n  title = {Structure, function, and evolution of coronavirus spike proteins},\n  journal = {Annu. Rev. Virol},\n  volume = {3},\n  pages = {237\u2013261},\n  doi = {doi: 10.1146/annurev-virology-110615-042301},\n  language = {}\n}\n@book{li2019a,\n  author = {Li, F. and Du, L.},\n  date = {2019},\n  title = {MERS coronavirus: an emerging zoonotic virus},\n  publisher = {Viruses 11: E663},\n  doi = {doi: 10.3390/v11070663},\n  language = {}\n}\n@article{li2005a,\n  author = {Li, F. and Li, W. and Farzan, M. and Harrison, S.C.},\n  date = {2005},\n  title = {Structure of SARS coronavirus spike receptor-binding domain complexed with receptor},\n  journal = {Science},\n  volume = {309},\n  pages = {1864\u20131868},\n  doi = {doi: 10.1126/science.1116480},\n  language = {}\n}\n@article{li2005b,\n  author = {Li, W. and Shi, Z. and Yu, M. and Ren, W. and Smith, C. and Epstein, J.H.},\n  date = {2005},\n  title = {Bats are natural reservoirs of SARS-like coronaviruses},\n  journal = {Science},\n  volume = {310},\n  pages = {676\u2013679},\n  doi = {doi: 10.1126/science.1118391},\n  more-authors = {true},\n  language = {}\n}\n@article{li2005c,\n  author = {Li, W. and Zhang, C. and Sui, J. and Kuhn, J.H. and Moore, M.J. and Luo, S.},\n  date = {2005},\n  title = {Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2},\n  journal = {EMBO J},\n  volume = {24},\n  pages = {1634\u20131643},\n  doi = {doi: 10.1038/sj.emboj.7600640},\n  more-authors = {true},\n  language = {}\n}\n@article{li2013b,\n  author = {Li, J. and Ulitzky, L. and Silberstein, E. and Taylor, D.R. and Viscidi, R.},\n  date = {2013},\n  title = {Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates},\n  journal = {Viral. Immunol},\n  volume = {26},\n  pages = {126\u2013132},\n  doi = {doi: 10.1089/vim.2012.0076},\n  language = {}\n}\n@article{li2004a,\n  author = {Li, W. and Greenough, T.C. and Moore, M.J. and Vasilieva, N. and Somasundaran, M. and Sullivan, J.L.},\n  date = {2004},\n  title = {Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2},\n  journal = {J. Virol},\n  volume = {78},\n  pages = {11429\u201311433},\n  doi = {doi: 10.1128/jvi.78.20.11429-11433.2004},\n  more-authors = {true},\n  language = {}\n}\n@article{li2017a,\n  author = {Li, W. and Hulswit, R.J.G. and Widjaja, I. and Raj, V.S. and McBride, R. and Peng, W.},\n  date = {2017},\n  title = {Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein},\n  journal = {Proc. Natl Acad. Sci. U. S. A},\n  volume = {114},\n  pages = {8508\u20138517},\n  doi = {doi: 10.1073/pnas.1712592114},\n  more-authors = {true},\n  language = {}\n}\n@article{li2003a,\n  author = {Li, W. and Moore, M.J. and Vasilieva, N. and Sui, J. and Wong, S.K. and Berne, M.A.},\n  date = {2003},\n  title = {Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus},\n  journal = {Nature},\n  volume = {426},\n  pages = {450\u2013454},\n  doi = {doi: 10.1038/nature02145},\n  more-authors = {true},\n  language = {}\n}\n@misc{liu2014a,\n  author = {Liu, D.X. and Fung, T.S. and Chong, K.K. and Shukla, A. and Hilgenfeld, R.},\n  date = {2014},\n  title = {Accessory proteins of SARS-CoV and other coronaviruses. Antiviral Res},\n  doi = {109},\n  pages = {97\u2013109},\n  unmatched-doi = {doi: 10.1016/j.antiviral.2014.06.013},\n  language = {}\n}\n@article{liu2005a,\n  author = {Liu, R.Y. and Wu, L.Z. and Huang, B.J. and Huang, J.L. and Zhang, Y.L. and Ke, M.L.},\n  date = {2005},\n  title = {Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats},\n  journal = {Virus Res},\n  volume = {112},\n  pages = {24\u201331},\n  doi = {doi: 10.1016/j.virusres.2005.02.009},\n  more-authors = {true},\n  language = {}\n}\n@article{liu2006a,\n  author = {Liu, S.J. and Leng, C.H. and Lien, S.P. and Chi, H.Y. and Huang, C.Y. and Lin, C.L.},\n  date = {2006},\n  title = {Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates},\n  journal = {Vaccine},\n  volume = {24},\n  pages = {3100\u20133108},\n  doi = {doi: 10.1016/j.vaccine.2006.01.058},\n  more-authors = {true},\n  language = {}\n}\n@book{liu2020a,\n  author = {Liu, S.L. and Saif, L.},\n  date = {2020},\n  title = {Emerging viruses without borders: the Wuhan coronavirus},\n  publisher = {Viruses 12: E130},\n  doi = {doi: 10.3390/v12020130},\n  language = {}\n}\n@article{lu2013b,\n  author = {Lu, G. and Hu, Y. and Wang, Q. and Qi, J. and Gao, F. and Li, Y.},\n  date = {2013},\n  title = {Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26},\n  journal = {Nature},\n  volume = {500},\n  pages = {227\u2013231},\n  doi = {doi: 10.1038/nature12328},\n  more-authors = {true},\n  language = {}\n}\n@article{lu2014a,\n  author = {Lu, L. and Liu, Q. and Zhu, Y. and Chan, K.H. and Qin, L. and Li, Y.},\n  date = {2014},\n  title = {Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor},\n  journal = {Nat. Commun},\n  volume = {5},\n  pages = {3067},\n  doi = {doi: 10.1038/ncomms4067},\n  more-authors = {true},\n  language = {}\n}\n@article{luo2018a,\n  author = {Luo, C.M. and Wang, N. and Yang, X.L. and Liu, H.Z. and Zhang, W. and Li, B.},\n  date = {2018},\n  title = {Discovery of novel bat coronaviruses in south China that use the same receptor as MERS coronavirus},\n  journal = {J. Virol},\n  volume = {92},\n  pages = {116\u2013118},\n  doi = {doi: 10.1128/jvi.00116-18},\n  more-authors = {true},\n  language = {}\n}\n@article{luo2018b,\n  author = {Luo, F. and Liao, F.L. and Wang, H. and Tang, H.B. and Yang, Z.Q. and Hou, W.},\n  date = {2018},\n  title = {Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV vaccine},\n  journal = {Virol. Sin},\n  volume = {33},\n  pages = {201\u2013204},\n  doi = {doi: 10.1007/s12250-018-0009-2},\n  language = {}\n}\n@article{ma2014a,\n  author = {Ma, C. and Li, Y. and Wang, L. and Zhao, G. and Tao, X.R. and Tseng, C.T.},\n  date = {2014},\n  title = {Intranasal vaccination with recombinant receptor-binding domain of MERSCoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines},\n  journal = {Vaccine},\n  volume = {32},\n  pages = {2100\u20132108},\n  doi = {doi: 10.1016/j.vaccine.2014.02.004},\n  more-authors = {true},\n  language = {}\n}\n@article{ma2014b,\n  author = {Ma, C. and Wang, L. and Tao, X. and Zhang, N. and Yang, Y. and Tseng, C.T.},\n  date = {2014},\n  title = {Searching for an ideal vaccine candidate among different MERS coronavirus receptorbinding fragments - The importance of immunofocusing in subunit vaccine design},\n  journal = {Vaccine},\n  volume = {32},\n  pages = {6170\u20136176},\n  doi = {doi: 10.1016/j.vaccine.2014.08.086},\n  more-authors = {true},\n  language = {}\n}\n@book{ma2015a,\n  author = {Ma, Y. and Zhang, Y. and Liang, X. and Lou, F. and Oglesbee, M. and Krakowka, S.},\n  date = {2015},\n  title = {Origin, evolution, and virulence of porcine deltacoronaviruses in the United States},\n  publisher = {mBio 6: e00064},\n  doi = {doi: 10.1128/mBio.00064-15},\n  more-authors = {true},\n  language = {}\n}\n@article{marra2003a,\n  author = {Marra, M.A. and Jones, S.J. and Astell, C.R. and Holt, R.A. and Brooks-Wilson, A. and Butterfield, Y.S.},\n  date = {2003},\n  title = {The genome sequence of the SARS-associated coronavirus},\n  journal = {Science},\n  volume = {300},\n  pages = {1399\u20131404},\n  doi = {doi: 10.1126/science.1085953},\n  more-authors = {true},\n  language = {}\n}\n@article{matoba2015a,\n  author = {Matoba, Y. and Abiko, C. and Ikeda, T. and Aoki, Y. and Suzuki, Y. and Yahagi, K.},\n  date = {2015},\n  title = {Detection of the human coronavirus 229E, HKU1, NL63, and OC43 between 2010 and 2013 in},\n  journal = {Yamagata, Japan. Jpn. J. Infect. Dis},\n  volume = {68},\n  pages = {138\u2013141},\n  doi = {doi: 10.7883/yoken. JJID.2014.266},\n  more-authors = {true},\n  language = {}\n}\n@article{mcintosh1967a,\n  author = {McIntosh, K. and Becker, W.B. and Chanock, R.M.},\n  date = {1967},\n  title = {Growth in suckling-mouse brain of IBV-like viruses from patients with upper respiratory tract disease},\n  journal = {Proc. Natl. Acad. Sci. U. S. A},\n  volume = {58},\n  pages = {2268\u20132273},\n  doi = {doi: 10.1073/pnas.58.6.2268},\n  language = {}\n}\n@article{menachery2017a,\n  author = {},\n  date = {2017},\n  title = {MERS-CoV accessory ORFs play key role for infection and pathogenesis},\n  journal = {mBio},\n  volume = {8},\n  pages = {00665\u201317},\n  doi = {doi: 10.1128/mBio.00665-17},\n  more-authors = {true},\n  language = {}\n}\n@article{mobaraki2019a,\n  author = {Mobaraki, K. and Ahmadzadeh, J.},\n  date = {2019},\n  title = {Current epidemiological status of Middle East respiratory syndrome coronavirus in the world from 1.1.2017 to 17.1.2018: a cross-sectional study},\n  journal = {BMC Infect. Dis},\n  doi = {19: 351. doi: 10.1186/s12879019-3987-2},\n  language = {}\n}\n@article{mou2013a,\n  author = {Mou, H. and Raj, V.S. and van Kuppeveld, F.J. and Rottier, P.J. and Haagmans, B.L. and Bosch, B.J.},\n  date = {2013},\n  title = {The receptor binding domain of the new Middle East Respiratory Syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies},\n  journal = {J. Virol},\n  volume = {87},\n  pages = {9379\u20139383},\n  doi = {doi: 10.1128/jvi.01277-13},\n  language = {}\n}\n@article{mourez2007a,\n  author = {Mourez, T. and Vabret, A. and Han, Y. and Dina, J. and Legrand, L. and Corbet, S.},\n  date = {2007},\n  title = {Baculovirus expression of HCoV-OC43 nucleocapsid protein and development of a Western blot assay for detection of human antibodies against HCoV-OC43},\n  journal = {J. Virol. Methods},\n  volume = {139},\n  pages = {175\u2013180},\n  doi = {doi: 10.1016/j.jviromet.2006.09.024},\n  more-authors = {true},\n  language = {}\n}\n@article{myint1994a,\n  author = {Myint, S.H.},\n  date = {1994},\n  title = {Human coronaviruses - A brief review},\n  journal = {Rev. Med. Virol},\n  volume = {4},\n  pages = {35\u201346},\n  doi = {doi: 10.1002/rmv.1980040108},\n  language = {}\n}\n@article{nicholls2003a,\n  author = {Nicholls, J.M. and Poon, L.L. and Lee, K.C. and Ng, W.F. and Lai, S.T. and Leung, C.},\n  journal = {Y., et al},\n  date = {2003},\n  title = {Lung pathology of fatal severe acute respiratory syndrome},\n  volume = {361},\n  pages = {1773\u20131778},\n  doi = {doi: 10.1016/s0140-6736(03)13413-7},\n  unmatched-journal = {Lancet},\n  language = {}\n}\n@article{nyon2018a,\n  author = {Nyon, M.P. and Du, L. and Tseng, C.K. and Seid, C.A. and Pollet, J. and Naceanceno, K.S.},\n  date = {2018},\n  title = {Engineering a stable CHO cell line for the expression of a MERScoronavirus vaccine antigen},\n  journal = {Vaccine},\n  volume = {36},\n  pages = {1853\u20131862},\n  doi = {doi: 10.1016/j.vaccine.2018.02.065},\n  more-authors = {true},\n  language = {}\n}\n@article{ou2017a,\n  author = {Ou, X. and Guan, H. and Qin, B. and Mu, Z. and Wojdyla, J.A. and Wang, M.},\n  date = {2017},\n  title = {Crystal structure of the receptor binding domain of the spike glycoprotein of human betacoronavirus HKU1},\n  journal = {Nat. Commun},\n  volume = {8},\n  pages = {2529},\n  doi = {doi: 10.1038/ncomms15216},\n  more-authors = {true},\n  language = {}\n}\n@article{pallesen2017b,\n  author = {Pallesen, J. and Wang, N. and Corbett, K.S. and Wrapp, D. and Kirchdoerfer, R.N. and Turner, H.L.},\n  date = {2017},\n  title = {Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen},\n  journal = {Proc. Natl. Acad. Sci. U. S. A},\n  volume = {114},\n  pages = {7348\u20137357},\n  doi = {doi: 10.1073/pnas.1707304114},\n  more-authors = {true},\n  language = {}\n}\n@misc{pedersen2014a,\n  author = {Pedersen, N.C.},\n  date = {2014},\n  title = {An update on feline infectious peritonitis: virology and immunopathogenesis. Vet},\n  pages = {123\u2013132},\n  doi = {doi: 10.1016/j.tvjl.2014.04.017},\n  language = {}\n}\n@article{pimentel2009a,\n  author = {Pimentel, T.A. and Yan, Z. and Jeffers, S.A. and Holmes, K.V. and Hodges, R.S. and Burkhard, P.},\n  date = {2009},\n  title = {Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine},\n  journal = {Chem. Biol. Drug Des},\n  volume = {73},\n  pages = {53\u201361},\n  doi = {doi: 10.1111/j.1747-0285.2008.00746.x},\n  language = {}\n}\n@article{poon2005a,\n  author = {Poon, L.L. and Chu, D.K. and Chan, K.H. and Wong, O.K. and Ellis, T.M. and Leung, Y.H.},\n  date = {2005},\n  title = {Identification of a novel coronavirus in bats},\n  journal = {J. Virol},\n  volume = {79},\n  pages = {2001\u20132009},\n  doi = {doi: 10.1128/jvi.79.4.2001-2009.2005},\n  more-authors = {true},\n  language = {}\n}\n@article{qiu2005a,\n  author = {Qiu, M. and Shi, Y. and Guo, Z. and Chen, Z. and He, R. and Chen, R.},\n  date = {2005},\n  title = {Antibody responses to individual proteins of SARS coronavirus and their neutralization activities},\n  journal = {Microbes Infect},\n  volume = {7},\n  pages = {882\u2013889},\n  doi = {doi: 10.1016/j.micinf.2005.02.006},\n  more-authors = {true},\n  language = {}\n}\n@article{raj2013a,\n  author = {Raj, V.S. and Mou, H. and Smits, S.L. and Dekkers, D.H. and Muller, M.A. and Dijkman, R.},\n  date = {2013},\n  title = {Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC},\n  journal = {Nature},\n  volume = {495},\n  pages = {251\u2013254},\n  doi = {doi: 10.1038/nature12005},\n  more-authors = {true},\n  language = {}\n}\n@article{regamey2008a,\n  author = {Regamey, N. and Kaiser, L. and Roiha, H.L. and Deffernez, C. and Kuehni, C.E. and Latzin, P.},\n  date = {2008},\n  title = {Viral etiology of acute respiratory infections with cough in infancy A community-based birth cohort study},\n  journal = {Pediatr. Infect. Dis. J},\n  volume = {27},\n  pages = {100\u2013105},\n  doi = {doi: 10.1097/INF.0b013e31815922c8},\n  more-authors = {true},\n  language = {}\n}\n@article{reusken2013a,\n  author = {Reusken, C.B. and Haagmans, B.L. and Muller, M.A. and Gutierrez, C. and Godeke, G.J. and Meyer, B.},\n  date = {2013},\n  title = {Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study},\n  journal = {Lancet Infect. Dis},\n  volume = {13},\n  pages = {859\u2013866},\n  doi = {doi: 10.1016/s1473-3099(13)70164-6},\n  more-authors = {true},\n  language = {}\n}\n@article{rota2003a,\n  author = {Rota, P.A. and Oberste, M.S. and Monroe, S.S. and Nix, W.A. and Campagnoli, R. and Icenogle, J.P.},\n  date = {2003},\n  title = {Characterization of a novel coronavirus associated with severe acute respiratory syndrome},\n  journal = {Science},\n  volume = {300},\n  pages = {1394\u20131399},\n  doi = {doi: 10.1126/science.1085952},\n  more-authors = {true},\n  language = {}\n}\n@article{scobey2013a,\n  author = {Scobey, T. and Yount, B.L. and Sims, A.C. and Donaldson, E.F. and Agnihothram, S.S. and Menachery, V.D.},\n  date = {2013},\n  title = {Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus},\n  journal = {Proc. Natl. Acad. Sci. U. S. A},\n  volume = {110},\n  pages = {16157\u201316162},\n  doi = {doi: 10.1073/pnas.1311542110},\n  more-authors = {true},\n  language = {}\n}\n@article{severance2008a,\n  author = {Severance, E.G. and Bossis, I. and Dickerson, F.B. and Stallings, C.R. and Origoni, A.E. and Sullens, A.},\n  date = {2008},\n  title = {Development of a nucleocapsid-based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a US metropolitan population},\n  journal = {Clin. Vaccine Immunol},\n  volume = {15},\n  pages = {1805\u20131810},\n  doi = {doi: 10.1128/cvi.00124-08},\n  more-authors = {true},\n  language = {}\n}\n@article{shao2007a,\n  author = {Shao, X. and Guo, X. and Esper, F. and Weibel, C. and Kahn, J.S.},\n  date = {2007},\n  title = {Seroepidemiology of group I human coronaviruses in children},\n  journal = {J. Clin. Virol},\n  volume = {40},\n  pages = {207\u2013213},\n  doi = {doi: 10.1016/j.jcv.2007.08.007},\n  language = {}\n}\n@article{snijder2003a,\n  author = {Snijder, E.J. and Bredenbeek, P.J. and Dobbe, J.C. and Thiel, V. and Ziebuhr, J. and Poon, L.L.},\n  date = {2003},\n  title = {Unique and conserved features of genome and proteome of SARScoronavirus, an early split-off from the coronavirus group 2 lineage},\n  journal = {J. Mol. Biol},\n  volume = {331},\n  pages = {991\u20131004},\n  doi = {doi: 10.1016/s0022-2836(03)00865-9},\n  more-authors = {true},\n  language = {}\n}\n@article{snijder2016a,\n  author = {Snijder, E.J. and Decroly, E. and Ziebuhr, J.},\n  date = {2016},\n  title = {The nonstructural proteins directing coronavirus RNA synthesis and processing},\n  journal = {Adv. Virus Res},\n  volume = {96},\n  pages = {59},\n  doi = {126. doi: 10.1016/bs.aivir.2016.08.008},\n  language = {}\n}\n@article{tai2017a,\n  author = {Tai, W. and Wang, Y. and Fett, C.A. and Zhao, G. and Li, F. and Perlman, S.},\n  date = {2017},\n  title = {Recombinant receptor-binding domains of multiple middle east respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants},\n  journal = {J. Virol},\n  volume = {91},\n  pages = {01651\u201316},\n  doi = {doi: 10.1128/jvi.01651-16},\n  more-authors = {true},\n  language = {}\n}\n@article{tai2016b,\n  author = {Tai, W. and Zhao, G. and Sun, S. and Guo, Y. and Wang, Y. and Tao, X.},\n  date = {2016},\n  title = {A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection},\n  journal = {Virology},\n  volume = {499},\n  pages = {375\u2013382},\n  doi = {doi: 10.1016/j.virol.2016.10.005},\n  more-authors = {true},\n  language = {}\n}\n@article{tang2015a,\n  author = {Tang, J. and Zhang, N. and Tao, X. and Zhao, G. and Guo, Y. and Tseng, C.T.},\n  date = {2015},\n  title = {Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus},\n  journal = {Hum. Vaccin. Immunother},\n  volume = {11},\n  pages = {1244\u20131250},\n  doi = {doi: 10.1080/21645515.2015.1021527},\n  more-authors = {true},\n  language = {}\n}\n@article{tomar2015a,\n  author = {Tomar, S. and Johnston, M.L. and St John, S.E. and Osswald, H.L. and Nyalapatla, P.R. and Paul, L.N.},\n  date = {2015},\n  title = {Ligand-induced dimerization of Middle East respiratory syndrome (MERS) coronavirus nsp5 protease},\n  publisher = {},\n  journal = {J. Biol. Chem},\n  volume = {290},\n  pages = {19403\u201319422},\n  doi = {doi: 10.1074/jbc. M115.651463},\n  more-authors = {true},\n  source = {implifications for nsp5 regulation and the development of antivirals},\n  language = {}\n}\n@article{tortorici2019a,\n  author = {Tortorici, M.A. and Walls, A.C. and Lang, Y. and Wang, C. and Li, Z. and Koerhuis, D.},\n  date = {2019},\n  title = {Structural basis for human coronavirus attachment to sialic acid receptors},\n  journal = {Nat. Struct. Mol. Biol},\n  volume = {26},\n  pages = \"481\u2013489.\" # \"10.3201/eid1012.040520\" # \"10.1136/bmj.1.5448.1467\" # \"10.1086/374222\",\n  doi = {doi: 10.1038/s41594-0190233-y},\n  unmatched-author = {Tu, C., Crameri, G., Kong, X., Chen, J., Sun, Y., Yu, M., et al. Tyrrell, D. A., and Bynoe, M. L. Vabret, A., Mourez, T., Gouarin, S., Petitjean, J., and Freymuth, F.},\n  more-authors = {true},\n  source = {Antibodies to SARS coronavirus in civets},\n  unmatched-journal = {Emerg. Infect. Dis.10, Br. Med. J.1, Clin. Infect. Dis.36,},\n  unmatched-volume = {2244\u20132248.doi: 1467\u20131470.doi: 985\u2013989.doi:},\n  unmatched-pages = {10.3201/eid1012.040520 10.1136/bmj.1.5448.1467 10.1086/374222},\n  language = {}\n}\n@book{van2012a,\n  author = {van Boheemen, S. and de Graaf, M. and Lauber, C. and Bestebroer, T.M. and Raj, V.S. and Zaki, A.M.},\n  date = {2012},\n  title = {Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans},\n  publisher = {mBio 3: e0047312},\n  doi = {doi: 10.1128/mBio.00473-12},\n  more-authors = {true},\n  language = {}\n}\n@article{van2004a,\n  author = {van der Hoek, L. and Pyrc, K. and Jebbink, M.F. and Vermeulen-Oost, W. and Berkhout, R.J. and Wolthers, K.C.},\n  date = {2004},\n  title = {Identification of a new human coronavirus},\n  journal = {Nat. Med},\n  volume = {10},\n  pages = {368\u2013373},\n  doi = {doi: 10.1038/nm1024},\n  more-authors = {true},\n  language = {}\n}\n@article{veit2018a,\n  author = {Veit, S. and Jany, S. and Fux, R. and Sutter, G. and Volz, A.},\n  date = {2018},\n  title = {CD8+ T cells responding to the Middle East Respiratory Syndrome coronavirus nucleocapsid protein delivered by vaccinia virus MVA in mice},\n  publisher = {Viruses 10: E718},\n  doi = {doi},\n  editor = {Zheng, X. and Gai, W. and Zhao, Y. and Wang, H. and Wang, H.},\n  journal = {Oncotarget},\n  volume = {8},\n  pages = {10\u201318632},\n  source = {MERSCoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques},\n  unmatched-publisher = {10.3390/v10120718 Wang, C.,},\n  more-editors = {true},\n  number = {12686\u201312694},\n  language = {}\n}\n@article{wang2015a,\n  author = {Wang, L. and Shi, W. and Joyce, M.G. and Modjarrad, K. and Zhang, Y. and Leung, K.},\n  date = {2015},\n  title = {Evaluation of candidate vaccine approaches for MERS-CoV},\n  journal = {Nat. Commun},\n  volume = {6},\n  pages = {7712},\n  doi = {doi: 10.1038/ncomms8712},\n  more-authors = {true},\n  language = {}\n}\n@article{wang2013a,\n  author = {Wang, N. and Shi, X. and Jiang, L. and Zhang, S. and Wang, D. and Tong, P.},\n  date = {2013},\n  title = {Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4},\n  journal = {Cell Res},\n  volume = {23},\n  pages = \"986\u2013993.\" # \"10.1080/21645515.2017.1296994\" # \"C300520200\" # \"884\u2013895.doi: 10.1128/jvi.79.2.884-895.2005\",\n  doi = {doi: 10.1038/cr.2013.92},\n  unmatched-author = {Wang, Y., Tai, W., Yang, J., Zhao, G., Sun, S., Tseng, C. K., et al. Wong, S. K., Li, W., Moore, M. J., Choe, H., and Farzan, M. Woo, P. C., Lau, S. K., Chu, C. M., Chan, K. H., Tsoi, H.},\n  more-authors = {true},\n  source = {Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection},\n  unmatched-journal = {Hum. Vaccin. Immunother.13, J. Biol. Chem.279, W., Huang, Y., et al. J.},\n  unmatched-volume = {1615\u20131624.doi: 3197\u20133201.doi: 10.1074/jbc. Virol.79,},\n  unmatched-pages = {10.1080/21645515.2017.1296994 C300520200 884\u2013895.doi: 10.1128/jvi.79.2.884-895.2005},\n  language = {}\n}\n@article{woo2009a,\n  author = {Woo, P.C. and Lau, S.K. and Lam, C.S. and Lai, K.K. and Huang, Y. and Lee, P.},\n  date = {2009},\n  title = {Comparative analysis of complete genome sequences of three avian coronaviruses reveals a novel group 3c coronavirus},\n  journal = {J. Virol},\n  volume = {83},\n  pages = {908\u2013917},\n  doi = {doi: 10.1128/jvi.01977-08},\n  more-authors = {true},\n  language = {}\n}\n@article{woo2012a,\n  author = {Woo, P.C. and Lau, S.K. and Lam, C.S. and Lau, C.C. and Tsang, A.K. and Lau, J.H.},\n  date = {2012},\n  title = {Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus},\n  journal = {J. Virol},\n  volume = {86},\n  pages = {3995\u20134008},\n  doi = {doi: 10.1128/jvi.06540-11},\n  more-authors = {true},\n  language = {}\n}\n@article{woo2014a,\n  author = {Woo, P.C. and Lau, S.K. and Lam, C.S. and Tsang, A.K. and Hui, S.W. and Fan, R.Y.},\n  date = {2014},\n  title = {Discovery of a novel bottlenose dolphin coronavirus reveals a distinct species of marine mammal coronavirus in gammacoronavirus},\n  journal = {J. Virol},\n  volume = {88},\n  pages = {1318\u20131331},\n  doi = {doi: 10.1128/jvi.02351-13},\n  more-authors = {true},\n  language = {}\n}\n@article{woo2009b,\n  author = {Woo, P.C. and Lau, S.K. and Yip, C.C. and Huang, Y. and Yuen, K.Y.},\n  date = {2009},\n  title = {More and more coronaviruses: human coronavirus HKU1},\n  journal = {Viruses},\n  volume = {1},\n  pages = {57\u201371},\n  doi = {doi: 10.3390/v1010057},\n  language = {}\n}\n@article{yang2014a,\n  author = {Yang, Y. and Deng, Y. and Wen, B. and Wang, H. and Meng, X. and Lan, J.},\n  date = {2014},\n  title = {The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents},\n  journal = {Viral Immunol},\n  volume = {27},\n  pages = {543\u2013550},\n  doi = {doi: 10.1089/vim.2014.0080},\n  more-authors = {true},\n  language = {}\n}\n@article{yang2014b,\n  author = {Yang, Y. and Du, L. and Liu, C. and Wang, L. and Ma, C. and Tang, J.},\n  date = {2014},\n  title = {Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-tohuman transmission of MERS coronavirus},\n  journal = {Proc. Natl. Acad. Sci. U. S. A},\n  volume = {111},\n  pages = {12516\u201312521},\n  doi = {doi: 10.1073/pnas.1405889111},\n  more-authors = {true},\n  language = {}\n}\n@article{yang2004a,\n  author = {Yang, Z.Y. and Kong, W.P. and Huang, Y. and Roberts, A. and Murphy, B.R. and Subbarao, K.},\n  date = {2004},\n  title = {A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice},\n  journal = {Nature},\n  volume = {428},\n  pages = {561\u2013564},\n  doi = {doi: 10.1038/nature02463},\n  more-authors = {true},\n  language = {}\n}\n@article{yuan2017a,\n  author = {Yuan, Y. and Cao, D. and Zhang, Y. and Ma, J. and Qi, J. and Wang, Q.},\n  date = {2017},\n  title = {CryoEM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains},\n  journal = {Nat. Commun},\n  volume = {8},\n  pages = {15092},\n  doi = {doi: 10.1038/ncomms15092},\n  more-authors = {true},\n  language = {}\n}\n@article{zakhartchouk2007b,\n  author = {Zakhartchouk, A.N. and Sharon, C. and Satkunarajah, M. and Auperin, T. and Viswanathan, S. and Mutwiri, G.},\n  date = {2007},\n  title = {Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine},\n  journal = {Vaccine},\n  volume = {25},\n  pages = {136\u2013143},\n  doi = {doi: 10.1016/j.vaccine.2006.06.084},\n  more-authors = {true},\n  language = {}\n}\n@article{zaki2012a,\n  author = {Zaki, A.M. and van Boheemen, S. and Bestebroer, T.M. and Osterhaus, A.D. and Fouchier, R.A.},\n  date = {2012},\n  title = {Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia},\n  journal = {N. Engl. J. Med},\n  volume = {367},\n  pages = {1814\u20131820},\n  doi = {doi: 10.1056/NEJMoa1211721},\n  language = {}\n}\n@article{zeng2004a,\n  author = {Zeng, F. and Chow, K.Y. and Hon, C.C. and Law, K.M. and Yip, C.W. and Chan, K.H.},\n  date = {2004},\n  title = {Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments},\n  journal = {Biochem. Biophys. Res. Commun},\n  volume = {315},\n  pages = {1134\u20131139},\n  doi = {doi: 10.1016/j.bbrc.2004.01.166},\n  more-authors = {true},\n  language = {}\n}\n@article{zhang2016a,\n  author = {Zhang, N. and Channappanavar, R. and Ma, C. and Wang, L. and Tang, J. and Garron, T.},\n  date = {2016},\n  title = {Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus},\n  journal = {Cell. Mol. Immunol},\n  volume = {13},\n  pages = {180\u2013190},\n  doi = {doi: 10.1038/cmi.2015.03},\n  more-authors = {true},\n  language = {}\n}\n@article{zhang2014a,\n  author = {Zhang, N. and Jiang, S. and Du, L.},\n  date = {2014},\n  title = {Current advancements and potential strategies in the development of MERS-CoV vaccines},\n  journal = {Expert Rev. Vaccines},\n  volume = {13},\n  pages = {761\u2013774},\n  doi = {doi: 10.1586/14760584.2014.912134},\n  language = {}\n}\n@article{zhang2015a,\n  author = {Zhang, N. and Tang, J. and Lu, L. and Jiang, S. and Du, L.},\n  date = {2015},\n  title = {Receptor-binding domainbased subunit vaccines against MERS-CoV},\n  journal = {Virus Res},\n  volume = {202},\n  pages = {151\u2013159},\n  doi = {doi: 10.1016/j.virusres.2014.11.013},\n  language = {}\n}\n@article{zhang2020a,\n  author = {Zhang, N. and Wang, L. and Deng, X. and Liang, R. and Su, M. and He, C.},\n  date = {2020},\n  title = {Recent advances in the detection of respiratory virus infection in humans},\n  journal = {J. Med. Virol. [Epub},\n  publisher = {ahead of print},\n  more-authors = {true},\n  language = {}\n}\n@article{zheng2009b,\n  author = {Zheng, N. and Xia, R. and Yang, C. and Yin, B. and Li, Y. and Duan, C.},\n  date = {2009},\n  title = {Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice},\n  journal = {Vaccine},\n  volume = {27},\n  pages = {5001\u20135007},\n  doi = {doi: 10.1016/j.vaccine.2009.05.073},\n  more-authors = {true},\n  language = {}\n}\n@incollection{zhong2003a,\n  author = {Zhong, N.S. and Zheng, B.J. and Li, Y.M. and Poon, L.L. and Xie, Z.H. and Chan, K.H.},\n  date = {2003},\n  title = {Epidemiology and cause of severe acute respiratory syndrome},\n  booktitle = {(SARS) in Guangdong, People\u2019s Republic of China, in February},\n  volume = {362},\n  pages = {1353\u20131358},\n  doi = {doi: 10.1016/s0140-6736(03)14630-2},\n  more-authors = {true},\n  language = {}\n}\n@article{zhou2020a,\n  author = {Zhou, P. and Yang, X.L. and Wang, X.G. and Hu, B. and Zhang, L. and Zhang, W.},\n  date = {2020},\n  title = {A pneumonia outbreak associated with a new coronavirus of probable bat origin},\n  journal = {Nature},\n  note = {Epub ahead of print},\n  more-authors = {true},\n  language = {}\n}\n@article{zhou2018a,\n  author = {Zhou, Y. and Jiang, S. and Du, L.},\n  date = {2018},\n  title = {Prospects for a MERS-CoV spike vaccine},\n  journal = {Expert Rev. Vaccines},\n  volume = {17},\n  pages = {677\u2013686},\n  doi = {doi: 10.1080/14760584.2018.150 6702},\n  language = {}\n}\n@book{zhou2019a,\n  author = {Zhou, Y. and Yang, Y. and Huang, J. and Jiang, S. and Du, L.},\n  date = {2019},\n  title = {Advances in MERSCoV vaccines and therapeutics based on the receptor-binding domain},\n  publisher = {Viruses 11: E60},\n  doi = {doi: 10.3390/v11010060},\n  language = {}\n}\n@misc{zhu2020a,\n  author = {Zhu, N. and Zhang, D. and Wang, W. and Li, X. and Yang, B. and Song, J.},\n  date = {2020},\n  title = {A novel coronavirus from patients with pneumonia in China, 2019},\n  editor = {Med, N.Engl J.},\n  note = {Epub ahead of print},\n  more-authors = {true},\n  language = {}\n}\n@article{zhu2013a,\n  author = {Zhu, X. and Liu, Q. and Du, L. and Lu, L. and Jiang, S.},\n  date = {2013},\n  title = {Receptor-binding domain as a target for developing SARS vaccines},\n  journal = {J. Thoracic Dis},\n  volume = {5},\n  pages = {142\u2013148},\n  doi = {doi: 10.3978/j.issn.2072-1439.2013.06.06},\n  language = {}\n}\n",
        "links": [
            "https://www.who.int/docs/default-source/coronaviruse/situation-reports/",
            "http://www.frontiersin.org",
            "https://clinicaltrials.gov/ct2/show/NCT03399578",
            "https://clinicaltrials.gov/ct2/show/NCT03615911",
            "https://www.who.int/emergencies/mers-cov/en/",
            "https://www.frontiersin.org/articles/10.3389/fmicb"
        ],
        "emails": [
            "shibojiang@fudan.edu.cn",
            "ldu@nybc.org"
        ],
        "references_ris": "TY  - GEN\nAU  - He\nPY  - 2006\nDA  - 2006\nC1  - true\nER  - \n\nTY  - JOUR\nAU  - Kam\nPY  - 2007\nDA  - 2007\nTI  - Jaume\nT2  - et al\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - He\nPY  - 2004\nDA  - 2004\nTI  - Du\nT2  - et al\nC1  - true\nLA  - \nER  - \n\nTY  - GEN\nAU  - Du\nPY  - 2009\nDA  - 2009\nC1  - true\nER  - \n\nTY  - GEN\nAU  - Du\nPY  - 2009\nDA  - 2009\nC1  - true\nER  - \n\nTY  - GEN\nAU  - Zakhartchouk\nPY  - 2007\nDA  - 2007\nC1  - true\nER  - \n\nTY  - JOUR\nAU  - Li\nPY  - 2013\nDA  - 2013\nTI  - Guo\nT2  - et al\nC1  - true\nLA  - \nER  - \n\nTY  - CHAP\nAU  - Zheng\nPY  - 2009\nDA  - 2009\nTI  - aAbs, antibodies; ADE, antibody-dependent enhancement; Alum hydro, aluminum hydroxide; CHO, Chinese hamster\nVL  - Interleukin\nC1  - Liu et al., He et al., ovary; CpG, cysteine-phosphate-guanine; I. D., intradermal; I. M., 10; I. P.,\nC1  - true\nT2  - intramuscular; IFN-\u03b3, interferon gamma; IL-2, interleukin 2; IL-4, interleukin\nLA  - \nER  - \n\nTY  - GEN\nAU  - rabbits (He\nPY  - 2005\nDA  - 2005\nTI  - In spite of their immunogenicity, it appears that these N- and M-based SARS subunit vaccines have not been investigated for their protective efficacy against SARS-CoV infection. Thus, it is unclear whether these nonS structural protein-based SARS subunit vaccines can prevent SARS-CoV infection\nC1  - true\nLA  - \nER  - \n\nTY  - CHAP\nTI  - The expression of recombinant protein-based SARS subunit vaccines may be changed by the following factors. First, addition of an intron splicing enhancer to the truncated SARS-CoV S protein fragments results in better enhancement of protein expression in mammalian cells than the exon splicing enhancers, and different cells may result in different fold increase of protein expression\nPB  - Chang et al\nPY  - 2006\nDA  - 2006\nT2  - Second, inclusion of a post-transcriptional gene silencing suppressor p19 protein from tomato bushy stunt virus to a SARS-CoV N protein may significantly increase its transient expression in tobacco\nC1  - (Zheng et al.,\nLA  - \nER  - \n\nTY  - JOUR\nTI  - Other factors that potentially affect the immunogenicity of SARS subunit vaccines include immunization routes and adjuvants (Zakhartchouk\nT2  - et al\nPY  - 2007\nDA  - 2007\nPB  - Li et al\nT2  - Significantly high-titer antibodies were induced by monomeric or trimeric SARS-CoV S and S1 proteins through the intramuscular (I. M.) route compared to the subcutaneous (S. C.) route\nC1  - true\nC1  - (Zakhartchouk et al.,\nLA  - \nER  - \n\nTY  - CHAP\nTI  - MERS-CoV Subunit Vaccines Based on RBD Numerous MERS-CoV RBD-based subunit vaccines have been developed and extensively evaluated in available animal models since the emergence of MERS-CoV\nPB  - Table\nPY  - 2013\nDA  - 2013\nT2  - In general, these subunit vaccines have strong immunogenicity and are capable of inducing high neutralizing antibodies and/or protection against MERSCoV infection (Ma et al\nC1  - (Zhou et al.,\nC1  - Tai et al., Zhou et al., Zhang et al., et al., Wang Y. et al.,\nC1  - true\nLA  - \nER  - \n\nTY  - CHAP\nTI  - Co-crystallographic analyses of MERS-CoV RBD and/or RBD/DPP4 complexes have confirmed that the RBD is attributed to residues 367\u2013588\nPB  - Chen et al\nPY  - 2013\nDA  - 2013\nSP  - 367\nEP  - 606\nAU  - Lu\nC1  - NHPs) (Lan et al\nN1  - However, it only partially protects\nT2  - in the MERS-CoV S1 subunit. Indeed, a recombinant MERS-CoV RBD (rRBD) fragment (residues 367\u2013606) elicits RBD-specific antibody and cellular immune responses and neutralizing antibodies in mice and/or non-human primates\nC1  - true\nLA  - \nER  - \n\nTY  - GEN\nAU  - Pallesen\nPY  - 2017\nDA  - 2017\nC1  - true\nER  - \n\nTY  - GEN\nAU  - Lan\nPY  - 2014\nDA  - 2014\nC1  - true\nER  - \n\nTY  - GEN\nAU  - Du\nPY  - 2013\nDA  - 2013\nTI  - Ma et al\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Du\nPY  - 2013\nDA  - 2013\nTI  - Zhang\nT2  - et al\nC1  - Ma et al., 2014b; Tang et al.,\nC1  - true\nT2  - Nyon et\nLA  - \nCY  - al\nER  - \n\nTY  - GEN\nAU  - Tai\nPY  - 2016\nDA  - 2016\nC1  - true\nER  - \n\nTY  - CHAP\nAU  - Du\nPY  - 2016\nDA  - 2016\nN1  - Jiaming\nTI  - Yang et al., 2014a aaa, amino acid; Abs, antibodies; Ad5, adenovirus serotype 5; Ad5-hDPP4 mice, Ad5-hDPP4-transuced mice; Alum hydro, aluminum hydroxide; Alum pho, Aluminum phosphate; hDPP4, human dipeptidyl peptidase\nPB  - TNF)-alpha\nC1  - Wang et al., Adney et al., et al., adjuvant; I. M., intramuscular; I. N.,\nC1  - true\nT2  - hDPP4-Tg mice, transgenic mice expressing MERS-CoV receptor human DPP4; IFA, incomplete Freund\u2019s\nLA  - \nER  - \n\nTY  - JOUR\nTI  - NHPs from MERS-CoV infection by alleviating pneumonia and clinical manifestations, as well as decreasing viral load\nPB  - Lan et al\nPY  - 2015\nDA  - 2015\nT2  - et al\nT2  - In addition, an RBD protein fragment containing MERSCoV S residues 377\u2013622 fused with the Fc tag of human IgG can induce MERS-CoV S1- and/or RBD-specific humoral and cellular immune responses in the immunized mice with neutralizing activity against MERS-CoV infection\nC1  - (Du et al., et al.,\nLA  - \nCY  - Ma\nER  - \n\nTY  - JOUR\nTI  - MERS-CoV Subunit Vaccines Based on Non-S Structural Proteins Unlike SARS subunit vaccines which have been designed based on viral N and M proteins, it appears that very few subunit vaccines have been developed based on the non-S structural protein(s) of MERS-CoV. One study reports the induction of specific antibodies by MERS-CoV N peptides (Yang et al., 2014a), and another report shows that N protein is used for development of vaccines based on viral vector Vaccinia virus, modified Vaccinia Ankara (MVA) (Veit\nT2  - et al\nPY  - 2018\nDA  - 2018\nT2  - This may be potentially a consequence of the weak immunogenicity and/or protective efficacy of non-S structural proteins, further confirming the role of MERS-CoV S protein as the key target for the development of MERS vaccines, including subunit vaccines\nLA  - \nER  - \n\nTY  - BOOK\nTI  - As described above, MERS-CoV subunit vaccines containing different antigens or fragment lengths, particularly those based on the RBD, have apparently variable immunogenicity and/or protective efficacy, and a critical neutralizing domain that contains an RBD fragment corresponding to residues 377\u2013588 of S protein elicits the highest neutralizing antibodies among several fragments tested\nPB  - et al., 2014b; Zhang et al\nPY  - 2015\nDA  - 2015\nLA  - \nCY  - Ma\nER  - \n\nTY  - CHAP\nTI  - Vaccination pathways are important in inducing efficient immune responses, and different immunization routes may elicit different immune responses to the same protein antigens. For example, immunization of mice with a MERS-CoV subunit vaccine (RBD-Fc) via the intranasal route induced higher levels of cellular immune responses and stronger local mucosal neutralizing antibody responses against MERS-CoV infection than those induced by the same vaccine via the S. C. pathway (Ma et al\nPY  - 2014\nDA  - 2014\nPB  - route (Lan et al\nT2  - In addition, while Freund\u2019s and CpG-adjuvanted rRBD protein elicited higher-level systematic and local IFN\u03b3-producing T cells via the S. C. route, this protein adjuvanted with Alum and CpG induced higher-level tumor necrosis factoralpha (TNF-\u03b1) and interleukin 4 (IL-4)-secreting T cells via the I. M\nLA  - \nER  - \n\nTY  - JOUR\nTI  - Antigen dosage, immunization doses, and intervals may significantly affect the immunogenicity of MERS-CoV subunit vaccines. Notably, a MERS-CoV RBD (S377-588-Fc) subunit vaccine immunized at 1 \u03bcg elicited strong humoral and cellular immune responses and neutralizing antibodies in mice although the one immunized at 5 and 20 \u03bcg elicited a higher level of S1-specific antibodies\nPB  - Tang et al\nPY  - 2015\nDA  - 2015\nT2  - et al\nT2  - In addition, among the regimens at one dose and two doses at 1-, 2-, and 3-week intervals, 2 doses of this protein boosted at 4 weeks resulted in the highest antibodies and neutralizing antibodies against MERS-CoV infection (Wang Y\nLA  - \nER  - \n\nTY  - CHAP\nAU  - Currently\nTI  - the newly identified 2019-nCoV is spreading to infect people, resulting in significant global concerns. It is critical to rapidly design and develop effective vaccines to prevent infection of this new coronavirus. Since S protein and its fragments, such as RBD, of SARS-CoV, and MERS-CoV are prime targets for developing subunit vaccines against these two highly pathogenic human CoVs, it is expected that similar regions of 2019-nCoV can also be used as key targets for developing vaccines against\nPB  - this new coronavirus (Jiang et al\nPY  - 2020\nDA  - 2020\nT2  - Similarly, other regions of 2019-nCoV, including S1 and S2 subunits of S protein and N protein, can be applied as alternative targets for vaccine development. Taken together, the approaches and strategies in the development of subunit vaccines against SARS and MERS described in this review will provide important information for the rapid design and development of safe and effective subunit vaccines against 2019-nCoV infection\nLA  - \nER  - \n\nTY  - BOOK\nAU  - Adney, D.R.\nAU  - Wang, L.\nAU  - van Doremalen, N.\nAU  - Shi, W.\nAU  - Zhang, Y.\nAU  - Kong, W.P.\nPY  - 2019\nDA  - 2019\nTI  - Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas\nPB  - Viruses 11: E212\nDO  - 10.3390/v11030212\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Al-Amri, S.S.\nAU  - Abbas, A.T.\nAU  - Siddiq, L.A.\nAU  - Alghamdi, A.\nAU  - Sanki, M.A.\nAU  - AlMuhanna, M.K.\nPY  - 2017\nDA  - 2017\nTI  - Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein\nT2  - Sci. Rep\nVL  - 7\nSP  - 44875\nDO  - 10.1038/srep 44875\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Annan, A.\nAU  - Baldwin, H.J.\nAU  - Corman, V.M.\nAU  - Klose, S.M.\nAU  - Owusu, M.\nAU  - Nkrumah, E.\nT2  - E., et al\nPY  - 2013\nDA  - 2013\nTI  - Human betacoronavirus 2c EMC/2012-related viruses in Bats, Ghana and Europe\nVL  - 19\nSP  - 456\nEP  - 459\nDO  - 10.3201/eid1903.121503\nC1  - Emerg. Infect. Dis.\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Arbour, N.\nAU  - Day, R.\nAU  - Newcombe, J.\nAU  - Talbot, P.J.\nPY  - 2000\nDA  - 2000\nTI  - Neuroinvasion by human respiratory coronaviruses\nT2  - J. Virol\nVL  - 74\nSP  - 8913\nEP  - 8921\nDO  - 10.1128/jvi.74.19.8913-8921.2000\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Azhar, E.I.\nAU  - El-Kafrawy, S.A.\nAU  - Farraj, S.A.\nAU  - Hassan, A.M.\nAU  - Al-Saeed, M.S.\nAU  - Hashem, A.M.\nPY  - 2014\nDA  - 2014\nTI  - Evidence for camel-to-human transmission of MERS coronavirus\nT2  - N. Engl. J. Med\nVL  - 370\nSP  - 2499\nEP  - 2505\nDO  - 10.1056/NEJMoa1401505\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Bailey-Elkin, B.A.\nAU  - Knaap, R.C.\nAU  - Johnson, G.G.\nAU  - Dalebout, T.J.\nAU  - Ninaber, D.K.\nAU  - van Kasteren, P.B.\nPY  - 2014\nDA  - 2014\nTI  - Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression\nT2  - J. Biol. Chem\nVL  - 289\nSP  - 34667\nEP  - 34682\nDO  - 10.1074/jbc. M114.609644\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Bisht, H.\nAU  - Roberts, A.\nAU  - Vogel, L.\nAU  - Bukreyev, A.\nAU  - Collins, P.L.\nAU  - Murphy, B.R.\nPY  - 2004\nDA  - 2004\nTI  - Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice\nT2  - Proc. Natl. Acad. Sci. U. S. A\nVL  - 101\nSP  - 6641\nEP  - 6646\nDO  - 10.1073/pnas.0401939101\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Buchholz, U.J.\nAU  - Bukreyev, A.\nAU  - Yang, L.J.\nAU  - Lamirande, E.W.\nAU  - Murphy, B.R.\nAU  - Subbarao, K.\nPY  - 2004\nDA  - 2004\nTI  - Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity\nT2  - Proc. Natl. Acad. Sci. U. S. A\nVL  - 101\nSP  - 9804\nEP  - 9809\nDO  - 10.1073/pnas.0403492101\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Bukreyev, A.\nAU  - Lamirande, E.W.\nAU  - Buchholz, U.J.\nAU  - Vogel, L.N.\nAU  - Elkins, W.R.\nAU  - St Claire, M.\nPY  - 2004\nDA  - 2004\nTI  - Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS\nT2  - Lancet\nVL  - 363\nSP  - 2122\nEP  - 2127\nDO  - 10.1016/s0140-6736(04)16501-x\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Chan, P.K.\nAU  - Ma, S.\nAU  - Ngai, S.M.\nPY  - 2011\nDA  - 2011\nTI  - Identification of T-cell epitopes of SARS-coronavirus for development of peptide-based vaccines and cellular immunity assessment methods\nT2  - Hong Kong Med. J\nVL  - 17\nSP  - 26\nEP  - 30\nIS  - 6\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Chang, C.Y.\nAU  - Hong, W.W.\nAU  - Chong, P.\nAU  - Wu, S.C.\nPY  - 2006\nDA  - 2006\nTI  - Influence of intron and exon splicing enhancers on mammalian cell expression of a truncated spike protein of SARS-CoV and its implication for subunit vaccine development\nT2  - Vaccine\nVL  - 24\nSP  - 1132\nEP  - 1141\nDO  - 10.1016/j.vaccine.2005.09.011\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Channappanavar, R.\nAU  - Perlman, S.\nPY  - 2017\nDA  - 2017\nTI  - Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology\nT2  - Semin. Immunopathol\nVL  - 39\nSP  - 529\nEP  - 539\nDO  - 10.1007/s00281-017-0629-x\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Chen, W.H.\nAU  - Du, L.\nAU  - Chag, S.M.\nAU  - Ma, C.\nAU  - Tricoche, N.\nAU  - Tao, X.\nPY  - 2014\nDA  - 2014\nTI  - Yeastexpressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate\nT2  - Hum. Vaccin. Immunother\nVL  - 10\nSP  - 648\nEP  - 658\nDO  - 10.4161/hv.27464\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Chen, Y.\nAU  - Rajashankar, K.R.\nAU  - Yang, Y.\nAU  - Agnihothram, S.S.\nAU  - Liu, C.\nAU  - Lin, Y.L.\nPY  - 2013\nDA  - 2013\nTI  - Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus\nT2  - J. Virol\nVL  - 87\nSP  - 10777\nEP  - 10783\nDO  - 10.1128/jvi.01756-13\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Chiu, S.S.\nAU  - Chan, K.H.\nAU  - Chu, K.W.\nAU  - Kwan, S.W.\nAU  - Guan, Y.\nAU  - Poon, L.L.\nPY  - 2005\nDA  - 2005\nTI  - Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China\nT2  - Clin. Infect. Dis\nVL  - 40\nSP  - 1721\nEP  - 1729\nDO  - 10.1086/430301\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Cho, H.\nAU  - Excler, J.L.\nAU  - Kim, J.H.\nAU  - Yoon, I.K.\nPY  - 2018\nDA  - 2018\nTI  - Development of Middle East respiratory syndrome coronavirus vaccines - advances and challenges\nT2  - Hum. Vaccin. Immunother\nVL  - 14\nSP  - 304\nEP  - 313\nDO  - 10.1080/21645515.2017.138 9362\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Cui, J.\nAU  - Li, F.\nAU  - Shi, Z.L.\nPY  - 2019\nDA  - 2019\nTI  - Origin and evolution of pathogenic coronaviruses\nT2  - Nat. Rev. Microbiol\nVL  - 17\nSP  - 181\nEP  - 192\nDO  - 10.1038/s41579-0180118-9\nLA  - \nER  - \n\nTY  - CHAP\nA2  - King, A.M.Q.\nA2  - Adams, M.J.\nA2  - Carstens, E.B.\nA2  - Lefkowitz, E.J.\nPY  - 2011\nDA  - 2011\nTI  - Family Coronaviridae, virus taxomomy: classification and nomenclature of viruses,\nT2  - Ninth Report of the International Committee on Taxonomy of Viruses\nPB  - Elsevier Academic Press\nSP  - 806\nEP  - 826\nAU  - De Groot, R.J.\nAU  - Baker, S.\nAU  - Baric, R.\nAU  - Enjuanes, L.\nAU  - Gorbalenya, A.\nAU  - Holmes, K.V.\nC1  - true\nLA  - \nCY  - Amsterdam\nER  - \n\nTY  - JOUR\nAU  - DeDiego, M.L.\nAU  - Nieto-Torres, J.L.\nAU  - Jimenez-Guardeno, J.M.\nAU  - Regla-Nava, J.A.\nAU  - Castano-Rodriguez, C.\nAU  - Fernandez-Delgado, R.\nPY  - 2014\nDA  - 2014\nTI  - Coronavirus virulence genes with main focus on SARS-CoV envelope gene\nT2  - Virus. Res\nVL  - 194\nSP  - 124\nEP  - 137\nDO  - 10.1016/j.virusres.2014.07.024\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Deng, M.P.\nAU  - Hu, Z.H.\nAU  - Wang, H.L.\nAU  - Deng, F.\nPY  - 2012\nDA  - 2012\nTI  - Developments of subunit and VLP vaccines against influenza A virus\nT2  - Virol. Sin\nVL  - 27\nSP  - 145\nEP  - 153\nDO  - 10.1007/s12250-012-3241-1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Desforges, M.\nAU  - Desjardins, J.\nAU  - Zhang, C.\nAU  - Talbot, P.J.\nPY  - 2013\nDA  - 2013\nTI  - The acetyl-esterase activity of the hemagglutinin-esterase protein of human coronavirus OC43 strongly enhances the production of infectious virus\nT2  - J. Virol\nVL  - 87\nSP  - 3097\nEP  - 3107\nDO  - 10.1128/jvi.02699-12\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Desforges, M.\nAU  - Le Coupanec, A.\nAU  - Brison, E.\nAU  - Meessen-Pinard, M.\nAU  - Talbot, P.J.\nPY  - 2014\nDA  - 2014\nTI  - Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans\nT2  - Adv. Exp. Med. Biol\nVL  - 807\nSP  - 75\nEP  - 96\nDO  - 10.1007/978-81-322-1777-0_6\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Drexler, J.F.\nAU  - Corman, V.M.\nAU  - Drosten, C.\nPY  - 2014\nDA  - 2014\nTI  - Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS\nT2  - Antiviral Res\nVL  - 101\nSP  - 45\nEP  - 56\nDO  - 10.1016/j.antiviral.2013.10.013\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Drosten, C.\nAU  - Gunther, S.\nAU  - Preiser, W.\nAU  - van der Werf, S.\nAU  - Brodt, H.R.\nAU  - Becker, S.\nPY  - 2003\nDA  - 2003\nTI  - Identification of a novel coronavirus in patients with severe acute respiratory syndrome\nT2  - N. Engl. J. Med\nVL  - 348\nSP  - 1967\nEP  - 1976\nDO  - 10.1056/NEJMoa030747\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Du, L.\nAU  - He, Y.\nAU  - Jiang, S.\nAU  - Zheng, B.J.\nPY  - 2008\nDA  - 2008\nTI  - Development of subunit vaccines against severe acute respiratory syndrome\nT2  - Drugs Today\nVL  - 44\nSP  - 63\nEP  - 73\nDO  - 10.1358/dot.2008.44.1.1131830\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Du, L.\nAU  - He, Y.\nAU  - Zhou, Y.\nAU  - Liu, S.\nAU  - Zheng, B.J.\nAU  - Jiang, S.\nPY  - 2009\nDA  - 2009\nTI  - The spike protein of SARS-CoV - a target for vaccine and therapeutic development\nT2  - Nat. Rev. Microbiol\nVL  - 7\nSP  - 226\nEP  - 236\nDO  - 10.1038/nrmicro2090\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Du, L.\nAU  - Jiang, S.\nPY  - 2015\nDA  - 2015\nTI  - Middle East respiratory syndrome: current status and future prospects for vaccine development\nT2  - Expert Opin. Biol. Ther\nVL  - 15\nSP  - 1647\nEP  - 1651\nDO  - 10.1517/14712598.2015.1092518\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Du, L.\nAU  - Kou, Z.\nAU  - Ma, C.\nAU  - Tao, X.\nAU  - Wang, L.\nAU  - Zhao, G.\nPY  - 2013\nDA  - 2013\nTI  - A truncated receptor-binding domain of MERS-CoV Spike protein potently inhibits MERSCoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines\nT2  - PLoS One\nVL  - 8\nSP  - 81587\nDO  - 10.1371/journal.pone.0081587\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Du, L.\nAU  - Ma, C.\nAU  - Jiang, S.\nPY  - 2013\nDA  - 2013\nTI  - Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC\nT2  - J. Infect\nVL  - 67\nSP  - 348\nEP  - 350\nDO  - 10.1016/j.jinf.2013.05.002\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Du, L.\nAU  - Tai, W.\nAU  - Yang, Y.\nAU  - Zhao, G.\nAU  - Zhu, Q.\nAU  - Sun, S.\nPY  - 2016\nDA  - 2016\nTI  - Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines\nT2  - Nat. Commun\nPB  - 7: 13473\nDO  - 10.1038/ncomms 13473\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Du, L.\nAU  - Tai, W.\nAU  - Zhou, Y.\nAU  - Jiang, S.\nPY  - 2016\nDA  - 2016\nTI  - Vaccines for the prevention against the threat of MERS-CoV\nT2  - Expert Rev. Vaccines\nVL  - 15\nSP  - 1123\nEP  - 1134\nDO  - 10.1586/14760584.2016.1167603\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Du, L.\nAU  - Yang, Y.\nAU  - Zhou, Y.\nAU  - Lu, L.\nAU  - Li, F.\nAU  - Jiang, S.\nPY  - 2017\nDA  - 2017\nTI  - MERS-CoV spike protein: a key target for antivirals. Expert Opin\nT2  - Ther. Targets\nVL  - 21\nSP  - 131\nEP  - 143\nDO  - 10.1080/14728222.2017.1271415\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Du, L.\nAU  - Zhao, G.\nAU  - Chan, C.C.\nAU  - Li, L.\nAU  - He, Y.\nAU  - Zhou, Y.\nPY  - 2010\nDA  - 2010\nTI  - A 219-mer CHOexpressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity\nT2  - Viral. Immunol\nVL  - 23\nSP  - 211\nEP  - 219\nDO  - 10.1089/vim.2009.0090\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Du, L.\nAU  - Zhao, G.\nAU  - Chan, C.C.\nAU  - Sun, S.\nAU  - Chen, M.\nAU  - Liu, Z.\nPY  - 2009\nDA  - 2009\nTI  - Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity\nT2  - Virology\nVL  - 393\nSP  - 144\nEP  - 150\nDO  - 10.1016/j.virol.2009.07.018\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Du, L.\nAU  - Zhao, G.\nAU  - He, Y.\nAU  - Guo, Y.\nAU  - Zheng, B.J.\nAU  - Jiang, S.\nPY  - 2007\nDA  - 2007\nTI  - Receptorbinding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model\nT2  - Vaccine\nVL  - 25\nSP  - 2832\nEP  - 2838\nDO  - 10.1016/j.vaccine.2006.10.031\nC1  - true\nLA  - \nER  - \n\nTY  - GEN\nAU  - Du, L.\nAU  - Zhao, G.\nAU  - Kou, Z.\nAU  - Ma, C.\nAU  - Sun, S.\nAU  - Poon, V.K.\nPY  - 2013\nDA  - 2013\nTI  - Identification of a receptor-binding domain in the S protein of the novel human coronavirus\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nTI  - Middle East Respiratory Syndrome coronavirus as an essential target for vaccine development\nT2  - J. Virol\nVL  - 87\nSP  - 9939\nEP  - 9942\nDO  - 10.1128/jvi.01048-13\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Du, L.\nAU  - Zhao, G.\nAU  - Li, L.\nAU  - He, Y.\nAU  - Zhou, Y.\nAU  - Zheng, B.J.\nPY  - 2009\nDA  - 2009\nTI  - Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells\nT2  - Biochem. Biophys. Res. Commun\nVL  - 384\nSP  - 486\nEP  - 490\nDO  - 10.1016/j.bbre.2009.05.003\nC1  - true\nLA  - \nER  - \n\nTY  - BOOK\nAU  - Elshabrawy, H.A.\nAU  - Coughlin, M.M.\nAU  - Baker, S.C.\nAU  - Prabhakar, B.S.\nPY  - 2012\nDA  - 2012\nTI  - Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing\nPB  - PLoS One 7: e50366\nDO  - 10.1371/journal.pone.0050366\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Esper, F.\nAU  - Weibel, C.\nAU  - Ferguson, D.\nAU  - Landry, M.L.\nAU  - Kahn, J.S.\nPY  - 2006\nDA  - 2006\nTI  - Coronavirus HKU1 infection in the United States\nT2  - Emerg. Infect. Dis\nVL  - 12\nSP  - 775\nEP  - 779\nDO  - 10.3201/eid1205.051316\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Falsey, A.R.\nAU  - Walsh, E.E.\nAU  - Hayden, F.G.\nPY  - 2002\nDA  - 2002\nTI  - Rhinovirus and coronavirus infection-associated hospitalizations among older adults\nT2  - J. Infect. Dis\nVL  - 185\nSP  - 1338\nEP  - 1341\nDO  - 10.1086/339881\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Fehr, A.R.\nAU  - Perlman, S.\nPY  - 2015\nDA  - 2015\nTI  - Coronaviruses: an overview of their replication and pathogenesis\nT2  - Methods Mol. Biol\nVL  - 1282\nSP  - 1\nEP  - 23\nDO  - 10.1007/978-1-49392438-7_1\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Fouchier, R.A.M.\nAU  - Hartwig, N.G.\nAU  - Bestebroer, T.M.\nAU  - Niemeyer, B.\nAU  - de Jong, J.C.\nAU  - Simon, J.H.\nPY  - 2004\nDA  - 2004\nTI  - A previously undescribed coronavirus associated with respiratory disease in humans\nT2  - Proc. Natl. Acad. Sci. U. S. A\nVL  - 101\nSP  - 6212\nEP  - 6216\nDO  - 10.1073/pnas.0400762101\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Ge, X.Y.\nAU  - Li, J.L.\nAU  - Yang, X.L.\nAU  - Chmura, A.A.\nAU  - Zhu, G.\nAU  - Epstein, J.H.\nPY  - 2013\nDA  - 2013\nTI  - Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor\nT2  - Nature\nVL  - 503\nSP  - 535\nEP  - 538\nDO  - 10.1038/nature12711\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Gerna, G.\nAU  - Campanini, G.\nAU  - Rovida, F.\nAU  - Percivalle, E.\nAU  - Sarasini, A.\nAU  - Marchi, A.\nPY  - 2006\nDA  - 2006\nTI  - Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients\nT2  - J. Med. Virol\nVL  - 78\nSP  - 938\nEP  - 949\nDO  - 10.1002/jmv.20645\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - He, Y.\nAU  - Li, J.\nAU  - Jiang, S.\nPY  - 2006\nDA  - 2006\nTI  - A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity\nT2  - Biochem. Biophys. Res. Commun\nVL  - 344\nSP  - 106\nEP  - 113\nDO  - 10.1016/j.bbrc.2006.03.139\nLA  - \nER  - \n\nTY  - JOUR\nAU  - He, Y.\nAU  - Li, J.\nAU  - Li, W.\nAU  - Lustigman, S.\nAU  - Farzan, M.\nAU  - Jiang, S.\nPY  - 2006\nDA  - 2006\nTI  - Crossneutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein\nT2  - J. Immunol\nVL  - 176\nSP  - 6085\nEP  - 6092\nDO  - 10.4049/jimmunol.176.10.6085\nLA  - \nER  - \n\nTY  - JOUR\nAU  - He, Y.\nAU  - Lu, H.\nAU  - Siddiqui, P.\nAU  - Zhou, Y.\nAU  - Jiang, S.\nPY  - 2005\nDA  - 2005\nTI  - Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies\nT2  - J. Immunol\nVL  - 174\nSP  - \"4908\nEP  - 4915.\" # \"10.1016/j.bbrc.2004.09.106\"\nDO  - 10.4049/jimmunol.174.8.4908\nC1  - He, Y., Zhou, Y., Liu, S., Kou, Z., Li, W., Farzan, M., et al.\nT2  - Receptorbinding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine\nC1  - Biochem. Biophys. Res. Commun.324,\nC1  - 773\u2013781.doi:\nC1  - 10.1016/j.bbrc.2004.09.106\nLA  - \nER  - \n\nTY  - JOUR\nAU  - He, Y.\nAU  - Zhou, Y.\nAU  - Siddiqui, P.\nAU  - Niu, J.\nAU  - Jiang, S.\nPY  - 2005\nDA  - 2005\nTI  - Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus\nT2  - J. Clin. Microbiol\nVL  - 43\nSP  - 3718\nEP  - 3726\nDO  - 10.1128/jcm.43.8.3718-3726.2005\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Hofmann, H.\nAU  - Pyrc, K.\nAU  - van der Hoek, L.\nAU  - Geier, M.\nAU  - Berkhout, B.\nAU  - Pohlmann, S.\nPY  - 2005\nDA  - 2005\nTI  - Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry\nT2  - Proc. Natl. Acad. Sci. U. S. A\nVL  - 102\nSP  - 7988\nEP  - 7993\nDO  - 10.1073/pnas.0409465102\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Jaume, M.\nAU  - Yip, M.S.\nAU  - Kam, Y.W.\nAU  - Cheung, C.Y.\nAU  - Kien, F.\nAU  - Roberts, A.\nPY  - 2012\nDA  - 2012\nTI  - SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement\nT2  - Hong Kong Med. J\nVL  - 18\nSP  - 31\nEP  - 36\nC1  - true\nIS  - 2\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Jiaming, L.\nAU  - Yanfeng, Y.\nAU  - Yao, D.\nAU  - Yawei, H.\nAU  - Linlin, B.\nAU  - Baoying, H.\nPY  - 2017\nDA  - 2017\nTI  - The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection\nT2  - Vaccine\nVL  - 35\nSP  - 10\nEP  - 18\nDO  - 10.1016/j.vaccine.2016.11.064\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Jiang, S.\nAU  - Bottazzi, M.E.\nAU  - Du, L.\nAU  - Lustigman, S.\nAU  - Tseng, C.T.\nAU  - Curti, E.\nPY  - 2012\nDA  - 2012\nTI  - Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome\nT2  - Expert Rev. Vaccines\nVL  - 11\nSP  - 1405\nEP  - 1413\nDO  - 10.1586/erv.12.126\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Jiang, S.\nAU  - Du, L.\nAU  - Shi, Z.\nPY  - 2020\nDA  - 2020\nTI  - An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies\nT2  - Emerg Microbes Infect\nVL  - 9\nSP  - \"275\nEP  - 277.\" # \"10.3201/1107.050219\"\nDO  - 10.1080/22221751.2020.1723441\nC1  - Jiang, S., He, Y., and Liu, S.\nT2  - SARS vaccine development\nC1  - Emerg. Infect. Dis.11,\nC1  - 1016\u20131020.doi:\nC1  - 10.3201/1107.050219\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Jiang, S.\nAU  - Lu, L.\nAU  - Du, L.\nAU  - Debnath, A.K.\nPY  - 2013\nDA  - 2013\nTI  - A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC\nT2  - J. Infect\nVL  - 66\nSP  - 464\nEP  - 466\nDO  - 10.1016/j.jinf.2012.12.003\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Kam, Y.W.\nAU  - Kien, F.\nAU  - Roberts, A.\nAU  - Cheung, Y.C.\nAU  - Lamirande, E.W.\nAU  - Vogel, L.\nPY  - 2007\nDA  - 2007\nTI  - Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro\nT2  - Vaccine\nVL  - 25\nSP  - \"729\nEP  - 740.\" # \"10.1093/infdis/119.3.282\"\nDO  - 10.1016/j.vaccine.2006.08.011\nC1  - Kapikian, A. Z., James, H. D., Kelly, S. J., Dees, J. H., Turner, H. C., McIntosh, K., et al.\nC1  - true\nT2  - Isolation from man of avian infectious bronchitis virus-like viruses (coronavirus) similar to 229E virus with some epidemiological observations\nC1  - J. Infect. Dis.119,\nC1  - 282\u2013290.doi:\nC1  - 10.1093/infdis/119.3.282\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Killerby, M.E.\nAU  - Biggs, H.M.\nAU  - Haynes, A.\nAU  - Dahl, R.M.\nAU  - Mustaquim, D.\nAU  - Gerber, S.I.\nPY  - 2018\nDA  - 2018\nTI  - Human coronavirus circulation in the United States 2014-2017\nT2  - J. Clin. Virol\nVL  - 101\nSP  - 52\nEP  - 56\nDO  - 10.1016/j.jcv.2018.01.019\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Kim, K.Y.\nAU  - Han, S.Y.\nAU  - Kim, H.S.\nAU  - Cheong, H.M.\nAU  - Kim, S.S.\nAU  - Kim, D.S.\nPY  - 2017\nDA  - 2017\nTI  - Human coronavirus in the 2014 winter season as a cause of lower respiratory tract infection\nT2  - Yonsei Med. J\nVL  - 58\nSP  - 174\nEP  - 179\nDO  - 10.3349/ymj.2017.58.1.174\nLA  - \nER  - \n\nTY  - JOUR\nAU  - King, A.M.Q.\nAU  - Lefkowitz, E.J.\nAU  - Mushegian, A.R.\nAU  - Adams, M.J.\nAU  - Dutilh, B.E.\nAU  - Gorbalenya, A.E.\nPY  - 2018\nDA  - 2018\nTI  - Changes to taxonomy and the international code of virus classification and nomenclature ratified by the international committee on taxonomy of viruses\nT2  - Virol\nVL  - 163\nSP  - 2601\nEP  - 2631\nDO  - 10.1007/s00705-018-3847-1\nC1  - true\nT2  - Arch\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Ksiazek, T.G.\nAU  - Erdman, D.\nAU  - Goldsmith, C.S.\nAU  - Zaki, S.R.\nAU  - Peret, T.\nAU  - Emery, S.\nPY  - 2003\nDA  - 2003\nTI  - A novel coronavirus associated with severe acute respiratory syndrome\nT2  - N. Engl. J. Med\nVL  - 348\nSP  - 1953\nEP  - 1966\nDO  - 10.1056/NEJMoa030781\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Kudelova, M.\nAU  - Belvoncikova, P.\nAU  - Vrbova, M.\nAU  - Kovalova, A.\nAU  - Stibraniova, I.\nAU  - Kocakova, P.\nPY  - 2015\nDA  - 2015\nTI  - Detection of murine herpesvirus 68 (MHV-68) in dermacentor reticulatus ticks\nT2  - Microb. Ecol\nVL  - 70\nSP  - 785\nEP  - 794\nDO  - 10.1007/s00248015-0622-7\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Kusanagi, K.\nAU  - Kuwahara, H.\nAU  - Katoh, T.\nAU  - Nunoya, T.\nAU  - Ishikawa, Y.\nAU  - Samejima, T.\nPY  - 1992\nDA  - 1992\nTI  - Isolation and serial propagation of porcine epidemic diarrhhea virus in cell-cultures and partial characterization of the isolate\nT2  - J. Vet. Med. Sci\nVL  - 54\nSP  - 313\nEP  - 318\nDO  - 10.1292/jvms.54.313\nC1  - true\nLA  - \nER  - \n\nTY  - BOOK\nAU  - Lan, J.\nAU  - Deng, Y.\nAU  - Chen, H.\nAU  - Lu, G.\nAU  - Wang, W.\nAU  - Guo, X.\nPY  - 2014\nDA  - 2014\nTI  - Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen\nPB  - PLoS One 9: e112602\nDO  - 10.1371/journal.pone.011 2602\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Lan, J.\nAU  - Yao, Y.\nAU  - Deng, Y.\nAU  - Chen, H.\nAU  - Lu, G.\nAU  - Wang, W.\nPY  - 2015\nDA  - 2015\nTI  - Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge\nT2  - EBioMedicine\nVL  - 2\nSP  - 1438\nEP  - 1446\nDO  - 10.1016/j.ebiom.2015.08.031\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Lau, S.K.\nAU  - Woo, P.C.\nAU  - Yip, C.C.\nAU  - Tse, H.\nAU  - Tsoi, H.W.\nAU  - Cheng, V.C.\nPY  - 2006\nDA  - 2006\nTI  - Coronavirus HKU1 and other coronavirus infections in Hong Kong\nT2  - J. Clin. Microbiol\nVL  - 44\nSP  - 2063\nEP  - 2071\nDO  - 10.1128/jcm.02614-05\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Lau, S.K.P.\nAU  - Zhang, L.\nAU  - Luk, H.K.H.\nAU  - Xiong, L.\nAU  - Peng, X.\nAU  - Li, K.S.M.\nPY  - 2018\nDA  - 2018\nTI  - Receptor usage of a novel bat lineage C betacoronavirus reveals evolution of Middle East respiratory syndrome-related coronavirus spike proteins for human dipeptidyl peptidase 4 binding\nT2  - J. Infect. Dis\nVL  - 218\nSP  - 197\nEP  - 207\nDO  - 10.1093/infdis/jiy018\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Lehmann, C.\nAU  - Wolf, H.\nAU  - Xu, J.G.\nAU  - Zhao, Q.B.\nAU  - Shao, Y.M.\nAU  - Motz, M.\nPY  - 2008\nDA  - 2008\nTI  - A line immunoassay utilizing recombinant nucleocapsid proteins for detection of antibodies to human coronaviruses\nT2  - Diagn. Microbiol. Infect. Dis\nVL  - 61\nSP  - 40\nEP  - 48\nDO  - 10.1016/j.diagmicrobio.2007.12.002\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Lelli, D.\nAU  - Papetti, A.\nAU  - Sabelli, C.\nAU  - Rosti, E.\nAU  - Moreno, A.\nAU  - Boniotti, M.B.\nPY  - 2013\nDA  - 2013\nTI  - Detection of coronaviruses in bats of various species in Italy\nT2  - Viruses\nVL  - 5\nSP  - 2679\nEP  - 2689\nDO  - 10.3390/v5112679\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Li, F.\nPY  - 2008\nDA  - 2008\nTI  - Structural analysis of major species barriers between humans and palm civets for severe acute respiratory syndrome coronavirus infections\nT2  - J. Virol\nVL  - 82\nSP  - 6984\nEP  - 6991\nDO  - 10.1128/jvi.00442-08\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Li, F.\nPY  - 2015\nDA  - 2015\nTI  - Receptor recognition mechanisms of coronaviruses: a decade of structural studies\nT2  - J. Virol\nVL  - 89\nSP  - 1954\nEP  - 1964\nDO  - 10.1128/jvi.02615-14\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Li, F.\nPY  - 2016\nDA  - 2016\nTI  - Structure, function, and evolution of coronavirus spike proteins\nT2  - Annu. Rev. Virol\nVL  - 3\nSP  - 237\nEP  - 261\nDO  - 10.1146/annurev-virology-110615-042301\nLA  - \nER  - \n\nTY  - BOOK\nAU  - Li, F.\nAU  - Du, L.\nPY  - 2019\nDA  - 2019\nTI  - MERS coronavirus: an emerging zoonotic virus\nPB  - Viruses 11: E663\nDO  - 10.3390/v11070663\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Li, F.\nAU  - Li, W.\nAU  - Farzan, M.\nAU  - Harrison, S.C.\nPY  - 2005\nDA  - 2005\nTI  - Structure of SARS coronavirus spike receptor-binding domain complexed with receptor\nT2  - Science\nVL  - 309\nSP  - 1864\nEP  - 1868\nDO  - 10.1126/science.1116480\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Li, W.\nAU  - Shi, Z.\nAU  - Yu, M.\nAU  - Ren, W.\nAU  - Smith, C.\nAU  - Epstein, J.H.\nPY  - 2005\nDA  - 2005\nTI  - Bats are natural reservoirs of SARS-like coronaviruses\nT2  - Science\nVL  - 310\nSP  - 676\nEP  - 679\nDO  - 10.1126/science.1118391\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Li, W.\nAU  - Zhang, C.\nAU  - Sui, J.\nAU  - Kuhn, J.H.\nAU  - Moore, M.J.\nAU  - Luo, S.\nPY  - 2005\nDA  - 2005\nTI  - Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2\nT2  - EMBO J\nVL  - 24\nSP  - 1634\nEP  - 1643\nDO  - 10.1038/sj.emboj.7600640\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Li, J.\nAU  - Ulitzky, L.\nAU  - Silberstein, E.\nAU  - Taylor, D.R.\nAU  - Viscidi, R.\nPY  - 2013\nDA  - 2013\nTI  - Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates\nT2  - Viral. Immunol\nVL  - 26\nSP  - 126\nEP  - 132\nDO  - 10.1089/vim.2012.0076\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Li, W.\nAU  - Greenough, T.C.\nAU  - Moore, M.J.\nAU  - Vasilieva, N.\nAU  - Somasundaran, M.\nAU  - Sullivan, J.L.\nPY  - 2004\nDA  - 2004\nTI  - Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2\nT2  - J. Virol\nVL  - 78\nSP  - 11429\nEP  - 11433\nDO  - 10.1128/jvi.78.20.11429-11433.2004\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Li, W.\nAU  - Hulswit, R.J.G.\nAU  - Widjaja, I.\nAU  - Raj, V.S.\nAU  - McBride, R.\nAU  - Peng, W.\nPY  - 2017\nDA  - 2017\nTI  - Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein\nT2  - Proc. Natl Acad. Sci. U. S. A\nVL  - 114\nSP  - 8508\nEP  - 8517\nDO  - 10.1073/pnas.1712592114\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Li, W.\nAU  - Moore, M.J.\nAU  - Vasilieva, N.\nAU  - Sui, J.\nAU  - Wong, S.K.\nAU  - Berne, M.A.\nPY  - 2003\nDA  - 2003\nTI  - Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus\nT2  - Nature\nVL  - 426\nSP  - 450\nEP  - 454\nDO  - 10.1038/nature02145\nC1  - true\nLA  - \nER  - \n\nTY  - GEN\nAU  - Liu, D.X.\nAU  - Fung, T.S.\nAU  - Chong, K.K.\nAU  - Shukla, A.\nAU  - Hilgenfeld, R.\nPY  - 2014\nDA  - 2014\nTI  - Accessory proteins of SARS-CoV and other coronaviruses. Antiviral Res\nDO  - 109\nSP  - 97\nEP  - 109\nC1  - doi: 10.1016/j.antiviral.2014.06.013\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Liu, R.Y.\nAU  - Wu, L.Z.\nAU  - Huang, B.J.\nAU  - Huang, J.L.\nAU  - Zhang, Y.L.\nAU  - Ke, M.L.\nPY  - 2005\nDA  - 2005\nTI  - Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats\nT2  - Virus Res\nVL  - 112\nSP  - 24\nEP  - 31\nDO  - 10.1016/j.virusres.2005.02.009\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Liu, S.J.\nAU  - Leng, C.H.\nAU  - Lien, S.P.\nAU  - Chi, H.Y.\nAU  - Huang, C.Y.\nAU  - Lin, C.L.\nPY  - 2006\nDA  - 2006\nTI  - Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates\nT2  - Vaccine\nVL  - 24\nSP  - 3100\nEP  - 3108\nDO  - 10.1016/j.vaccine.2006.01.058\nC1  - true\nLA  - \nER  - \n\nTY  - BOOK\nAU  - Liu, S.L.\nAU  - Saif, L.\nPY  - 2020\nDA  - 2020\nTI  - Emerging viruses without borders: the Wuhan coronavirus\nPB  - Viruses 12: E130\nDO  - 10.3390/v12020130\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Lu, G.\nAU  - Hu, Y.\nAU  - Wang, Q.\nAU  - Qi, J.\nAU  - Gao, F.\nAU  - Li, Y.\nPY  - 2013\nDA  - 2013\nTI  - Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26\nT2  - Nature\nVL  - 500\nSP  - 227\nEP  - 231\nDO  - 10.1038/nature12328\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Lu, L.\nAU  - Liu, Q.\nAU  - Zhu, Y.\nAU  - Chan, K.H.\nAU  - Qin, L.\nAU  - Li, Y.\nPY  - 2014\nDA  - 2014\nTI  - Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor\nT2  - Nat. Commun\nVL  - 5\nSP  - 3067\nDO  - 10.1038/ncomms4067\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Luo, C.M.\nAU  - Wang, N.\nAU  - Yang, X.L.\nAU  - Liu, H.Z.\nAU  - Zhang, W.\nAU  - Li, B.\nPY  - 2018\nDA  - 2018\nTI  - Discovery of novel bat coronaviruses in south China that use the same receptor as MERS coronavirus\nT2  - J. Virol\nVL  - 92\nSP  - 116\nEP  - 118\nDO  - 10.1128/jvi.00116-18\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Luo, F.\nAU  - Liao, F.L.\nAU  - Wang, H.\nAU  - Tang, H.B.\nAU  - Yang, Z.Q.\nAU  - Hou, W.\nPY  - 2018\nDA  - 2018\nTI  - Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV vaccine\nT2  - Virol. Sin\nVL  - 33\nSP  - 201\nEP  - 204\nDO  - 10.1007/s12250-018-0009-2\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Ma, C.\nAU  - Li, Y.\nAU  - Wang, L.\nAU  - Zhao, G.\nAU  - Tao, X.R.\nAU  - Tseng, C.T.\nPY  - 2014\nDA  - 2014\nTI  - Intranasal vaccination with recombinant receptor-binding domain of MERSCoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines\nT2  - Vaccine\nVL  - 32\nSP  - 2100\nEP  - 2108\nDO  - 10.1016/j.vaccine.2014.02.004\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Ma, C.\nAU  - Wang, L.\nAU  - Tao, X.\nAU  - Zhang, N.\nAU  - Yang, Y.\nAU  - Tseng, C.T.\nPY  - 2014\nDA  - 2014\nTI  - Searching for an ideal vaccine candidate among different MERS coronavirus receptorbinding fragments - The importance of immunofocusing in subunit vaccine design\nT2  - Vaccine\nVL  - 32\nSP  - 6170\nEP  - 6176\nDO  - 10.1016/j.vaccine.2014.08.086\nC1  - true\nLA  - \nER  - \n\nTY  - BOOK\nAU  - Ma, Y.\nAU  - Zhang, Y.\nAU  - Liang, X.\nAU  - Lou, F.\nAU  - Oglesbee, M.\nAU  - Krakowka, S.\nPY  - 2015\nDA  - 2015\nTI  - Origin, evolution, and virulence of porcine deltacoronaviruses in the United States\nPB  - mBio 6: e00064\nDO  - 10.1128/mBio.00064-15\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Marra, M.A.\nAU  - Jones, S.J.\nAU  - Astell, C.R.\nAU  - Holt, R.A.\nAU  - Brooks-Wilson, A.\nAU  - Butterfield, Y.S.\nPY  - 2003\nDA  - 2003\nTI  - The genome sequence of the SARS-associated coronavirus\nT2  - Science\nVL  - 300\nSP  - 1399\nEP  - 1404\nDO  - 10.1126/science.1085953\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Matoba, Y.\nAU  - Abiko, C.\nAU  - Ikeda, T.\nAU  - Aoki, Y.\nAU  - Suzuki, Y.\nAU  - Yahagi, K.\nPY  - 2015\nDA  - 2015\nTI  - Detection of the human coronavirus 229E, HKU1, NL63, and OC43 between 2010 and 2013 in\nT2  - Yamagata, Japan. Jpn. J. Infect. Dis\nVL  - 68\nSP  - 138\nEP  - 141\nDO  - 10.7883/yoken. JJID.2014.266\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - McIntosh, K.\nAU  - Becker, W.B.\nAU  - Chanock, R.M.\nPY  - 1967\nDA  - 1967\nTI  - Growth in suckling-mouse brain of IBV-like viruses from patients with upper respiratory tract disease\nT2  - Proc. Natl. Acad. Sci. U. S. A\nVL  - 58\nSP  - 2268\nEP  - 2273\nDO  - 10.1073/pnas.58.6.2268\nLA  - \nER  - \n\nTY  - JOUR\nPY  - 2017\nDA  - 2017\nTI  - MERS-CoV accessory ORFs play key role for infection and pathogenesis\nT2  - mBio\nVL  - 8\nSP  - 00665\nEP  - 17\nDO  - 10.1128/mBio.00665-17\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Mobaraki, K.\nAU  - Ahmadzadeh, J.\nPY  - 2019\nDA  - 2019\nTI  - Current epidemiological status of Middle East respiratory syndrome coronavirus in the world from 1.1.2017 to 17.1.2018: a cross-sectional study\nT2  - BMC Infect. Dis\nDO  - 19: 351. doi: 10.1186/s12879019-3987-2\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Mou, H.\nAU  - Raj, V.S.\nAU  - van Kuppeveld, F.J.\nAU  - Rottier, P.J.\nAU  - Haagmans, B.L.\nAU  - Bosch, B.J.\nPY  - 2013\nDA  - 2013\nTI  - The receptor binding domain of the new Middle East Respiratory Syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies\nT2  - J. Virol\nVL  - 87\nSP  - 9379\nEP  - 9383\nDO  - 10.1128/jvi.01277-13\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Mourez, T.\nAU  - Vabret, A.\nAU  - Han, Y.\nAU  - Dina, J.\nAU  - Legrand, L.\nAU  - Corbet, S.\nPY  - 2007\nDA  - 2007\nTI  - Baculovirus expression of HCoV-OC43 nucleocapsid protein and development of a Western blot assay for detection of human antibodies against HCoV-OC43\nT2  - J. Virol. Methods\nVL  - 139\nSP  - 175\nEP  - 180\nDO  - 10.1016/j.jviromet.2006.09.024\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Myint, S.H.\nPY  - 1994\nDA  - 1994\nTI  - Human coronaviruses - A brief review\nT2  - Rev. Med. Virol\nVL  - 4\nSP  - 35\nEP  - 46\nDO  - 10.1002/rmv.1980040108\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Nicholls, J.M.\nAU  - Poon, L.L.\nAU  - Lee, K.C.\nAU  - Ng, W.F.\nAU  - Lai, S.T.\nAU  - Leung, C.\nT2  - Y., et al\nPY  - 2003\nDA  - 2003\nTI  - Lung pathology of fatal severe acute respiratory syndrome\nVL  - 361\nSP  - 1773\nEP  - 1778\nDO  - 10.1016/s0140-6736(03)13413-7\nC1  - Lancet\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Nyon, M.P.\nAU  - Du, L.\nAU  - Tseng, C.K.\nAU  - Seid, C.A.\nAU  - Pollet, J.\nAU  - Naceanceno, K.S.\nPY  - 2018\nDA  - 2018\nTI  - Engineering a stable CHO cell line for the expression of a MERScoronavirus vaccine antigen\nT2  - Vaccine\nVL  - 36\nSP  - 1853\nEP  - 1862\nDO  - 10.1016/j.vaccine.2018.02.065\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Ou, X.\nAU  - Guan, H.\nAU  - Qin, B.\nAU  - Mu, Z.\nAU  - Wojdyla, J.A.\nAU  - Wang, M.\nPY  - 2017\nDA  - 2017\nTI  - Crystal structure of the receptor binding domain of the spike glycoprotein of human betacoronavirus HKU1\nT2  - Nat. Commun\nVL  - 8\nSP  - 2529\nDO  - 10.1038/ncomms15216\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Pallesen, J.\nAU  - Wang, N.\nAU  - Corbett, K.S.\nAU  - Wrapp, D.\nAU  - Kirchdoerfer, R.N.\nAU  - Turner, H.L.\nPY  - 2017\nDA  - 2017\nTI  - Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen\nT2  - Proc. Natl. Acad. Sci. U. S. A\nVL  - 114\nSP  - 7348\nEP  - 7357\nDO  - 10.1073/pnas.1707304114\nC1  - true\nLA  - \nER  - \n\nTY  - GEN\nAU  - Pedersen, N.C.\nPY  - 2014\nDA  - 2014\nTI  - An update on feline infectious peritonitis: virology and immunopathogenesis. Vet\nSP  - 123\nEP  - 132\nDO  - 10.1016/j.tvjl.2014.04.017\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Pimentel, T.A.\nAU  - Yan, Z.\nAU  - Jeffers, S.A.\nAU  - Holmes, K.V.\nAU  - Hodges, R.S.\nAU  - Burkhard, P.\nPY  - 2009\nDA  - 2009\nTI  - Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine\nT2  - Chem. Biol. Drug Des\nVL  - 73\nSP  - 53\nEP  - 61\nDO  - 10.1111/j.1747-0285.2008.00746.x\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Poon, L.L.\nAU  - Chu, D.K.\nAU  - Chan, K.H.\nAU  - Wong, O.K.\nAU  - Ellis, T.M.\nAU  - Leung, Y.H.\nPY  - 2005\nDA  - 2005\nTI  - Identification of a novel coronavirus in bats\nT2  - J. Virol\nVL  - 79\nSP  - 2001\nEP  - 2009\nDO  - 10.1128/jvi.79.4.2001-2009.2005\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Qiu, M.\nAU  - Shi, Y.\nAU  - Guo, Z.\nAU  - Chen, Z.\nAU  - He, R.\nAU  - Chen, R.\nPY  - 2005\nDA  - 2005\nTI  - Antibody responses to individual proteins of SARS coronavirus and their neutralization activities\nT2  - Microbes Infect\nVL  - 7\nSP  - 882\nEP  - 889\nDO  - 10.1016/j.micinf.2005.02.006\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Raj, V.S.\nAU  - Mou, H.\nAU  - Smits, S.L.\nAU  - Dekkers, D.H.\nAU  - Muller, M.A.\nAU  - Dijkman, R.\nPY  - 2013\nDA  - 2013\nTI  - Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC\nT2  - Nature\nVL  - 495\nSP  - 251\nEP  - 254\nDO  - 10.1038/nature12005\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Regamey, N.\nAU  - Kaiser, L.\nAU  - Roiha, H.L.\nAU  - Deffernez, C.\nAU  - Kuehni, C.E.\nAU  - Latzin, P.\nPY  - 2008\nDA  - 2008\nTI  - Viral etiology of acute respiratory infections with cough in infancy A community-based birth cohort study\nT2  - Pediatr. Infect. Dis. J\nVL  - 27\nSP  - 100\nEP  - 105\nDO  - 10.1097/INF.0b013e31815922c8\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Reusken, C.B.\nAU  - Haagmans, B.L.\nAU  - Muller, M.A.\nAU  - Gutierrez, C.\nAU  - Godeke, G.J.\nAU  - Meyer, B.\nPY  - 2013\nDA  - 2013\nTI  - Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study\nT2  - Lancet Infect. Dis\nVL  - 13\nSP  - 859\nEP  - 866\nDO  - 10.1016/s1473-3099(13)70164-6\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Rota, P.A.\nAU  - Oberste, M.S.\nAU  - Monroe, S.S.\nAU  - Nix, W.A.\nAU  - Campagnoli, R.\nAU  - Icenogle, J.P.\nPY  - 2003\nDA  - 2003\nTI  - Characterization of a novel coronavirus associated with severe acute respiratory syndrome\nT2  - Science\nVL  - 300\nSP  - 1394\nEP  - 1399\nDO  - 10.1126/science.1085952\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Scobey, T.\nAU  - Yount, B.L.\nAU  - Sims, A.C.\nAU  - Donaldson, E.F.\nAU  - Agnihothram, S.S.\nAU  - Menachery, V.D.\nPY  - 2013\nDA  - 2013\nTI  - Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus\nT2  - Proc. Natl. Acad. Sci. U. S. A\nVL  - 110\nSP  - 16157\nEP  - 16162\nDO  - 10.1073/pnas.1311542110\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Severance, E.G.\nAU  - Bossis, I.\nAU  - Dickerson, F.B.\nAU  - Stallings, C.R.\nAU  - Origoni, A.E.\nAU  - Sullens, A.\nPY  - 2008\nDA  - 2008\nTI  - Development of a nucleocapsid-based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a US metropolitan population\nT2  - Clin. Vaccine Immunol\nVL  - 15\nSP  - 1805\nEP  - 1810\nDO  - 10.1128/cvi.00124-08\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Shao, X.\nAU  - Guo, X.\nAU  - Esper, F.\nAU  - Weibel, C.\nAU  - Kahn, J.S.\nPY  - 2007\nDA  - 2007\nTI  - Seroepidemiology of group I human coronaviruses in children\nT2  - J. Clin. Virol\nVL  - 40\nSP  - 207\nEP  - 213\nDO  - 10.1016/j.jcv.2007.08.007\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Snijder, E.J.\nAU  - Bredenbeek, P.J.\nAU  - Dobbe, J.C.\nAU  - Thiel, V.\nAU  - Ziebuhr, J.\nAU  - Poon, L.L.\nPY  - 2003\nDA  - 2003\nTI  - Unique and conserved features of genome and proteome of SARScoronavirus, an early split-off from the coronavirus group 2 lineage\nT2  - J. Mol. Biol\nVL  - 331\nSP  - 991\nEP  - 1004\nDO  - 10.1016/s0022-2836(03)00865-9\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Snijder, E.J.\nAU  - Decroly, E.\nAU  - Ziebuhr, J.\nPY  - 2016\nDA  - 2016\nTI  - The nonstructural proteins directing coronavirus RNA synthesis and processing\nT2  - Adv. Virus Res\nVL  - 96\nSP  - 59\nDO  - 126. doi: 10.1016/bs.aivir.2016.08.008\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Tai, W.\nAU  - Wang, Y.\nAU  - Fett, C.A.\nAU  - Zhao, G.\nAU  - Li, F.\nAU  - Perlman, S.\nPY  - 2017\nDA  - 2017\nTI  - Recombinant receptor-binding domains of multiple middle east respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants\nT2  - J. Virol\nVL  - 91\nSP  - 01651\nEP  - 16\nDO  - 10.1128/jvi.01651-16\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Tai, W.\nAU  - Zhao, G.\nAU  - Sun, S.\nAU  - Guo, Y.\nAU  - Wang, Y.\nAU  - Tao, X.\nPY  - 2016\nDA  - 2016\nTI  - A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection\nT2  - Virology\nVL  - 499\nSP  - 375\nEP  - 382\nDO  - 10.1016/j.virol.2016.10.005\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Tang, J.\nAU  - Zhang, N.\nAU  - Tao, X.\nAU  - Zhao, G.\nAU  - Guo, Y.\nAU  - Tseng, C.T.\nPY  - 2015\nDA  - 2015\nTI  - Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus\nT2  - Hum. Vaccin. Immunother\nVL  - 11\nSP  - 1244\nEP  - 1250\nDO  - 10.1080/21645515.2015.1021527\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Tomar, S.\nAU  - Johnston, M.L.\nAU  - St John, S.E.\nAU  - Osswald, H.L.\nAU  - Nyalapatla, P.R.\nAU  - Paul, L.N.\nPY  - 2015\nDA  - 2015\nTI  - Ligand-induced dimerization of Middle East respiratory syndrome (MERS) coronavirus nsp5 protease\nPB  - \nT2  - J. Biol. Chem\nVL  - 290\nSP  - 19403\nEP  - 19422\nDO  - 10.1074/jbc. M115.651463\nC1  - true\nT2  - implifications for nsp5 regulation and the development of antivirals\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Tortorici, M.A.\nAU  - Walls, A.C.\nAU  - Lang, Y.\nAU  - Wang, C.\nAU  - Li, Z.\nAU  - Koerhuis, D.\nPY  - 2019\nDA  - 2019\nTI  - Structural basis for human coronavirus attachment to sialic acid receptors\nT2  - Nat. Struct. Mol. Biol\nVL  - 26\nSP  - \"481\nEP  - 489.\" # \"10.3201/eid1012.040520\" # \"10.1136/bmj.1.5448.1467\" # \"10.1086/374222\"\nDO  - 10.1038/s41594-0190233-y\nC1  - Tu, C., Crameri, G., Kong, X., Chen, J., Sun, Y., Yu, M., et al. Tyrrell, D. A., and Bynoe, M. L. Vabret, A., Mourez, T., Gouarin, S., Petitjean, J., and Freymuth, F.\nC1  - true\nT2  - Antibodies to SARS coronavirus in civets\nC1  - Emerg. Infect. Dis.10, Br. Med. J.1, Clin. Infect. Dis.36,\nC1  - 2244\u20132248.doi: 1467\u20131470.doi: 985\u2013989.doi:\nC1  - 10.3201/eid1012.040520 10.1136/bmj.1.5448.1467 10.1086/374222\nLA  - \nER  - \n\nTY  - BOOK\nAU  - van Boheemen, S.\nAU  - de Graaf, M.\nAU  - Lauber, C.\nAU  - Bestebroer, T.M.\nAU  - Raj, V.S.\nAU  - Zaki, A.M.\nPY  - 2012\nDA  - 2012\nTI  - Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans\nPB  - mBio 3: e0047312\nDO  - 10.1128/mBio.00473-12\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - van der Hoek, L.\nAU  - Pyrc, K.\nAU  - Jebbink, M.F.\nAU  - Vermeulen-Oost, W.\nAU  - Berkhout, R.J.\nAU  - Wolthers, K.C.\nPY  - 2004\nDA  - 2004\nTI  - Identification of a new human coronavirus\nT2  - Nat. Med\nVL  - 10\nSP  - 368\nEP  - 373\nDO  - 10.1038/nm1024\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Veit, S.\nAU  - Jany, S.\nAU  - Fux, R.\nAU  - Sutter, G.\nAU  - Volz, A.\nPY  - 2018\nDA  - 2018\nTI  - CD8+ T cells responding to the Middle East Respiratory Syndrome coronavirus nucleocapsid protein delivered by vaccinia virus MVA in mice\nPB  - Viruses 10: E718\nDO  - doi\nA2  - Zheng, X.\nA2  - Gai, W.\nA2  - Zhao, Y.\nA2  - Wang, H.\nA2  - Wang, H.\nT2  - Oncotarget\nVL  - 8\nSP  - 10\nEP  - 18632\nT2  - MERSCoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques\nC1  - 10.3390/v10120718 Wang, C.,\nC1  - true\nIS  - 12686\u201312694\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Wang, L.\nAU  - Shi, W.\nAU  - Joyce, M.G.\nAU  - Modjarrad, K.\nAU  - Zhang, Y.\nAU  - Leung, K.\nPY  - 2015\nDA  - 2015\nTI  - Evaluation of candidate vaccine approaches for MERS-CoV\nT2  - Nat. Commun\nVL  - 6\nSP  - 7712\nDO  - 10.1038/ncomms8712\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Wang, N.\nAU  - Shi, X.\nAU  - Jiang, L.\nAU  - Zhang, S.\nAU  - Wang, D.\nAU  - Tong, P.\nPY  - 2013\nDA  - 2013\nTI  - Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4\nT2  - Cell Res\nVL  - 23\nSP  - \"986\nEP  - 993.\" # \"10.1080/21645515.2017.1296994\" # \"C300520200\" # \"884\nDO  - 10.1038/cr.2013.92\nC1  - Wang, Y., Tai, W., Yang, J., Zhao, G., Sun, S., Tseng, C. K., et al. Wong, S. K., Li, W., Moore, M. J., Choe, H., and Farzan, M. Woo, P. C., Lau, S. K., Chu, C. M., Chan, K. H., Tsoi, H.\nC1  - true\nT2  - Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection\nC1  - Hum. Vaccin. Immunother.13, J. Biol. Chem.279, W., Huang, Y., et al. J.\nC1  - 1615\u20131624.doi: 3197\u20133201.doi: 10.1074/jbc. Virol.79,\nC1  - 10.1080/21645515.2017.1296994 C300520200 884\u2013895.doi: 10.1128/jvi.79.2.884-895.2005\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Woo, P.C.\nAU  - Lau, S.K.\nAU  - Lam, C.S.\nAU  - Lai, K.K.\nAU  - Huang, Y.\nAU  - Lee, P.\nPY  - 2009\nDA  - 2009\nTI  - Comparative analysis of complete genome sequences of three avian coronaviruses reveals a novel group 3c coronavirus\nT2  - J. Virol\nVL  - 83\nSP  - 908\nEP  - 917\nDO  - 10.1128/jvi.01977-08\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Woo, P.C.\nAU  - Lau, S.K.\nAU  - Lam, C.S.\nAU  - Lau, C.C.\nAU  - Tsang, A.K.\nAU  - Lau, J.H.\nPY  - 2012\nDA  - 2012\nTI  - Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus\nT2  - J. Virol\nVL  - 86\nSP  - 3995\nEP  - 4008\nDO  - 10.1128/jvi.06540-11\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Woo, P.C.\nAU  - Lau, S.K.\nAU  - Lam, C.S.\nAU  - Tsang, A.K.\nAU  - Hui, S.W.\nAU  - Fan, R.Y.\nPY  - 2014\nDA  - 2014\nTI  - Discovery of a novel bottlenose dolphin coronavirus reveals a distinct species of marine mammal coronavirus in gammacoronavirus\nT2  - J. Virol\nVL  - 88\nSP  - 1318\nEP  - 1331\nDO  - 10.1128/jvi.02351-13\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Woo, P.C.\nAU  - Lau, S.K.\nAU  - Yip, C.C.\nAU  - Huang, Y.\nAU  - Yuen, K.Y.\nPY  - 2009\nDA  - 2009\nTI  - More and more coronaviruses: human coronavirus HKU1\nT2  - Viruses\nVL  - 1\nSP  - 57\nEP  - 71\nDO  - 10.3390/v1010057\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Yang, Y.\nAU  - Deng, Y.\nAU  - Wen, B.\nAU  - Wang, H.\nAU  - Meng, X.\nAU  - Lan, J.\nPY  - 2014\nDA  - 2014\nTI  - The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents\nT2  - Viral Immunol\nVL  - 27\nSP  - 543\nEP  - 550\nDO  - 10.1089/vim.2014.0080\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Yang, Y.\nAU  - Du, L.\nAU  - Liu, C.\nAU  - Wang, L.\nAU  - Ma, C.\nAU  - Tang, J.\nPY  - 2014\nDA  - 2014\nTI  - Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-tohuman transmission of MERS coronavirus\nT2  - Proc. Natl. Acad. Sci. U. S. A\nVL  - 111\nSP  - 12516\nEP  - 12521\nDO  - 10.1073/pnas.1405889111\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Yang, Z.Y.\nAU  - Kong, W.P.\nAU  - Huang, Y.\nAU  - Roberts, A.\nAU  - Murphy, B.R.\nAU  - Subbarao, K.\nPY  - 2004\nDA  - 2004\nTI  - A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice\nT2  - Nature\nVL  - 428\nSP  - 561\nEP  - 564\nDO  - 10.1038/nature02463\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Yuan, Y.\nAU  - Cao, D.\nAU  - Zhang, Y.\nAU  - Ma, J.\nAU  - Qi, J.\nAU  - Wang, Q.\nPY  - 2017\nDA  - 2017\nTI  - CryoEM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains\nT2  - Nat. Commun\nVL  - 8\nSP  - 15092\nDO  - 10.1038/ncomms15092\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zakhartchouk, A.N.\nAU  - Sharon, C.\nAU  - Satkunarajah, M.\nAU  - Auperin, T.\nAU  - Viswanathan, S.\nAU  - Mutwiri, G.\nPY  - 2007\nDA  - 2007\nTI  - Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine\nT2  - Vaccine\nVL  - 25\nSP  - 136\nEP  - 143\nDO  - 10.1016/j.vaccine.2006.06.084\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zaki, A.M.\nAU  - van Boheemen, S.\nAU  - Bestebroer, T.M.\nAU  - Osterhaus, A.D.\nAU  - Fouchier, R.A.\nPY  - 2012\nDA  - 2012\nTI  - Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia\nT2  - N. Engl. J. Med\nVL  - 367\nSP  - 1814\nEP  - 1820\nDO  - 10.1056/NEJMoa1211721\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zeng, F.\nAU  - Chow, K.Y.\nAU  - Hon, C.C.\nAU  - Law, K.M.\nAU  - Yip, C.W.\nAU  - Chan, K.H.\nPY  - 2004\nDA  - 2004\nTI  - Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments\nT2  - Biochem. Biophys. Res. Commun\nVL  - 315\nSP  - 1134\nEP  - 1139\nDO  - 10.1016/j.bbrc.2004.01.166\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zhang, N.\nAU  - Channappanavar, R.\nAU  - Ma, C.\nAU  - Wang, L.\nAU  - Tang, J.\nAU  - Garron, T.\nPY  - 2016\nDA  - 2016\nTI  - Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus\nT2  - Cell. Mol. Immunol\nVL  - 13\nSP  - 180\nEP  - 190\nDO  - 10.1038/cmi.2015.03\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zhang, N.\nAU  - Jiang, S.\nAU  - Du, L.\nPY  - 2014\nDA  - 2014\nTI  - Current advancements and potential strategies in the development of MERS-CoV vaccines\nT2  - Expert Rev. Vaccines\nVL  - 13\nSP  - 761\nEP  - 774\nDO  - 10.1586/14760584.2014.912134\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zhang, N.\nAU  - Tang, J.\nAU  - Lu, L.\nAU  - Jiang, S.\nAU  - Du, L.\nPY  - 2015\nDA  - 2015\nTI  - Receptor-binding domainbased subunit vaccines against MERS-CoV\nT2  - Virus Res\nVL  - 202\nSP  - 151\nEP  - 159\nDO  - 10.1016/j.virusres.2014.11.013\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zhang, N.\nAU  - Wang, L.\nAU  - Deng, X.\nAU  - Liang, R.\nAU  - Su, M.\nAU  - He, C.\nPY  - 2020\nDA  - 2020\nTI  - Recent advances in the detection of respiratory virus infection in humans\nT2  - J. Med. Virol. [Epub\nPB  - ahead of print\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zheng, N.\nAU  - Xia, R.\nAU  - Yang, C.\nAU  - Yin, B.\nAU  - Li, Y.\nAU  - Duan, C.\nPY  - 2009\nDA  - 2009\nTI  - Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice\nT2  - Vaccine\nVL  - 27\nSP  - 5001\nEP  - 5007\nDO  - 10.1016/j.vaccine.2009.05.073\nC1  - true\nLA  - \nER  - \n\nTY  - CHAP\nAU  - Zhong, N.S.\nAU  - Zheng, B.J.\nAU  - Li, Y.M.\nAU  - Poon, L.L.\nAU  - Xie, Z.H.\nAU  - Chan, K.H.\nPY  - 2003\nDA  - 2003\nTI  - Epidemiology and cause of severe acute respiratory syndrome\nT2  - (SARS) in Guangdong, People\u2019s Republic of China, in February\nVL  - 362\nSP  - 1353\nEP  - 1358\nDO  - 10.1016/s0140-6736(03)14630-2\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zhou, P.\nAU  - Yang, X.L.\nAU  - Wang, X.G.\nAU  - Hu, B.\nAU  - Zhang, L.\nAU  - Zhang, W.\nPY  - 2020\nDA  - 2020\nTI  - A pneumonia outbreak associated with a new coronavirus of probable bat origin\nT2  - Nature\nN1  - Epub ahead of print\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zhou, Y.\nAU  - Jiang, S.\nAU  - Du, L.\nPY  - 2018\nDA  - 2018\nTI  - Prospects for a MERS-CoV spike vaccine\nT2  - Expert Rev. Vaccines\nVL  - 17\nSP  - 677\nEP  - 686\nDO  - 10.1080/14760584.2018.150 6702\nLA  - \nER  - \n\nTY  - BOOK\nAU  - Zhou, Y.\nAU  - Yang, Y.\nAU  - Huang, J.\nAU  - Jiang, S.\nAU  - Du, L.\nPY  - 2019\nDA  - 2019\nTI  - Advances in MERSCoV vaccines and therapeutics based on the receptor-binding domain\nPB  - Viruses 11: E60\nDO  - 10.3390/v11010060\nLA  - \nER  - \n\nTY  - GEN\nAU  - Zhu, N.\nAU  - Zhang, D.\nAU  - Wang, W.\nAU  - Li, X.\nAU  - Yang, B.\nAU  - Song, J.\nPY  - 2020\nDA  - 2020\nTI  - A novel coronavirus from patients with pneumonia in China, 2019\nA2  - Med, N.Engl J.\nN1  - Epub ahead of print\nC1  - true\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Zhu, X.\nAU  - Liu, Q.\nAU  - Du, L.\nAU  - Lu, L.\nAU  - Jiang, S.\nPY  - 2013\nDA  - 2013\nTI  - Receptor-binding domain as a target for developing SARS vaccines\nT2  - J. Thoracic Dis\nVL  - 5\nSP  - 142\nEP  - 148\nDO  - 10.3978/j.issn.2072-1439.2013.06.06\nLA  - \nER  - \n\n",
        "author_conclusions": [],
        "table_captions": [
            {
                "id": "1",
                "caption": "Subunit Vaccines against SARS-CoVa. Continued"
            },
            {
                "id": "2",
                "caption": "Subunit Vaccines against MERS-CoVa"
            }
        ],
        "figure_captions": [
            {
                "id": "1",
                "caption": "Phylogenetic tree of coronaviruses (CoVs) based on the nucleotide sequences of RNA dependent RNA polymerase (RdRp). The Tree, with 1,000 bootstrap values, was constructed by the maximum likelihood method using MEGA 6. The four main phylogenetic clusters correspond to genera alpha-CoV, beta-CoV, gamma-CoV, and delta-CoV. Each CoV genus contains different subgenera. The letters in blue indicate human CoVs"
            },
            {
                "id": "2",
                "caption": "Schematic structure of SARS-CoV, MERS-CoV, and 2019-nCoV. (A) Schematic diagram of genomic organization of SARS-CoV, MERS-CoV, and 2019-nCoV. The genomic regions or open-reading frames (ORFs) are compared. Structural proteins, including spike (S), envelope (E), membrane (M) and nucleocapsid (N) proteins, as well as non-structural proteins translated from ORF 1a and ORF 1b and accessory proteins, including 3a, 3b, 6, 7a, 7b, 8a, 8b, and 9b (for SARS-CoV), 3, 4a, 4b, 5, and 8b (for MERS-CoV), and 3a, 6, 7a, 7b, 8, and 10 (for 2019-nCoV) are indicated. 5 -UTR and 3 -UTR, untranslated regions at the Nand C-terminal regions, respectively. Kb, kilobase pair. (B) Schematic structure of virion of SARS-CoV, MERS-CoV, and 2019-nCoV and its major structural proteins"
            },
            {
                "id": "S1",
                "caption": "Structures of SARS-CoV and MERS-CoV S proteins, RBDs, and their complexes with respective receptor. Trimeric S proteins of SARS-CoV (PDB: 5\u00d75b) (A) and MERS-CoV (PDB: 5\u00d75f) (C) are colored differently for each monomer. Two conformations of the RBD in each trimeric S protein are labeled as standing and lying states. The RBDs of each S protein are shown as light blue on the right panel. ACE2 and DPP4 receptors are respectively modeled to the trimeric S proteins by match-alignment of SARS-CoV RBD-ACE2 complex (PDB: 2AJF) to SARS-CoV S trimer (B) or MERS-CoV RBD-DPP4 complex (PDB: 4kr0) to MERS-CoV S trimer (D). Each of the RBD-receptor complexes is shown on the right panel. ACE2, angiotensin-converting enzyme 2; DPP4, dipeptidyl peptidase 4; RBD, receptor-binding domain; S, spike"
            }
        ],
        "tables_url": "https://scholarcy.nyc3.digitaloceanspaces.com/tables/docker-test/013cfc70858e0ba4113be5b05a5a1633.xlsx",
        "figure_urls": [
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/013cfc70858e0ba4113be5b05a5a1633/img-000.png",
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/013cfc70858e0ba4113be5b05a5a1633/img-001.png"
        ]
    },
    "sections": {
        "introduction": [
            "Coronaviruses (CoVs) belong to the subfamily Othocoronavirinae, in the family Coronaviridae of the order Nidovirales. According to the 10th Report on Virus Taxonomy from the International Committee on Taxonomy of Viruses (ICTV), the Othocoronavirinae is comprised of four genera, including alphacoronavirus (alpha-CoV), betacoronavirus (beta-CoV), gammacoronavirus<br/><br/>Subunit Vaccines Against Coronaviruses (gamma-CoV), and deltacoronavirus (delta-CoV) (<a class=\"ref-link\" id=\"cKing_et+al_2018_a\" href=\"#rKing_et+al_2018_a\">King et al, 2018</a>). Alpha- and beta-CoVs can infect mammals, including but not limited to bats, pigs, cats, mice, and humans (<a class=\"ref-link\" id=\"cKusanagi_et+al_1992_a\" href=\"#rKusanagi_et+al_1992_a\">Kusanagi et al, 1992</a>; <a class=\"ref-link\" id=\"cLi_et+al_2005_b\" href=\"#rLi_et+al_2005_b\">Li et al, 2005b</a>; <a class=\"ref-link\" id=\"cPoon_et+al_2005_a\" href=\"#rPoon_et+al_2005_a\">Poon et al, 2005</a>; <a class=\"ref-link\" id=\"cDrexler_et+al_2014_a\" href=\"#rDrexler_et+al_2014_a\">Drexler et al, 2014</a>; <a class=\"ref-link\" id=\"cPedersen_2014_a\" href=\"#rPedersen_2014_a\">Pedersen, 2014</a>; <a class=\"ref-link\" id=\"cKudelova_et+al_2015_a\" href=\"#rKudelova_et+al_2015_a\">Kudelova et al, 2015</a>; <a class=\"ref-link\" id=\"cCui_et+al_2019_a\" href=\"#rCui_et+al_2019_a\">Cui et al, 2019</a>). Gamma- and delta-CoVs usually infect birds, while some of them could infect mammals (<a class=\"ref-link\" id=\"cWoo_et+al_2009_a\" href=\"#rWoo_et+al_2009_a\">Woo et al, 2009a</a>, 2012, 2014; <a class=\"ref-link\" id=\"cMa_et+al_2015_a\" href=\"#rMa_et+al_2015_a\">Ma et al, 2015</a>). Since the late sixties, CoVs have been recognized as one of the viral sources responsible for the common cold. Among all CoVs identified so far, seven have the ability to infect humans, including human coronavirus 229E (HCoV-229E) and human coronavirus NL63 (HCoV-NL63), which belong to alpha-CoVs (Hamre and Procknow, 1966; <a class=\"ref-link\" id=\"cChiu_et+al_2005_a\" href=\"#rChiu_et+al_2005_a\">Chiu et al, 2005</a>), as well as human coronavirus OC43 (HCoV-OC43), human coronavirus HKU1 (HCoV-HKU1), severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and the newly emerged coronavirus (2019-nCoV), which are known to be beta-CoVs (<a class=\"ref-link\" id=\"cDrosten_et+al_2003_a\" href=\"#rDrosten_et+al_2003_a\">Drosten et al, 2003</a>; <a class=\"ref-link\" id=\"cKsiazek_et+al_2003_a\" href=\"#rKsiazek_et+al_2003_a\">Ksiazek et al, 2003</a>; Vabret et al, 2003; Woo et al, 2005; <a class=\"ref-link\" id=\"cZaki_et+al_2012_a\" href=\"#rZaki_et+al_2012_a\">Zaki et al, 2012</a>; <a class=\"ref-link\" id=\"cDu_et+al_2016_b\" href=\"#rDu_et+al_2016_b\">Du et al, 2016b</a>; <a class=\"ref-link\" id=\"cZhang_et+al_2020_a\" href=\"#rZhang_et+al_2020_a\">Zhang et al, 2020</a>; <a class=\"ref-link\" id=\"cZhu_et+al_2020_a\" href=\"#rZhu_et+al_2020_a\">Zhu et al, 2020</a>) (Figure 1)."
        ],
        "funding": [
            "This work was supported by the NIH grants R01AI137472 and R01AI139092."
        ],
        "supplementary": [
            "MATERIAL<br/><br/>The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb. 2020.00298/full#supplementary-material"
        ],
        "disclosures": [
            "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."
        ],
        "data_availability": [
            "Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb.2020.00298/full#supplementary-material"
        ],
        "supplementary_references": {
            "supplementary_data_references": [
                "Supplementary Material"
            ],
            "supplementary_figure_references": [
                "Supplementary Figures S1A,B.",
                "Supplementary Figures S1C,D."
            ]
        }
    },
    "structured_content": {
        "INTRODUCTION": [
            "Coronaviruses (CoVs) belong to the subfamily Othocoronavirinae, in the family Coronaviridae of the order Nidovirales. According to the 10th Report on Virus Taxonomy from the International Committee on Taxonomy of Viruses (ICTV), the Othocoronavirinae is comprised of four genera, including alphacoronavirus (alpha-CoV), betacoronavirus (beta-CoV), gammacoronavirus",
            "Subunit Vaccines Against Coronaviruses (gamma-CoV), and deltacoronavirus (delta-CoV) (<a class=\"ref-link\" id=\"cKing_et+al_2018_a\" href=\"#rKing_et+al_2018_a\">King et al, 2018</a>). Alpha- and beta-CoVs can infect mammals, including but not limited to bats, pigs, cats, mice, and humans (<a class=\"ref-link\" id=\"cKusanagi_et+al_1992_a\" href=\"#rKusanagi_et+al_1992_a\">Kusanagi et al, 1992</a>; <a class=\"ref-link\" id=\"cLi_et+al_2005_b\" href=\"#rLi_et+al_2005_b\">Li et al, 2005b</a>; <a class=\"ref-link\" id=\"cPoon_et+al_2005_a\" href=\"#rPoon_et+al_2005_a\">Poon et al, 2005</a>; <a class=\"ref-link\" id=\"cDrexler_et+al_2014_a\" href=\"#rDrexler_et+al_2014_a\">Drexler et al, 2014</a>; <a class=\"ref-link\" id=\"cPedersen_2014_a\" href=\"#rPedersen_2014_a\">Pedersen, 2014</a>; <a class=\"ref-link\" id=\"cKudelova_et+al_2015_a\" href=\"#rKudelova_et+al_2015_a\">Kudelova et al, 2015</a>; <a class=\"ref-link\" id=\"cCui_et+al_2019_a\" href=\"#rCui_et+al_2019_a\">Cui et al, 2019</a>). Gamma- and delta-CoVs usually infect birds, while some of them could infect mammals (<a class=\"ref-link\" id=\"cWoo_et+al_2009_a\" href=\"#rWoo_et+al_2009_a\">Woo et al, 2009a</a>, 2012, 2014; <a class=\"ref-link\" id=\"cMa_et+al_2015_a\" href=\"#rMa_et+al_2015_a\">Ma et al, 2015</a>). Since the late sixties, CoVs have been recognized as one of the viral sources responsible for the common cold. Among all CoVs identified so far, seven have the ability to infect humans, including human coronavirus 229E (HCoV-229E) and human coronavirus NL63 (HCoV-NL63), which belong to alpha-CoVs (Hamre and Procknow, 1966; <a class=\"ref-link\" id=\"cChiu_et+al_2005_a\" href=\"#rChiu_et+al_2005_a\">Chiu et al, 2005</a>), as well as human coronavirus OC43 (HCoV-OC43), human coronavirus HKU1 (HCoV-HKU1), severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and the newly emerged coronavirus (2019-nCoV), which are known to be beta-CoVs (<a class=\"ref-link\" id=\"cDrosten_et+al_2003_a\" href=\"#rDrosten_et+al_2003_a\">Drosten et al, 2003</a>; <a class=\"ref-link\" id=\"cKsiazek_et+al_2003_a\" href=\"#rKsiazek_et+al_2003_a\">Ksiazek et al, 2003</a>; Vabret et al, 2003; Woo et al, 2005; <a class=\"ref-link\" id=\"cZaki_et+al_2012_a\" href=\"#rZaki_et+al_2012_a\">Zaki et al, 2012</a>; <a class=\"ref-link\" id=\"cDu_et+al_2016_b\" href=\"#rDu_et+al_2016_b\">Du et al, 2016b</a>; <a class=\"ref-link\" id=\"cZhang_et+al_2020_a\" href=\"#rZhang_et+al_2020_a\">Zhang et al, 2020</a>; <a class=\"ref-link\" id=\"cZhu_et+al_2020_a\" href=\"#rZhu_et+al_2020_a\">Zhu et al, 2020</a>) (Figure 1).",
            "Four human CoVs, including HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1, have been identified in humans, but without causing severe infections. HCoV-229E was isolated from nasal secretions of medical students with minor upper respiratory disease. This virus was an original isolate, and was first reported in the 1960s (Hamre and Procknow, 1966). In addition to HCoV-229E, several studies have reported the recovery of HCoV-OC43 from patients with upper respiratory tract illness (Tyrrell and Bynoe, 1965; Hamre et al, 1967; <a class=\"ref-link\" id=\"cMcintosh_et+al_1967_a\" href=\"#rMcintosh_et+al_1967_a\">McIntosh et al, 1967</a>; Kapikian et al, 1969). In 2004, HCoV-NL63 was isolated from clinical species of infants suffering from pneumonia or bronchiolitis, and characterized for its ability to infect human respiratory tract (<a class=\"ref-link\" id=\"cFouchier_et+al_2004_a\" href=\"#rFouchier_et+al_2004_a\"><a class=\"ref-link\" id=\"cFouchier_et+al_2004_a\" href=\"#rFouchier_et+al_2004_a\">Fouchier et al, 2004</a></a>; <a class=\"ref-link\" id=\"cvan_der_Hoek_et+al_2004_a\" href=\"#rvan_der_Hoek_et+al_2004_a\">van der Hoek et al, 2004</a>). The subsequent study in 2005 identified a new member of CoVs, named HCoV-HKU1, from a 71-year-old man with pneumonia (Woo et al, 2005). Generally, these four viruses are the most common pathogens causing mild upper respiratory infection or asymptomatic infection, and count for about 30% of all colds (<a class=\"ref-link\" id=\"cMyint_1994_a\" href=\"#rMyint_1994_a\">Myint, 1994</a>; <a class=\"ref-link\" id=\"cLau_et+al_2006_a\" href=\"#rLau_et+al_2006_a\"><a class=\"ref-link\" id=\"cLau_et+al_2006_a\" href=\"#rLau_et+al_2006_a\">Lau et al, 2006</a></a>; <a class=\"ref-link\" id=\"cKim_et+al_2017_a\" href=\"#rKim_et+al_2017_a\">Kim et al, 2017</a>). In the serological surveillance on healthy adults, HCoV-229E, HCoV-NL63, and HCoV-OC43 demonstrated more than 90% seropositive with the immunological assay. It appears common for these CoVs to infect children (<a class=\"ref-link\" id=\"cMourez_et+al_2007_a\" href=\"#rMourez_et+al_2007_a\">Mourez et al, 2007</a>; <a class=\"ref-link\" id=\"cShao_et+al_2007_a\" href=\"#rShao_et+al_2007_a\">Shao et al, 2007</a>; <a class=\"ref-link\" id=\"cSeverance_et+al_2008_a\" href=\"#rSeverance_et+al_2008_a\"><a class=\"ref-link\" id=\"cSeverance_et+al_2008_a\" href=\"#rSeverance_et+al_2008_a\">Severance et al, 2008</a></a>). In contrast to the above three human CoVs, HCoV-HKU1 has around 50% seropositive in healthy individuals and a relatively low exposure rate in children (<a class=\"ref-link\" id=\"cLehmann_et+al_2008_a\" href=\"#rLehmann_et+al_2008_a\">Lehmann et al, 2008</a>; <a class=\"ref-link\" id=\"cSeverance_et+al_2008_a\" href=\"#rSeverance_et+al_2008_a\"><a class=\"ref-link\" id=\"cSeverance_et+al_2008_a\" href=\"#rSeverance_et+al_2008_a\">Severance et al, 2008</a></a>). Although the prevalence of various CoVs is different, the incidence among these viruses shows no significant difference (<a class=\"ref-link\" id=\"cWoo_et+al_2009_b\" href=\"#rWoo_et+al_2009_b\">Woo et al, 2009b</a>). The afore-mentioned four CoVs have been detected in 2.1\u201317.9% of clinical specimens (<a class=\"ref-link\" id=\"cEsper_et+al_2006_a\" href=\"#rEsper_et+al_2006_a\">Esper et al, 2006</a>; <a class=\"ref-link\" id=\"cLau_et+al_2006_a\" href=\"#rLau_et+al_2006_a\"><a class=\"ref-link\" id=\"cLau_et+al_2006_a\" href=\"#rLau_et+al_2006_a\">Lau et al, 2006</a></a>; Gerna et al, 2007; <a class=\"ref-link\" id=\"cRegamey_et+al_2008_a\" href=\"#rRegamey_et+al_2008_a\">Regamey et al, 2008</a>; <a class=\"ref-link\" id=\"cMatoba_et+al_2015_a\" href=\"#rMatoba_et+al_2015_a\">Matoba et al, 2015</a>; <a class=\"ref-link\" id=\"cKillerby_et+al_2018_a\" href=\"#rKillerby_et+al_2018_a\">Killerby et al, 2018</a>). These viruses have also been associated with lower respiratory tract illness in children, elders, and immunodeficient individuals (<a class=\"ref-link\" id=\"cFalsey_et+al_2002_a\" href=\"#rFalsey_et+al_2002_a\">Falsey et al, 2002</a>; <a class=\"ref-link\" id=\"cFouchier_et+al_2004_a\" href=\"#rFouchier_et+al_2004_a\"><a class=\"ref-link\" id=\"cFouchier_et+al_2004_a\" href=\"#rFouchier_et+al_2004_a\">Fouchier et al, 2004</a></a>; Woo et al, 2005; <a class=\"ref-link\" id=\"cGerna_et+al_2006_a\" href=\"#rGerna_et+al_2006_a\">Gerna et al, 2006</a>). HCoV229E and HCoV-OC43 may lead to central nervous system infection since viral RNAs are detected in the brain of some patients (<a class=\"ref-link\" id=\"cArbour_et+al_2000_a\" href=\"#rArbour_et+al_2000_a\">Arbour et al, 2000</a>; <a class=\"ref-link\" id=\"cDesforges_et+al_2014_a\" href=\"#rDesforges_et+al_2014_a\">Desforges et al, 2014</a>).",
            "Unlike the above four human CoVs, SARS-CoV, MERSCoV, and 2019-nCoV have caused severe pneumonia and/or failure of other organs, even death, among infected populations (<a class=\"ref-link\" id=\"cNicholls_et+al_2003_a\" href=\"#rNicholls_et+al_2003_a\">Nicholls et al, 2003</a>; <a class=\"ref-link\" id=\"cZhong_et+al_2003_a\" href=\"#rZhong_et+al_2003_a\">Zhong et al, 2003</a>; <a class=\"ref-link\" id=\"cZaki_et+al_2012_a\" href=\"#rZaki_et+al_2012_a\">Zaki et al, 2012</a>; <a class=\"ref-link\" id=\"cZhu_et+al_2020_a\" href=\"#rZhu_et+al_2020_a\">Zhu et al, 2020</a>). The epidemic outbreak of SARS-CoV began in the Guangdong Province of China in November 2002, and spread through human-to-human transmission to other parts of the world within a few months (<a class=\"ref-link\" id=\"cKsiazek_et+al_2003_a\" href=\"#rKsiazek_et+al_2003_a\">Ksiazek et al, 2003</a>). From November 2002 to August 2003, SARS-CoV infected more than 8,098 people in 29 counties, resulting in over 774 deaths with \u223c10% fatality rate (Du et al, 2009a). Palm civets serving as a potential intermediate host of this virus were traced immediately (Tu et al, 2004). Chinese horseshoe bats (Rhinolophus sinicus) are the natural reservoir of SARS-CoV (<a class=\"ref-link\" id=\"cLi_et+al_2005_b\" href=\"#rLi_et+al_2005_b\">Li et al, 2005b</a>). Various bat SARS-related CoVs (SARSr-CoV) have been identified in Yunnan, China, several of which can infect human cells, and have been further characterized (<a class=\"ref-link\" id=\"cGe_et+al_2013_a\" href=\"#rGe_et+al_2013_a\">Ge et al, 2013</a>; Hu et al, 2017). These discoveries indicate the threat of re-emergence of SARSCoV or SARSr-CoV.",
            "A decade later, another highly pathogenic human CoV, MERS-CoV, emerged, and the first patient with MERS-CoV infection was reported in Saudi Arabia in June 2012 (<a class=\"ref-link\" id=\"cZaki_et+al_2012_a\" href=\"#rZaki_et+al_2012_a\"><a class=\"ref-link\" id=\"cZaki_et+al_2012_a\" href=\"#rZaki_et+al_2012_a\">Zaki et al, 2012</a></a>). By December 26, 2019, a total of 2,494 laboratoryconfirmed cases of MERS, including 858 associated deaths in 27 countries (fatality rate 34.4%), were reported to the WHO1. Globally, the majority (about 80%) of human cases have been reported in Saudi Arabia, where people get infected through direct contact with infected dromedary camels or persons2 (<a class=\"ref-link\" id=\"cZaki_et+al_2012_a\" href=\"#rZaki_et+al_2012_a\"><a class=\"ref-link\" id=\"cZaki_et+al_2012_a\" href=\"#rZaki_et+al_2012_a\">Zaki et al, 2012</a></a>). Isolation of MERS-CoV and detection of neutralizing antibodies from dromedary camels suggest that these camels are potentially an important intermediate host (<a class=\"ref-link\" id=\"cReusken_et+al_2013_a\" href=\"#rReusken_et+al_2013_a\">Reusken et al, 2013</a>; <a class=\"ref-link\" id=\"cAzhar_et+al_2014_a\" href=\"#rAzhar_et+al_2014_a\">Azhar et al, 2014</a>). Similar to SARSCoV, MERS-CoV is also an emerging zoonotic virus (<a class=\"ref-link\" id=\"cLi_2019_a\" href=\"#rLi_2019_a\">Li and Du, 2019</a>). Bats habituate several CoVs phylogenetically related to MERS-CoV, and some of them are identical to MERS-CoVs, suggesting that MERS-CoV may originate from bats (<a class=\"ref-link\" id=\"cAnnan_et+al_2013_a\" href=\"#rAnnan_et+al_2013_a\">Annan et al, 2013</a>; <a class=\"ref-link\" id=\"cLelli_et+al_2013_a\" href=\"#rLelli_et+al_2013_a\">Lelli et al, 2013</a>; <a class=\"ref-link\" id=\"cLau_et+al_2018_a\" href=\"#rLau_et+al_2018_a\">Lau et al, 2018</a>; <a class=\"ref-link\" id=\"cLuo_et+al_2018_a\" href=\"#rLuo_et+al_2018_a\">Luo et al, 2018a</a>). Different from SARS-CoV, which has not caused infections in humans since 2004 (Du et al, 2009a), the transmission of MERS-CoV has not been interrupted, and the infected human cases continue increasing1 (<a class=\"ref-link\" id=\"cMobaraki_2019_a\" href=\"#rMobaraki_2019_a\">Mobaraki and Ahmadzadeh, 2019</a>). Currently, human-to-human transmission of MERSCoV is limited.",
            "A new CoV, 2019-nCoV, has caught worldwide attention (<a class=\"ref-link\" id=\"cLiu_2020_a\" href=\"#rLiu_2020_a\">Liu and Saif, 2020</a>; <a class=\"ref-link\" id=\"cZhang_et+al_2020_a\" href=\"#rZhang_et+al_2020_a\">Zhang et al, 2020</a>). It was first identified in Wuhan, China in December 2019, from patients with pneumonia (<a class=\"ref-link\" id=\"cZhu_et+al_2020_a\" href=\"#rZhu_et+al_2020_a\">Zhu et al, 2020</a>), and has infected more than 70000 people globally, including 2,009 deaths (\u223c2.7% fatality",
            "1https://www.who.int/emergencies/mers-cov/en/ 2https://www.who.int/docs/default-source/coronaviruse/situation-reports/ 20200219-sitrep-30-covid-19.pdf?sfvrsn=6e50645_2",
            "rate), as of February 19, 2020, particularly in China, and the other parts of the world, including Australia, Japan, Malaysia, Singapore, South Korea, Viet Nam, Cambodia, Philippines, Thailand, Nepal, Sri Lanka, India, United States, Canada, France, Finland, Germany, Italy, Russian Federation, Spain, Sweden, United Kingdom, Belgium, Egypt, and United Arab Emirates3. Different from MERS-CoV but similar to SARS-CoV, 2019-nCoV can cause human-to-human transmission, and its intermediate host that leads to the current human infection and outbreak is still under investigation.",
            "3https://www.who.int/docs/default-source/coronaviruse/situation-reports/ 20200204-sitrep-15-ncov.pdf?sfvrsn=88fe8ad6_2",
            "GENOME OF EMERGING HUMAN CORONAVIRUSES, AS WELL AS STRUCTURE AND FUNCTION OF THEIR KEY PROTEINS",
            "The human CoVs are enveloped viruses with a positive-sense, single-stranded RNA genome. They are 80\u2013160 nm in diameter. Like other CoVs, human CoVs contain the largest viral genome [27\u201332 kilobase pairs (kb)] among the RNA viruses, and they share similar genome organization (<a class=\"ref-link\" id=\"cFehr_2015_a\" href=\"#rFehr_2015_a\"><a class=\"ref-link\" id=\"cFehr_2015_a\" href=\"#rFehr_2015_a\"><a class=\"ref-link\" id=\"cFehr_2015_a\" href=\"#rFehr_2015_a\"><a class=\"ref-link\" id=\"cFehr_2015_a\" href=\"#rFehr_2015_a\">Fehr and Perlman, 2015</a></a></a></a>). Two large overlapping open reading frames (ORFs), ORF 1a and ORF 1b, occupy two-thirds of the genome at the 5 -terminus, and a third of the genome at the 3 -terminus encodes four common structural proteins in the gene order of spike (S), envelope (E), membrane (M), and nucleocapsid (N) (5 \u20133 ) (<a class=\"ref-link\" id=\"cFehr_2015_a\" href=\"#rFehr_2015_a\"><a class=\"ref-link\" id=\"cFehr_2015_a\" href=\"#rFehr_2015_a\"><a class=\"ref-link\" id=\"cFehr_2015_a\" href=\"#rFehr_2015_a\"><a class=\"ref-link\" id=\"cFehr_2015_a\" href=\"#rFehr_2015_a\">Fehr and Perlman, 2015</a></a></a></a>). The large ORF 1ab is a replicase gene encoding polyproteins 1a (pp1a) and pp1b/1ab, which can be cleaved into 15\u201316 non-structural proteins (nsp2-nsp16 or nsp1-nsp16) by 3C-like proteinase (3CLpro, nsp5) and papain-like proteinase (PLpro, nsp3) (<a class=\"ref-link\" id=\"cBailey-Elkin_et+al_2014_a\" href=\"#rBailey-Elkin_et+al_2014_a\">Bailey-Elkin et al, 2014</a>; <a class=\"ref-link\" id=\"cFehr_2015_a\" href=\"#rFehr_2015_a\"><a class=\"ref-link\" id=\"cFehr_2015_a\" href=\"#rFehr_2015_a\"><a class=\"ref-link\" id=\"cFehr_2015_a\" href=\"#rFehr_2015_a\"><a class=\"ref-link\" id=\"cFehr_2015_a\" href=\"#rFehr_2015_a\">Fehr and Perlman, 2015</a></a></a></a>; <a class=\"ref-link\" id=\"cTomar_et+al_2015_a\" href=\"#rTomar_et+al_2015_a\">Tomar et al, 2015</a>; <a class=\"ref-link\" id=\"cSnijder_et+al_2016_a\" href=\"#rSnijder_et+al_2016_a\">Snijder et al, 2016</a>). In addition to the genes encoding the above structural proteins, the genes encoding accessory proteins have also been detected in the 3 region between S\u2013E\u2013M\u2013N (<a class=\"ref-link\" id=\"cFehr_2015_a\" href=\"#rFehr_2015_a\"><a class=\"ref-link\" id=\"cFehr_2015_a\" href=\"#rFehr_2015_a\"><a class=\"ref-link\" id=\"cFehr_2015_a\" href=\"#rFehr_2015_a\"><a class=\"ref-link\" id=\"cFehr_2015_a\" href=\"#rFehr_2015_a\">Fehr and Perlman, 2015</a></a></a></a>). Some beta-CoVs, such as HCoV-OC43 and HCoV-HKU1, contain hemagglutininesterase (HE) gene located between ORF 1ab and S gene encoding an additional structural protein, HE (<a class=\"ref-link\" id=\"cde_Groot_et+al_2011_a\" href=\"#rde_Groot_et+al_2011_a\">De Groot et al, 2011</a>; <a class=\"ref-link\" id=\"cDesforges_et+al_2013_a\" href=\"#rDesforges_et+al_2013_a\">Desforges et al, 2013</a>; Huang et al, 2015). Similar to other human CoVs, SARS-CoV possesses a \u223c29-kb genome, which encodes pp1a and pp1ab, four main structural proteins (S, E, M, and N), and eight accessory proteins, such as 3a, 3b, 6, 7a, 7b, 8a, 8b, and 9b (Figure 2A) (<a class=\"ref-link\" id=\"cMarra_et+al_2003_a\" href=\"#rMarra_et+al_2003_a\">Marra et al, 2003</a>; <a class=\"ref-link\" id=\"cSnijder_et+al_2003_a\" href=\"#rSnijder_et+al_2003_a\">Snijder et al, 2003</a>). The MERS-CoV genome is about 30 kb in length and encodes pp1a, pp1ab, four structural proteins (S, E, M, and N), and five accessory proteins (3, 4a, 4b, 5, and 8b) (Figure 2A) (<a class=\"ref-link\" id=\"cvan_Boheemen_et+al_2012_a\" href=\"#rvan_Boheemen_et+al_2012_a\">van Boheemen et al, 2012</a>). The genomic RNA of SARS-CoV and MERS-CoV is packed inside capsid formed by the N protein, while the M, E, and S proteins form the envelope surrounding the capsid (Figure 2B). Accessory genes may incorporate into virions at low levels (<a class=\"ref-link\" id=\"cLiu_et+al_2014_a\" href=\"#rLiu_et+al_2014_a\">Liu et al, 2014</a>). Nevertheless, neither SARS-CoV nor MERS-CoV appears to contain the HE gene (<a class=\"ref-link\" id=\"cRota_et+al_2003_a\" href=\"#rRota_et+al_2003_a\">Rota et al, 2003</a>; <a class=\"ref-link\" id=\"cZaki_et+al_2012_a\" href=\"#rZaki_et+al_2012_a\">Zaki et al, 2012</a>).",
            "Several proteins of human CoVs are important for viral infection and/or pathogenesis. For example, most nsps participate in viral RNA replication and/or transcription (<a class=\"ref-link\" id=\"cSnijder_et+al_2016_a\" href=\"#rSnijder_et+al_2016_a\">Snijder et al, 2016</a>). The accessory proteins interact with host cells, potentially helping the viruses to evade the immune system and increase their virulence (Menachery et al, 2017). The HE protein assists in the attachment of virus\u2013host cells, thus playing a key role in the production of infectious virions, as in the case of HCoV-OC43 (<a class=\"ref-link\" id=\"cDesforges_et+al_2013_a\" href=\"#rDesforges_et+al_2013_a\">Desforges et al, 2013</a>). The M and E proteins are responsible for virus assembly or promote virulence (<a class=\"ref-link\" id=\"cScobey_et+al_2013_a\" href=\"#rScobey_et+al_2013_a\">Scobey et al, 2013</a>; <a class=\"ref-link\" id=\"cDediego_et+al_2014_a\" href=\"#rDediego_et+al_2014_a\">DeDiego et al, 2014</a>). Different from the above proteins, the S protein of human CoVs mediates viral entry into host cells and subsequent membrane fusion, enabling viral infection (Du et al, 2009a; <a class=\"ref-link\" id=\"cLu_et+al_2014_a\" href=\"#rLu_et+al_2014_a\"><a class=\"ref-link\" id=\"cLu_et+al_2014_a\" href=\"#rLu_et+al_2014_a\">Lu et al, 2014</a></a>). The S protein is a class I viral protein, which can be cleaved into two functional subunits, an amino-terminal S1 subunit and a carboxyl-terminal S2 subunit. The S1 subunit is responsible for virus\u2013host cell receptor binding, whereas the S2 subunit is involved in virus\u2013 host membrane fusion (<a class=\"ref-link\" id=\"cLi_et+al_2005_a\" href=\"#rLi_et+al_2005_a\">Li et al, 2005a</a>; <a class=\"ref-link\" id=\"cLu_et+al_2014_a\" href=\"#rLu_et+al_2014_a\"><a class=\"ref-link\" id=\"cLu_et+al_2014_a\" href=\"#rLu_et+al_2014_a\">Lu et al, 2014</a></a>). The S1 contains two major domains, an N-terminal domain (NTD) and a C-terminal domain (CTD). In general, NTDs mediate sugar binding (<a class=\"ref-link\" id=\"cLi_2016_a\" href=\"#rLi_2016_a\">Li, 2016</a>; <a class=\"ref-link\" id=\"cLi_et+al_2017_a\" href=\"#rLi_et+al_2017_a\">Li et al, 2017</a>; <a class=\"ref-link\" id=\"cOu_et+al_2017_a\" href=\"#rOu_et+al_2017_a\">Ou et al, 2017</a>; Hulswit et al, 2019; <a class=\"ref-link\" id=\"cTortorici_et+al_2019_a\" href=\"#rTortorici_et+al_2019_a\">Tortorici et al, 2019</a>), whereas CTDs facilitate protein receptor recognition (Wong et al, 2004; Hofmann et al, 2006; Lu et al, 2013). The NTDs and CTDs of the S1 subunit can bind host receptors or function as receptor-binding domains (RBDs) (Lu et al, 2013; Hulswit et al, 2019). The entry of human CoVs relies on the interaction between viral and cellular membrane proteins. Recognition of S1 subunit with a receptor and/or sugar on the cell surface initiates the infection (<a class=\"ref-link\" id=\"cLi_2015_a\" href=\"#rLi_2015_a\"><a class=\"ref-link\" id=\"cLi_2015_a\" href=\"#rLi_2015_a\">Li, 2015</a></a>). After the initial recognition and binding, the S protein undergoes conformational changes, followed by membrane fusion through the S2 region (<a class=\"ref-link\" id=\"cLi_2015_a\" href=\"#rLi_2015_a\"><a class=\"ref-link\" id=\"cLi_2015_a\" href=\"#rLi_2015_a\">Li, 2015</a></a>, 2016; <a class=\"ref-link\" id=\"cDu_et+al_2017_a\" href=\"#rDu_et+al_2017_a\">Du et al, 2017</a>). Consequently, the viral genetic materials are delivered into the host cell through the fusion core (Du et al, 2009a).",
            "Similar to HCoV-NL63 (<a class=\"ref-link\" id=\"cHofmann_et+al_2005_a\" href=\"#rHofmann_et+al_2005_a\">Hofmann et al, 2005</a>; <a class=\"ref-link\" id=\"cLi_2015_a\" href=\"#rLi_2015_a\">Li, 2015</a>), SARS-CoV recognizes, through the RBD in the CTD region of its S1 subunit, angiotensin-converting enzyme 2 (ACE2) as the receptor on the target cell (<a class=\"ref-link\" id=\"cLi_et+al_2003_a\" href=\"#rLi_et+al_2003_a\">Li et al, 2003</a>). The RBD (CTD) in two states (standing or lying) has been observed in the trimeric S protein. ACE2 binds to standing RBD, specifically in the receptorbinding motif (RBM), keeping the RBD in the \u201cstanding\u201d state (<a class=\"ref-link\" id=\"cYuan_et+al_2017_a\" href=\"#rYuan_et+al_2017_a\">Yuan et al, 2017</a>). In addition to human ACE2, SARS-CoV S protein could also bind to palm civet and mouse ACE2s (<a class=\"ref-link\" id=\"cLi_et+al_2004_a\" href=\"#rLi_et+al_2004_a\">Li et al, 2004</a>; <a class=\"ref-link\" id=\"cLi_2008_a\" href=\"#rLi_2008_a\"><a class=\"ref-link\" id=\"cLi_2008_a\" href=\"#rLi_2008_a\">Li, 2008</a></a>). Mutations in the RBD of S1 subunit are required for cross-species transmission of SARS-CoV (<a class=\"ref-link\" id=\"cLi_et+al_2005_c\" href=\"#rLi_et+al_2005_c\">Li et al, 2005c</a>; <a class=\"ref-link\" id=\"cLi_2008_a\" href=\"#rLi_2008_a\"><a class=\"ref-link\" id=\"cLi_2008_a\" href=\"#rLi_2008_a\">Li, 2008</a></a>, 2016). Several bat SARSr-CoVs have been identified, and these CoVs can utilize human ACE2 as their receptor to bind the target cells (<a class=\"ref-link\" id=\"cGe_et+al_2013_a\" href=\"#rGe_et+al_2013_a\">Ge et al, 2013</a>; Hu et al, 2017). The structure of SARS-CoV S trimer and RBD binding to the ACE2 receptor is shown in Supplementary Figures S1A,B.",
            "MERS-CoV RBD shares a structure similar to that of the homology domain of SARS-CoV (<a class=\"ref-link\" id=\"cWang_et+al_2013_a\" href=\"#rWang_et+al_2013_a\">Wang et al, 2013</a>). However, antibodies induced by SARS-CoV RBD have no cross-reactivity and/or cross-neutralizing activity to MERS-CoV (Du et al, 2013b). Moreover, MERS-CoV utilizes dipeptidyl peptidase 4 (DPP4) as a receptor through the RBD (CTD) region (<a class=\"ref-link\" id=\"cRaj_et+al_2013_a\" href=\"#rRaj_et+al_2013_a\">Raj et al, 2013</a>), which is distinct from the SARS-CoV receptor ACE2. Although the core regions of SARS-CoV and MERS-CoV RBDs are similar, their RBM regions are significantly different, which explains why they recognize different receptors (<a class=\"ref-link\" id=\"cLi_2015_a\" href=\"#rLi_2015_a\">Li, 2015</a>). MERSCoV S trimer also maintains a structure similar to that of SARSCoV S trimer. Both standing and lying states can be detected in the MERS-CoV RBDs, whereas DPP4 only binds to the standing RBD (Pallesen et al, 2017; <a class=\"ref-link\" id=\"cYuan_et+al_2017_a\" href=\"#rYuan_et+al_2017_a\">Yuan et al, 2017</a>). MERS-CoV is clustered with Ty-BatCoV HKU4 and Pi-BatCoV HKU5 in the subgenus Merbecovirus. Ty-BatCoV HKU4, but not Pi-BatCoV HKU5, could use human DPP4 as a receptor (<a class=\"ref-link\" id=\"cYang_et+al_2014_b\" href=\"#rYang_et+al_2014_b\">Yang et al, 2014b</a>). Recently, some MERS-related CoVs (MERSr-CoVs) have been discovered from bats that can enter human DPP4-expressing cells (<a class=\"ref-link\" id=\"cLau_et+al_2018_a\" href=\"#rLau_et+al_2018_a\">Lau et al, 2018</a>; <a class=\"ref-link\" id=\"cLuo_et+al_2018_a\" href=\"#rLuo_et+al_2018_a\">Luo et al, 2018a</a>). These findings suggest that the emergence of MERSr-CoV may threaten human health owing to their potential for cross-species transmission. The MERS-CoV S protein and RBD and their complexes, along with the DPP4 receptor, are shown in Supplementary Figures S1C,D.",
            "Recent studies have found that the new human CoV, 2019nCoV, which belongs to the species of SARSr-CoV, shares high sequence identify (about 79.5%) to SARS-CoV (<a class=\"ref-link\" id=\"cZhou_et+al_2020_a\" href=\"#rZhou_et+al_2020_a\">Zhou et al, 2020</a>). The genome of 2019-nCoV encodes pp1ab (translated from ORF 1ab), four structural proteins (S, E, M, and N), and six accessory proteins (3a, 6, 7a, 7b, 8, and 10) (Figure 2A). Same as SARSCoV and MERS-CoV, 2019-nCoV appears to have no HE gene. The virion of 2019-nCoV consists of similar structure as SARSCoV and MERS-CoV (Figure 2B). Like SARS-CoV, 2019-nCoV",
            "also uses ACE2 as its cellular receptor to enter host cells (<a class=\"ref-link\" id=\"cZhou_et+al_2020_a\" href=\"#rZhou_et+al_2020_a\">Zhou et al, 2020</a>). Currently, the structure of 2019-nCoV RBD and/or its binding with the viral receptor has not yet been available.",
            "Unlike the four low pathogenic human CoVs, including HCoV-229E, HCoV-NL63, HCoV-OC43, and HCoV-HKU1, which cause mild to no pathogenesis in humans, SARS-CoV, MERS-CoV, and 2019-CoV are three highly pathogenic human CoVs (<a class=\"ref-link\" id=\"cChannappanavar_2017_a\" href=\"#rChannappanavar_2017_a\">Channappanavar and Perlman, 2017</a>; <a class=\"ref-link\" id=\"cCui_et+al_2019_a\" href=\"#rCui_et+al_2019_a\">Cui et al, 2019</a>; <a class=\"ref-link\" id=\"cZhu_et+al_2020_a\" href=\"#rZhu_et+al_2020_a\">Zhu et al, 2020</a>). With the increasing numbers of 2019-nCoV and MERS-CoV infections and continuous threat of re-emergence of SARS-CoV, as well as the potential of SARS- and MERS-related CoVs to cause human infections, it is critical to develop vaccines with strong efficacy and safety targeting these viruses to prevent their infections in humans. Since the vaccines against 2019-nCoV have not been available, the rest of the review will focus on the vaccines against SARS-CoV and MERS-CoV.",
            "Although a variety of vaccines have been developed against SARS-CoV and MERS-CoV, most of them are in the preclinical studies, and only several have been tested in clinical trials4,5 (<a class=\"ref-link\" id=\"cDu_et+al_2016_b\" href=\"#rDu_et+al_2016_b\">Du et al, 2016b</a>; <a class=\"ref-link\" id=\"cCho_et+al_2018_a\" href=\"#rCho_et+al_2018_a\">Cho et al, 2018</a>). Nevertheless, no vaccines",
            "4https://clinicaltrials.gov/ct2/show/NCT03615911 5https://clinicaltrials.gov/ct2/show/NCT03399578",
            "have been approved for the prevention of SARS and MERS in humans, demonstrating the need to develop effective and safe vaccines to control current MERS-CoV infection, or to be stockpiled for potential use against re-emerged SARS-CoV or SARSr-CoV. Particularly, effective and safe vaccines are urgently needed to prevent and control the current outbreak of 2019-nCoV.",
            "Most SARS-CoV and MERS-CoV vaccines developed thus far are based on the inactivated or live attenuated viruses, DNAs, proteins, nanoparticles, viral vectors, including viruslike particles (VLPs) (<a class=\"ref-link\" id=\"cZeng_et+al_2004_a\" href=\"#rZeng_et+al_2004_a\">Zeng et al, 2004</a>; Jiang et al, 2005; <a class=\"ref-link\" id=\"cLiu_et+al_2005_a\" href=\"#rLiu_et+al_2005_a\">Liu et al, 2005</a>; Du et al, 2009a, 2016b; <a class=\"ref-link\" id=\"cPimentel_et+al_2009_a\" href=\"#rPimentel_et+al_2009_a\">Pimentel et al, 2009</a>; <a class=\"ref-link\" id=\"cAl-Amri_et+al_2017_a\" href=\"#rAl-Amri_et+al_2017_a\">Al-Amri et al, 2017</a>). Each vaccine type has different advantages and disadvantages. For instance, inactivated and liveattenuated virus-based vaccines are vaccine types developed using the most traditional approaches. Although they generally induce highly potent immune responses and/or protection, the possibility for incomplete inactivation of viruses or recovering virulence exists, resulting in significant safety concerns (<a class=\"ref-link\" id=\"cZhang_et+al_2014_a\" href=\"#rZhang_et+al_2014_a\"><a class=\"ref-link\" id=\"cZhang_et+al_2014_a\" href=\"#rZhang_et+al_2014_a\">Zhang et al, 2014</a></a>). Also, these traditional vaccines may induce the antibody-dependent enhancement (ADE) effect, as in the case of SARS-CoV infection (<a class=\"ref-link\" id=\"cLuo_et+al_2018_b\" href=\"#rLuo_et+al_2018_b\">Luo et al, 2018b</a>). Similarly, some viral-vectored vaccines can elicit specific antibody and cellular immune responses with neutralizing activity and protection, but they might also induce anti-vector immunity or present preexisting immunity, causing some harmful immune responses. Instead, DNA and nanoparticle vaccines maintain strong safety profile; however, the immunogenicity of these vaccines is usually lower than that of virus- or viral vector-based vaccines, often requiring optimization of sequences, components, or immunization routes, inclusion of appropriate adjuvants, or application of combinational immunization approaches (<a class=\"ref-link\" id=\"cZhang_et+al_2014_a\" href=\"#rZhang_et+al_2014_a\"><a class=\"ref-link\" id=\"cZhang_et+al_2014_a\" href=\"#rZhang_et+al_2014_a\">Zhang et al, 2014</a></a>).",
            "Subunit vaccines are vaccines developed based on the synthetic peptides or recombinant proteins. Unlike inactivated or liveattenuated virus and some viral vectored vaccines, this vaccine type mainly contains specific viral antigenic fragments, but without including any components of infectious viruses, eliminating the concerns of incomplete inactivation, virulence recovery, or pre-existing immunity (<a class=\"ref-link\" id=\"cDu_et+al_2008_a\" href=\"#rDu_et+al_2008_a\"><a class=\"ref-link\" id=\"cDu_et+al_2008_a\" href=\"#rDu_et+al_2008_a\">Du et al, 2008</a></a>; <a class=\"ref-link\" id=\"cDeng_et+al_2012_a\" href=\"#rDeng_et+al_2012_a\">Deng et al, 2012</a>). Similar to DNA or VLP-based vaccines, subunit vaccines are generally safe without causing potential harmful immune responses, making them promising vaccine candidates. Moreover, subunit vaccines may target specific, well-defined neutralizing epitopes with improved immunogenicity and/or efficacy (<a class=\"ref-link\" id=\"cDu_et+al_2008_a\" href=\"#rDu_et+al_2008_a\"><a class=\"ref-link\" id=\"cDu_et+al_2008_a\" href=\"#rDu_et+al_2008_a\">Du et al, 2008</a></a>; <a class=\"ref-link\" id=\"cZhang_et+al_2014_a\" href=\"#rZhang_et+al_2014_a\">Zhang et al, 2014</a>).",
            "A number of subunit vaccines against SARS-CoV and MERS-CoV have been developed, and these are described in detail in the next paragraphs. The targets used for the development of SARS-CoV and MERS-CoV subunit vaccines are also be discussed.",
            "The S protein of SARS-CoV and MERS-CoV plays a vital role in receptor binding and membrane fusion. Thus, the S protein, but not other structural proteins, is the major antigen to induce protective neutralizing antibodies to block viruses from binding their respective receptor and thus inhibit viral infection (<a class=\"ref-link\" id=\"cBisht_et+al_2004_a\" href=\"#rBisht_et+al_2004_a\">Bisht et al, 2004</a>; <a class=\"ref-link\" id=\"cBuchholz_et+al_2004_a\" href=\"#rBuchholz_et+al_2004_a\">Buchholz et al, 2004</a>; <a class=\"ref-link\" id=\"cBukreyev_et+al_2004_a\" href=\"#rBukreyev_et+al_2004_a\">Bukreyev et al, 2004</a>; <a class=\"ref-link\" id=\"cYang_et+al_2004_a\" href=\"#rYang_et+al_2004_a\">Yang et al, 2004</a>). As a result, the S protein is also a major target for the development of subunit vaccines against SARS-CoV and MERSCoV. Both full-length S protein and its antigenic fragments, including S1 subunit, NTD, RBD, and S2 subunit, can serve as important targets for the development of subunit vaccines (Guo et al, 2005; <a class=\"ref-link\" id=\"cMou_et+al_2013_a\" href=\"#rMou_et+al_2013_a\">Mou et al, 2013</a>; <a class=\"ref-link\" id=\"cWang_et+al_2015_a\" href=\"#rWang_et+al_2015_a\">Wang et al, 2015</a>; <a class=\"ref-link\" id=\"cJiaming_et+al_2017_a\" href=\"#rJiaming_et+al_2017_a\">Jiaming et al, 2017</a>; <a class=\"ref-link\" id=\"cZhou_et+al_2018_a\" href=\"#rZhou_et+al_2018_a\">Zhou et al, 2018</a>).",
            "Although subunit vaccines based on the full-length S protein may elicit potent immune responses and/or protection, studies have found that antibodies induced by some of these vaccines mediate enhancement of viral infection in vitro, as in the case of SARS-CoV (Kam et al, 2007; <a class=\"ref-link\" id=\"cJaume_et+al_2012_a\" href=\"#rJaume_et+al_2012_a\">Jaume et al, 2012</a>), raising safety concerns for the development of full-length S protein-based subunit vaccines against SARS-CoV and MERSCoV. In contrast, RBD-based subunit vaccines comprise the major critical neutralizing domain (<a class=\"ref-link\" id=\"cDu_2015_a\" href=\"#rDu_2015_a\">Du and Jiang, 2015</a>; <a class=\"ref-link\" id=\"cZhou_et+al_2019_a\" href=\"#rZhou_et+al_2019_a\">Zhou et al, 2019</a>). Therefore, these vaccines may generate potent neutralizing antibodies with strong protective immunity against viral infection. S1 subunit, for example, is much shorter than the full-length S protein, but it is no less able to induce strong immune responses and/or protection against viral infection (Li et al, 2013; <a class=\"ref-link\" id=\"cAdney_et+al_2019_a\" href=\"#rAdney_et+al_2019_a\">Adney et al, 2019</a>). Thus, this fragment can be used as an alternative target for subunit vaccine development. Despite their ability to induce immune responses and/or neutralizing antibodies, NTD and S2 as the targets of subunit vaccines are less immunogenic, eliciting significantly lower antibody titers, cellular immune responses, and/or protection than the other regions, such as full-length, S1, and RBD (Guo et al, 2005; <a class=\"ref-link\" id=\"cJiaming_et+al_2017_a\" href=\"#rJiaming_et+al_2017_a\">Jiaming et al, 2017</a>). Therefore, in terms of safety and efficacy, the RBD and/or S1 of S protein could be applied as critical targets for the development of subunit vaccine candidates against SARS-CoV, MERS-CoV, SARSr-CoV, and MERSr-CoV. Because of its conserved amino acid sequences and high homology among different virus strains (<a class=\"ref-link\" id=\"cElshabrawy_et+al_2012_a\" href=\"#rElshabrawy_et+al_2012_a\">Elshabrawy et al, 2012</a>; <a class=\"ref-link\" id=\"cZhou_et+al_2018_a\" href=\"#rZhou_et+al_2018_a\">Zhou et al, 2018</a>), the S2 subunit has potential to be used as a target for the development of universal vaccines against divergent virus strains.",
            "In addition to the S protein, the N protein of SARS-CoV and MERS-CoV may serve as an additional target for the development of subunit vaccines. Unlike S protein, the N protein has no ability to elicit neutralizing antibodies to block virusreceptor interaction and neutralize viral infection, but it may induce specific antibody and cellular immune responses (<a class=\"ref-link\" id=\"cLiu_et+al_2006_a\" href=\"#rLiu_et+al_2006_a\"><a class=\"ref-link\" id=\"cLiu_et+al_2006_a\" href=\"#rLiu_et+al_2006_a\">Liu et al, 2006</a></a>; Zheng et al, 2009). Several immunodominant B-cell and T-cell epitopes have been identified in the N protein of SARSCoV and MERS-CoV, some of which are conserved in mice, non-human primates, and humans (<a class=\"ref-link\" id=\"cLiu_et+al_2006_a\" href=\"#rLiu_et+al_2006_a\"><a class=\"ref-link\" id=\"cLiu_et+al_2006_a\" href=\"#rLiu_et+al_2006_a\">Liu et al, 2006</a></a>; <a class=\"ref-link\" id=\"cChan_et+al_2011_a\" href=\"#rChan_et+al_2011_a\">Chan et al, 2011</a>; <a class=\"ref-link\" id=\"cVeit_et+al_2018_a\" href=\"#rVeit_et+al_2018_a\">Veit et al, 2018</a>). Other proteins, such as M protein, can be used as potential targets of SARS-CoV and MERS-CoV subunit vaccines. Notably, SARS-CoV M protein-derived peptides have immunogenicity to induce high-titer antibody responses in the immunized animals (<a class=\"ref-link\" id=\"cHe_et+al_2005_b\" href=\"#rHe_et+al_2005_b\">He et al, 2005b</a>), suggesting the potential for utilizing this protein to develop subunit vaccines.",
            "Numerous subunit vaccines against SARS-CoV have been developed since the outbreak of SARS, the majority of which use the S protein and/or its antigenic fragments, in particular, RBD, as the vaccine target (Table 1).",
            "SARS-CoV Subunit Vaccines Based on Full-Length S Protein Subunit vaccines based on SARS-CoV S protein, including fulllength or trimeric S protein, are immunogenic with protection against SARS-CoV infection (He et al, 2006a; Kam et al, 2007; Li et al, 2013). Either insect cell-expressed full-length (FL-S) or extracellular domain (EC-S) SARS-CoV S protein developed high-titer S-specific antibodies with neutralizing activity against pseudotyped SARS-CoV expressing S protein of representative SARS-CoV human and palm civet strains (Tor2, GD03, and SZ3) isolated during the 2002 and 2003 or 2003 and 2004 outbreaks (He et al, 2006a). In addition, full-length S-ectodomain proteins fused with or without a foldon trimeric motif (S or S-foldon) could elicit specific antibody responses and neutralizing antibodies, protecting immunized mice against SARS-CoV challenge with undetectable virus titers in the lungs (Li et al, 2013). Moreover, a subunit vaccine (triSpike) based on a full-length S protein trimer induced specific serum and mucosal antibody responses and efficient neutralizing antibodies against SARS-CoV infection (Kam et al, 2007). Nevertheless, this vaccine also resulted in Fc\u03b3 receptor II (Fc\u03b3RII)-dependent and ACE2-independent ADE, particularly in human monocytic or lymphoblastic cell lines infected with pseudotyped SARS-CoV expressing viral S protein, or in Raji B cells (B-cell lymphoma line) infected with live SARS-CoV (Kam et al, 2007; <a class=\"ref-link\" id=\"cJaume_et+al_2012_a\" href=\"#rJaume_et+al_2012_a\">Jaume et al, 2012</a>), raising significant concerns over the use of full-length S protein as a SARS vaccine target.",
            "SARS-CoV Subunit Vaccines Based on RBD SARS-CoV RBD contains multiple conformation-dependent epitopes capable of eliciting high-titer neutralizing antibodies; thus, it is a major target for the development of SARS vaccines (He et al, 2004, 2005a; <a class=\"ref-link\" id=\"cJiang_et+al_2012_a\" href=\"#rJiang_et+al_2012_a\">Jiang et al, 2012</a>; <a class=\"ref-link\" id=\"cZhu_et+al_2013_a\" href=\"#rZhu_et+al_2013_a\">Zhu et al, 2013</a>). Subunit vaccines based on the SARS-CoV RBD have been extensively explored. Studies have found that a fusion protein containing RBD and the fragment crystallizable (Fc) region of human IgG1 (RBD-Fc) elicited highly potent neutralizing antibodies against SARS-CoV in the immunized rabbits and mice, which strongly blocked the binding between S1 protein and SARS-CoV receptor ACE2 (He et al, 2004). This RBD protein induced long-term, high-level SARS-CoV S-specific antibodies and neutralizing antibodies that could be maintained for 12 months after immunization, protecting most of the vaccinated mice against SARS-CoV infection (<a class=\"ref-link\" id=\"cDu_et+al_2007_a\" href=\"#rDu_et+al_2007_a\">Du et al, 2007</a>). In addition, recombinant RBDs (residues 318\u2013510 or 318\u2013536) stably or transiently expressed in Chinese hamster ovary (CHO) cells bound strongly to RBD-specific monoclonal antibodies (mAbs), elicited hightiter anti-SARS-CoV neutralizing antibodies, and protected most, or all, of the SARS-CoV-challenged mice, with undetectable viral RNA and undetectable or significantly reduced viral load (<a class=\"ref-link\" id=\"cDu_et+al_2009_c\" href=\"#rDu_et+al_2009_c\">Du et al, 2009c</a>, 2010). Significantly, a 293T cell-expressed RBD protein maintains excellent conformation and good antigenicity to bind SARS-CoV RBD-specific neutralizing mAbs. It elicited highly potent neutralizing antibodies that completely protected immunized mice against SARS-CoV challenge (Du et al, 2009b). Particularly, RBDs from the S proteins of Tor2, GD03, and SZ3, representative strains of SARS-CoV isolated from human 2002\u2013 2003, 2003\u20132004, and palm civet strains, can induce high-titer cross-neutralizing antibodies against pseudotyped SARS-CoV expressing respective S proteins (<a class=\"ref-link\" id=\"cHe_et+al_2006_c\" href=\"#rHe_et+al_2006_c\">He et al, 2006c</a>). Different from the full-length S protein-based SARS subunit vaccines, no obvious pathogenic effects have been identified in the RBD-based SARS subunit vaccines (Kam et al, 2007; <a class=\"ref-link\" id=\"cJaume_et+al_2012_a\" href=\"#rJaume_et+al_2012_a\">Jaume et al, 2012</a>).",
            "SARS-CoV Subunit Vaccines Based on Non-RBD S Protein Fragments SARS subunit vaccines based on S protein fragments (S1 and S2), other than the RBD, have shown immunogenicity and/or protective efficacy against SARS-CoV infection (Guo et al, 2005; Li et al, 2013). For example, recombinant S1 proteins fused with or without foldon elicited specific antibodies with neutralizing activity that protected immunized mice against high-dose SARSCoV challenge (Li et al, 2013). Although some studies have demonstrated that recombinant SARS-CoV S2 (residues 681\u2013 980) protein elicits specific non-neutralizing antibody response in mice (Guo et al, 2005), others have indicated that mAbs targeting highly conserved heptad repeat 1 (HR1) and HR2 domains of SARS-CoV S protein have broad neutralizing activity against pseudotyped SARS-CoV expressing S protein of divergent strains (<a class=\"ref-link\" id=\"cElshabrawy_et+al_2012_a\" href=\"#rElshabrawy_et+al_2012_a\">Elshabrawy et al, 2012</a>), indicating the potential of utilizing the S2 region as a broad-spectrum anti-SARS-CoV vaccine target (Zheng et al, 2009).",
            "SARS-CoV Subunit Vaccines Based on Non-S Structural Proteins Subunit vaccines based on the N and M proteins of SARSCoV have shown immunogenicity in vaccinated animals (<a class=\"ref-link\" id=\"cLiu_et+al_2006_a\" href=\"#rLiu_et+al_2006_a\"><a class=\"ref-link\" id=\"cLiu_et+al_2006_a\" href=\"#rLiu_et+al_2006_a\">Liu et al, 2006</a></a>; Zheng et al, 2009). Studies have revealed that a plant-expressed SARS-CoV N protein conjugated with Freund\u2019s adjuvant elicited specific IgG antibodies, including IgG1 and IgG2a subtypes, and cellular immune responses in mice, whereas another E. coli-expressed N protein conjugated with Montanide ISA-51 and cysteine-phosphate-guanine (CpG) adjuvants induced specific IgG antibodies toward a Th1 (IgG2a)-type response in mice (<a class=\"ref-link\" id=\"cLiu_et+al_2006_a\" href=\"#rLiu_et+al_2006_a\"><a class=\"ref-link\" id=\"cLiu_et+al_2006_a\" href=\"#rLiu_et+al_2006_a\">Liu et al, 2006</a></a>; Zheng et al, 2009). Although N-specific antibodies have been detected in convalescent-phase SARS patient and immunized rabbit sera, they have no neutralizing activity against SARS-CoV infection (<a class=\"ref-link\" id=\"cQiu_et+al_2005_a\" href=\"#rQiu_et+al_2005_a\">Qiu et al, 2005</a>). In addition, immunodominant M protein peptides (M1-31 and M132-161) identified using convalescentphase sera of SARS patients and immunized mouse and rabbit sera have immunogenicity to elicit specific IgG antibodies in",
            "S.C.",
            "I.P. or S.C.",
            "I.D. orI.M.",
            "Binds to SARS-CoV RBD-specific mAbs (neutralizing 24H8, 31H12, 35B5, 33G4, 19B2; non-neutralizing 17H9)"
        ],
        "References": [
            "Pallesen et al, 2017",
            "Lan et al, 2014, 2015",
            "<a class=\"ref-link\" id=\"cDu_et+al_2013_c\" href=\"#rDu_et+al_2013_c\">Du et al, 2013c</a>; <a class=\"ref-link\" id=\"cMa_et+al_2014_b\" href=\"#rMa_et+al_2014_b\">Ma et al, 2014b</a>",
            "Du et al, 2013a; <a class=\"ref-link\" id=\"cMa_et+al_2014_b\" href=\"#rMa_et+al_2014_b\">Ma et al, 2014b</a>; <a class=\"ref-link\" id=\"cTang_et+al_2015_a\" href=\"#rTang_et+al_2015_a\">Tang et al, 2015</a>; <a class=\"ref-link\" id=\"cZhang_et+al_2016_a\" href=\"#rZhang_et+al_2016_a\">Zhang et al, 2016</a>; <a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\">Nyon et al, 2018</a>",
            "Tai et al, 2016",
            "TABLE 2 | Continued",
            "RBD (T579N) protein",
            "Binds to receptor DPP4 and MERS-CoV RBD-specific neutralizing mAbs (hMS-1, m336, m337, and m338)",
            "Montanide; Alum",
            "Subunit vaccines based on non-RBD MERS-CoV S protein fragments",
            "S1 protein",
            "Ribi; Alum pho",
            "Advax + SAS rNTD protein",
            "Alum pho + CpG",
            "SP3 peptide (aa736-761)",
            "BALB/c mice; hDPP4-Tg mice",
            "Dromedary camels; Alpacas",
            "BALB/c mice; Ad5-hDPP4 mice",
            "BALB/c mice; NZW rabbits",
            "Elicits neutralizing Abs (> 1:3 \u00d7 103) in mice against live MERS-CoV (EMC2012 strain)",
            "Elicits MERS-CoV S1-specific Abs in mice (IgG and IgG1) and NHPs (IgG), neutralizing 8 pseudotyped and live MERS-CoV (JordanN3 strain)",
            "Elicits neutralizing Abs in dromedary camels (\u2265 1:80) and alpacas (\u2265 1:6.4 \u00d7 102) against live MERS-CoV (EMC2012 strain)",
            "Elicits MERS-CoV S-NTD-specific Abs (IgG, \u2265 1:104) in mice, neutralizing pseudotyped and live (1:40) MERS-CoV (EMC2012 strain)",
            "Elicits MERS-CoV S-specific Abs (IgG, 1:104) in rabbits, neutralizing pseudotyped MERS-CoV",
            "Induces MERS-CoV S-NTD-specific cellular immune responses (IFN-\u03b3, IL-2, IL-6, IL-10, and IL-17A) in mice N/A",
            "Protects all vaccinated hDPP4-Tg mice from challenge of MERS-CoV (EMC2012 strain, 104 TCID50)",
            "Protects vaccinated NHPs from challenge of MERS-CoV (JordanN3 strain, 5 \u00d7 106 PFU) with reduced abnormalities on chest CT Protects vaccinated dromedary camels and alpacas from challenge of MERS-CoV (EMC2012 strain, 107 TCID50) with reduced and delayed viral shedding in the upper airways (in camels) or complete protection (in alpacas) Protects vaccinated Ad5-hDPP4transduced mice from challenge of MERS-CoV (EMC2012 strain, 105 PFU) with reduced lung abnormalities and respiratory tract pathology N/A",
            "Du et al, 2016a <a class=\"ref-link\" id=\"cWang_et+al_2015_a\" href=\"#rWang_et+al_2015_a\">Wang et al, 2015</a> <a class=\"ref-link\" id=\"cAdney_et+al_2019_a\" href=\"#rAdney_et+al_2019_a\">Adney et al, 2019</a> <a class=\"ref-link\" id=\"cJiaming_et+al_2017_a\" href=\"#rJiaming_et+al_2017_a\">Jiaming et al, 2017</a> <a class=\"ref-link\" id=\"cYang_et+al_2014_a\" href=\"#rYang_et+al_2014_a\">Yang et al, 2014a</a> aaa, amino acid; Abs, antibodies; Ad5, adenovirus serotype 5; Ad5-hDPP4 mice, Ad5-hDPP4-transuced mice; Alum hydro, aluminum hydroxide; Alum pho, Aluminum phosphate; hDPP4, human dipeptidyl peptidase 4; hDPP4-Tg mice, transgenic mice expressing MERS-CoV receptor human DPP4; IFA, incomplete Freund\u2019s adjuvant; I.M., intramuscular; I.N., intranasal; mAbs, monoclonal antibodies; Montanide, Montanide ISA51; N/A, not reported; NHPs, non-human primates; NZW, rabbits, New Zealand White rabbits; PFU, plaque-forming unit; rRBD, recombinant RBD; SAS, Sigma Adjuvant System; S.C., subcutaneous; TCID50, median tissue culture infectious dose; TNF-\u03b1, tumor necrosis factor (TNF)-alpha.",
            "NHPs from MERS-CoV infection by alleviating pneumonia and clinical manifestations, as well as decreasing viral load (<a class=\"ref-link\" id=\"cLan_et+al_2015_a\" href=\"#rLan_et+al_2015_a\">Lan et al, 2015</a>). In addition, an RBD protein fragment containing MERSCoV S residues 377\u2013622 fused with the Fc tag of human IgG can induce MERS-CoV S1- and/or RBD-specific humoral and cellular immune responses in the immunized mice with neutralizing activity against MERS-CoV infection (<a class=\"ref-link\" id=\"cDu_et+al_2013_c\" href=\"#rDu_et+al_2013_c\">Du et al, 2013c</a>; <a class=\"ref-link\" id=\"cJiang_et+al_2013_a\" href=\"#rJiang_et+al_2013_a\">Jiang et al, 2013</a>). However, after comparing several versions of MERSCoV RBD fragments with different lengths, it was found that a truncated RBD (residues 377\u2013588) had the highest DPP4binding affinity and induced the highest-titer IgG antibodies and neutralizing antibodies against MERS-CoV, identifying its role as a critical neutralizing domain (<a class=\"ref-link\" id=\"cMa_et+al_2014_b\" href=\"#rMa_et+al_2014_b\">Ma et al, 2014b</a>).",
            "Subsequently, several MERS-CoV subunit vaccines have been designed based on the identified critical neutralizing domain of RBD fragment, including those expressed in a stable CHO cell line (S377-588-Fc), fusing with a trimeric motif foldon (RBDFd), or containing single or multiple mutations in the RBD of representative human and camel strains from the 2012\u20132015 MERS outbreaks (Tai et al, 2016, 2017; <a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\"><a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\"><a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\">Nyon et al, 2018</a></a></a>). These RBD proteins maintain good conformation, functionality, antigenicity, and immunogenicity, with ability to bind the DPP4 receptor and RBD-specific neutralizing mAbs and to elicit robust neutralizing antibodies cross-neutralizing multiple strains of MERS pseudoviruses and live MERS-CoV (Tai et al, 2016, 2017; <a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\"><a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\"><a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\">Nyon et al, 2018</a></a></a>). It is noted that the wild-type MERS-CoV RBD proteins consisting of the identified critical neutralizing domain confer partial protection of hDPP4-transgenic (hDPP4-Tg) mice from MERS-CoV infection without causing immunological toxicity or eosinophilic immune enhancement (Tai et al, 2016; Wang Y. et al, 2017; <a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\"><a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\"><a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\">Nyon et al, 2018</a></a></a>); nevertheless, a structurally designed mutant version of such RBD protein with a non-neutralizing epitope masked (T579N) preserves intact conformation and significantly improves overall neutralizing activity and protective efficacy, resulting in the full protection of hDPP4-Tg mice against high-dose MERS-CoV challenge (Du et al, 2016a).",
            "The above studies indicate that protein lengths to be chosen as MERS-CoV subunit vaccines and/or structure-based vaccine design can impact on the immunogenicity and/or protection of RBD-based subunit vaccines.",
            "MERS-CoV Subunit Vaccines Based on Non-RBD S Protein Fragments MERS vaccines targeting non-RBD regions of S protein have been developed and investigated in mice and NHPs. It has been shown that a MERS-CoV S1 protein formulated with Ribi (for mice) or aluminum phosphate (for NHPs) adjuvant elicited robust neutralizing antibodies in mice and NHPs against divergent strains of pseudotyped and live MERSCoV, protecting NHPs from MERS-CoV infection (<a class=\"ref-link\" id=\"cWang_et+al_2015_a\" href=\"#rWang_et+al_2015_a\">Wang et al, 2015</a>). In addition, MERS-CoV S1 protein adjuvanted with Advax and Sigma Adjuvant System induced low-titer neutralizing antibodies in dromedary camels with reduced and delayed viral shedding after MERS-CoV challenge, but high-titer neutralizing antibodies in alpacas with complete protection of viral shedding from viral infection, indicating that protection of MERS-CoV infection is positively correlated with serum neutralizing antibody titers (<a class=\"ref-link\" id=\"cAdney_et+al_2019_a\" href=\"#rAdney_et+al_2019_a\">Adney et al, 2019</a>). Moreover, immunization with a recombinant MERS-CoV NTD protein (rNTD) can induce neutralizing antibodies and cellmediated responses, protecting Ad-hDPP4-transduced mice against MERS-CoV challenge (<a class=\"ref-link\" id=\"cJiaming_et+al_2017_a\" href=\"#rJiaming_et+al_2017_a\">Jiaming et al, 2017</a>). Notably, specific antibodies with neutralizing activity have been elicited by a S2 peptide sequence (residues 736\u2013761) of MERS-CoV in rabbits (<a class=\"ref-link\" id=\"cYang_et+al_2014_a\" href=\"#rYang_et+al_2014_a\">Yang et al, 2014a</a>), but the protective efficacy of this peptide vaccine is unknown. The above reports demonstrate the potential for the development of MERS subunit vaccines based on the non-RBD fragments of MERSCoV S protein.",
            "MERS-CoV Subunit Vaccines Based on Non-S Structural Proteins Unlike SARS subunit vaccines which have been designed based on viral N and M proteins, it appears that very few subunit vaccines have been developed based on the non-S structural protein(s) of MERS-CoV. One study reports the induction of specific antibodies by MERS-CoV N peptides (<a class=\"ref-link\" id=\"cYang_et+al_2014_a\" href=\"#rYang_et+al_2014_a\">Yang et al, 2014a</a>), and another report shows that N protein is used for development of vaccines based on viral vector Vaccinia virus, modified Vaccinia Ankara (MVA) (<a class=\"ref-link\" id=\"cVeit_et+al_2018_a\" href=\"#rVeit_et+al_2018_a\">Veit et al, 2018</a>). This may be potentially a consequence of the weak immunogenicity and/or protective efficacy of non-S structural proteins, further confirming the role of MERS-CoV S protein as the key target for the development of MERS vaccines, including subunit vaccines.",
            "Potential Factors Affecting MERS-CoV Subunit Vaccines Similar to SARS-CoV subunit vaccines, the immunogenicity and/or protection of MERS-CoV subunit vaccines may also be affected by a number of factors, such as antigen sequences, fragment lengths, adjuvants, vaccination pathways, antigen doses, immunization doses and intervals used.",
            "As described above, MERS-CoV subunit vaccines containing different antigens or fragment lengths, particularly those based on the RBD, have apparently variable immunogenicity and/or protective efficacy, and a critical neutralizing domain that contains an RBD fragment corresponding to residues 377\u2013588 of S protein elicits the highest neutralizing antibodies among several fragments tested (<a class=\"ref-link\" id=\"cMa_et+al_2014_b\" href=\"#rMa_et+al_2014_b\">Ma et al, 2014b</a>; <a class=\"ref-link\" id=\"cZhang_et+al_2015_a\" href=\"#rZhang_et+al_2015_a\">Zhang et al, 2015</a>).",
            "Adjuvants play an essential role in enhancing host immune responses to MERS-CoV subunit vaccines, including those based on the RBD, and different adjuvants can promote host immune responses to variant levels (Lan et al, 2014; <a class=\"ref-link\" id=\"cZhang_et+al_2016_a\" href=\"#rZhang_et+al_2016_a\"><a class=\"ref-link\" id=\"cZhang_et+al_2016_a\" href=\"#rZhang_et+al_2016_a\">Zhang et al, 2016</a></a>). For example, while a MERS-CoV RBD subunit vaccine (S377-588 protein fused with Fc) alone induced detectable neutralizing antibody and T-cell responses in immunized mice, inclusion of an adjuvant enhanced its immunogenicity. Particularly, among the adjuvants (Freund\u2019s, aluminum, Monophosphoryl lipid A, Montanide ISA51 and MF59) conjugated with this RBD protein, MF59 could best potentiate the protein to induce the highest-titer anti-S antibodies and neutralizing antibodies, protecting mice against MERS-CoV infection (<a class=\"ref-link\" id=\"cZhang_et+al_2016_a\" href=\"#rZhang_et+al_2016_a\"><a class=\"ref-link\" id=\"cZhang_et+al_2016_a\" href=\"#rZhang_et+al_2016_a\">Zhang et al, 2016</a></a>). Moreover, a recombinant RBD (rRBD) protein plus alum and CpG adjuvants elicited the highest neutralizing antibodies against pseudotyped MERS-CoV infection, whereas the strongest T-cell responses were induced by this protein plus Freund\u2019s and CpG adjuvants (Lan et al, 2014).",
            "Vaccination pathways are important in inducing efficient immune responses, and different immunization routes may elicit different immune responses to the same protein antigens. For example, immunization of mice with a MERS-CoV subunit vaccine (RBD-Fc) via the intranasal route induced higher levels of cellular immune responses and stronger local mucosal neutralizing antibody responses against MERS-CoV infection than those induced by the same vaccine via the S.C. pathway (<a class=\"ref-link\" id=\"cMa_et+al_2014_a\" href=\"#rMa_et+al_2014_a\">Ma et al, 2014a</a>). In addition, while Freund\u2019s and CpG-adjuvanted rRBD protein elicited higher-level systematic and local IFN\u03b3-producing T cells via the S.C. route, this protein adjuvanted with Alum and CpG induced higher-level tumor necrosis factoralpha (TNF-\u03b1) and interleukin 4 (IL-4)-secreting T cells via the I.M. route (Lan et al, 2014).",
            "Antigen dosage, immunization doses, and intervals may significantly affect the immunogenicity of MERS-CoV subunit vaccines. Notably, a MERS-CoV RBD (S377-588-Fc) subunit vaccine immunized at 1 \u03bcg elicited strong humoral and cellular immune responses and neutralizing antibodies in mice although the one immunized at 5 and 20 \u03bcg elicited a higher level of S1-specific antibodies (<a class=\"ref-link\" id=\"cTang_et+al_2015_a\" href=\"#rTang_et+al_2015_a\">Tang et al, 2015</a>). In addition, among the regimens at one dose and two doses at 1-, 2-, and 3-week intervals, 2 doses of this protein boosted at 4 weeks resulted in the highest antibodies and neutralizing antibodies against MERS-CoV infection (Wang Y. et al, 2017).",
            "POTENTIAL CHALLENGES AND FUTURE PERSPECTIVES FOR SARS-CoV AND MERS-CoV SUBUNIT VACCINES",
            "Compared with other vaccine types such as inactivated virus and viral-vectored vaccines, SARS and MERS subunit vaccines are much safer and do not cause obvious side effects. However, these subunit vaccines may face some important challenges, mostly arising from their relatively low immunogenicity, which must be combined with appropriate adjuvants or optimized for suitable protein sequences, fragment lengths, and immunization schedules. In addition, structure and epitope-based vaccine design has become a promising strategy to improve the efficacy of subunit vaccines. This is evidenced by a structurally designed MERS-CoV RBD-based protein which has significantly improved neutralizing activity and protection against MERS-CoV infection (Du et al, 2016a). It is prospected that more structureguided novel strategies will be developed to improve the overall immunogenicity and efficacy of subunit vaccines against emerging pathogenic human coronaviruses, including those targeting SARS-CoV and MERS-CoV. Although a large number of SARS and MERS subunit vaccines have been developed with potent immunogenicity and/or protection in available animal models, virtually all remain in the preclinical stage. It is thus expected that one or several of these promising subunit vaccines can be further processed into clinical trials to confirm their immunogenicity against viral infections in humans.",
            "RAPID DEVELOPMENT OF SUBUNIT VACCINES AGAINST THE NEW PATHOGENIC HUMAN CORONAVIRUS",
            "Currently, the newly identified 2019-nCoV is spreading to infect people, resulting in significant global concerns. It is critical to rapidly design and develop effective vaccines to prevent infection of this new coronavirus. Since S protein and its fragments, such as RBD, of SARS-CoV, and MERS-CoV are prime targets for developing subunit vaccines against these two highly pathogenic human CoVs, it is expected that similar regions of 2019-nCoV can also be used as key targets for developing vaccines against this new coronavirus (<a class=\"ref-link\" id=\"cJiang_et+al_2020_a\" href=\"#rJiang_et+al_2020_a\">Jiang et al, 2020</a>). Similarly, other regions of 2019-nCoV, including S1 and S2 subunits of S protein and N protein, can be applied as alternative targets for vaccine development. Taken together, the approaches and strategies in the development of subunit vaccines against SARS and MERS described in this review will provide important information for the rapid design and development of safe and effective subunit vaccines against 2019-nCoV infection.",
            "AUTHOR CONTRIBUTIONS",
            "SJ and LD conceived the idea and revised and edited the manuscript. NW and LD collected information and drafted the manuscript. JS performed the structural analysis. All authors read and made final approval of the manuscript."
        ],
        "FUNDING": [
            "This work was supported by the NIH grants R01AI137472 and R01AI139092."
        ],
        "SUPPLEMENTARY": [
            "The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmicb. 2020.00298/full#supplementary-material"
        ],
        "REFERENCES": [
            "Adney, D. R., Wang, L., van Doremalen, N., Shi, W., Zhang, Y., Kong, W. P., et al (2019). Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas. Viruses 11:E212. doi: 10.3390/v11030212",
            "Al-Amri, S. S., Abbas, A. T., Siddiq, L. A., Alghamdi, A., Sanki, M. A., AlMuhanna, M. K., et al (2017). Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein. Sci. Rep. 7:44875. doi: 10.1038/srep 44875",
            "Annan, A., Baldwin, H. J., Corman, V. M., Klose, S. M., Owusu, M., Nkrumah, E. E., et al (2013). Human betacoronavirus 2c EMC/2012-related viruses in Bats, Ghana and Europe. Emerg. Infect. Dis. 19, 456\u2013459. doi: 10.3201/eid1903. 121503",
            "Arbour, N., Day, R., Newcombe, J., and Talbot, P. J. (2000). Neuroinvasion by human respiratory coronaviruses. J. Virol. 74, 8913\u20138921. doi: 10.1128/jvi.74. 19.8913-8921.2000",
            "Azhar, E. I., El-Kafrawy, S. A., Farraj, S. A., Hassan, A. M., Al-Saeed, M. S., Hashem, A. M., et al (2014). Evidence for camel-to-human transmission of MERS coronavirus. N. Engl. J. Med. 370, 2499\u20132505. doi: 10.1056/NEJMoa1401505",
            "Bailey-Elkin, B. A., Knaap, R. C., Johnson, G. G., Dalebout, T. J., Ninaber, D. K., van Kasteren, P. B., et al (2014). Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression. J. Biol. Chem. 289, 34667\u201334682. doi: 10. 1074/jbc.M114.609644",
            "Bisht, H., Roberts, A., Vogel, L., Bukreyev, A., Collins, P. L., Murphy, B. R., et al (2004). Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. U.S.A. 101, 6641\u20136646. doi: 10.1073/pnas.0401939101",
            "Buchholz, U. J., Bukreyev, A., Yang, L. J., Lamirande, E. W., Murphy, B. R., Subbarao, K., et al (2004). Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. U.S.A. 101, 9804\u20139809. doi: 10.1073/pnas.0403492101",
            "Bukreyev, A., Lamirande, E. W., Buchholz, U. J., Vogel, L. N., Elkins, W. R., St Claire, M., et al (2004). Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363, 2122\u20132127. doi: 10.1016/s0140-6736(04)16501-x",
            "Chan, P. K., Ma, S., and Ngai, S. M. (2011). Identification of T-cell epitopes of SARS-coronavirus for development of peptide-based vaccines and cellular immunity assessment methods. Hong Kong Med. J. 17(Suppl. 6), 26\u201330.",
            "Chang, C. Y., Hong, W. W., Chong, P., and Wu, S. C. (2006). Influence of intron and exon splicing enhancers on mammalian cell expression of a truncated spike protein of SARS-CoV and its implication for subunit vaccine development. Vaccine 24, 1132\u20131141. doi: 10.1016/j.vaccine.2005.09.011",
            "Channappanavar, R., and Perlman, S. (2017). Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 39, 529\u2013539. doi: 10.1007/s00281-017-0629-x",
            "Chen, W. H., Du, L., Chag, S. M., Ma, C., Tricoche, N., Tao, X., et al (2014). Yeastexpressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum. Vaccin. Immunother. 10, 648\u2013658. doi: 10.4161/hv.27464",
            "Chen, Y., Rajashankar, K. R., Yang, Y., Agnihothram, S. S., Liu, C., Lin, Y. L., et al (2013). Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J. Virol. 87, 10777\u201310783. doi: 10.1128/jvi.01756-13",
            "Chiu, S. S., Chan, K. H., Chu, K. W., Kwan, S. W., Guan, Y., Poon, L. L., et al (2005). Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China. Clin. Infect. Dis. 40, 1721\u20131729. doi: 10.1086/430301",
            "Cho, H., Excler, J. L., Kim, J. H., and Yoon, I. K. (2018). Development of Middle East respiratory syndrome coronavirus vaccines - advances and challenges. Hum. Vaccin. Immunother. 14, 304\u2013313. doi: 10.1080/21645515.2017.138 9362",
            "Cui, J., <a class=\"ref-link\" id=\"cLi_2019_a\" href=\"#rLi_2019_a\">Li, F., and Shi, Z. L. (2019</a>). Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17, 181\u2013192. doi: 10.1038/s41579-0180118-9",
            "De Groot, R. J., Baker, S., Baric, R., Enjuanes, L., Gorbalenya, A., Holmes, K. V., et al (2011). \u201cFamily Coronaviridae, virus taxomomy: classification and nomenclature of viruses,\u201d in Ninth Report of the International Committee on Taxonomy of Viruses, eds A. M. Q. King, M. J. Adams, E. B. Carstens, and E. J. Lefkowitz (Amsterdam: Elsevier Academic Press), 806\u2013826.",
            "DeDiego, M. L., Nieto-Torres, J. L., Jimenez-Guardeno, J. M., Regla-Nava, J. A., Castano-Rodriguez, C., Fernandez-Delgado, R., et al (2014). Coronavirus virulence genes with main focus on SARS-CoV envelope gene. Virus. Res. 194, 124\u2013137. doi: 10.1016/j.virusres.2014.07.024",
            "Deng, M. P., Hu, Z. H., Wang, H. L., and Deng, F. (2012). Developments of subunit and VLP vaccines against influenza A virus. Virol. Sin. 27, 145\u2013153. doi: 10.1007/s12250-012-3241-1",
            "Desforges, M., Desjardins, J., Zhang, C., and Talbot, P. J. (2013). The acetyl-esterase activity of the hemagglutinin-esterase protein of human coronavirus OC43 strongly enhances the production of infectious virus. J. Virol. 87, 3097\u20133107. doi: 10.1128/jvi.02699-12",
            "Desforges, M., Le Coupanec, A., Brison, E., Meessen-Pinard, M., and Talbot, P. J. (2014). Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans. Adv. Exp. Med. Biol. 807, 75\u201396. doi: 10.1007/978-81-322-1777-0_6",
            "Drexler, J. F., Corman, V. M., and Drosten, C. (2014). Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS. Antiviral Res. 101, 45\u201356. doi: 10.1016/j.antiviral.2013.10.013",
            "Drosten, C., Gunther, S., Preiser, W., van der Werf, S., Brodt, H. R., Becker, S., et al (2003). Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967\u20131976. doi: 10.1056/ NEJMoa030747",
            "Du, L., He, Y., Jiang, S., and Zheng, B. J. (2008). Development of subunit vaccines against severe acute respiratory syndrome. Drugs Today 44, 63\u201373. doi: 10.1358/ dot.2008.44.1.1131830",
            "Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B. J., and Jiang, S. (2009a). The spike protein of SARS-CoV - a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 226\u2013236. doi: 10.1038/nrmicro2090",
            "Du, L., and Jiang, S. (2015). Middle East respiratory syndrome: current status and future prospects for vaccine development. Expert Opin. Biol. Ther. 15, 1647\u20131651. doi: 10.1517/14712598.2015.1092518",
            "Du, L., Kou, Z., Ma, C., Tao, X., <a class=\"ref-link\" id=\"cWang_et+al_2013_a\" href=\"#rWang_et+al_2013_a\">Wang, L., Zhao, G., et al (2013a</a>). A truncated receptor-binding domain of MERS-CoV Spike protein potently inhibits MERSCoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 8:e81587. doi: 10.1371/ journal.pone.0081587",
            "Du, L., Ma, C., and Jiang, S. (2013b). Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC. J. Infect. 67, 348\u2013350. doi: 10.1016/j.jinf.2013.05.002",
            "Du, L., Tai, W., Yang, Y., Zhao, G., Zhu, Q., Sun, S., et al (2016a). Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat. Commun. 7:13473. doi: 10.1038/ncomms 13473",
            "Du, L., Tai, W., Zhou, Y., and Jiang, S. (2016b). Vaccines for the prevention against the threat of MERS-CoV. Expert Rev. Vaccines 15, 1123\u20131134. doi: 10.1586/ 14760584.2016.1167603",
            "Du, L., Yang, Y., Zhou, Y., Lu, L., <a class=\"ref-link\" id=\"cLi_et+al_2017_a\" href=\"#rLi_et+al_2017_a\">Li, F., and Jiang, S. (2017</a>). MERS-CoV spike protein: a key target for antivirals. Expert Opin. Ther. Targets 21, 131\u2013143. doi: 10.1080/14728222.2017.1271415",
            "Du, L., Zhao, G., Chan, C. C., Li, L., He, Y., Zhou, Y., et al (2010). A 219-mer CHOexpressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. Viral. Immunol. 23, 211\u2013219. doi: 10.1089/vim.2009.0090",
            "Du, L., Zhao, G., Chan, C. C., Sun, S., Chen, M., Liu, Z., et al (2009b). Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 393, 144\u2013150. doi: 10.1016/j.virol.2009.07.018",
            "Du, L., Zhao, G., He, Y., Guo, Y., Zheng, B. J., Jiang, S., et al (2007). Receptorbinding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 25, 2832\u20132838. doi: 10.1016/j.vaccine. 2006.10.031",
            "Du, L., Zhao, G., Kou, Z., Ma, C., Sun, S., Poon, V. K., et al (2013c). Identification of a receptor-binding domain in the S protein of the novel human coronavirus",
            "Middle East Respiratory Syndrome coronavirus as an essential target for vaccine development. J. Virol. 87, 9939\u20139942. doi: 10.1128/jvi.01048-13 Du, L., Zhao, G., Li, L., He, Y., Zhou, Y., Zheng, B. J., et al (2009c). Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem. Biophys. Res. Commun. 384, 486\u2013490. doi: 10.1016/j.bbre.2009.05.003 Elshabrawy, H. A., Coughlin, M. M., Baker, S. C., and Prabhakar, B. S. (2012). Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoS One 7:e50366. doi: 10.1371/journal.pone.0050366 Esper, F., Weibel, C., Ferguson, D., Landry, M. L., and Kahn, J. S. (2006). Coronavirus HKU1 infection in the United States. Emerg. Infect. Dis. 12, 775\u2013779. doi: 10.3201/eid1205.051316 Falsey, A. R., Walsh, E. E., and Hayden, F. G. (2002). Rhinovirus and coronavirus infection-associated hospitalizations among older adults. J. Infect. Dis. 185, 1338\u20131341. doi: 10.1086/339881 Fehr, A. R., and Perlman, S. (2015). Coronaviruses: an overview of their replication and pathogenesis. Methods Mol. Biol. 1282, 1\u201323. doi: 10.1007/978-1-49392438-7_1 Fouchier, R. A. M., Hartwig, N. G., Bestebroer, T. M., Niemeyer, B., de Jong, J. C., Simon, J. H., et al (2004). A previously undescribed coronavirus associated with respiratory disease in humans. Proc. Natl. Acad. Sci. U.S.A. 101, 6212\u20136216. doi: 10.1073/pnas.0400762101 Ge, X. Y., Li, J. L., Yang, X. L., Chmura, A. A., <a class=\"ref-link\" id=\"cZhu_et+al_2013_a\" href=\"#rZhu_et+al_2013_a\">Zhu, G., Epstein, J. H., et al (2013</a>). Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535\u2013538. doi: 10.1038/nature12711 Gerna, G., Campanini, G., Rovida, F., Percivalle, E., Sarasini, A., Marchi, A., et al (2006). Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients. J. Med. Virol. 78, 938\u2013949. doi: 10.1002/jmv.20645 Gerna, G., Percivalle, E., Sarasini, A., Campanini, G., Piralla, A., Rovida, F., et al (2007). Human respiratory coronavirus HKU1 versus other coronavirus infections in Italian hospitalised patients. J. Clin. Virol. 38, 244\u2013250. doi: 10. 1016/j.jcv.2006.12.008 Guo, Y., Sun, S., Wang, K., Zhang, S., Zhu, W., and Chen, Z. (2005). Elicitation of immunity in mice after immunization with the S2 subunit of the severe acute respiratory syndrome coronavirus. DNA Cell Biol. 24, 510\u2013515. doi: 10.1089/ dna.2005.24.510 Haagmans, B. L., van den Brand, J. M., Raj, V. S., Volz, A., Wohlsein, P., Smits, S. L., et al (2016). An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels. Science 351, 77\u201381. doi: 10.1126/ science.aad1283 Hamre, D., Kindig, D. A., and Mann, J. (1967). Growth and intracellular development of a new respiratory virus. J. Virol. 1, 810\u2013816. doi: 10.1128/jvi. 1.4.810-816.1967 Hamre, D., and Procknow, J. J. (1966). A new virus isolated from human respiratory tract. Proc. Soc. Exp. Biol. Med. 121, 190\u2013193. doi: 10.3181/ 00379727-121-30734 He, Y., Li, J., Heck, S., Lustigman, S., and Jiang, S. (2006a). Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design. J. Virol. 80, 5757\u20135767. doi: 10.1128/jvi.00083-06 He, Y., Li, J., and Jiang, S. (2006b). A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity. Biochem. Biophys. Res. Commun. 344, 106\u2013113. doi: 10.1016/j.bbrc.2006.03.139 He, Y., Li, J., Li, W., Lustigman, S., Farzan, M., and Jiang, S. (2006c). Crossneutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J. Immunol. 176, 6085\u20136092. doi: 10.4049/jimmunol.176.10.6085 He, Y., Lu, H., Siddiqui, P., Zhou, Y., and Jiang, S. (2005a). Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J. Immunol. 174, 4908\u20134915. doi: 10.4049/jimmunol. 174.8.4908 He, Y., Zhou, Y., Liu, S., Kou, Z., <a class=\"ref-link\" id=\"cLi_et+al_2004_a\" href=\"#rLi_et+al_2004_a\">Li, W., Farzan, M., et al (2004</a>). Receptorbinding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem. Biophys. Res. Commun. 324, 773\u2013781. doi: 10.1016/j.bbrc.2004.09.106 He, Y., Zhou, Y., Siddiqui, P., Niu, J., and Jiang, S. (2005b). Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. J. Clin. Microbiol. 43, 3718\u20133726. doi: 10.1128/jcm.43.8.3718-3726.2005 Hofmann, H., Pyrc, K., van der Hoek, L., Geier, M., Berkhout, B., and Pohlmann, S. (2005). Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc. Natl. Acad. Sci. U.S.A. 102, 7988\u20137993. doi: 10.1073/pnas.0409465102 Hofmann, H., Simmons, G., Rennekamp, A. J., Chaipan, C., Gramberg, T., Heck, E., et al (2006). Highly conserved regions within the spike proteins of human coronaviruses 229E and NL63 determine recognition of their respective cellular receptors. J. Virol. 80, 8639\u20138652. doi: 10.1128/jvi.005 60-06 Hu, B., Zeng, L. P., Yang, X. L., Ge, X. Y., Zhang, W., Li, B., et al (2017). Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus. PLoS Pathog. 13:e1006698. doi: 10.1371/ journal.ppat.1006698 Huang, X., Dong, W., Milewska, A., Golda, A., Qi, Y., Zhu, Q. K., et al (2015). Human coronavirus HKU1 spike protein uses O-Acetylated sialic acid as an attachment receptor determinant and employs hemagglutinin-esterase protein as a receptor-destroying enzyme. J. Virol. 89, 7202\u20137213. doi: 10.1128/jvi. 00854-15 Hulswit, R. J. G., Lang, Y., Bakkers, M. J. G., Li, W., Li, Z., Schouten, A., et al (2019). Human coronaviruses OC43 and HKU1 bind to 9-O-acetylated sialic acids via a conserved receptor-binding site in spike protein domain A. Proc. Natl Acad. Sci. U.S.A. 116, 2681\u20132690. doi: 10.1073/pnas.1809667116 Jaume, M., Yip, M. S., Kam, Y. W., Cheung, C. Y., Kien, F., Roberts, A., et al (2012). SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement. Hong Kong Med. J. 18(Suppl. 2), 31\u201336. Jiaming, L., Yanfeng, Y., Yao, D., Yawei, H., Linlin, B., Baoying, H., et al (2017). The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine 35, 10\u201318. doi: 10.1016/j.vaccine.2016.11.064 Jiang, S., Bottazzi, M. E., Du, L., Lustigman, S., Tseng, C. T., Curti, E., et al (2012). Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev. Vaccines 11, 1405\u20131413. doi: 10.1586/erv.12.126 Jiang, S., Du, L., and Shi, Z. (2020). An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerg Microbes Infect. 9, 275\u2013277. doi: 10.1080/22221751.2020. 1723441 Jiang, S., <a class=\"ref-link\" id=\"cHe_et+al_2005_a\" href=\"#rHe_et+al_2005_a\">He, Y., and Liu, S. (2005</a>). SARS vaccine development. Emerg. Infect. Dis. 11, 1016\u20131020. doi: 10.3201/1107.050219 Jiang, S., Lu, L., <a class=\"ref-link\" id=\"cDu_2013_a\" href=\"#rDu_2013_a\">Du, L., and Debnath, A. K. (2013</a>). A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. J. Infect. 66, 464\u2013466. doi: 10.1016/j.jinf.2012.12.003 Kam, Y. W., Kien, F., Roberts, A., Cheung, Y. C., Lamirande, E. W., Vogel, L., et al (2007). Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine 25, 729\u2013740. doi: 10.1016/j.vaccine.2006. 08.011 Kapikian, A. Z., James, H. D., Kelly, S. J., Dees, J. H., Turner, H. C., McIntosh, K., et al (1969). Isolation from man of avian infectious bronchitis virus-like viruses (coronavirus) similar to 229E virus with some epidemiological observations. J. Infect. Dis. 119, 282\u2013290. doi: 10.1093/infdis/119.3.282 Killerby, M. E., Biggs, H. M., Haynes, A., Dahl, R. M., Mustaquim, D., Gerber, S. I., et al (2018). Human coronavirus circulation in the United States 2014-2017. J. Clin. Virol. 101, 52\u201356. doi: 10.1016/j.jcv.2018.01.019 Kim, K. Y., Han, S. Y., Kim, H. S., Cheong, H. M., Kim, S. S., and Kim, D. S. (2017). Human coronavirus in the 2014 winter season as a cause of lower respiratory tract infection. Yonsei Med. J. 58, 174\u2013179. doi: 10.3349/ymj.2017.58.1.174 King, A. M. Q., Lefkowitz, E. J., Mushegian, A. R., Adams, M. J., Dutilh, B. E., Gorbalenya, A. E., et al (2018). Changes to taxonomy and the international code of virus classification and nomenclature ratified by the international committee on taxonomy of viruses (2018). Arch. Virol. 163, 2601\u20132631. doi: 10.1007/s00705-018-3847-1",
            "Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., et al (2003). A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953\u20131966. doi: 10.1056/NEJMoa030781",
            "Kudelova, M., Belvoncikova, P., Vrbova, M., Kovalova, A., Stibraniova, I., Kocakova, P., et al (2015). Detection of murine herpesvirus 68 (MHV-68) in dermacentor reticulatus ticks. Microb. Ecol. 70, 785\u2013794. doi: 10.1007/s00248015-0622-7",
            "Kusanagi, K., Kuwahara, H., Katoh, T., Nunoya, T., Ishikawa, Y., Samejima, T., et al (1992). Isolation and serial propagation of porcine epidemic diarrhhea virus in cell-cultures and partial characterization of the isolate. J. Vet. Med. Sci. 54, 313\u2013318. doi: 10.1292/jvms.54.313",
            "Lan, J., Deng, Y., Chen, H., Lu, G., Wang, W., Guo, X., et al (2014). Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS One 9:e112602. doi: 10.1371/journal.pone.011 2602",
            "Lan, J., Yao, Y., Deng, Y., Chen, H., Lu, G., Wang, W., et al (2015). Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine 2, 1438\u20131446. doi: 10.1016/j.ebiom.2015. 08.031",
            "Lau, S. K., Woo, P. C., Yip, C. C., Tse, H., Tsoi, H. W., Cheng, V. C., et al (2006). Coronavirus HKU1 and other coronavirus infections in Hong Kong. J. Clin. Microbiol. 44, 2063\u20132071. doi: 10.1128/jcm.02614-05",
            "Lau, S. K. P., Zhang, L., Luk, H. K. H., Xiong, L., Peng, X., Li, K. S. M., et al (2018). Receptor usage of a novel bat lineage C betacoronavirus reveals evolution of Middle East respiratory syndrome-related coronavirus spike proteins for human dipeptidyl peptidase 4 binding. J. Infect. Dis. 218, 197\u2013207. doi: 10.1093/ infdis/jiy018",
            "Lehmann, C., Wolf, H., Xu, J. G., Zhao, Q. B., Shao, Y. M., Motz, M., et al (2008). A line immunoassay utilizing recombinant nucleocapsid proteins for detection of antibodies to human coronaviruses. Diagn. Microbiol. Infect. Dis. 61, 40\u201348. doi: 10.1016/j.diagmicrobio.2007.12.002",
            "Lelli, D., Papetti, A., Sabelli, C., Rosti, E., Moreno, A., and Boniotti, M. B. (2013). Detection of coronaviruses in bats of various species in Italy. Viruses 5, 2679\u20132689. doi: 10.3390/v5112679",
            "<a class=\"ref-link\" id=\"cLi_2008_a\" href=\"#rLi_2008_a\">Li, F. (2008</a>). Structural analysis of major species barriers between humans and palm civets for severe acute respiratory syndrome coronavirus infections. J. Virol. 82, 6984\u20136991. doi: 10.1128/jvi.00442-08",
            "<a class=\"ref-link\" id=\"cLi_2015_a\" href=\"#rLi_2015_a\">Li, F. (2015</a>). Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J. Virol. 89, 1954\u20131964. doi: 10.1128/jvi.02615-14",
            "<a class=\"ref-link\" id=\"cLi_2016_a\" href=\"#rLi_2016_a\">Li, F. (2016</a>). Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 3, 237\u2013261. doi: 10.1146/annurev-virology-110615-042301",
            "Li, F., and Du, L. (2019). MERS coronavirus: an emerging zoonotic virus. Viruses 11:E663. doi: 10.3390/v11070663",
            "Li, F., Li, W., Farzan, M., and Harrison, S. C. (2005a). Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309, 1864\u20131868. doi: 10.1126/science.1116480",
            "Li, W., Shi, Z., Yu, M., Ren, W., Smith, C., Epstein, J. H., et al (2005b). Bats are natural reservoirs of SARS-like coronaviruses. Science 310, 676\u2013679. doi: 10.1126/science.1118391",
            "Li, W., Zhang, C., Sui, J., Kuhn, J. H., Moore, M. J., Luo, S., et al (2005c). Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 24, 1634\u20131643. doi: 10.1038/sj.emboj.7600640",
            "Li, J., Ulitzky, L., Silberstein, E., Taylor, D. R., and Viscidi, R. (2013). Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates. Viral. Immunol. 26, 126\u2013132. doi: 10.1089/vim.2012.0076",
            "Li, W., Greenough, T. C., Moore, M. J., Vasilieva, N., Somasundaran, M., Sullivan, J. L., et al (2004). Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2. J. Virol. 78, 11429\u201311433. doi: 10.1128/jvi.78.20.11429-11433. 2004",
            "Li, W., Hulswit, R. J. G., Widjaja, I., Raj, V. S., McBride, R., Peng, W., et al (2017). Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. Proc. Natl Acad. Sci. U.S.A. 114, E8508\u2013E8517. doi: 10.1073/pnas.1712592114",
            "Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., et al (2003). Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450\u2013454. doi: 10.1038/nature02145",
            "Liu, D. X., Fung, T. S., Chong, K. K., Shukla, A., and Hilgenfeld, R. (2014). Accessory proteins of SARS-CoV and other coronaviruses. Antiviral Res. 109, 97\u2013109. doi: 10.1016/j.antiviral.2014.06.013",
            "Liu, R. Y., Wu, L. Z., Huang, B. J., Huang, J. L., Zhang, Y. L., Ke, M. L., et al (2005). Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats. Virus Res. 112, 24\u201331. doi: 10.1016/j.virusres.2005.02.009",
            "Liu, S. J., Leng, C. H., Lien, S. P., Chi, H. Y., Huang, C. Y., Lin, C. L., et al (2006). Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Vaccine 24, 3100\u20133108. doi: 10.1016/j.vaccine.2006. 01.058",
            "Liu, S. L., and Saif, L. (2020). Emerging viruses without borders: the Wuhan coronavirus. Viruses 12:E130. doi: 10.3390/v12020130",
            "Lu, G., Hu, Y., Wang, Q., Qi, J., Gao, F., Li, Y., et al (2013). Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500, 227\u2013231. doi: 10.1038/nature12328",
            "Lu, L., Liu, Q., Zhu, Y., Chan, K. H., Qin, L., Li, Y., et al (2014). Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun. 5:3067. doi: 10.1038/ncomms4067",
            "Luo, C. M., Wang, N., Yang, X. L., Liu, H. Z., Zhang, W., Li, B., et al (2018a). Discovery of novel bat coronaviruses in south China that use the same receptor as MERS coronavirus. J. Virol. 92, e116\u2013e118. doi: 10.1128/jvi.00116-18",
            "Luo, F., Liao, F. L., Wang, H., Tang, H. B., Yang, Z. Q., and Hou, W. (2018b). Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV vaccine. Virol. Sin. 33, 201\u2013204. doi: 10.1007/s12250-018-0009-2",
            "Ma, C., Li, Y., Wang, L., Zhao, G., Tao, X. R., Tseng, C. T., et al (2014a). Intranasal vaccination with recombinant receptor-binding domain of MERSCoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine 32, 2100\u20132108. doi: 10.1016/j.vaccine.2014.02.004",
            "Ma, C., Wang, L., Tao, X., Zhang, N., <a class=\"ref-link\" id=\"cYang_et+al_2014_b\" href=\"#rYang_et+al_2014_b\">Yang, Y., Tseng, C. T., et al (2014b</a>). Searching for an ideal vaccine candidate among different MERS coronavirus receptorbinding fragments - The importance of immunofocusing in subunit vaccine design. Vaccine 32, 6170\u20136176. doi: 10.1016/j.vaccine.2014.08.086",
            "Ma, Y., Zhang, Y., Liang, X., Lou, F., Oglesbee, M., Krakowka, S., et al (2015). Origin, evolution, and virulence of porcine deltacoronaviruses in the United States. mBio 6:e00064. doi: 10.1128/mBio.00064-15",
            "Marra, M. A., Jones, S. J., Astell, C. R., Holt, R. A., Brooks-Wilson, A., Butterfield, Y. S., et al (2003). The genome sequence of the SARS-associated coronavirus. Science 300, 1399\u20131404. doi: 10.1126/science.1085953",
            "Matoba, Y., Abiko, C., Ikeda, T., Aoki, Y., Suzuki, Y., Yahagi, K., et al (2015). Detection of the human coronavirus 229E, HKU1, NL63, and OC43 between 2010 and 2013 in Yamagata, Japan. Jpn. J. Infect. Dis. 68, 138\u2013141. doi: 10.7883/ yoken.JJID.2014.266",
            "McIntosh, K., Becker, W. B., and Chanock, R. M. (1967). Growth in suckling-mouse brain of IBV-like viruses from patients with upper respiratory tract disease. Proc. Natl. Acad. Sci. U.S.A. 58, 2268\u20132273. doi: 10.1073/pnas.58.6.2268",
            "Menachery, V. D., Mitchell, H. D., Cockrell, A. S., Gralinski, L. E., Yount, BL Jr, Graham, R. L., et al (2017). MERS-CoV accessory ORFs play key role for infection and pathogenesis. mBio 8:e00665-17. doi: 10.1128/mBio.00665-17",
            "Mobaraki, K., and Ahmadzadeh, J. (2019). Current epidemiological status of Middle East respiratory syndrome coronavirus in the world from 1.1.2017 to 17.1.2018: a cross-sectional study. BMC Infect. Dis. 19:351. doi: 10.1186/s12879019-3987-2",
            "Mou, H., Raj, V. S., van Kuppeveld, F. J., Rottier, P. J., Haagmans, B. L., and Bosch, B. J. (2013). The receptor binding domain of the new Middle East Respiratory Syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J. Virol. 87, 9379\u20139383. doi: 10.1128/jvi.01277-13",
            "Mourez, T., Vabret, A., Han, Y., Dina, J., Legrand, L., Corbet, S., et al (2007). Baculovirus expression of HCoV-OC43 nucleocapsid protein and development of a Western blot assay for detection of human antibodies against HCoV-OC43. J. Virol. Methods 139, 175\u2013180. doi: 10.1016/j.jviromet.2006.09.024",
            "<a class=\"ref-link\" id=\"cMyint_1994_a\" href=\"#rMyint_1994_a\">Myint, S. H. (1994</a>). Human coronaviruses - A brief review. Rev. Med. Virol. 4, 35\u201346. doi: 10.1002/rmv.1980040108",
            "Nicholls, J. M., Poon, L. L., Lee, K. C., Ng, W. F., Lai, S. T., Leung, C. Y., et al (2003). Lung pathology of fatal severe acute respiratory syndrome. Lancet 361, 1773\u20131778. doi: 10.1016/s0140-6736(03)13413-7",
            "Nyon, M. P., Du, L., Tseng, C. K., Seid, C. A., Pollet, J., Naceanceno, K. S., et al (2018). Engineering a stable CHO cell line for the expression of a MERScoronavirus vaccine antigen. Vaccine 36, 1853\u20131862. doi: 10.1016/j.vaccine. 2018.02.065",
            "Ou, X., Guan, H., Qin, B., Mu, Z., Wojdyla, J. A., Wang, M., et al (2017). Crystal structure of the receptor binding domain of the spike glycoprotein of human betacoronavirus HKU1. Nat. Commun. 8:2529. doi: 10.1038/ncomms15216",
            "Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., et al (2017). Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl. Acad. Sci. U.S.A. 114, E7348\u2013E7357. doi: 10.1073/pnas.1707304114",
            "<a class=\"ref-link\" id=\"cPedersen_2014_a\" href=\"#rPedersen_2014_a\">Pedersen, N. C. (2014</a>). An update on feline infectious peritonitis: virology and immunopathogenesis. Vet. J. 201, 123\u2013132. doi: 10.1016/j.tvjl.2014.04.017",
            "Pimentel, T. A., Yan, Z., Jeffers, S. A., Holmes, K. V., Hodges, R. S., and Burkhard, P. (2009). Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem. Biol. Drug Des. 73, 53\u201361. doi: 10.1111/j.1747-0285.2008.00746.x",
            "Poon, L. L., Chu, D. K., Chan, K. H., Wong, O. K., Ellis, T. M., Leung, Y. H., et al (2005). Identification of a novel coronavirus in bats. J. Virol. 79, 2001\u20132009. doi: 10.1128/jvi.79.4.2001-2009.2005",
            "Qiu, M., Shi, Y., Guo, Z., Chen, Z., <a class=\"ref-link\" id=\"cHe_et+al_2005_a\" href=\"#rHe_et+al_2005_a\">He, R., Chen, R., et al (2005</a>). Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. Microbes Infect. 7, 882\u2013889. doi: 10.1016/j.micinf.2005.02.006",
            "Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H., Muller, M. A., Dijkman, R., et al (2013). Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495, 251\u2013254. doi: 10.1038/nature12005",
            "Regamey, N., Kaiser, L., Roiha, H. L., Deffernez, C., Kuehni, C. E., Latzin, P., et al (2008). Viral etiology of acute respiratory infections with cough in infancy A community-based birth cohort study. Pediatr. Infect. Dis. J. 27, 100\u2013105. doi: 10.1097/INF.0b013e31815922c8",
            "Reusken, C. B., Haagmans, B. L., Muller, M. A., Gutierrez, C., Godeke, G. J., Meyer, B., et al (2013). Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect. Dis. 13, 859\u2013866. doi: 10.1016/s1473-3099(13)70164-6",
            "Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R., Icenogle, J. P., et al (2003). Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394\u20131399. doi: 10.1126/science. 1085952",
            "Scobey, T., Yount, B. L., Sims, A. C., Donaldson, E. F., Agnihothram, S. S., Menachery, V. D., et al (2013). Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. U.S.A. 110, 16157\u201316162. doi: 10.1073/pnas.1311542110",
            "Severance, E. G., Bossis, I., Dickerson, F. B., Stallings, C. R., Origoni, A. E., Sullens, A., et al (2008). Development of a nucleocapsid-based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a US metropolitan population. Clin. Vaccine Immunol. 15, 1805\u20131810. doi: 10.1128/ cvi.00124-08",
            "Shao, X., Guo, X., Esper, F., Weibel, C., and Kahn, J. S. (2007). Seroepidemiology of group I human coronaviruses in children. J. Clin. Virol. 40, 207\u2013213. doi: 10.1016/j.jcv.2007.08.007",
            "Snijder, E. J., Bredenbeek, P. J., Dobbe, J. C., Thiel, V., Ziebuhr, J., Poon, L. L., et al (2003). Unique and conserved features of genome and proteome of SARScoronavirus, an early split-off from the coronavirus group 2 lineage. J. Mol. Biol. 331, 991\u20131004. doi: 10.1016/s0022-2836(03)00865-9",
            "Snijder, E. J., Decroly, E., and Ziebuhr, J. (2016). The nonstructural proteins directing coronavirus RNA synthesis and processing. Adv. Virus Res. 96, 59\u2013 126. doi: 10.1016/bs.aivir.2016.08.008",
            "Tai, W., Wang, Y., Fett, C. A., Zhao, G., <a class=\"ref-link\" id=\"cLi_et+al_2017_a\" href=\"#rLi_et+al_2017_a\">Li, F., Perlman, S., et al (2017</a>). Recombinant receptor-binding domains of multiple middle east respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants. J. Virol 91:e01651-16. doi: 10.1128/jvi.01651-16",
            "Tai, W., Zhao, G., Sun, S., Guo, Y., Wang, Y., Tao, X., et al (2016). A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology 499, 375\u2013382. doi: 10.1016/j.virol.2016.10.005 Tang, J., Zhang, N., Tao, X., Zhao, G., Guo, Y., Tseng, C. T., et al (2015). Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum. Vaccin. Immunother. 11, 1244\u20131250. doi: 10.1080/21645515.2015.1021527 Tomar, S., Johnston, M. L., St John, S. E., Osswald, H. L., Nyalapatla, P. R., Paul, L. N., et al (2015). Ligand-induced dimerization of Middle East respiratory syndrome (MERS) coronavirus nsp5 protease (3CLpro): implifications for nsp5 regulation and the development of antivirals. J. Biol. Chem. 290, 19403\u201319422. doi: 10.1074/jbc.M115.651463 Tortorici, M. A., Walls, A. C., Lang, Y., Wang, C., Li, Z., Koerhuis, D., et al (2019). Structural basis for human coronavirus attachment to sialic acid receptors. Nat. Struct. Mol. Biol. 26, 481\u2013489. doi: 10.1038/s41594-0190233-y Tu, C., Crameri, G., Kong, X., Chen, J., Sun, Y., Yu, M., et al (2004). Antibodies to SARS coronavirus in civets. Emerg. Infect. Dis. 10, 2244\u20132248. doi: 10.3201/ eid1012.040520 Tyrrell, D. A., and Bynoe, M. L. (1965). Cultivation of a novel type of commoncold virus in organ cultures. Br. Med. J. 1, 1467\u20131470. doi: 10.1136/bmj.1.5448. 1467 Vabret, A., Mourez, T., Gouarin, S., Petitjean, J., and Freymuth, F. (2003). An outbreak of coronavirus OC43 respiratory infection in Normandy, France. Clin. Infect. Dis. 36, 985\u2013989. doi: 10.1086/374222 van Boheemen, S., de Graaf, M., Lauber, C., Bestebroer, T. M., Raj, V. S., <a class=\"ref-link\" id=\"cZaki_et+al_2012_a\" href=\"#rZaki_et+al_2012_a\">Zaki, A. M., et al (2012</a>). Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 3:e0047312. doi: 10.1128/mBio.00473-12 van der Hoek, L., Pyrc, K., Jebbink, M. F., Vermeulen-Oost, W., Berkhout, R. J., Wolthers, K. C., et al (2004). Identification of a new human coronavirus. Nat. Med. 10, 368\u2013373. doi: 10.1038/nm1024 Veit, S., Jany, S., Fux, R., Sutter, G., and Volz, A. (2018). CD8+ T cells responding to the Middle East Respiratory Syndrome coronavirus nucleocapsid protein delivered by vaccinia virus MVA in mice. Viruses 10:E718. doi: 10.3390/ v10120718 Wang, C., Zheng, X., Gai, W., Zhao, Y., Wang, H., Wang, H., et al (2017). MERSCoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques. Oncotarget 8, 12686\u201312694. doi: 10.18632/oncotarget.8475 Wang, L., Shi, W., Joyce, M. G., Modjarrad, K., <a class=\"ref-link\" id=\"cZhang_et+al_2015_a\" href=\"#rZhang_et+al_2015_a\">Zhang, Y., Leung, K., et al (2015</a>). Evaluation of candidate vaccine approaches for MERS-CoV. Nat. Commun. 6:7712. doi: 10.1038/ncomms8712 Wang, N., Shi, X., Jiang, L., Zhang, S., <a class=\"ref-link\" id=\"cWang_et+al_2013_a\" href=\"#rWang_et+al_2013_a\">Wang, D., Tong, P., et al (2013</a>). Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 23, 986\u2013993. doi: 10.1038/cr. 2013.92 Wang, Y., Tai, W., Yang, J., Zhao, G., Sun, S., Tseng, C. K., et al (2017). Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Hum. Vaccin. Immunother. 13, 1615\u20131624. doi: 10.1080/21645515. 2017.1296994 Wong, S. K., Li, W., Moore, M. J., Choe, H., and Farzan, M. (2004). A 193amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 279, 3197\u20133201. doi: 10.1074/ jbc.C300520200 Woo, P. C., Lau, S. K., Chu, C. M., Chan, K. H., Tsoi, H. W., Huang, Y., et al (2005). Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J. Virol. 79, 884\u2013895. doi: 10.1128/jvi.79.2.884-895.2005 Woo, P. C., Lau, S. K., Lam, C. S., Lai, K. K., Huang, Y., Lee, P., et al (2009a). Comparative analysis of complete genome sequences of three avian coronaviruses reveals a novel group 3c coronavirus. J. Virol. 83, 908\u2013917. doi: 10.1128/jvi.01977-08 Woo, P. C., Lau, S. K., Lam, C. S., Lau, C. C., Tsang, A. K., Lau, J. H., et al (2012). Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J. Virol. 86, 3995\u20134008. doi: 10.1128/jvi.06540-11",
            "Woo, P. C., Lau, S. K., Lam, C. S., Tsang, A. K., Hui, S. W., Fan, R. Y., et al (2014). Discovery of a novel bottlenose dolphin coronavirus reveals a distinct species of marine mammal coronavirus in gammacoronavirus. J. Virol. 88, 1318\u20131331. doi: 10.1128/jvi.02351-13",
            "Woo, P. C., Lau, S. K., Yip, C. C., Huang, Y., and Yuen, K. Y. (2009b). More and more coronaviruses: human coronavirus HKU1. Viruses 1, 57\u201371. doi: 10.3390/v1010057",
            "Yang, Y., Deng, Y., Wen, B., Wang, H., Meng, X., Lan, J., et al (2014a). The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. Viral Immunol. 27, 543\u2013550. doi: 10.1089/vim.2014.0080",
            "Yang, Y., Du, L., Liu, C., Wang, L., <a class=\"ref-link\" id=\"cMa_et+al_2014_b\" href=\"#rMa_et+al_2014_b\">Ma, C., Tang, J., et al (2014b</a>). Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-tohuman transmission of MERS coronavirus. Proc. Natl. Acad. Sci. U.S.A. 111, 12516\u201312521. doi: 10.1073/pnas.1405889111",
            "Yang, Z. Y., Kong, W. P., Huang, Y., Roberts, A., Murphy, B. R., Subbarao, K., et al (2004). A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428, 561\u2013564. doi: 10.1038/nature02463",
            "Yuan, Y., Cao, D., Zhang, Y., Ma, J., Qi, J., Wang, Q., et al (2017). CryoEM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat. Commun. 8:15092. doi: 10.1038/ ncomms15092",
            "Zakhartchouk, A. N., Sharon, C., Satkunarajah, M., Auperin, T., Viswanathan, S., Mutwiri, G., et al (2007). Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. Vaccine 25, 136\u2013143. doi: 10.1016/j.vaccine.2006.06.084",
            "Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D., and Fouchier, R. A. (2012). Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814\u20131820. doi: 10.1056/NEJMoa1211721",
            "Zeng, F., Chow, K. Y., Hon, C. C., Law, K. M., Yip, C. W., Chan, K. H., et al (2004). Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments. Biochem. Biophys. Res. Commun. 315, 1134\u20131139. doi: 10.1016/j.bbrc.2004.01.166",
            "Zhang, N., Channappanavar, R., Ma, C., Wang, L., Tang, J., Garron, T., et al (2016). Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell. Mol. Immunol. 13, 180\u2013190. doi: 10.1038/cmi.2015.03",
            "Zhang, N., Jiang, S., and Du, L. (2014). Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev. Vaccines 13, 761\u2013774. doi: 10.1586/14760584.2014.912134",
            "Zhang, N., Tang, J., Lu, L., Jiang, S., and Du, L. (2015). Receptor-binding domainbased subunit vaccines against MERS-CoV. Virus Res. 202, 151\u2013159. doi: 10. 1016/j.virusres.2014.11.013",
            "Zhang, N., Wang, L., Deng, X., Liang, R., Su, M., He, C., et al (2020). Recent advances in the detection of respiratory virus infection in humans. J. Med. Virol. [Epub ahead of print].",
            "Zheng, N., Xia, R., Yang, C., Yin, B., Li, Y., Duan, C., et al (2009). Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice. Vaccine 27, 5001\u20135007. doi: 10.1016/j.vaccine.2009. 05.073",
            "Zhong, N. S., Zheng, B. J., Li, Y. M., Poon, L. L., Xie, Z. H., Chan, K. H., et al (2003). Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People\u2019s Republic of China, in February, 2003. Lancet 362, 1353\u20131358. doi: 10.1016/s0140-6736(03)14630-2",
            "Zhou, P., Yang, X. L., Wang, X. G., Hu, B., <a class=\"ref-link\" id=\"cZhang_et+al_2020_a\" href=\"#rZhang_et+al_2020_a\">Zhang, L., Zhang, W., et al (2020</a>). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Epub ahead of print].",
            "Zhou, Y., Jiang, S., and Du, L. (2018). Prospects for a MERS-CoV spike vaccine. Expert Rev. Vaccines 17, 677\u2013686. doi: 10.1080/14760584.2018.150 6702",
            "Zhou, Y., Yang, Y., Huang, J., Jiang, S., and Du, L. (2019). Advances in MERSCoV vaccines and therapeutics based on the receptor-binding domain. Viruses 11:E60. doi: 10.3390/v11010060",
            "Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al (2020). A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. [Epub ahead of print].",
            "Zhu, X., Liu, Q., Du, L., Lu, L., and Jiang, S. (2013). Receptor-binding domain as a target for developing SARS vaccines. J. Thoracic Dis. 5, S142\u2013S148. doi: 10.3978/j.issn.2072-1439.2013.06.06",
            "Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.",
            "Copyright \u00a9 2020 Wang, Shang, Jiang and Du. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms."
        ]
    },
    "participants": [
        {
            "participant": "people",
            "number": 70000,
            "context": "Among them, three emerging pathogenic CoVs, including severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and a newly identified CoV (2019-nCoV), once caused or continue to cause severe infections in humans, posing significant threats to global public health. <mark class=\"stats\">SARS-CoV infection in humans (with about 10% case fatality rate) was first reported from China in 2002, while MERS-CoV infection in humans (with about 34.4% case fatality rate) was first reported from Saudi Arabia in June 2012. 2019-nCoV was first reported from China in December 2019, and is currently infecting more than 70000 people (with about 2.7% case fatality rate)</mark>. Both SARS-CoV and MERS-CoV are zoonotic viruses, using bats as their natural reservoirs, and then transmitting through intermediate hosts, leading to human infections"
        },
        {
            "participant": "people",
            "number": 8098,
            "context": "The epidemic outbreak of SARS-CoV began in the Guangdong Province of China in November 2002, and spread through human-to-human transmission to other parts of the world within a few months (<a class=\"ref-link\" id=\"cKsiazek_et+al_2003_a\" href=\"#rKsiazek_et+al_2003_a\">Ksiazek et al, 2003</a>). <mark class=\"stats\">From November 2002 to August 2003, SARS-CoV infected more than 8,098 people in 29 counties, resulting in over 774 deaths with \u223c10% fatality rate (Du et al, 2009a)</mark>. Palm civets serving as a potential intermediate host of this virus were traced immediately (Tu et al, 2004)"
        },
        {
            "participant": "laboratoryconfirmed cases",
            "number": 2494,
            "context": "A decade later, another highly pathogenic human CoV, MERS-CoV, emerged, and the first patient with MERS-CoV infection was reported in Saudi Arabia in June 2012 (<a class=\"ref-link\" id=\"cZaki_et+al_2012_a\" href=\"#rZaki_et+al_2012_a\"><a class=\"ref-link\" id=\"cZaki_et+al_2012_a\" href=\"#rZaki_et+al_2012_a\">Zaki et al, 2012</a></a>). <mark class=\"stats\">By December 26, 2019, a total of 2,494 laboratoryconfirmed cases of MERS, including 858 associated deaths in 27 countries (fatality rate 34.4%), were reported to the WHO1</mark>. Globally, the majority (about 80%) of human cases have been reported in Saudi Arabia, where people get infected through direct contact with infected dromedary camels or persons2 (<a class=\"ref-link\" id=\"cZaki_et+al_2012_a\" href=\"#rZaki_et+al_2012_a\"><a class=\"ref-link\" id=\"cZaki_et+al_2012_a\" href=\"#rZaki_et+al_2012_a\">Zaki et al, 2012</a></a>)"
        },
        {
            "participant": "people",
            "number": 70000,
            "context": "A new CoV, 2019-nCoV, has caught worldwide attention (<a class=\"ref-link\" id=\"cLiu_2020_a\" href=\"#rLiu_2020_a\">Liu and Saif, 2020</a>; <a class=\"ref-link\" id=\"cZhang_et+al_2020_a\" href=\"#rZhang_et+al_2020_a\">Zhang et al, 2020</a>). <mark class=\"stats\">It was first identified in Wuhan, China in December 2019, from patients with pneumonia (<a class=\"ref-link\" id=\"cZhu_et+al_2020_a\" href=\"#rZhu_et+al_2020_a\">Zhu et al, 2020</a>), and has infected more than 70000 people globally, including 2,009 deaths (\u223c2.7% fatality</mark>. 1https://www.who.int/emergencies/mers-cov/en/ 2https://www.who.int/docs/default-source/coronaviruse/situation-reports/ 20200219-sitrep-30-covid-19.pdf?sfvrsn=6e50645_2"
        },
        {
            "participant": "main structural proteins",
            "number": 4,
            "context": "Some beta-CoVs, such as HCoV-OC43 and HCoV-HKU1, contain hemagglutininesterase (HE) gene located between ORF 1ab and S gene encoding an additional structural protein, HE (<a class=\"ref-link\" id=\"cde_Groot_et+al_2011_a\" href=\"#rde_Groot_et+al_2011_a\">De Groot et al, 2011</a>; <a class=\"ref-link\" id=\"cDesforges_et+al_2013_a\" href=\"#rDesforges_et+al_2013_a\">Desforges et al, 2013</a>; Huang et al, 2015). <mark class=\"stats\">Similar to other human CoVs, SARS-CoV possesses a \u223c29-kb genome, which encodes pp1a and pp1ab, four main structural proteins (S, E, M, and N), and eight accessory proteins, such as 3a, 3b, 6, 7a, 7b, 8a, 8b, and 9b (Figure 2A) (<a class=\"ref-link\" id=\"cMarra_et+al_2003_a\" href=\"#rMarra_et+al_2003_a\">Marra et al, 2003</a>; <a class=\"ref-link\" id=\"cSnijder_et+al_2003_a\" href=\"#rSnijder_et+al_2003_a\">Snijder et al, 2003</a>)</mark>. The MERS-CoV genome is about 30 kb in length and encodes pp1a, pp1ab, four structural proteins (S, E, M, and N), and five accessory proteins (3, 4a, 4b, 5, and 8b) (Figure 2A) (<a class=\"ref-link\" id=\"cvan_Boheemen_et+al_2012_a\" href=\"#rvan_Boheemen_et+al_2012_a\">van Boheemen et al, 2012</a>)"
        },
        {
            "participant": "structural proteins",
            "number": 4,
            "context": "Similar to other human CoVs, SARS-CoV possesses a \u223c29-kb genome, which encodes pp1a and pp1ab, four main structural proteins (S, E, M, and N), and eight accessory proteins, such as 3a, 3b, 6, 7a, 7b, 8a, 8b, and 9b (Figure 2A) (<a class=\"ref-link\" id=\"cMarra_et+al_2003_a\" href=\"#rMarra_et+al_2003_a\">Marra et al, 2003</a>; <a class=\"ref-link\" id=\"cSnijder_et+al_2003_a\" href=\"#rSnijder_et+al_2003_a\">Snijder et al, 2003</a>). <mark class=\"stats\">The MERS-CoV genome is about 30 kb in length and encodes pp1a, pp1ab, four structural proteins (S, E, M, and N), and five accessory proteins (3, 4a, 4b, 5, and 8b) (Figure 2A) (<a class=\"ref-link\" id=\"cvan_Boheemen_et+al_2012_a\" href=\"#rvan_Boheemen_et+al_2012_a\">van Boheemen et al, 2012</a>)</mark>. The genomic RNA of SARS-CoV and MERS-CoV is packed inside capsid formed by the N protein, while the M, E, and S proteins form the envelope surrounding the capsid (Figure 2B)"
        },
        {
            "participant": "structural proteins",
            "number": 4,
            "context": "Recent studies have found that the new human CoV, 2019nCoV, which belongs to the species of SARSr-CoV, shares high sequence identify (about 79.5%) to SARS-CoV (<a class=\"ref-link\" id=\"cZhou_et+al_2020_a\" href=\"#rZhou_et+al_2020_a\">Zhou et al, 2020</a>). <mark class=\"stats\">The genome of 2019-nCoV encodes pp1ab (translated from ORF 1ab), four structural proteins (S, E, M, and N), and six accessory proteins (3a, 6, 7a, 7b, 8, and 10) (Figure 2A)</mark>. Same as SARSCoV and MERS-CoV, 2019-nCoV appears to have no HE gene"
        }
    ],
    "statistics": [
        {
            "tests": {
                "context": "<mark class=\"stats\">Phylogenetic tree of coronaviruses (CoVs) based on the nucleotide sequences of RNA dependent RNA polymerase (RdRp). The Tree, with 1,000 bootstrap values, was constructed by the maximum likelihood method using MEGA 6. The four main phylogenetic clusters correspond to genera alpha-CoV, beta-CoV, gamma-CoV, and delta-CoV. Each CoV genus contains different subgenera. The letters in blue indicate human CoVs</mark>",
                "tests": [
                    {
                        "test": "maximum likelihood method"
                    }
                ]
            }
        }
    ],
    "keywords": [
        "dipeptidyl peptidase 4",
        "MERS",
        "open reading frames",
        "non-human primates",
        "interleukin 4",
        "receptor-binding domains",
        "HKU1",
        "tumor necrosis factor",
        "case fatality rate",
        "betacoronavirus",
        "human coronaviruses",
        "recombinant MERS-CoV NTD protein",
        "sars subunit vaccine",
        "coronavirus",
        "subunit vaccines",
        "Chinese hamster ovary",
        "sars cov infection",
        "receptorbinding domain",
        "fragment crystallizable",
        "recombinant MERS-CoV RBD",
        "antibody-dependent enhancement",
        "OC43",
        "SARS",
        "Fc\u03b3 receptor II",
        "viruslike particles",
        "E. coli",
        "non s structural",
        "SARS-CoV",
        "s protein",
        "MERS-CoV",
        "cov infection",
        "C-terminal domain",
        "taxonomy",
        "2019-nCoV",
        "monoclonal antibodies",
        "human coronavirus",
        "respiratory syndrome coronavirus",
        "East Respiratory syndrome",
        "NL63",
        "pneumonia",
        "International Committee on Taxonomy of Viruses",
        "pathogenesis",
        "N-terminal domain",
        "angiotensin-converting enzyme 2",
        "heptad repeat 1",
        "receptorbinding motif",
        "pathogenic",
        "mer cov",
        "modified Vaccinia Ankara"
    ],
    "keyword_relevance": {
        "SARS": 0.13571869216533003,
        "MERS": 0.1295496607032696,
        "MERS-CoV": 0.10302282541640963,
        "SARS-CoV": 0.09808760024676126,
        "coronavirus": 0.0931523750771129,
        "receptor-binding domains": 0.0851326341764343,
        "receptorbinding domain": 0.08389882788402221,
        "subunit vaccines": 0.03701418877236274,
        "dipeptidyl peptidase 4": 0.025909932140653916,
        "respiratory syndrome coronavirus": 0.016039481801357187,
        "2019-nCoV": 0.015422578655151141,
        "human coronavirus": 0.013571869216533004,
        "angiotensin-converting enzyme 2": 0.012954966070326958,
        "Chinese hamster ovary": 0.012338062924120914,
        "N-terminal domain": 0.011104256631708822,
        "non-human primates": 0.010487353485502776,
        "monoclonal antibodies": 0.010487353485502776,
        "HKU1": 0.00987045033929673,
        "OC43": 0.00987045033929673,
        "fragment crystallizable": 0.00863664404688464,
        "NL63": 0.007402837754472548,
        "open reading frames": 0.006785934608266502,
        "pneumonia": 0.006785934608266502,
        "pathogenic": 0.005552128315854411,
        "interleukin 4": 0.00431832202344232,
        "antibody-dependent enhancement": 0.00431832202344232,
        "C-terminal domain": 0.00431832202344232,
        "tumor necrosis factor": 0.003701418877236274,
        "recombinant MERS-CoV RBD": 0.003701418877236274,
        "pathogenesis": 0.003701418877236274,
        "betacoronavirus": 0.0030845157310302285,
        "human coronaviruses": 0.0030845157310302285,
        "s protein": 0.0030845157310302285,
        "viruslike particles": 0.0024676125848241827,
        "case fatality rate": 0.001850709438618137,
        "recombinant MERS-CoV NTD protein": 0.001850709438618137,
        "E. coli": 0.001850709438618137,
        "International Committee on Taxonomy of Viruses": 0.001850709438618137,
        "heptad repeat 1": 0.001850709438618137,
        "receptorbinding motif": 0.001850709438618137,
        "modified Vaccinia Ankara": 0.001850709438618137,
        "Fc\u03b3 receptor II": 0.0012338062924120913,
        "taxonomy": 0.0012338062924120913,
        "sars subunit vaccine": 0.0,
        "sars cov infection": 0.0,
        "non s structural": 0.0,
        "cov infection": 0.0,
        "East Respiratory syndrome": 0.0,
        "mer cov": 0.0
    },
    "species": [
        "E. coli"
    ],
    "summary": [
        "Coronaviruses (CoVs) belong to the subfamily Othocoronavirinae, in the family Coronaviridae of the order Nidovirales.",
        "2016a <a class=\"ref-link\" id=\"cWang_et+al_2015_a\" href=\"#rWang_et+al_2015_a\"><a class=\"ref-link\" id=\"cWang_et+al_2015_a\" href=\"#rWang_et+al_2015_a\">Wang et al, 2015</a></a> <a class=\"ref-link\" id=\"cAdney_et+al_2019_a\" href=\"#rAdney_et+al_2019_a\">Adney et al, 2019</a> <a class=\"ref-link\" id=\"cJiaming_et+al_2017_a\" href=\"#rJiaming_et+al_2017_a\">Jiaming et al, 2017</a> <a class=\"ref-link\" id=\"cYang_et+al_2014_a\" href=\"#rYang_et+al_2014_a\">Yang et al, 2014a</a> aaa, amino acid; Abs, antibodies; Ad5, adenovirus serotype 5; Ad5-hDPP4 mice, Ad5-hDPP4-transuced mice; Alum hydro, aluminum hydroxide; Alum pho, Aluminum phosphate; hDPP4, human dipeptidyl peptidase 4; hDPP4-Tg mice, transgenic mice expressing MERS-CoV receptor human DPP4; IFA, incomplete Freund\u2019s adjuvant; I.M., intramuscular; I.N., intranasal; mAbs, monoclonal antibodies; Montanide, Montanide ISA51; N/A, not reported; NHPs, non-human primates; NZW, rabbits, New Zealand White rabbits; PFU, plaque-forming unit; rRBD, recombinant RBD; SAS, Sigma Adjuvant System; S.C., subcutaneous; TCID50, median tissue culture infectious dose; TNF-\u03b1, tumor necrosis factor (TNF)-alpha.",
        "An RBD protein fragment containing MERSCoV S residues 377\u2013622 fused with the Fc tag of human IgG can induce MERS-CoV S1- and/or RBD-specific humoral and cellular immune responses in the immunized mice with neutralizing activity against MERS-CoV infection (<a class=\"ref-link\" id=\"cDu_et+al_2013_c\" href=\"#rDu_et+al_2013_c\">Du et al, 2013c</a>; <a class=\"ref-link\" id=\"cJiang_et+al_2013_a\" href=\"#rJiang_et+al_2013_a\">Jiang et al, 2013</a>).",
        "Several MERS-CoV subunit vaccines have been designed based on the identified critical neutralizing domain of RBD fragment, including those expressed in a stable CHO cell line (S377-588-Fc), fusing with a trimeric motif foldon (RBDFd), or containing single or multiple mutations in the RBD of representative human and camel strains from the 2012\u20132015 MERS outbreaks (Tai et al, 2016, 2017; <a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\"><a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\">Nyon et al, 2018</a></a>).",
        "These RBD proteins maintain good conformation, functionality, antigenicity, and immunogenicity, with ability to bind the DPP4 receptor and RBD-specific neutralizing mAbs and to elicit robust neutralizing antibodies cross-neutralizing multiple strains of MERS pseudoviruses and live MERS-CoV (Tai et al, 2016, 2017; <a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\"><a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\">Nyon et al, 2018</a></a>).",
        "MERS-CoV Subunit Vaccines Based on Non-RBD S Protein Fragments MERS vaccines targeting non-RBD regions of S protein have been developed and investigated in mice and NHPs. It has been shown that a MERS-CoV S1 protein formulated with Ribi or aluminum phosphate adjuvant elicited robust neutralizing antibodies in mice and NHPs against divergent strains of pseudotyped and live MERSCoV, protecting NHPs from MERS-CoV infection (<a class=\"ref-link\" id=\"cWang_et+al_2015_a\" href=\"#rWang_et+al_2015_a\"><a class=\"ref-link\" id=\"cWang_et+al_2015_a\" href=\"#rWang_et+al_2015_a\">Wang et al, 2015</a></a>).",
        "MERS-CoV subunit vaccines containing different antigens or fragment lengths, those based on the RBD, have apparently variable immunogenicity and/or protective efficacy, and a critical neutralizing domain that contains an RBD fragment corresponding to residues 377\u2013588 of S protein elicits the highest neutralizing antibodies among several fragments tested (<a class=\"ref-link\" id=\"cMa_et+al_2014_b\" href=\"#rMa_et+al_2014_b\">Ma et al, 2014b</a>; <a class=\"ref-link\" id=\"cZhang_et+al_2015_a\" href=\"#rZhang_et+al_2015_a\">Zhang et al, 2015</a>).",
        "While a MERS-CoV RBD subunit vaccine (S377-588 protein fused with Fc) alone induced detectable neutralizing antibody and T-cell responses in immunized mice, inclusion of an adjuvant enhanced its immunogenicity."
    ],
    "structured_summary": {
        "Introduction": [
            "Coronaviruses (CoVs) belong to the subfamily Othocoronavirinae, in the family Coronaviridae of the order Nidovirales.",
            "2016a <a class=\"ref-link\" id=\"cWang_et+al_2015_a\" href=\"#rWang_et+al_2015_a\"><a class=\"ref-link\" id=\"cWang_et+al_2015_a\" href=\"#rWang_et+al_2015_a\">Wang et al, 2015</a></a> <a class=\"ref-link\" id=\"cAdney_et+al_2019_a\" href=\"#rAdney_et+al_2019_a\">Adney et al, 2019</a> <a class=\"ref-link\" id=\"cJiaming_et+al_2017_a\" href=\"#rJiaming_et+al_2017_a\">Jiaming et al, 2017</a> <a class=\"ref-link\" id=\"cYang_et+al_2014_a\" href=\"#rYang_et+al_2014_a\">Yang et al, 2014a</a> aaa, amino acid; Abs, antibodies; Ad5, adenovirus serotype 5; Ad5-hDPP4 mice, Ad5-hDPP4-transuced mice; Alum hydro, aluminum hydroxide; Alum pho, Aluminum phosphate; hDPP4, human dipeptidyl peptidase 4; hDPP4-Tg mice, transgenic mice expressing MERS-CoV receptor human DPP4; IFA, incomplete Freund\u2019s adjuvant; I.M., intramuscular; I.N., intranasal; mAbs, monoclonal antibodies; Montanide, Montanide ISA51; N/A, not reported; NHPs, non-human primates; NZW, rabbits, New Zealand White rabbits; PFU, plaque-forming unit; rRBD, recombinant RBD; SAS, Sigma Adjuvant System; S.C., subcutaneous; TCID50, median tissue culture infectious dose; TNF-\u03b1, tumor necrosis factor (TNF)-alpha."
        ],
        "Results": [
            "An RBD protein fragment containing MERSCoV S residues 377\u2013622 fused with the Fc tag of human IgG can induce MERS-CoV S1- and/or RBD-specific humoral and cellular immune responses in the immunized mice with neutralizing activity against MERS-CoV infection (<a class=\"ref-link\" id=\"cDu_et+al_2013_c\" href=\"#rDu_et+al_2013_c\">Du et al, 2013c</a>; <a class=\"ref-link\" id=\"cJiang_et+al_2013_a\" href=\"#rJiang_et+al_2013_a\">Jiang et al, 2013</a>).",
            "Several MERS-CoV subunit vaccines have been designed based on the identified critical neutralizing domain of RBD fragment, including those expressed in a stable CHO cell line (S377-588-Fc), fusing with a trimeric motif foldon (RBDFd), or containing single or multiple mutations in the RBD of representative human and camel strains from the 2012\u20132015 MERS outbreaks (Tai et al, 2016, 2017; <a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\"><a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\">Nyon et al, 2018</a></a>).",
            "These RBD proteins maintain good conformation, functionality, antigenicity, and immunogenicity, with ability to bind the DPP4 receptor and RBD-specific neutralizing mAbs and to elicit robust neutralizing antibodies cross-neutralizing multiple strains of MERS pseudoviruses and live MERS-CoV (Tai et al, 2016, 2017; <a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\"><a class=\"ref-link\" id=\"cNyon_et+al_2018_a\" href=\"#rNyon_et+al_2018_a\">Nyon et al, 2018</a></a>).",
            "MERS-CoV Subunit Vaccines Based on Non-RBD S Protein Fragments MERS vaccines targeting non-RBD regions of S protein have been developed and investigated in mice and NHPs. It has been shown that a MERS-CoV S1 protein formulated with Ribi or aluminum phosphate adjuvant elicited robust neutralizing antibodies in mice and NHPs against divergent strains of pseudotyped and live MERSCoV, protecting NHPs from MERS-CoV infection (<a class=\"ref-link\" id=\"cWang_et+al_2015_a\" href=\"#rWang_et+al_2015_a\"><a class=\"ref-link\" id=\"cWang_et+al_2015_a\" href=\"#rWang_et+al_2015_a\">Wang et al, 2015</a></a>)."
        ],
        "Conclusion": [
            "MERS-CoV subunit vaccines containing different antigens or fragment lengths, those based on the RBD, have apparently variable immunogenicity and/or protective efficacy, and a critical neutralizing domain that contains an RBD fragment corresponding to residues 377\u2013588 of S protein elicits the highest neutralizing antibodies among several fragments tested (<a class=\"ref-link\" id=\"cMa_et+al_2014_b\" href=\"#rMa_et+al_2014_b\">Ma et al, 2014b</a>; <a class=\"ref-link\" id=\"cZhang_et+al_2015_a\" href=\"#rZhang_et+al_2015_a\">Zhang et al, 2015</a>).",
            "While a MERS-CoV RBD subunit vaccine (S377-588 protein fused with Fc) alone induced detectable neutralizing antibody and T-cell responses in immunized mice, inclusion of an adjuvant enhanced its immunogenicity."
        ]
    },
    "reference_links": [
        {
            "id": "He_2006_a",
            "alt_id": "1",
            "entry": "He et al., 2006a",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=He%20et%20al%202006a"
        },
        {
            "id": "Kam_2007_a",
            "alt_id": "2",
            "entry": "Kam et al., 2007; Jaume et al., 2012",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Kam%20Jaume%202007",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Kam%20Jaume%202007",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Kam%20Jaume%202007"
        },
        {
            "id": "He_2004_a",
            "alt_id": "3",
            "entry": "He et al., 2004; Du et al., 2007",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=He%20Du%202004",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=He%20Du%202004",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=He%20Du%202004"
        },
        {
            "id": "Du_2009_a",
            "alt_id": "4",
            "entry": "Du et al., 2009c, 2010 (Continued)",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Du%20et%20al%202009c%202010%20Continued"
        },
        {
            "id": "Du_2009_b",
            "alt_id": "5",
            "entry": "Du et al., 2009b",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Du%20et%20al%202009b"
        },
        {
            "id": "Zakhartchouk_2007_a",
            "alt_id": "6",
            "entry": "Zakhartchouk et al., 2007",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zakhartchouk%20et%20al%202007"
        },
        {
            "id": "Li_2013_a",
            "alt_id": "7",
            "entry": "Li et al., 2013 Guo et al., 2005",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Li%20Guo%202013",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Li%20Guo%202013",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Li%20Guo%202013"
        },
        {
            "id": "Zheng_2009_a",
            "alt_id": "8",
            "entry": "Zheng et al., 2009 Liu et al., 2006 He et al., 2005b aAbs, antibodies; ADE, antibody-dependent enhancement; Alum hydro, aluminum hydroxide; CHO, Chinese hamster ovary; CpG, cysteine-phosphate-guanine; I.D., intradermal; I.M., intramuscular; IFN-\u03b3, interferon gamma; IL-2, interleukin 2; IL-4, interleukin 4; IL-10, Interleukin 10; I.P., intraperitoneal; mAbs, monoclonal antibodies; Montanide, Montanide ISA-51; MPL + TDM, monophosphoryl lipid A and trehalose dicorynomycolate; N/A, not reported; NTD, N-terminal domain; NZW rabbits, New Zealand White rabbits; RBD, receptor-binding domain; SAS, Sigma adjuvant system; S.C., subcutaneous; TCID50, median tissue culture infectious dose.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zheng%20aAbs%2C%20antibodies%3B%20ADE%2C%20antibody-dependent%20enhancement%3B%20Alum%20hydro%2C%20aluminum%20hydroxide%3B%20CHO%2C%20Chinese%20hamster%202009",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Zheng%20aAbs%2C%20antibodies%3B%20ADE%2C%20antibody-dependent%20enhancement%3B%20Alum%20hydro%2C%20aluminum%20hydroxide%3B%20CHO%2C%20Chinese%20hamster%202009",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Zheng%20aAbs%2C%20antibodies%3B%20ADE%2C%20antibody-dependent%20enhancement%3B%20Alum%20hydro%2C%20aluminum%20hydroxide%3B%20CHO%2C%20Chinese%20hamster%202009"
        },
        {
            "id": "Rabbits_2005_a",
            "alt_id": "9",
            "entry": "rabbits (He et al., 2005b). In spite of their immunogenicity, it appears that these N- and M-based SARS subunit vaccines have not been investigated for their protective efficacy against SARS-CoV infection. Thus, it is unclear whether these nonS structural protein-based SARS subunit vaccines can prevent SARS-CoV infection.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=rabbits%20%28He%20In%20spite%20of%20their%20immunogenicity%2C%20it%20appears%20that%20these%20N-%20and%20M-based%20SARS%20subunit%20vaccines%20have%20not%20been%20investigated%20for%20their%20protective%20efficacy%20against%20SARS-CoV%20infection.%20Thus%2C%20it%20is%20unclear%20whether%20these%20nonS%20structural%20protein-based%20SARS%20subunit%20vaccines%20can%20prevent%20SARS-CoV%20infection%202005"
        },
        {
            "id": "The_2006_a",
            "alt_id": "10",
            "entry": "The expression of recombinant protein-based SARS subunit vaccines may be changed by the following factors. First, addition of an intron splicing enhancer to the truncated SARS-CoV S protein fragments results in better enhancement of protein expression in mammalian cells than the exon splicing enhancers, and different cells may result in different fold increase of protein expression (Chang et al., 2006). Second, inclusion of a post-transcriptional gene silencing suppressor p19 protein from tomato bushy stunt virus to a SARS-CoV N protein may significantly increase its transient expression in tobacco (Zheng et al., 2009).",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=The%20expression%20of%20recombinant%20proteinbased%20SARS%20subunit%20vaccines%20may%20be%20changed%20by%20the%20following%20factors%20First%20addition%20of%20an%20intron%20splicing%20enhancer%20to%20the%20truncated%20SARSCoV%20S%20protein%20fragments%20results%20in%20better%20enhancement%20of%20protein%20expression%20in%20mammalian%20cells%20than%20the%20exon%20splicing%20enhancers%20and%20different%20cells%20may%20result%20in%20different%20fold%20increase%20of%20protein%20expression%20Chang%20et%20al%202006%20Second%20inclusion%20of%20a%20posttranscriptional%20gene%20silencing%20suppressor%20p19%20protein%20from%20tomato%20bushy%20stunt%20virus%20to%20a%20SARSCoV%20N%20protein%20may%20significantly%20increase%20its%20transient%20expression%20in%20tobacco%20Zheng%20et%20al%202009",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=The%20expression%20of%20recombinant%20proteinbased%20SARS%20subunit%20vaccines%20may%20be%20changed%20by%20the%20following%20factors%20First%20addition%20of%20an%20intron%20splicing%20enhancer%20to%20the%20truncated%20SARSCoV%20S%20protein%20fragments%20results%20in%20better%20enhancement%20of%20protein%20expression%20in%20mammalian%20cells%20than%20the%20exon%20splicing%20enhancers%20and%20different%20cells%20may%20result%20in%20different%20fold%20increase%20of%20protein%20expression%20Chang%20et%20al%202006%20Second%20inclusion%20of%20a%20posttranscriptional%20gene%20silencing%20suppressor%20p19%20protein%20from%20tomato%20bushy%20stunt%20virus%20to%20a%20SARSCoV%20N%20protein%20may%20significantly%20increase%20its%20transient%20expression%20in%20tobacco%20Zheng%20et%20al%202009",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=The%20expression%20of%20recombinant%20proteinbased%20SARS%20subunit%20vaccines%20may%20be%20changed%20by%20the%20following%20factors%20First%20addition%20of%20an%20intron%20splicing%20enhancer%20to%20the%20truncated%20SARSCoV%20S%20protein%20fragments%20results%20in%20better%20enhancement%20of%20protein%20expression%20in%20mammalian%20cells%20than%20the%20exon%20splicing%20enhancers%20and%20different%20cells%20may%20result%20in%20different%20fold%20increase%20of%20protein%20expression%20Chang%20et%20al%202006%20Second%20inclusion%20of%20a%20posttranscriptional%20gene%20silencing%20suppressor%20p19%20protein%20from%20tomato%20bushy%20stunt%20virus%20to%20a%20SARSCoV%20N%20protein%20may%20significantly%20increase%20its%20transient%20expression%20in%20tobacco%20Zheng%20et%20al%202009"
        },
        {
            "id": "Other_2007_a",
            "alt_id": "11",
            "entry": "Other factors that potentially affect the immunogenicity of SARS subunit vaccines include immunization routes and adjuvants (Zakhartchouk et al., 2007; Li et al., 2013). Significantly high-titer antibodies were induced by monomeric or trimeric SARS-CoV S and S1 proteins through the intramuscular (I.M.) route compared to the subcutaneous (S.C.) route (Li et al., 2013). Moreover, a SARS-CoV RBD subunit vaccine conjugated with Alum plus CpG adjuvants elicited a higher level of IgG2a antibody and interferon gamma (IFN-\u03b3) secretion than the RBD with Alum alone (Zakhartchouk et al., 2007).",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Other%20factors%20that%20potentially%20affect%20the%20immunogenicity%20of%20SARS%20subunit%20vaccines%20include%20immunization%20routes%20and%20adjuvants%20Zakhartchouk%20et%20al%202007%20Li%20et%20al%202013%20Significantly%20hightiter%20antibodies%20were%20induced%20by%20monomeric%20or%20trimeric%20SARSCoV%20S%20and%20S1%20proteins%20through%20the%20intramuscular%20IM%20route%20compared%20to%20the%20subcutaneous%20SC%20route%20Li%20et%20al%202013%20Moreover%20a%20SARSCoV%20RBD%20subunit%20vaccine%20conjugated%20with%20Alum%20plus%20CpG%20adjuvants%20elicited%20a%20higher%20level%20of%20IgG2a%20antibody%20and%20interferon%20gamma%20IFN%CE%B3%20secretion%20than%20the%20RBD%20with%20Alum%20alone%20Zakhartchouk%20et%20al%202007",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Other%20factors%20that%20potentially%20affect%20the%20immunogenicity%20of%20SARS%20subunit%20vaccines%20include%20immunization%20routes%20and%20adjuvants%20Zakhartchouk%20et%20al%202007%20Li%20et%20al%202013%20Significantly%20hightiter%20antibodies%20were%20induced%20by%20monomeric%20or%20trimeric%20SARSCoV%20S%20and%20S1%20proteins%20through%20the%20intramuscular%20IM%20route%20compared%20to%20the%20subcutaneous%20SC%20route%20Li%20et%20al%202013%20Moreover%20a%20SARSCoV%20RBD%20subunit%20vaccine%20conjugated%20with%20Alum%20plus%20CpG%20adjuvants%20elicited%20a%20higher%20level%20of%20IgG2a%20antibody%20and%20interferon%20gamma%20IFN%CE%B3%20secretion%20than%20the%20RBD%20with%20Alum%20alone%20Zakhartchouk%20et%20al%202007",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Other%20factors%20that%20potentially%20affect%20the%20immunogenicity%20of%20SARS%20subunit%20vaccines%20include%20immunization%20routes%20and%20adjuvants%20Zakhartchouk%20et%20al%202007%20Li%20et%20al%202013%20Significantly%20hightiter%20antibodies%20were%20induced%20by%20monomeric%20or%20trimeric%20SARSCoV%20S%20and%20S1%20proteins%20through%20the%20intramuscular%20IM%20route%20compared%20to%20the%20subcutaneous%20SC%20route%20Li%20et%20al%202013%20Moreover%20a%20SARSCoV%20RBD%20subunit%20vaccine%20conjugated%20with%20Alum%20plus%20CpG%20adjuvants%20elicited%20a%20higher%20level%20of%20IgG2a%20antibody%20and%20interferon%20gamma%20IFN%CE%B3%20secretion%20than%20the%20RBD%20with%20Alum%20alone%20Zakhartchouk%20et%20al%202007"
        },
        {
            "id": "MERS-CoV_2013_a",
            "alt_id": "12",
            "entry": "MERS-CoV Subunit Vaccines Based on RBD Numerous MERS-CoV RBD-based subunit vaccines have been developed and extensively evaluated in available animal models since the emergence of MERS-CoV (Table 2) (Du et al., 2013c; Tai et al., 2017; Zhou et al., 2018). In general, these subunit vaccines have strong immunogenicity and are capable of inducing high neutralizing antibodies and/or protection against MERSCoV infection (Ma et al., 2014b; Zhang et al., 2016; Tai et al., 2017; Wang Y. et al., 2017). Most subunit vaccines based on the MERS-CoV RBD have been described in detail in a previous review article (Zhou et al., 2019). In this section, we will briefly introduce these RBD-targeting MERS vaccines, and compare their functionality, antigenicity, immunogenicity, and protection against MERS-CoV infection.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=MERSCoV%20Subunit%20Vaccines%20Based%20on%20RBD%20Numerous%20MERSCoV%20RBDbased%20subunit%20vaccines%20have%20been%20developed%20and%20extensively%20evaluated%20in%20available%20animal%20models%20since%20the%20emergence%20of%20MERSCoV%20Table%202%20Du%20et%20al%202013c%20Tai%20et%20al%202017%20Zhou%20et%20al%202018%20In%20general%20these%20subunit%20vaccines%20have%20strong%20immunogenicity%20and%20are%20capable%20of%20inducing%20high%20neutralizing%20antibodies%20andor%20protection%20against%20MERSCoV%20infection%20Ma%20et%20al%202014b%20Zhang%20et%20al%202016%20Tai%20et%20al%202017%20Wang%20Y%20et%20al%202017%20Most%20subunit%20vaccines%20based%20on%20the%20MERSCoV%20RBD%20have%20been%20described%20in%20detail%20in%20a%20previous%20review%20article%20Zhou%20et%20al%202019%20In%20this%20section%20we%20will%20briefly%20introduce%20these%20RBDtargeting%20MERS%20vaccines%20and%20compare%20their%20functionality%20antigenicity%20immunogenicity%20and%20protection%20against%20MERSCoV%20infection",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=MERSCoV%20Subunit%20Vaccines%20Based%20on%20RBD%20Numerous%20MERSCoV%20RBDbased%20subunit%20vaccines%20have%20been%20developed%20and%20extensively%20evaluated%20in%20available%20animal%20models%20since%20the%20emergence%20of%20MERSCoV%20Table%202%20Du%20et%20al%202013c%20Tai%20et%20al%202017%20Zhou%20et%20al%202018%20In%20general%20these%20subunit%20vaccines%20have%20strong%20immunogenicity%20and%20are%20capable%20of%20inducing%20high%20neutralizing%20antibodies%20andor%20protection%20against%20MERSCoV%20infection%20Ma%20et%20al%202014b%20Zhang%20et%20al%202016%20Tai%20et%20al%202017%20Wang%20Y%20et%20al%202017%20Most%20subunit%20vaccines%20based%20on%20the%20MERSCoV%20RBD%20have%20been%20described%20in%20detail%20in%20a%20previous%20review%20article%20Zhou%20et%20al%202019%20In%20this%20section%20we%20will%20briefly%20introduce%20these%20RBDtargeting%20MERS%20vaccines%20and%20compare%20their%20functionality%20antigenicity%20immunogenicity%20and%20protection%20against%20MERSCoV%20infection",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=MERSCoV%20Subunit%20Vaccines%20Based%20on%20RBD%20Numerous%20MERSCoV%20RBDbased%20subunit%20vaccines%20have%20been%20developed%20and%20extensively%20evaluated%20in%20available%20animal%20models%20since%20the%20emergence%20of%20MERSCoV%20Table%202%20Du%20et%20al%202013c%20Tai%20et%20al%202017%20Zhou%20et%20al%202018%20In%20general%20these%20subunit%20vaccines%20have%20strong%20immunogenicity%20and%20are%20capable%20of%20inducing%20high%20neutralizing%20antibodies%20andor%20protection%20against%20MERSCoV%20infection%20Ma%20et%20al%202014b%20Zhang%20et%20al%202016%20Tai%20et%20al%202017%20Wang%20Y%20et%20al%202017%20Most%20subunit%20vaccines%20based%20on%20the%20MERSCoV%20RBD%20have%20been%20described%20in%20detail%20in%20a%20previous%20review%20article%20Zhou%20et%20al%202019%20In%20this%20section%20we%20will%20briefly%20introduce%20these%20RBDtargeting%20MERS%20vaccines%20and%20compare%20their%20functionality%20antigenicity%20immunogenicity%20and%20protection%20against%20MERSCoV%20infection"
        },
        {
            "id": "Lu_2013_a",
            "alt_id": "13",
            "entry": "Co-crystallographic analyses of MERS-CoV RBD and/or RBD/DPP4 complexes have confirmed that the RBD is attributed to residues 367\u2013588 (Chen et al., 2013) or 367\u2013606 (Lu et al., 2013) in the MERS-CoV S1 subunit. Indeed, a recombinant MERS-CoV RBD (rRBD) fragment (residues 367\u2013606) elicits RBD-specific antibody and cellular immune responses and neutralizing antibodies in mice and/or non-human primates (NHPs) (Lan et al., 2014, 2015). However, it only partially protects",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Lu%20Co-crystallographic%20analyses%20of%20MERS-CoV%20RBD%20and/or%20RBD/DPP4%20complexes%20have%20confirmed%20that%20the%20RBD%20is%20attributed%20to%20residues%20367%E2%80%93588%202013",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Lu%20Co-crystallographic%20analyses%20of%20MERS-CoV%20RBD%20and/or%20RBD/DPP4%20complexes%20have%20confirmed%20that%20the%20RBD%20is%20attributed%20to%20residues%20367%E2%80%93588%202013",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Lu%20Co-crystallographic%20analyses%20of%20MERS-CoV%20RBD%20and/or%20RBD/DPP4%20complexes%20have%20confirmed%20that%20the%20RBD%20is%20attributed%20to%20residues%20367%E2%80%93588%202013"
        },
        {
            "id": "Pallesen_2017_a",
            "alt_id": "14",
            "entry": "Pallesen et al., 2017",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Pallesen%20et%20al%202017"
        },
        {
            "id": "Lan_2014_a",
            "alt_id": "15",
            "entry": "Lan et al., 2014, 2015",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Lan%20et%20al%202014%202015"
        },
        {
            "id": "Du_2013_a",
            "alt_id": "16",
            "entry": "Du et al., 2013c; Ma et al., 2014b",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Du%20Ma%20et%20al%202013"
        },
        {
            "id": "Du_2013_b",
            "alt_id": "17",
            "entry": "Du et al., 2013a; Ma et al., 2014b; Tang et al., 2015; Zhang et al., 2016; Nyon et al., 2018",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Du%20Zhang%202013",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Du%20Zhang%202013",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Du%20Zhang%202013"
        },
        {
            "id": "Tai_2016_a",
            "alt_id": "18",
            "entry": "Tai et al., 2016 (Continued)",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Tai%20et%20al%202016%20Continued"
        },
        {
            "id": "Du_2016_a",
            "alt_id": "19",
            "entry": "Du et al., 2016a Wang et al., 2015 Adney et al., 2019 Jiaming et al., 2017 Yang et al., 2014a aaa, amino acid; Abs, antibodies; Ad5, adenovirus serotype 5; Ad5-hDPP4 mice, Ad5-hDPP4-transuced mice; Alum hydro, aluminum hydroxide; Alum pho, Aluminum phosphate; hDPP4, human dipeptidyl peptidase 4; hDPP4-Tg mice, transgenic mice expressing MERS-CoV receptor human DPP4; IFA, incomplete Freund\u2019s adjuvant; I.M., intramuscular; I.N., intranasal; mAbs, monoclonal antibodies; Montanide, Montanide ISA51; N/A, not reported; NHPs, non-human primates; NZW, rabbits, New Zealand White rabbits; PFU, plaque-forming unit; rRBD, recombinant RBD; SAS, Sigma Adjuvant System; S.C., subcutaneous; TCID50, median tissue culture infectious dose; TNF-\u03b1, tumor necrosis factor (TNF)-alpha.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Du%20Yang%20et%20al.%2C%202014a%20aaa%2C%20amino%20acid%3B%20Abs%2C%20antibodies%3B%20Ad5%2C%20adenovirus%20serotype%205%3B%20Ad5-hDPP4%20mice%2C%20Ad5-hDPP4-transuced%20mice%3B%20Alum%20hydro%2C%20aluminum%20hydroxide%3B%20Alum%20pho%2C%20Aluminum%20phosphate%3B%20hDPP4%2C%20human%20dipeptidyl%20peptidase%202016",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Du%20Yang%20et%20al.%2C%202014a%20aaa%2C%20amino%20acid%3B%20Abs%2C%20antibodies%3B%20Ad5%2C%20adenovirus%20serotype%205%3B%20Ad5-hDPP4%20mice%2C%20Ad5-hDPP4-transuced%20mice%3B%20Alum%20hydro%2C%20aluminum%20hydroxide%3B%20Alum%20pho%2C%20Aluminum%20phosphate%3B%20hDPP4%2C%20human%20dipeptidyl%20peptidase%202016",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Du%20Yang%20et%20al.%2C%202014a%20aaa%2C%20amino%20acid%3B%20Abs%2C%20antibodies%3B%20Ad5%2C%20adenovirus%20serotype%205%3B%20Ad5-hDPP4%20mice%2C%20Ad5-hDPP4-transuced%20mice%3B%20Alum%20hydro%2C%20aluminum%20hydroxide%3B%20Alum%20pho%2C%20Aluminum%20phosphate%3B%20hDPP4%2C%20human%20dipeptidyl%20peptidase%202016"
        },
        {
            "id": "NHPs_2015_a",
            "alt_id": "20",
            "entry": "NHPs from MERS-CoV infection by alleviating pneumonia and clinical manifestations, as well as decreasing viral load (Lan et al., 2015). In addition, an RBD protein fragment containing MERSCoV S residues 377\u2013622 fused with the Fc tag of human IgG can induce MERS-CoV S1- and/or RBD-specific humoral and cellular immune responses in the immunized mice with neutralizing activity against MERS-CoV infection (Du et al., 2013c; Jiang et al., 2013). However, after comparing several versions of MERSCoV RBD fragments with different lengths, it was found that a truncated RBD (residues 377\u2013588) had the highest DPP4binding affinity and induced the highest-titer IgG antibodies and neutralizing antibodies against MERS-CoV, identifying its role as a critical neutralizing domain (Ma et al., 2014b).",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=NHPs%20from%20MERSCoV%20infection%20by%20alleviating%20pneumonia%20and%20clinical%20manifestations%20as%20well%20as%20decreasing%20viral%20load%20Lan%20et%20al%202015%20In%20addition%20an%20RBD%20protein%20fragment%20containing%20MERSCoV%20S%20residues%20377622%20fused%20with%20the%20Fc%20tag%20of%20human%20IgG%20can%20induce%20MERSCoV%20S1%20andor%20RBDspecific%20humoral%20and%20cellular%20immune%20responses%20in%20the%20immunized%20mice%20with%20neutralizing%20activity%20against%20MERSCoV%20infection%20Du%20et%20al%202013c%20Jiang%20et%20al%202013%20However%20after%20comparing%20several%20versions%20of%20MERSCoV%20RBD%20fragments%20with%20different%20lengths%20it%20was%20found%20that%20a%20truncated%20RBD%20residues%20377588%20had%20the%20highest%20DPP4binding%20affinity%20and%20induced%20the%20highesttiter%20IgG%20antibodies%20and%20neutralizing%20antibodies%20against%20MERSCoV%20identifying%20its%20role%20as%20a%20critical%20neutralizing%20domain%20Ma%20et%20al%202014b",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=NHPs%20from%20MERSCoV%20infection%20by%20alleviating%20pneumonia%20and%20clinical%20manifestations%20as%20well%20as%20decreasing%20viral%20load%20Lan%20et%20al%202015%20In%20addition%20an%20RBD%20protein%20fragment%20containing%20MERSCoV%20S%20residues%20377622%20fused%20with%20the%20Fc%20tag%20of%20human%20IgG%20can%20induce%20MERSCoV%20S1%20andor%20RBDspecific%20humoral%20and%20cellular%20immune%20responses%20in%20the%20immunized%20mice%20with%20neutralizing%20activity%20against%20MERSCoV%20infection%20Du%20et%20al%202013c%20Jiang%20et%20al%202013%20However%20after%20comparing%20several%20versions%20of%20MERSCoV%20RBD%20fragments%20with%20different%20lengths%20it%20was%20found%20that%20a%20truncated%20RBD%20residues%20377588%20had%20the%20highest%20DPP4binding%20affinity%20and%20induced%20the%20highesttiter%20IgG%20antibodies%20and%20neutralizing%20antibodies%20against%20MERSCoV%20identifying%20its%20role%20as%20a%20critical%20neutralizing%20domain%20Ma%20et%20al%202014b",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=NHPs%20from%20MERSCoV%20infection%20by%20alleviating%20pneumonia%20and%20clinical%20manifestations%20as%20well%20as%20decreasing%20viral%20load%20Lan%20et%20al%202015%20In%20addition%20an%20RBD%20protein%20fragment%20containing%20MERSCoV%20S%20residues%20377622%20fused%20with%20the%20Fc%20tag%20of%20human%20IgG%20can%20induce%20MERSCoV%20S1%20andor%20RBDspecific%20humoral%20and%20cellular%20immune%20responses%20in%20the%20immunized%20mice%20with%20neutralizing%20activity%20against%20MERSCoV%20infection%20Du%20et%20al%202013c%20Jiang%20et%20al%202013%20However%20after%20comparing%20several%20versions%20of%20MERSCoV%20RBD%20fragments%20with%20different%20lengths%20it%20was%20found%20that%20a%20truncated%20RBD%20residues%20377588%20had%20the%20highest%20DPP4binding%20affinity%20and%20induced%20the%20highesttiter%20IgG%20antibodies%20and%20neutralizing%20antibodies%20against%20MERSCoV%20identifying%20its%20role%20as%20a%20critical%20neutralizing%20domain%20Ma%20et%20al%202014b"
        },
        {
            "id": "MERS-CoV_2018_a",
            "alt_id": "21",
            "entry": "MERS-CoV Subunit Vaccines Based on Non-S Structural Proteins Unlike SARS subunit vaccines which have been designed based on viral N and M proteins, it appears that very few subunit vaccines have been developed based on the non-S structural protein(s) of MERS-CoV. One study reports the induction of specific antibodies by MERS-CoV N peptides (Yang et al., 2014a), and another report shows that N protein is used for development of vaccines based on viral vector Vaccinia virus, modified Vaccinia Ankara (MVA) (Veit et al., 2018). This may be potentially a consequence of the weak immunogenicity and/or protective efficacy of non-S structural proteins, further confirming the role of MERS-CoV S protein as the key target for the development of MERS vaccines, including subunit vaccines.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=MERSCoV%20Subunit%20Vaccines%20Based%20on%20NonS%20Structural%20Proteins%20Unlike%20SARS%20subunit%20vaccines%20which%20have%20been%20designed%20based%20on%20viral%20N%20and%20M%20proteins%20it%20appears%20that%20very%20few%20subunit%20vaccines%20have%20been%20developed%20based%20on%20the%20nonS%20structural%20proteins%20of%20MERSCoV%20One%20study%20reports%20the%20induction%20of%20specific%20antibodies%20by%20MERSCoV%20N%20peptides%20Yang%20et%20al%202014a%20and%20another%20report%20shows%20that%20N%20protein%20is%20used%20for%20development%20of%20vaccines%20based%20on%20viral%20vector%20Vaccinia%20virus%20modified%20Vaccinia%20Ankara%20MVA%20Veit%20et%20al%202018%20This%20may%20be%20potentially%20a%20consequence%20of%20the%20weak%20immunogenicity%20andor%20protective%20efficacy%20of%20nonS%20structural%20proteins%20further%20confirming%20the%20role%20of%20MERSCoV%20S%20protein%20as%20the%20key%20target%20for%20the%20development%20of%20MERS%20vaccines%20including%20subunit%20vaccines",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=MERSCoV%20Subunit%20Vaccines%20Based%20on%20NonS%20Structural%20Proteins%20Unlike%20SARS%20subunit%20vaccines%20which%20have%20been%20designed%20based%20on%20viral%20N%20and%20M%20proteins%20it%20appears%20that%20very%20few%20subunit%20vaccines%20have%20been%20developed%20based%20on%20the%20nonS%20structural%20proteins%20of%20MERSCoV%20One%20study%20reports%20the%20induction%20of%20specific%20antibodies%20by%20MERSCoV%20N%20peptides%20Yang%20et%20al%202014a%20and%20another%20report%20shows%20that%20N%20protein%20is%20used%20for%20development%20of%20vaccines%20based%20on%20viral%20vector%20Vaccinia%20virus%20modified%20Vaccinia%20Ankara%20MVA%20Veit%20et%20al%202018%20This%20may%20be%20potentially%20a%20consequence%20of%20the%20weak%20immunogenicity%20andor%20protective%20efficacy%20of%20nonS%20structural%20proteins%20further%20confirming%20the%20role%20of%20MERSCoV%20S%20protein%20as%20the%20key%20target%20for%20the%20development%20of%20MERS%20vaccines%20including%20subunit%20vaccines",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=MERSCoV%20Subunit%20Vaccines%20Based%20on%20NonS%20Structural%20Proteins%20Unlike%20SARS%20subunit%20vaccines%20which%20have%20been%20designed%20based%20on%20viral%20N%20and%20M%20proteins%20it%20appears%20that%20very%20few%20subunit%20vaccines%20have%20been%20developed%20based%20on%20the%20nonS%20structural%20proteins%20of%20MERSCoV%20One%20study%20reports%20the%20induction%20of%20specific%20antibodies%20by%20MERSCoV%20N%20peptides%20Yang%20et%20al%202014a%20and%20another%20report%20shows%20that%20N%20protein%20is%20used%20for%20development%20of%20vaccines%20based%20on%20viral%20vector%20Vaccinia%20virus%20modified%20Vaccinia%20Ankara%20MVA%20Veit%20et%20al%202018%20This%20may%20be%20potentially%20a%20consequence%20of%20the%20weak%20immunogenicity%20andor%20protective%20efficacy%20of%20nonS%20structural%20proteins%20further%20confirming%20the%20role%20of%20MERSCoV%20S%20protein%20as%20the%20key%20target%20for%20the%20development%20of%20MERS%20vaccines%20including%20subunit%20vaccines"
        },
        {
            "id": "As_2015_b",
            "alt_id": "22",
            "entry": "As described above, MERS-CoV subunit vaccines containing different antigens or fragment lengths, particularly those based on the RBD, have apparently variable immunogenicity and/or protective efficacy, and a critical neutralizing domain that contains an RBD fragment corresponding to residues 377\u2013588 of S protein elicits the highest neutralizing antibodies among several fragments tested (Ma et al., 2014b; Zhang et al., 2015).",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=As%20described%20above%20MERSCoV%20subunit%20vaccines%20containing%20different%20antigens%20or%20fragment%20lengths%20particularly%20those%20based%20on%20the%20RBD%20have%20apparently%20variable%20immunogenicity%20andor%20protective%20efficacy%20and%20a%20critical%20neutralizing%20domain%20that%20contains%20an%20RBD%20fragment%20corresponding%20to%20residues%20377588%20of%20S%20protein%20elicits%20the%20highest%20neutralizing%20antibodies%20among%20several%20fragments%20tested%20Ma%20et%20al%202014b%20Zhang%20et%20al%202015"
        },
        {
            "id": "Vaccination_2014_a",
            "alt_id": "23",
            "entry": "Vaccination pathways are important in inducing efficient immune responses, and different immunization routes may elicit different immune responses to the same protein antigens. For example, immunization of mice with a MERS-CoV subunit vaccine (RBD-Fc) via the intranasal route induced higher levels of cellular immune responses and stronger local mucosal neutralizing antibody responses against MERS-CoV infection than those induced by the same vaccine via the S.C. pathway (Ma et al., 2014a). In addition, while Freund\u2019s and CpG-adjuvanted rRBD protein elicited higher-level systematic and local IFN\u03b3-producing T cells via the S.C. route, this protein adjuvanted with Alum and CpG induced higher-level tumor necrosis factoralpha (TNF-\u03b1) and interleukin 4 (IL-4)-secreting T cells via the I.M. route (Lan et al., 2014).",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Vaccination%20pathways%20are%20important%20in%20inducing%20efficient%20immune%20responses%20and%20different%20immunization%20routes%20may%20elicit%20different%20immune%20responses%20to%20the%20same%20protein%20antigens%20For%20example%20immunization%20of%20mice%20with%20a%20MERSCoV%20subunit%20vaccine%20RBDFc%20via%20the%20intranasal%20route%20induced%20higher%20levels%20of%20cellular%20immune%20responses%20and%20stronger%20local%20mucosal%20neutralizing%20antibody%20responses%20against%20MERSCoV%20infection%20than%20those%20induced%20by%20the%20same%20vaccine%20via%20the%20SC%20pathway%20Ma%20et%20al%202014a%20In%20addition%20while%20Freunds%20and%20CpGadjuvanted%20rRBD%20protein%20elicited%20higherlevel%20systematic%20and%20local%20IFN%CE%B3producing%20T%20cells%20via%20the%20SC%20route%20this%20protein%20adjuvanted%20with%20Alum%20and%20CpG%20induced%20higherlevel%20tumor%20necrosis%20factoralpha%20TNF%CE%B1%20and%20interleukin%204%20IL4secreting%20T%20cells%20via%20the%20IM%20route%20Lan%20et%20al%202014",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Vaccination%20pathways%20are%20important%20in%20inducing%20efficient%20immune%20responses%20and%20different%20immunization%20routes%20may%20elicit%20different%20immune%20responses%20to%20the%20same%20protein%20antigens%20For%20example%20immunization%20of%20mice%20with%20a%20MERSCoV%20subunit%20vaccine%20RBDFc%20via%20the%20intranasal%20route%20induced%20higher%20levels%20of%20cellular%20immune%20responses%20and%20stronger%20local%20mucosal%20neutralizing%20antibody%20responses%20against%20MERSCoV%20infection%20than%20those%20induced%20by%20the%20same%20vaccine%20via%20the%20SC%20pathway%20Ma%20et%20al%202014a%20In%20addition%20while%20Freunds%20and%20CpGadjuvanted%20rRBD%20protein%20elicited%20higherlevel%20systematic%20and%20local%20IFN%CE%B3producing%20T%20cells%20via%20the%20SC%20route%20this%20protein%20adjuvanted%20with%20Alum%20and%20CpG%20induced%20higherlevel%20tumor%20necrosis%20factoralpha%20TNF%CE%B1%20and%20interleukin%204%20IL4secreting%20T%20cells%20via%20the%20IM%20route%20Lan%20et%20al%202014",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Vaccination%20pathways%20are%20important%20in%20inducing%20efficient%20immune%20responses%20and%20different%20immunization%20routes%20may%20elicit%20different%20immune%20responses%20to%20the%20same%20protein%20antigens%20For%20example%20immunization%20of%20mice%20with%20a%20MERSCoV%20subunit%20vaccine%20RBDFc%20via%20the%20intranasal%20route%20induced%20higher%20levels%20of%20cellular%20immune%20responses%20and%20stronger%20local%20mucosal%20neutralizing%20antibody%20responses%20against%20MERSCoV%20infection%20than%20those%20induced%20by%20the%20same%20vaccine%20via%20the%20SC%20pathway%20Ma%20et%20al%202014a%20In%20addition%20while%20Freunds%20and%20CpGadjuvanted%20rRBD%20protein%20elicited%20higherlevel%20systematic%20and%20local%20IFN%CE%B3producing%20T%20cells%20via%20the%20SC%20route%20this%20protein%20adjuvanted%20with%20Alum%20and%20CpG%20induced%20higherlevel%20tumor%20necrosis%20factoralpha%20TNF%CE%B1%20and%20interleukin%204%20IL4secreting%20T%20cells%20via%20the%20IM%20route%20Lan%20et%20al%202014"
        },
        {
            "id": "Antigen_2015_c",
            "alt_id": "24",
            "entry": "Antigen dosage, immunization doses, and intervals may significantly affect the immunogenicity of MERS-CoV subunit vaccines. Notably, a MERS-CoV RBD (S377-588-Fc) subunit vaccine immunized at 1 \u03bcg elicited strong humoral and cellular immune responses and neutralizing antibodies in mice although the one immunized at 5 and 20 \u03bcg elicited a higher level of S1-specific antibodies (Tang et al., 2015). In addition, among the regimens at one dose and two doses at 1-, 2-, and 3-week intervals, 2 doses of this protein boosted at 4 weeks resulted in the highest antibodies and neutralizing antibodies against MERS-CoV infection (Wang Y. et al., 2017).",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Antigen%20dosage%20immunization%20doses%20and%20intervals%20may%20significantly%20affect%20the%20immunogenicity%20of%20MERSCoV%20subunit%20vaccines%20Notably%20a%20MERSCoV%20RBD%20S377588Fc%20subunit%20vaccine%20immunized%20at%201%20%CE%BCg%20elicited%20strong%20humoral%20and%20cellular%20immune%20responses%20and%20neutralizing%20antibodies%20in%20mice%20although%20the%20one%20immunized%20at%205%20and%2020%20%CE%BCg%20elicited%20a%20higher%20level%20of%20S1specific%20antibodies%20Tang%20et%20al%202015%20In%20addition%20among%20the%20regimens%20at%20one%20dose%20and%20two%20doses%20at%201%202%20and%203week%20intervals%202%20doses%20of%20this%20protein%20boosted%20at%204%20weeks%20resulted%20in%20the%20highest%20antibodies%20and%20neutralizing%20antibodies%20against%20MERSCoV%20infection%20Wang%20Y%20et%20al%202017",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Antigen%20dosage%20immunization%20doses%20and%20intervals%20may%20significantly%20affect%20the%20immunogenicity%20of%20MERSCoV%20subunit%20vaccines%20Notably%20a%20MERSCoV%20RBD%20S377588Fc%20subunit%20vaccine%20immunized%20at%201%20%CE%BCg%20elicited%20strong%20humoral%20and%20cellular%20immune%20responses%20and%20neutralizing%20antibodies%20in%20mice%20although%20the%20one%20immunized%20at%205%20and%2020%20%CE%BCg%20elicited%20a%20higher%20level%20of%20S1specific%20antibodies%20Tang%20et%20al%202015%20In%20addition%20among%20the%20regimens%20at%20one%20dose%20and%20two%20doses%20at%201%202%20and%203week%20intervals%202%20doses%20of%20this%20protein%20boosted%20at%204%20weeks%20resulted%20in%20the%20highest%20antibodies%20and%20neutralizing%20antibodies%20against%20MERSCoV%20infection%20Wang%20Y%20et%20al%202017",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Antigen%20dosage%20immunization%20doses%20and%20intervals%20may%20significantly%20affect%20the%20immunogenicity%20of%20MERSCoV%20subunit%20vaccines%20Notably%20a%20MERSCoV%20RBD%20S377588Fc%20subunit%20vaccine%20immunized%20at%201%20%CE%BCg%20elicited%20strong%20humoral%20and%20cellular%20immune%20responses%20and%20neutralizing%20antibodies%20in%20mice%20although%20the%20one%20immunized%20at%205%20and%2020%20%CE%BCg%20elicited%20a%20higher%20level%20of%20S1specific%20antibodies%20Tang%20et%20al%202015%20In%20addition%20among%20the%20regimens%20at%20one%20dose%20and%20two%20doses%20at%201%202%20and%203week%20intervals%202%20doses%20of%20this%20protein%20boosted%20at%204%20weeks%20resulted%20in%20the%20highest%20antibodies%20and%20neutralizing%20antibodies%20against%20MERSCoV%20infection%20Wang%20Y%20et%20al%202017"
        },
        {
            "id": "Currently_2020_a",
            "alt_id": "25",
            "entry": "Currently, the newly identified 2019-nCoV is spreading to infect people, resulting in significant global concerns. It is critical to rapidly design and develop effective vaccines to prevent infection of this new coronavirus. Since S protein and its fragments, such as RBD, of SARS-CoV, and MERS-CoV are prime targets for developing subunit vaccines against these two highly pathogenic human CoVs, it is expected that similar regions of 2019-nCoV can also be used as key targets for developing vaccines against this new coronavirus (Jiang et al., 2020). Similarly, other regions of 2019-nCoV, including S1 and S2 subunits of S protein and N protein, can be applied as alternative targets for vaccine development. Taken together, the approaches and strategies in the development of subunit vaccines against SARS and MERS described in this review will provide important information for the rapid design and development of safe and effective subunit vaccines against 2019-nCoV infection.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Currently%20the%20newly%20identified%202019nCoV%20is%20spreading%20to%20infect%20people%20resulting%20in%20significant%20global%20concerns%20It%20is%20critical%20to%20rapidly%20design%20and%20develop%20effective%20vaccines%20to%20prevent%20infection%20of%20this%20new%20coronavirus%20Since%20S%20protein%20and%20its%20fragments%20such%20as%20RBD%20of%20SARSCoV%20and%20MERSCoV%20are%20prime%20targets%20for%20developing%20subunit%20vaccines%20against%20these%20two%20highly%20pathogenic%20human%20CoVs%20it%20is%20expected%20that%20similar%20regions%20of%202019nCoV%20can%20also%20be%20used%20as%20key%20targets%20for%20developing%20vaccines%20against%20this%20new%20coronavirus%20Jiang%20et%20al%202020%20Similarly%20other%20regions%20of%202019nCoV%20including%20S1%20and%20S2%20subunits%20of%20S%20protein%20and%20N%20protein%20can%20be%20applied%20as%20alternative%20targets%20for%20vaccine%20development%20Taken%20together%20the%20approaches%20and%20strategies%20in%20the%20development%20of%20subunit%20vaccines%20against%20SARS%20and%20MERS%20described%20in%20this%20review%20will%20provide%20important%20information%20for%20the%20rapid%20design%20and%20development%20of%20safe%20and%20effective%20subunit%20vaccines%20against%202019nCoV%20infection",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Currently%20the%20newly%20identified%202019nCoV%20is%20spreading%20to%20infect%20people%20resulting%20in%20significant%20global%20concerns%20It%20is%20critical%20to%20rapidly%20design%20and%20develop%20effective%20vaccines%20to%20prevent%20infection%20of%20this%20new%20coronavirus%20Since%20S%20protein%20and%20its%20fragments%20such%20as%20RBD%20of%20SARSCoV%20and%20MERSCoV%20are%20prime%20targets%20for%20developing%20subunit%20vaccines%20against%20these%20two%20highly%20pathogenic%20human%20CoVs%20it%20is%20expected%20that%20similar%20regions%20of%202019nCoV%20can%20also%20be%20used%20as%20key%20targets%20for%20developing%20vaccines%20against%20this%20new%20coronavirus%20Jiang%20et%20al%202020%20Similarly%20other%20regions%20of%202019nCoV%20including%20S1%20and%20S2%20subunits%20of%20S%20protein%20and%20N%20protein%20can%20be%20applied%20as%20alternative%20targets%20for%20vaccine%20development%20Taken%20together%20the%20approaches%20and%20strategies%20in%20the%20development%20of%20subunit%20vaccines%20against%20SARS%20and%20MERS%20described%20in%20this%20review%20will%20provide%20important%20information%20for%20the%20rapid%20design%20and%20development%20of%20safe%20and%20effective%20subunit%20vaccines%20against%202019nCoV%20infection",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Currently%20the%20newly%20identified%202019nCoV%20is%20spreading%20to%20infect%20people%20resulting%20in%20significant%20global%20concerns%20It%20is%20critical%20to%20rapidly%20design%20and%20develop%20effective%20vaccines%20to%20prevent%20infection%20of%20this%20new%20coronavirus%20Since%20S%20protein%20and%20its%20fragments%20such%20as%20RBD%20of%20SARSCoV%20and%20MERSCoV%20are%20prime%20targets%20for%20developing%20subunit%20vaccines%20against%20these%20two%20highly%20pathogenic%20human%20CoVs%20it%20is%20expected%20that%20similar%20regions%20of%202019nCoV%20can%20also%20be%20used%20as%20key%20targets%20for%20developing%20vaccines%20against%20this%20new%20coronavirus%20Jiang%20et%20al%202020%20Similarly%20other%20regions%20of%202019nCoV%20including%20S1%20and%20S2%20subunits%20of%20S%20protein%20and%20N%20protein%20can%20be%20applied%20as%20alternative%20targets%20for%20vaccine%20development%20Taken%20together%20the%20approaches%20and%20strategies%20in%20the%20development%20of%20subunit%20vaccines%20against%20SARS%20and%20MERS%20described%20in%20this%20review%20will%20provide%20important%20information%20for%20the%20rapid%20design%20and%20development%20of%20safe%20and%20effective%20subunit%20vaccines%20against%202019nCoV%20infection"
        },
        {
            "id": "Adney_et+al_2019_a",
            "alt_id": "26",
            "entry": "Adney, D. R., Wang, L., van Doremalen, N., Shi, W., Zhang, Y., Kong, W. P., et al. (2019). Efficacy of an adjuvanted Middle East respiratory syndrome coronavirus spike protein vaccine in dromedary camels and alpacas. Viruses 11:E212. doi: 10.3390/v11030212",
            "crossref": "https://dx.doi.org/10.3390/v11030212",
            "scite": "https://scite.ai/reports/10.3390/v11030212"
        },
        {
            "id": "Al-Amri_et+al_2017_a",
            "alt_id": "27",
            "entry": "Al-Amri, S. S., Abbas, A. T., Siddiq, L. A., Alghamdi, A., Sanki, M. A., AlMuhanna, M. K., et al. (2017). Immunogenicity of candidate MERS-CoV DNA vaccines based on the spike protein. Sci. Rep. 7:44875. doi: 10.1038/srep 44875",
            "crossref": "https://dx.doi.org/10.1038/srep",
            "scite": "https://scite.ai/reports/10.1038/srep",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/srep"
        },
        {
            "id": "Annan_et+al_2013_a",
            "alt_id": "28",
            "entry": "Annan, A., Baldwin, H. J., Corman, V. M., Klose, S. M., Owusu, M., Nkrumah, E. E., et al. (2013). Human betacoronavirus 2c EMC/2012-related viruses in Bats, Ghana and Europe. Emerg. Infect. Dis. 19, 456\u2013459. doi: 10.3201/eid1903. 121503",
            "crossref": "https://dx.doi.org/10.3201/eid1903.121503",
            "scite": "https://scite.ai/reports/10.3201/eid1903.121503",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.3201/eid1903.121503"
        },
        {
            "id": "Arbour_et+al_2000_a",
            "alt_id": "29",
            "entry": "Arbour, N., Day, R., Newcombe, J., and Talbot, P. J. (2000). Neuroinvasion by human respiratory coronaviruses. J. Virol. 74, 8913\u20138921. doi: 10.1128/jvi.74. 19.8913-8921.2000",
            "crossref": "https://dx.doi.org/10.1128/jvi.74.19.8913-8921.2000",
            "scite": "https://scite.ai/reports/10.1128/jvi.74.19.8913-8921.2000",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/jvi.74.19.8913-8921.2000"
        },
        {
            "id": "Azhar_et+al_2014_a",
            "alt_id": "30",
            "entry": "Azhar, E. I., El-Kafrawy, S. A., Farraj, S. A., Hassan, A. M., Al-Saeed, M. S., Hashem, A. M., et al. (2014). Evidence for camel-to-human transmission of MERS coronavirus. N. Engl. J. Med. 370, 2499\u20132505. doi: 10.1056/NEJMoa1401505",
            "crossref": "https://dx.doi.org/10.1056/NEJMoa1401505",
            "scite": "https://scite.ai/reports/10.1056/NEJMoa1401505",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1056/NEJMoa1401505"
        },
        {
            "id": "Bailey-Elkin_et+al_2014_a",
            "alt_id": "31",
            "entry": "Bailey-Elkin, B. A., Knaap, R. C., Johnson, G. G., Dalebout, T. J., Ninaber, D. K., van Kasteren, P. B., et al. (2014). Crystal structure of the Middle East respiratory syndrome coronavirus (MERS-CoV) papain-like protease bound to ubiquitin facilitates targeted disruption of deubiquitinating activity to demonstrate its role in innate immune suppression. J. Biol. Chem. 289, 34667\u201334682. doi: 10. 1074/jbc.M114.609644",
            "crossref": "https://dx.doi.org/10.1074/jbc.M114.609644",
            "scite": "https://scite.ai/reports/10.1074/jbc.M114.609644",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1074/jbc.M114.609644"
        },
        {
            "id": "Bisht_et+al_2004_a",
            "alt_id": "32",
            "entry": "Bisht, H., Roberts, A., Vogel, L., Bukreyev, A., Collins, P. L., Murphy, B. R., et al. (2004). Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc. Natl. Acad. Sci. U.S.A. 101, 6641\u20136646. doi: 10.1073/pnas.0401939101",
            "crossref": "https://dx.doi.org/10.1073/pnas.0401939101",
            "scite": "https://scite.ai/reports/10.1073/pnas.0401939101",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1073/pnas.0401939101"
        },
        {
            "id": "Buchholz_et+al_2004_a",
            "alt_id": "33",
            "entry": "Buchholz, U. J., Bukreyev, A., Yang, L. J., Lamirande, E. W., Murphy, B. R., Subbarao, K., et al. (2004). Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc. Natl. Acad. Sci. U.S.A. 101, 9804\u20139809. doi: 10.1073/pnas.0403492101",
            "crossref": "https://dx.doi.org/10.1073/pnas.0403492101",
            "scite": "https://scite.ai/reports/10.1073/pnas.0403492101",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1073/pnas.0403492101"
        },
        {
            "id": "Bukreyev_et+al_2004_a",
            "alt_id": "34",
            "entry": "Bukreyev, A., Lamirande, E. W., Buchholz, U. J., Vogel, L. N., Elkins, W. R., St Claire, M., et al. (2004). Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. Lancet 363, 2122\u20132127. doi: 10.1016/s0140-6736(04)16501-x",
            "crossref": "https://dx.doi.org/10.1016/s0140-6736(04)16501-x",
            "scite": "https://scite.ai/reports/10.1016/s0140-6736(04)16501-x",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/s0140-6736%2804%2916501-x"
        },
        {
            "id": "Chan_et+al_2011_a",
            "alt_id": "35",
            "entry": "Chan, P. K., Ma, S., and Ngai, S. M. (2011). Identification of T-cell epitopes of SARS-coronavirus for development of peptide-based vaccines and cellular immunity assessment methods. Hong Kong Med. J. 17(Suppl. 6), 26\u201330.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Chan%2C%20P.K.%20Ma%2C%20S.%20Ngai%2C%20S.M.%20Identification%20of%20T-cell%20epitopes%20of%20SARS-coronavirus%20for%20development%20of%20peptide-based%20vaccines%20and%20cellular%20immunity%20assessment%20methods%202011",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Chan%2C%20P.K.%20Ma%2C%20S.%20Ngai%2C%20S.M.%20Identification%20of%20T-cell%20epitopes%20of%20SARS-coronavirus%20for%20development%20of%20peptide-based%20vaccines%20and%20cellular%20immunity%20assessment%20methods%202011",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Chan%2C%20P.K.%20Ma%2C%20S.%20Ngai%2C%20S.M.%20Identification%20of%20T-cell%20epitopes%20of%20SARS-coronavirus%20for%20development%20of%20peptide-based%20vaccines%20and%20cellular%20immunity%20assessment%20methods%202011"
        },
        {
            "id": "Chang_et+al_2006_a",
            "alt_id": "36",
            "entry": "Chang, C. Y., Hong, W. W., Chong, P., and Wu, S. C. (2006). Influence of intron and exon splicing enhancers on mammalian cell expression of a truncated spike protein of SARS-CoV and its implication for subunit vaccine development. Vaccine 24, 1132\u20131141. doi: 10.1016/j.vaccine.2005.09.011",
            "crossref": "https://dx.doi.org/10.1016/j.vaccine.2005.09.011",
            "scite": "https://scite.ai/reports/10.1016/j.vaccine.2005.09.011",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.vaccine.2005.09.011"
        },
        {
            "id": "Channappanavar_2017_a",
            "alt_id": "37",
            "entry": "Channappanavar, R., and Perlman, S. (2017). Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 39, 529\u2013539. doi: 10.1007/s00281-017-0629-x",
            "crossref": "https://dx.doi.org/10.1007/s00281-017-0629-x",
            "scite": "https://scite.ai/reports/10.1007/s00281-017-0629-x",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1007/s00281-017-0629-x"
        },
        {
            "id": "Chen_et+al_2014_a",
            "alt_id": "38",
            "entry": "Chen, W. H., Du, L., Chag, S. M., Ma, C., Tricoche, N., Tao, X., et al. (2014). Yeastexpressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum. Vaccin. Immunother. 10, 648\u2013658. doi: 10.4161/hv.27464",
            "crossref": "https://dx.doi.org/10.4161/hv.27464",
            "scite": "https://scite.ai/reports/10.4161/hv.27464",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.4161/hv.27464"
        },
        {
            "id": "Chen_et+al_2013_a",
            "alt_id": "39",
            "entry": "Chen, Y., Rajashankar, K. R., Yang, Y., Agnihothram, S. S., Liu, C., Lin, Y. L., et al. (2013). Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J. Virol. 87, 10777\u201310783. doi: 10.1128/jvi.01756-13",
            "crossref": "https://dx.doi.org/10.1128/jvi.01756-13",
            "scite": "https://scite.ai/reports/10.1128/jvi.01756-13",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/jvi.01756-13"
        },
        {
            "id": "Chiu_et+al_2005_a",
            "alt_id": "40",
            "entry": "Chiu, S. S., Chan, K. H., Chu, K. W., Kwan, S. W., Guan, Y., Poon, L. L., et al. (2005). Human coronavirus NL63 infection and other coronavirus infections in children hospitalized with acute respiratory disease in Hong Kong, China. Clin. Infect. Dis. 40, 1721\u20131729. doi: 10.1086/430301",
            "crossref": "https://dx.doi.org/10.1086/430301",
            "scite": "https://scite.ai/reports/10.1086/430301",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1086/430301"
        },
        {
            "id": "Cho_et+al_2018_a",
            "alt_id": "41",
            "entry": "Cho, H., Excler, J. L., Kim, J. H., and Yoon, I. K. (2018). Development of Middle East respiratory syndrome coronavirus vaccines - advances and challenges. Hum. Vaccin. Immunother. 14, 304\u2013313. doi: 10.1080/21645515.2017.138 9362",
            "crossref": "https://dx.doi.org/10.1080/21645515.2017.138",
            "scite": "https://scite.ai/reports/10.1080/21645515.2017.138",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1080/21645515.2017.138"
        },
        {
            "id": "Cui_et+al_2019_a",
            "alt_id": "42",
            "entry": "Cui, J., Li, F., and Shi, Z. L. (2019). Origin and evolution of pathogenic coronaviruses. Nat. Rev. Microbiol. 17, 181\u2013192. doi: 10.1038/s41579-0180118-9",
            "crossref": "https://dx.doi.org/10.1038/s41579-0180118-9",
            "scite": "https://scite.ai/reports/10.1038/s41579-0180118-9",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/s41579-0180118-9"
        },
        {
            "id": "de_Groot_et+al_2011_a",
            "alt_id": "43",
            "entry": "De Groot, R. J., Baker, S., Baric, R., Enjuanes, L., Gorbalenya, A., Holmes, K. V., et al. (2011). \u201cFamily Coronaviridae, virus taxomomy: classification and nomenclature of viruses,\u201d in Ninth Report of the International Committee on Taxonomy of Viruses, eds A. M. Q. King, M. J. Adams, E. B. Carstens, and E. J. Lefkowitz (Amsterdam: Elsevier Academic Press), 806\u2013826.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=De%20Groot%2C%20R.J.%20Baker%2C%20S.%20Baric%2C%20R.%20Enjuanes%2C%20L.%20Family%20Coronaviridae%2C%20virus%20taxomomy%3A%20classification%20and%20nomenclature%20of%20viruses%2C%202011",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=De%20Groot%2C%20R.J.%20Baker%2C%20S.%20Baric%2C%20R.%20Enjuanes%2C%20L.%20Family%20Coronaviridae%2C%20virus%20taxomomy%3A%20classification%20and%20nomenclature%20of%20viruses%2C%202011",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=De%20Groot%2C%20R.J.%20Baker%2C%20S.%20Baric%2C%20R.%20Enjuanes%2C%20L.%20Family%20Coronaviridae%2C%20virus%20taxomomy%3A%20classification%20and%20nomenclature%20of%20viruses%2C%202011"
        },
        {
            "id": "Dediego_et+al_2014_a",
            "alt_id": "44",
            "entry": "DeDiego, M. L., Nieto-Torres, J. L., Jimenez-Guardeno, J. M., Regla-Nava, J. A., Castano-Rodriguez, C., Fernandez-Delgado, R., et al. (2014). Coronavirus virulence genes with main focus on SARS-CoV envelope gene. Virus. Res. 194, 124\u2013137. doi: 10.1016/j.virusres.2014.07.024",
            "crossref": "https://dx.doi.org/10.1016/j.virusres.2014.07.024",
            "scite": "https://scite.ai/reports/10.1016/j.virusres.2014.07.024",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.virusres.2014.07.024"
        },
        {
            "id": "Deng_et+al_2012_a",
            "alt_id": "45",
            "entry": "Deng, M. P., Hu, Z. H., Wang, H. L., and Deng, F. (2012). Developments of subunit and VLP vaccines against influenza A virus. Virol. Sin. 27, 145\u2013153. doi: 10.1007/s12250-012-3241-1",
            "crossref": "https://dx.doi.org/10.1007/s12250-012-3241-1",
            "scite": "https://scite.ai/reports/10.1007/s12250-012-3241-1",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1007/s12250-012-3241-1"
        },
        {
            "id": "Desforges_et+al_2013_a",
            "alt_id": "46",
            "entry": "Desforges, M., Desjardins, J., Zhang, C., and Talbot, P. J. (2013). The acetyl-esterase activity of the hemagglutinin-esterase protein of human coronavirus OC43 strongly enhances the production of infectious virus. J. Virol. 87, 3097\u20133107. doi: 10.1128/jvi.02699-12",
            "crossref": "https://dx.doi.org/10.1128/jvi.02699-12",
            "scite": "https://scite.ai/reports/10.1128/jvi.02699-12",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/jvi.02699-12"
        },
        {
            "id": "Desforges_et+al_2014_a",
            "alt_id": "47",
            "entry": "Desforges, M., Le Coupanec, A., Brison, E., Meessen-Pinard, M., and Talbot, P. J. (2014). Neuroinvasive and neurotropic human respiratory coronaviruses: potential neurovirulent agents in humans. Adv. Exp. Med. Biol. 807, 75\u201396. doi: 10.1007/978-81-322-1777-0_6",
            "crossref": "https://dx.doi.org/10.1007/978-81-322-1777-0_6",
            "scite": "https://scite.ai/reports/10.1007/978-81-322-1777-0_6",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1007/978-81-322-1777-0_6"
        },
        {
            "id": "Drexler_et+al_2014_a",
            "alt_id": "48",
            "entry": "Drexler, J. F., Corman, V. M., and Drosten, C. (2014). Ecology, evolution and classification of bat coronaviruses in the aftermath of SARS. Antiviral Res. 101, 45\u201356. doi: 10.1016/j.antiviral.2013.10.013",
            "crossref": "https://dx.doi.org/10.1016/j.antiviral.2013.10.013",
            "scite": "https://scite.ai/reports/10.1016/j.antiviral.2013.10.013",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.antiviral.2013.10.013"
        },
        {
            "id": "Drosten_et+al_2003_a",
            "alt_id": "49",
            "entry": "Drosten, C., Gunther, S., Preiser, W., van der Werf, S., Brodt, H. R., Becker, S., et al. (2003). Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1967\u20131976. doi: 10.1056/ NEJMoa030747",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Drosten%2C%20C.%20Gunther%2C%20S.%20Preiser%2C%20W.%20van%20der%20Werf%2C%20S.%20Identification%20of%20a%20novel%20coronavirus%20in%20patients%20with%20severe%20acute%20respiratory%20syndrome%202003",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Drosten%2C%20C.%20Gunther%2C%20S.%20Preiser%2C%20W.%20van%20der%20Werf%2C%20S.%20Identification%20of%20a%20novel%20coronavirus%20in%20patients%20with%20severe%20acute%20respiratory%20syndrome%202003",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Drosten%2C%20C.%20Gunther%2C%20S.%20Preiser%2C%20W.%20van%20der%20Werf%2C%20S.%20Identification%20of%20a%20novel%20coronavirus%20in%20patients%20with%20severe%20acute%20respiratory%20syndrome%202003"
        },
        {
            "id": "Du_et+al_2008_a",
            "alt_id": "50",
            "entry": "Du, L., He, Y., Jiang, S., and Zheng, B. J. (2008). Development of subunit vaccines against severe acute respiratory syndrome. Drugs Today 44, 63\u201373. doi: 10.1358/ dot.2008.44.1.1131830",
            "crossref": "https://dx.doi.org/10.1358/dot.2008.44.1.1131830",
            "scite": "https://scite.ai/reports/10.1358/dot.2008.44.1.1131830",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1358/dot.2008.44.1.1131830"
        },
        {
            "id": "Du_et+al_2009_c",
            "alt_id": "51",
            "entry": "Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B. J., and Jiang, S. (2009a). The spike protein of SARS-CoV - a target for vaccine and therapeutic development. Nat. Rev. Microbiol. 7, 226\u2013236. doi: 10.1038/nrmicro2090",
            "crossref": "https://dx.doi.org/10.1038/nrmicro2090",
            "scite": "https://scite.ai/reports/10.1038/nrmicro2090",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/nrmicro2090"
        },
        {
            "id": "Du_2015_a",
            "alt_id": "52",
            "entry": "Du, L., and Jiang, S. (2015). Middle East respiratory syndrome: current status and future prospects for vaccine development. Expert Opin. Biol. Ther. 15, 1647\u20131651. doi: 10.1517/14712598.2015.1092518",
            "crossref": "https://dx.doi.org/10.1517/14712598.2015.1092518",
            "scite": "https://scite.ai/reports/10.1517/14712598.2015.1092518",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1517/14712598.2015.1092518"
        },
        {
            "id": "Du_et+al_2013_c",
            "alt_id": "53",
            "entry": "Du, L., Kou, Z., Ma, C., Tao, X., Wang, L., Zhao, G., et al. (2013a). A truncated receptor-binding domain of MERS-CoV Spike protein potently inhibits MERSCoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One 8:e81587. doi: 10.1371/ journal.pone.0081587",
            "crossref": "https://dx.doi.org/10.1371/journal.pone.0081587",
            "scite": "https://scite.ai/reports/10.1371/journal.pone.0081587",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1371/journal.pone.0081587"
        },
        {
            "id": "Du_et+al_2013_d",
            "alt_id": "54",
            "entry": "Du, L., Ma, C., and Jiang, S. (2013b). Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC. J. Infect. 67, 348\u2013350. doi: 10.1016/j.jinf.2013.05.002",
            "crossref": "https://dx.doi.org/10.1016/j.jinf.2013.05.002",
            "scite": "https://scite.ai/reports/10.1016/j.jinf.2013.05.002",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.jinf.2013.05.002"
        },
        {
            "id": "Du_et+al_2016_b",
            "alt_id": "55",
            "entry": "Du, L., Tai, W., Yang, Y., Zhao, G., Zhu, Q., Sun, S., et al. (2016a). Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat. Commun. 7:13473. doi: 10.1038/ncomms 13473",
            "crossref": "https://dx.doi.org/10.1038/ncomms",
            "scite": "https://scite.ai/reports/10.1038/ncomms",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/ncomms"
        },
        {
            "id": "Du_et+al_2016_c",
            "alt_id": "56",
            "entry": "Du, L., Tai, W., Zhou, Y., and Jiang, S. (2016b). Vaccines for the prevention against the threat of MERS-CoV. Expert Rev. Vaccines 15, 1123\u20131134. doi: 10.1586/ 14760584.2016.1167603",
            "crossref": "https://dx.doi.org/10.1586/14760584.2016.1167603",
            "scite": "https://scite.ai/reports/10.1586/14760584.2016.1167603",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1586/14760584.2016.1167603"
        },
        {
            "id": "Du_et+al_2017_a",
            "alt_id": "57",
            "entry": "Du, L., Yang, Y., Zhou, Y., Lu, L., Li, F., and Jiang, S. (2017). MERS-CoV spike protein: a key target for antivirals. Expert Opin. Ther. Targets 21, 131\u2013143. doi: 10.1080/14728222.2017.1271415",
            "crossref": "https://dx.doi.org/10.1080/14728222.2017.1271415",
            "scite": "https://scite.ai/reports/10.1080/14728222.2017.1271415",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1080/14728222.2017.1271415"
        },
        {
            "id": "Du_et+al_2010_a",
            "alt_id": "58",
            "entry": "Du, L., Zhao, G., Chan, C. C., Li, L., He, Y., Zhou, Y., et al. (2010). A 219-mer CHOexpressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. Viral. Immunol. 23, 211\u2013219. doi: 10.1089/vim.2009.0090",
            "crossref": "https://dx.doi.org/10.1089/vim.2009.0090",
            "scite": "https://scite.ai/reports/10.1089/vim.2009.0090",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1089/vim.2009.0090"
        },
        {
            "id": "Du_et+al_2009_d",
            "alt_id": "59",
            "entry": "Du, L., Zhao, G., Chan, C. C., Sun, S., Chen, M., Liu, Z., et al. (2009b). Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology 393, 144\u2013150. doi: 10.1016/j.virol.2009.07.018",
            "crossref": "https://dx.doi.org/10.1016/j.virol.2009.07.018",
            "scite": "https://scite.ai/reports/10.1016/j.virol.2009.07.018",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.virol.2009.07.018"
        },
        {
            "id": "Du_et+al_2007_a",
            "alt_id": "60",
            "entry": "Du, L., Zhao, G., He, Y., Guo, Y., Zheng, B. J., Jiang, S., et al. (2007). Receptorbinding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine 25, 2832\u20132838. doi: 10.1016/j.vaccine. 2006.10.031",
            "crossref": "https://dx.doi.org/10.1016/j.vaccine.2006.10.031",
            "scite": "https://scite.ai/reports/10.1016/j.vaccine.2006.10.031",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.vaccine.2006.10.031"
        },
        {
            "id": "Du_et+al_2013_e",
            "alt_id": "61",
            "entry": "Du, L., Zhao, G., Kou, Z., Ma, C., Sun, S., Poon, V. K., et al. (2013c). Identification of a receptor-binding domain in the S protein of the novel human coronavirus",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Du%2C%20L.%20Zhao%2C%20G.%20Kou%2C%20Z.%20Ma%2C%20C.%20Identification%20of%20a%20receptor-binding%20domain%20in%20the%20S%20protein%20of%20the%20novel%20human%20coronavirus%202013"
        },
        {
            "id": "Middle_0000_a",
            "alt_id": "62",
            "entry": "Middle East Respiratory Syndrome coronavirus as an essential target for vaccine development. J. Virol. 87, 9939\u20139942. doi: 10.1128/jvi.01048-13",
            "crossref": "https://dx.doi.org/10.1128/jvi.01048-13",
            "scite": "https://scite.ai/reports/10.1128/jvi.01048-13",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/jvi.01048-13"
        },
        {
            "id": "Du_et+al_2009_e",
            "alt_id": "63",
            "entry": "Du, L., Zhao, G., Li, L., He, Y., Zhou, Y., Zheng, B. J., et al. (2009c). Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem. Biophys. Res. Commun. 384, 486\u2013490. doi: 10.1016/j.bbre.2009.05.003",
            "crossref": "https://dx.doi.org/10.1016/j.bbre.2009.05.003",
            "scite": "https://scite.ai/reports/10.1016/j.bbre.2009.05.003",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.bbre.2009.05.003"
        },
        {
            "id": "Elshabrawy_et+al_2012_a",
            "alt_id": "64",
            "entry": "Elshabrawy, H. A., Coughlin, M. M., Baker, S. C., and Prabhakar, B. S. (2012). Human monoclonal antibodies against highly conserved HR1 and HR2 domains of the SARS-CoV spike protein are more broadly neutralizing. PLoS One 7:e50366. doi: 10.1371/journal.pone.0050366",
            "crossref": "https://dx.doi.org/10.1371/journal.pone.0050366",
            "scite": "https://scite.ai/reports/10.1371/journal.pone.0050366"
        },
        {
            "id": "Esper_et+al_2006_a",
            "alt_id": "65",
            "entry": "Esper, F., Weibel, C., Ferguson, D., Landry, M. L., and Kahn, J. S. (2006). Coronavirus HKU1 infection in the United States. Emerg. Infect. Dis. 12, 775\u2013779. doi: 10.3201/eid1205.051316",
            "crossref": "https://dx.doi.org/10.3201/eid1205.051316",
            "scite": "https://scite.ai/reports/10.3201/eid1205.051316",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.3201/eid1205.051316"
        },
        {
            "id": "Falsey_et+al_2002_a",
            "alt_id": "66",
            "entry": "Falsey, A. R., Walsh, E. E., and Hayden, F. G. (2002). Rhinovirus and coronavirus infection-associated hospitalizations among older adults. J. Infect. Dis. 185, 1338\u20131341. doi: 10.1086/339881",
            "crossref": "https://dx.doi.org/10.1086/339881",
            "scite": "https://scite.ai/reports/10.1086/339881",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1086/339881"
        },
        {
            "id": "Fehr_2015_a",
            "alt_id": "67",
            "entry": "Fehr, A. R., and Perlman, S. (2015). Coronaviruses: an overview of their replication and pathogenesis. Methods Mol. Biol. 1282, 1\u201323. doi: 10.1007/978-1-49392438-7_1",
            "crossref": "https://dx.doi.org/10.1007/978-1-49392438-7_1",
            "scite": "https://scite.ai/reports/10.1007/978-1-49392438-7_1",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1007/978-1-49392438-7_1"
        },
        {
            "id": "Fouchier_et+al_2004_a",
            "alt_id": "68",
            "entry": "Fouchier, R. A. M., Hartwig, N. G., Bestebroer, T. M., Niemeyer, B., de Jong, J. C., Simon, J. H., et al. (2004). A previously undescribed coronavirus associated with respiratory disease in humans. Proc. Natl. Acad. Sci. U.S.A. 101, 6212\u20136216. doi: 10.1073/pnas.0400762101",
            "crossref": "https://dx.doi.org/10.1073/pnas.0400762101",
            "scite": "https://scite.ai/reports/10.1073/pnas.0400762101",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1073/pnas.0400762101"
        },
        {
            "id": "Ge_et+al_2013_a",
            "alt_id": "69",
            "entry": "Ge, X. Y., Li, J. L., Yang, X. L., Chmura, A. A., Zhu, G., Epstein, J. H., et al. (2013). Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor. Nature 503, 535\u2013538. doi: 10.1038/nature12711",
            "crossref": "https://dx.doi.org/10.1038/nature12711",
            "scite": "https://scite.ai/reports/10.1038/nature12711",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/nature12711"
        },
        {
            "id": "Gerna_et+al_2006_a",
            "alt_id": "70",
            "entry": "Gerna, G., Campanini, G., Rovida, F., Percivalle, E., Sarasini, A., Marchi, A., et al. (2006). Genetic variability of human coronavirus OC43-, 229E-, and NL63-like strains and their association with lower respiratory tract infections of hospitalized infants and immunocompromised patients. J. Med. Virol. 78, 938\u2013949. doi: 10.1002/jmv.20645",
            "crossref": "https://dx.doi.org/10.1002/jmv.20645",
            "scite": "https://scite.ai/reports/10.1002/jmv.20645",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1002/jmv.20645"
        },
        {
            "id": "He_et+al_2006_b",
            "alt_id": "71",
            "entry": "He, Y., Li, J., and Jiang, S. (2006b). A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity. Biochem. Biophys. Res. Commun. 344, 106\u2013113. doi: 10.1016/j.bbrc.2006.03.139",
            "crossref": "https://dx.doi.org/10.1016/j.bbrc.2006.03.139",
            "scite": "https://scite.ai/reports/10.1016/j.bbrc.2006.03.139",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.bbrc.2006.03.139"
        },
        {
            "id": "He_et+al_2006_c",
            "alt_id": "72",
            "entry": "He, Y., Li, J., Li, W., Lustigman, S., Farzan, M., and Jiang, S. (2006c). Crossneutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein. J. Immunol. 176, 6085\u20136092. doi: 10.4049/jimmunol.176.10.6085",
            "crossref": "https://dx.doi.org/10.4049/jimmunol.176.10.6085",
            "scite": "https://scite.ai/reports/10.4049/jimmunol.176.10.6085",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.4049/jimmunol.176.10.6085"
        },
        {
            "id": "He_et+al_2005_a",
            "alt_id": "73",
            "entry": "He, Y., Lu, H., Siddiqui, P., Zhou, Y., and Jiang, S. (2005a). Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J. Immunol. 174, 4908\u20134915. doi: 10.4049/jimmunol. 174.8.4908 He, Y., Zhou, Y., Liu, S., Kou, Z., Li, W., Farzan, M., et al. (2004). Receptorbinding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine. Biochem. Biophys. Res. Commun. 324, 773\u2013781. doi: 10.1016/j.bbrc.2004.09.106",
            "crossref": "https://dx.doi.org/10.4049/jimmunol.174.8.4908",
            "scite": "https://scite.ai/reports/10.4049/jimmunol.174.8.4908",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.4049/jimmunol.174.8.4908"
        },
        {
            "id": "He_et+al_2005_b",
            "alt_id": "74",
            "entry": "He, Y., Zhou, Y., Siddiqui, P., Niu, J., and Jiang, S. (2005b). Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus. J. Clin. Microbiol. 43, 3718\u20133726. doi: 10.1128/jcm.43.8.3718-3726.2005",
            "crossref": "https://dx.doi.org/10.1128/jcm.43.8.3718-3726.2005",
            "scite": "https://scite.ai/reports/10.1128/jcm.43.8.3718-3726.2005",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/jcm.43.8.3718-3726.2005"
        },
        {
            "id": "Hofmann_et+al_2005_a",
            "alt_id": "75",
            "entry": "Hofmann, H., Pyrc, K., van der Hoek, L., Geier, M., Berkhout, B., and Pohlmann, S. (2005). Human coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for cellular entry. Proc. Natl. Acad. Sci. U.S.A. 102, 7988\u20137993. doi: 10.1073/pnas.0409465102",
            "crossref": "https://dx.doi.org/10.1073/pnas.0409465102",
            "scite": "https://scite.ai/reports/10.1073/pnas.0409465102",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1073/pnas.0409465102"
        },
        {
            "id": "Jaume_et+al_2012_a",
            "alt_id": "76",
            "entry": "Jaume, M., Yip, M. S., Kam, Y. W., Cheung, C. Y., Kien, F., Roberts, A., et al. (2012). SARS CoV subunit vaccine: antibody-mediated neutralisation and enhancement. Hong Kong Med. J. 18(Suppl. 2), 31\u201336.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Jaume%2C%20M.%20Yip%2C%20M.S.%20Kam%2C%20Y.W.%20Cheung%2C%20C.Y.%20SARS%20CoV%20subunit%20vaccine%3A%20antibody-mediated%20neutralisation%20and%20enhancement%202012",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Jaume%2C%20M.%20Yip%2C%20M.S.%20Kam%2C%20Y.W.%20Cheung%2C%20C.Y.%20SARS%20CoV%20subunit%20vaccine%3A%20antibody-mediated%20neutralisation%20and%20enhancement%202012",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Jaume%2C%20M.%20Yip%2C%20M.S.%20Kam%2C%20Y.W.%20Cheung%2C%20C.Y.%20SARS%20CoV%20subunit%20vaccine%3A%20antibody-mediated%20neutralisation%20and%20enhancement%202012"
        },
        {
            "id": "Jiaming_et+al_2017_a",
            "alt_id": "77",
            "entry": "Jiaming, L., Yanfeng, Y., Yao, D., Yawei, H., Linlin, B., Baoying, H., et al. (2017). The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection. Vaccine 35, 10\u201318. doi: 10.1016/j.vaccine.2016.11.064",
            "crossref": "https://dx.doi.org/10.1016/j.vaccine.2016.11.064",
            "scite": "https://scite.ai/reports/10.1016/j.vaccine.2016.11.064",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.vaccine.2016.11.064"
        },
        {
            "id": "Jiang_et+al_2012_a",
            "alt_id": "78",
            "entry": "Jiang, S., Bottazzi, M. E., Du, L., Lustigman, S., Tseng, C. T., Curti, E., et al. (2012). Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev. Vaccines 11, 1405\u20131413. doi: 10.1586/erv.12.126",
            "crossref": "https://dx.doi.org/10.1586/erv.12.126",
            "scite": "https://scite.ai/reports/10.1586/erv.12.126",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1586/erv.12.126"
        },
        {
            "id": "Jiang_et+al_2020_a",
            "alt_id": "79",
            "entry": "Jiang, S., Du, L., and Shi, Z. (2020). An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerg Microbes Infect. 9, 275\u2013277. doi: 10.1080/22221751.2020. 1723441 Jiang, S., He, Y., and Liu, S. (2005). SARS vaccine development. Emerg. Infect. Dis. 11, 1016\u20131020. doi: 10.3201/1107.050219",
            "crossref": "https://dx.doi.org/10.1080/22221751.2020.1723441",
            "scite": "https://scite.ai/reports/10.1080/22221751.2020.1723441",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1080/22221751.2020.1723441"
        },
        {
            "id": "Jiang_et+al_2013_a",
            "alt_id": "80",
            "entry": "Jiang, S., Lu, L., Du, L., and Debnath, A. K. (2013). A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. J. Infect. 66, 464\u2013466. doi: 10.1016/j.jinf.2012.12.003",
            "crossref": "https://dx.doi.org/10.1016/j.jinf.2012.12.003",
            "scite": "https://scite.ai/reports/10.1016/j.jinf.2012.12.003",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.jinf.2012.12.003"
        },
        {
            "id": "Kam_et+al_2007_b",
            "alt_id": "81",
            "entry": "Kam, Y. W., Kien, F., Roberts, A., Cheung, Y. C., Lamirande, E. W., Vogel, L., et al. (2007). Antibodies against trimeric S glycoprotein protect hamsters against SARS-CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. Vaccine 25, 729\u2013740. doi: 10.1016/j.vaccine.2006. 08.011 Kapikian, A. Z., James, H. D., Kelly, S. J., Dees, J. H., Turner, H. C., McIntosh, K., et al. (1969). Isolation from man of avian infectious bronchitis virus-like viruses (coronavirus) similar to 229E virus with some epidemiological observations. J. Infect. Dis. 119, 282\u2013290. doi: 10.1093/infdis/119.3.282",
            "crossref": "https://dx.doi.org/10.1016/j.vaccine.2006.08.011",
            "scite": "https://scite.ai/reports/10.1016/j.vaccine.2006.08.011",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.vaccine.2006.08.011"
        },
        {
            "id": "Killerby_et+al_2018_a",
            "alt_id": "82",
            "entry": "Killerby, M. E., Biggs, H. M., Haynes, A., Dahl, R. M., Mustaquim, D., Gerber, S. I., et al. (2018). Human coronavirus circulation in the United States 2014-2017. J. Clin. Virol. 101, 52\u201356. doi: 10.1016/j.jcv.2018.01.019",
            "crossref": "https://dx.doi.org/10.1016/j.jcv.2018.01.019",
            "scite": "https://scite.ai/reports/10.1016/j.jcv.2018.01.019",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.jcv.2018.01.019"
        },
        {
            "id": "Kim_et+al_2017_a",
            "alt_id": "83",
            "entry": "Kim, K. Y., Han, S. Y., Kim, H. S., Cheong, H. M., Kim, S. S., and Kim, D. S. (2017). Human coronavirus in the 2014 winter season as a cause of lower respiratory tract infection. Yonsei Med. J. 58, 174\u2013179. doi: 10.3349/ymj.2017.58.1.174",
            "crossref": "https://dx.doi.org/10.3349/ymj.2017.58.1.174",
            "scite": "https://scite.ai/reports/10.3349/ymj.2017.58.1.174",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.3349/ymj.2017.58.1.174"
        },
        {
            "id": "King_et+al_2018_a",
            "alt_id": "84",
            "entry": "King, A. M. Q., Lefkowitz, E. J., Mushegian, A. R., Adams, M. J., Dutilh, B. E., Gorbalenya, A. E., et al. (2018). Changes to taxonomy and the international code of virus classification and nomenclature ratified by the international committee on taxonomy of viruses (2018). Arch. Virol. 163, 2601\u20132631. doi: 10.1007/s00705-018-3847-1",
            "crossref": "https://dx.doi.org/10.1007/s00705-018-3847-1",
            "scite": "https://scite.ai/reports/10.1007/s00705-018-3847-1",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1007/s00705-018-3847-1"
        },
        {
            "id": "Ksiazek_et+al_2003_a",
            "alt_id": "85",
            "entry": "Ksiazek, T. G., Erdman, D., Goldsmith, C. S., Zaki, S. R., Peret, T., Emery, S., et al. (2003). A novel coronavirus associated with severe acute respiratory syndrome. N. Engl. J. Med. 348, 1953\u20131966. doi: 10.1056/NEJMoa030781",
            "crossref": "https://dx.doi.org/10.1056/NEJMoa030781",
            "scite": "https://scite.ai/reports/10.1056/NEJMoa030781",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1056/NEJMoa030781"
        },
        {
            "id": "Kudelova_et+al_2015_a",
            "alt_id": "86",
            "entry": "Kudelova, M., Belvoncikova, P., Vrbova, M., Kovalova, A., Stibraniova, I., Kocakova, P., et al. (2015). Detection of murine herpesvirus 68 (MHV-68) in dermacentor reticulatus ticks. Microb. Ecol. 70, 785\u2013794. doi: 10.1007/s00248015-0622-7",
            "crossref": "https://dx.doi.org/10.1007/s00248015-0622-7",
            "scite": "https://scite.ai/reports/10.1007/s00248015-0622-7",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1007/s00248015-0622-7"
        },
        {
            "id": "Kusanagi_et+al_1992_a",
            "alt_id": "87",
            "entry": "Kusanagi, K., Kuwahara, H., Katoh, T., Nunoya, T., Ishikawa, Y., Samejima, T., et al. (1992). Isolation and serial propagation of porcine epidemic diarrhhea virus in cell-cultures and partial characterization of the isolate. J. Vet. Med. Sci. 54, 313\u2013318. doi: 10.1292/jvms.54.313",
            "crossref": "https://dx.doi.org/10.1292/jvms.54.313",
            "scite": "https://scite.ai/reports/10.1292/jvms.54.313",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1292/jvms.54.313"
        },
        {
            "id": "Lan_et+al_2014_b",
            "alt_id": "88",
            "entry": "Lan, J., Deng, Y., Chen, H., Lu, G., Wang, W., Guo, X., et al. (2014). Tailoring subunit vaccine immunity with adjuvant combinations and delivery routes using the Middle East respiratory coronavirus (MERS-CoV) receptor-binding domain as an antigen. PLoS One 9:e112602. doi: 10.1371/journal.pone.011 2602",
            "crossref": "https://dx.doi.org/10.1371/journal.pone.011",
            "scite": "https://scite.ai/reports/10.1371/journal.pone.011"
        },
        {
            "id": "Lan_et+al_2015_a",
            "alt_id": "89",
            "entry": "Lan, J., Yao, Y., Deng, Y., Chen, H., Lu, G., Wang, W., et al. (2015). Recombinant receptor binding domain protein induces partial protective immunity in rhesus macaques against Middle East respiratory syndrome coronavirus challenge. EBioMedicine 2, 1438\u20131446. doi: 10.1016/j.ebiom.2015. 08.031",
            "crossref": "https://dx.doi.org/10.1016/j.ebiom.2015.08.031",
            "scite": "https://scite.ai/reports/10.1016/j.ebiom.2015.08.031",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.ebiom.2015.08.031"
        },
        {
            "id": "Lau_et+al_2006_a",
            "alt_id": "90",
            "entry": "Lau, S. K., Woo, P. C., Yip, C. C., Tse, H., Tsoi, H. W., Cheng, V. C., et al. (2006). Coronavirus HKU1 and other coronavirus infections in Hong Kong. J. Clin. Microbiol. 44, 2063\u20132071. doi: 10.1128/jcm.02614-05",
            "crossref": "https://dx.doi.org/10.1128/jcm.02614-05",
            "scite": "https://scite.ai/reports/10.1128/jcm.02614-05",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/jcm.02614-05"
        },
        {
            "id": "Lau_et+al_2018_a",
            "alt_id": "91",
            "entry": "Lau, S. K. P., Zhang, L., Luk, H. K. H., Xiong, L., Peng, X., Li, K. S. M., et al. (2018). Receptor usage of a novel bat lineage C betacoronavirus reveals evolution of Middle East respiratory syndrome-related coronavirus spike proteins for human dipeptidyl peptidase 4 binding. J. Infect. Dis. 218, 197\u2013207. doi: 10.1093/ infdis/jiy018",
            "crossref": "https://dx.doi.org/10.1093/infdis/jiy018",
            "scite": "https://scite.ai/reports/10.1093/infdis/jiy018",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1093/infdis/jiy018"
        },
        {
            "id": "Lehmann_et+al_2008_a",
            "alt_id": "92",
            "entry": "Lehmann, C., Wolf, H., Xu, J. G., Zhao, Q. B., Shao, Y. M., Motz, M., et al. (2008). A line immunoassay utilizing recombinant nucleocapsid proteins for detection of antibodies to human coronaviruses. Diagn. Microbiol. Infect. Dis. 61, 40\u201348. doi: 10.1016/j.diagmicrobio.2007.12.002",
            "crossref": "https://dx.doi.org/10.1016/j.diagmicrobio.2007.12.002",
            "scite": "https://scite.ai/reports/10.1016/j.diagmicrobio.2007.12.002",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.diagmicrobio.2007.12.002"
        },
        {
            "id": "Lelli_et+al_2013_a",
            "alt_id": "93",
            "entry": "Lelli, D., Papetti, A., Sabelli, C., Rosti, E., Moreno, A., and Boniotti, M. B. (2013). Detection of coronaviruses in bats of various species in Italy. Viruses 5, 2679\u20132689. doi: 10.3390/v5112679",
            "crossref": "https://dx.doi.org/10.3390/v5112679",
            "scite": "https://scite.ai/reports/10.3390/v5112679",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.3390/v5112679"
        },
        {
            "id": "Li_2008_a",
            "alt_id": "94",
            "entry": "Li, F. (2008). Structural analysis of major species barriers between humans and palm civets for severe acute respiratory syndrome coronavirus infections. J. Virol. 82, 6984\u20136991. doi: 10.1128/jvi.00442-08",
            "crossref": "https://dx.doi.org/10.1128/jvi.00442-08",
            "scite": "https://scite.ai/reports/10.1128/jvi.00442-08",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/jvi.00442-08"
        },
        {
            "id": "Li_2015_a",
            "alt_id": "95",
            "entry": "Li, F. (2015). Receptor recognition mechanisms of coronaviruses: a decade of structural studies. J. Virol. 89, 1954\u20131964. doi: 10.1128/jvi.02615-14",
            "crossref": "https://dx.doi.org/10.1128/jvi.02615-14",
            "scite": "https://scite.ai/reports/10.1128/jvi.02615-14",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/jvi.02615-14"
        },
        {
            "id": "Li_2016_a",
            "alt_id": "96",
            "entry": "Li, F. (2016). Structure, function, and evolution of coronavirus spike proteins. Annu. Rev. Virol. 3, 237\u2013261. doi: 10.1146/annurev-virology-110615-042301",
            "crossref": "https://dx.doi.org/10.1146/annurev-virology-110615-042301",
            "scite": "https://scite.ai/reports/10.1146/annurev-virology-110615-042301",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1146/annurev-virology-110615-042301"
        },
        {
            "id": "Li_2019_a",
            "alt_id": "97",
            "entry": "Li, F., and Du, L. (2019). MERS coronavirus: an emerging zoonotic virus. Viruses 11:E663. doi: 10.3390/v11070663",
            "crossref": "https://dx.doi.org/10.3390/v11070663",
            "scite": "https://scite.ai/reports/10.3390/v11070663"
        },
        {
            "id": "Li_et+al_2005_a",
            "alt_id": "98",
            "entry": "Li, F., Li, W., Farzan, M., and Harrison, S. C. (2005a). Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science 309, 1864\u20131868. doi: 10.1126/science.1116480",
            "crossref": "https://dx.doi.org/10.1126/science.1116480",
            "scite": "https://scite.ai/reports/10.1126/science.1116480",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1126/science.1116480"
        },
        {
            "id": "Li_et+al_2005_b",
            "alt_id": "99",
            "entry": "Li, W., Shi, Z., Yu, M., Ren, W., Smith, C., Epstein, J. H., et al. (2005b). Bats are natural reservoirs of SARS-like coronaviruses. Science 310, 676\u2013679. doi: 10.1126/science.1118391",
            "crossref": "https://dx.doi.org/10.1126/science.1118391",
            "scite": "https://scite.ai/reports/10.1126/science.1118391",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1126/science.1118391"
        },
        {
            "id": "Li_et+al_2005_c",
            "alt_id": "100",
            "entry": "Li, W., Zhang, C., Sui, J., Kuhn, J. H., Moore, M. J., Luo, S., et al. (2005c). Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2. EMBO J. 24, 1634\u20131643. doi: 10.1038/sj.emboj.7600640",
            "crossref": "https://dx.doi.org/10.1038/sj.emboj.7600640",
            "scite": "https://scite.ai/reports/10.1038/sj.emboj.7600640",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/sj.emboj.7600640"
        },
        {
            "id": "Li_et+al_2013_b",
            "alt_id": "101",
            "entry": "Li, J., Ulitzky, L., Silberstein, E., Taylor, D. R., and Viscidi, R. (2013). Immunogenicity and protection efficacy of monomeric and trimeric recombinant SARS coronavirus spike protein subunit vaccine candidates. Viral. Immunol. 26, 126\u2013132. doi: 10.1089/vim.2012.0076",
            "crossref": "https://dx.doi.org/10.1089/vim.2012.0076",
            "scite": "https://scite.ai/reports/10.1089/vim.2012.0076",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1089/vim.2012.0076"
        },
        {
            "id": "Li_et+al_2004_a",
            "alt_id": "102",
            "entry": "Li, W., Greenough, T. C., Moore, M. J., Vasilieva, N., Somasundaran, M., Sullivan, J. L., et al. (2004). Efficient replication of severe acute respiratory syndrome coronavirus in mouse cells is limited by murine angiotensin-converting enzyme 2. J. Virol. 78, 11429\u201311433. doi: 10.1128/jvi.78.20.11429-11433. 2004",
            "crossref": "https://dx.doi.org/10.1128/jvi.78.20.11429-11433.2004",
            "scite": "https://scite.ai/reports/10.1128/jvi.78.20.11429-11433.2004",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/jvi.78.20.11429-11433.2004"
        },
        {
            "id": "Li_et+al_2017_a",
            "alt_id": "103",
            "entry": "Li, W., Hulswit, R. J. G., Widjaja, I., Raj, V. S., McBride, R., Peng, W., et al. (2017). Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. Proc. Natl Acad. Sci. U.S.A. 114, E8508\u2013E8517. doi: 10.1073/pnas.1712592114",
            "crossref": "https://dx.doi.org/10.1073/pnas.1712592114",
            "scite": "https://scite.ai/reports/10.1073/pnas.1712592114",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1073/pnas.1712592114"
        },
        {
            "id": "Li_et+al_2003_a",
            "alt_id": "104",
            "entry": "Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., et al. (2003). Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature 426, 450\u2013454. doi: 10.1038/nature02145",
            "crossref": "https://dx.doi.org/10.1038/nature02145",
            "scite": "https://scite.ai/reports/10.1038/nature02145",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/nature02145"
        },
        {
            "id": "Liu_et+al_2014_a",
            "alt_id": "105",
            "entry": "Liu, D. X., Fung, T. S., Chong, K. K., Shukla, A., and Hilgenfeld, R. (2014). Accessory proteins of SARS-CoV and other coronaviruses. Antiviral Res. 109, 97\u2013109. doi: 10.1016/j.antiviral.2014.06.013",
            "crossref": "https://dx.doi.org/10.1016/j.antiviral.2014.06.013",
            "scite": "https://scite.ai/reports/10.1016/j.antiviral.2014.06.013"
        },
        {
            "id": "Liu_et+al_2005_a",
            "alt_id": "106",
            "entry": "Liu, R. Y., Wu, L. Z., Huang, B. J., Huang, J. L., Zhang, Y. L., Ke, M. L., et al. (2005). Adenoviral expression of a truncated S1 subunit of SARS-CoV spike protein results in specific humoral immune responses against SARS-CoV in rats. Virus Res. 112, 24\u201331. doi: 10.1016/j.virusres.2005.02.009",
            "crossref": "https://dx.doi.org/10.1016/j.virusres.2005.02.009",
            "scite": "https://scite.ai/reports/10.1016/j.virusres.2005.02.009",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.virusres.2005.02.009"
        },
        {
            "id": "Liu_et+al_2006_a",
            "alt_id": "107",
            "entry": "Liu, S. J., Leng, C. H., Lien, S. P., Chi, H. Y., Huang, C. Y., Lin, C. L., et al. (2006). Immunological characterizations of the nucleocapsid protein based SARS vaccine candidates. Vaccine 24, 3100\u20133108. doi: 10.1016/j.vaccine.2006. 01.058",
            "crossref": "https://dx.doi.org/10.1016/j.vaccine.2006.01.058",
            "scite": "https://scite.ai/reports/10.1016/j.vaccine.2006.01.058",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.vaccine.2006.01.058"
        },
        {
            "id": "Liu_2020_a",
            "alt_id": "108",
            "entry": "Liu, S. L., and Saif, L. (2020). Emerging viruses without borders: the Wuhan coronavirus. Viruses 12:E130. doi: 10.3390/v12020130",
            "crossref": "https://dx.doi.org/10.3390/v12020130",
            "scite": "https://scite.ai/reports/10.3390/v12020130"
        },
        {
            "id": "Lu_et+al_2013_b",
            "alt_id": "109",
            "entry": "Lu, G., Hu, Y., Wang, Q., Qi, J., Gao, F., Li, Y., et al. (2013). Molecular basis of binding between novel human coronavirus MERS-CoV and its receptor CD26. Nature 500, 227\u2013231. doi: 10.1038/nature12328",
            "crossref": "https://dx.doi.org/10.1038/nature12328",
            "scite": "https://scite.ai/reports/10.1038/nature12328",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/nature12328"
        },
        {
            "id": "Lu_et+al_2014_a",
            "alt_id": "110",
            "entry": "Lu, L., Liu, Q., Zhu, Y., Chan, K. H., Qin, L., Li, Y., et al. (2014). Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat. Commun. 5:3067. doi: 10.1038/ncomms4067",
            "crossref": "https://dx.doi.org/10.1038/ncomms4067",
            "scite": "https://scite.ai/reports/10.1038/ncomms4067",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/ncomms4067"
        },
        {
            "id": "Luo_et+al_2018_a",
            "alt_id": "111",
            "entry": "Luo, C. M., Wang, N., Yang, X. L., Liu, H. Z., Zhang, W., Li, B., et al. (2018a). Discovery of novel bat coronaviruses in south China that use the same receptor as MERS coronavirus. J. Virol. 92, e116\u2013e118. doi: 10.1128/jvi.00116-18",
            "crossref": "https://dx.doi.org/10.1128/jvi.00116-18",
            "scite": "https://scite.ai/reports/10.1128/jvi.00116-18",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/jvi.00116-18"
        },
        {
            "id": "Luo_et+al_2018_b",
            "alt_id": "112",
            "entry": "Luo, F., Liao, F. L., Wang, H., Tang, H. B., Yang, Z. Q., and Hou, W. (2018b). Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV vaccine. Virol. Sin. 33, 201\u2013204. doi: 10.1007/s12250-018-0009-2",
            "crossref": "https://dx.doi.org/10.1007/s12250-018-0009-2",
            "scite": "https://scite.ai/reports/10.1007/s12250-018-0009-2",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1007/s12250-018-0009-2"
        },
        {
            "id": "Ma_et+al_2014_a",
            "alt_id": "113",
            "entry": "Ma, C., Li, Y., Wang, L., Zhao, G., Tao, X. R., Tseng, C. T., et al. (2014a). Intranasal vaccination with recombinant receptor-binding domain of MERSCoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: implication for designing novel mucosal MERS vaccines. Vaccine 32, 2100\u20132108. doi: 10.1016/j.vaccine.2014.02.004",
            "crossref": "https://dx.doi.org/10.1016/j.vaccine.2014.02.004",
            "scite": "https://scite.ai/reports/10.1016/j.vaccine.2014.02.004",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.vaccine.2014.02.004"
        },
        {
            "id": "Ma_et+al_2014_b",
            "alt_id": "114",
            "entry": "Ma, C., Wang, L., Tao, X., Zhang, N., Yang, Y., Tseng, C. T., et al. (2014b). Searching for an ideal vaccine candidate among different MERS coronavirus receptorbinding fragments - The importance of immunofocusing in subunit vaccine design. Vaccine 32, 6170\u20136176. doi: 10.1016/j.vaccine.2014.08.086",
            "crossref": "https://dx.doi.org/10.1016/j.vaccine.2014.08.086",
            "scite": "https://scite.ai/reports/10.1016/j.vaccine.2014.08.086",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.vaccine.2014.08.086"
        },
        {
            "id": "Ma_et+al_2015_a",
            "alt_id": "115",
            "entry": "Ma, Y., Zhang, Y., Liang, X., Lou, F., Oglesbee, M., Krakowka, S., et al. (2015). Origin, evolution, and virulence of porcine deltacoronaviruses in the United States. mBio 6:e00064. doi: 10.1128/mBio.00064-15",
            "crossref": "https://dx.doi.org/10.1128/mBio.00064-15",
            "scite": "https://scite.ai/reports/10.1128/mBio.00064-15"
        },
        {
            "id": "Marra_et+al_2003_a",
            "alt_id": "116",
            "entry": "Marra, M. A., Jones, S. J., Astell, C. R., Holt, R. A., Brooks-Wilson, A., Butterfield, Y. S., et al. (2003). The genome sequence of the SARS-associated coronavirus. Science 300, 1399\u20131404. doi: 10.1126/science.1085953",
            "crossref": "https://dx.doi.org/10.1126/science.1085953",
            "scite": "https://scite.ai/reports/10.1126/science.1085953",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1126/science.1085953"
        },
        {
            "id": "Matoba_et+al_2015_a",
            "alt_id": "117",
            "entry": "Matoba, Y., Abiko, C., Ikeda, T., Aoki, Y., Suzuki, Y., Yahagi, K., et al. (2015). Detection of the human coronavirus 229E, HKU1, NL63, and OC43 between 2010 and 2013 in Yamagata, Japan. Jpn. J. Infect. Dis. 68, 138\u2013141. doi: 10.7883/ yoken.JJID.2014.266",
            "crossref": "https://dx.doi.org/10.7883/yoken.JJID.2014.266",
            "scite": "https://scite.ai/reports/10.7883/yoken.JJID.2014.266",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.7883/yoken.JJID.2014.266"
        },
        {
            "id": "Mcintosh_et+al_1967_a",
            "alt_id": "118",
            "entry": "McIntosh, K., Becker, W. B., and Chanock, R. M. (1967). Growth in suckling-mouse brain of IBV-like viruses from patients with upper respiratory tract disease. Proc. Natl. Acad. Sci. U.S.A. 58, 2268\u20132273. doi: 10.1073/pnas.58.6.2268",
            "crossref": "https://dx.doi.org/10.1073/pnas.58.6.2268",
            "scite": "https://scite.ai/reports/10.1073/pnas.58.6.2268",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1073/pnas.58.6.2268"
        },
        {
            "id": "Menachery_2017_a",
            "alt_id": "119",
            "entry": "Menachery, V. D., Mitchell, H. D., Cockrell, A. S., Gralinski, L. E., Yount, BL Jr, Graham, R. L., et al. (2017). MERS-CoV accessory ORFs play key role for infection and pathogenesis. mBio 8:e00665-17. doi: 10.1128/mBio.00665-17",
            "crossref": "https://dx.doi.org/10.1128/mBio.00665-17",
            "scite": "https://scite.ai/reports/10.1128/mBio.00665-17",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/mBio.00665-17"
        },
        {
            "id": "Mobaraki_2019_a",
            "alt_id": "120",
            "entry": "Mobaraki, K., and Ahmadzadeh, J. (2019). Current epidemiological status of Middle East respiratory syndrome coronavirus in the world from 1.1.2017 to 17.1.2018: a cross-sectional study. BMC Infect. Dis. 19:351. doi: 10.1186/s12879019-3987-2",
            "crossref": "https://dx.doi.org/10.1186/s12879019-3987-2",
            "scite": "https://scite.ai/reports/10.1186/s12879019-3987-2",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1186/s12879019-3987-2"
        },
        {
            "id": "Mou_et+al_2013_a",
            "alt_id": "121",
            "entry": "Mou, H., Raj, V. S., van Kuppeveld, F. J., Rottier, P. J., Haagmans, B. L., and Bosch, B. J. (2013). The receptor binding domain of the new Middle East Respiratory Syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J. Virol. 87, 9379\u20139383. doi: 10.1128/jvi.01277-13",
            "crossref": "https://dx.doi.org/10.1128/jvi.01277-13",
            "scite": "https://scite.ai/reports/10.1128/jvi.01277-13",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/jvi.01277-13"
        },
        {
            "id": "Mourez_et+al_2007_a",
            "alt_id": "122",
            "entry": "Mourez, T., Vabret, A., Han, Y., Dina, J., Legrand, L., Corbet, S., et al. (2007). Baculovirus expression of HCoV-OC43 nucleocapsid protein and development of a Western blot assay for detection of human antibodies against HCoV-OC43. J. Virol. Methods 139, 175\u2013180. doi: 10.1016/j.jviromet.2006.09.024",
            "crossref": "https://dx.doi.org/10.1016/j.jviromet.2006.09.024",
            "scite": "https://scite.ai/reports/10.1016/j.jviromet.2006.09.024",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.jviromet.2006.09.024"
        },
        {
            "id": "Myint_1994_a",
            "alt_id": "123",
            "entry": "Myint, S. H. (1994). Human coronaviruses - A brief review. Rev. Med. Virol. 4, 35\u201346. doi: 10.1002/rmv.1980040108",
            "crossref": "https://dx.doi.org/10.1002/rmv.1980040108",
            "scite": "https://scite.ai/reports/10.1002/rmv.1980040108",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1002/rmv.1980040108"
        },
        {
            "id": "Nicholls_et+al_2003_a",
            "alt_id": "124",
            "entry": "Nicholls, J. M., Poon, L. L., Lee, K. C., Ng, W. F., Lai, S. T., Leung, C. Y., et al. (2003). Lung pathology of fatal severe acute respiratory syndrome. Lancet 361, 1773\u20131778. doi: 10.1016/s0140-6736(03)13413-7",
            "crossref": "https://dx.doi.org/10.1016/s0140-6736(03)13413-7",
            "scite": "https://scite.ai/reports/10.1016/s0140-6736(03)13413-7",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/s0140-6736%2803%2913413-7"
        },
        {
            "id": "Nyon_et+al_2018_a",
            "alt_id": "125",
            "entry": "Nyon, M. P., Du, L., Tseng, C. K., Seid, C. A., Pollet, J., Naceanceno, K. S., et al. (2018). Engineering a stable CHO cell line for the expression of a MERScoronavirus vaccine antigen. Vaccine 36, 1853\u20131862. doi: 10.1016/j.vaccine. 2018.02.065",
            "crossref": "https://dx.doi.org/10.1016/j.vaccine.2018.02.065",
            "scite": "https://scite.ai/reports/10.1016/j.vaccine.2018.02.065",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.vaccine.2018.02.065"
        },
        {
            "id": "Ou_et+al_2017_a",
            "alt_id": "126",
            "entry": "Ou, X., Guan, H., Qin, B., Mu, Z., Wojdyla, J. A., Wang, M., et al. (2017). Crystal structure of the receptor binding domain of the spike glycoprotein of human betacoronavirus HKU1. Nat. Commun. 8:2529. doi: 10.1038/ncomms15216",
            "crossref": "https://dx.doi.org/10.1038/ncomms15216",
            "scite": "https://scite.ai/reports/10.1038/ncomms15216",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/ncomms15216"
        },
        {
            "id": "Pallesen_et+al_2017_b",
            "alt_id": "127",
            "entry": "Pallesen, J., Wang, N., Corbett, K. S., Wrapp, D., Kirchdoerfer, R. N., Turner, H. L., et al. (2017). Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc. Natl. Acad. Sci. U.S.A. 114, E7348\u2013E7357. doi: 10.1073/pnas.1707304114",
            "crossref": "https://dx.doi.org/10.1073/pnas.1707304114",
            "scite": "https://scite.ai/reports/10.1073/pnas.1707304114",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1073/pnas.1707304114"
        },
        {
            "id": "Pedersen_2014_a",
            "alt_id": "128",
            "entry": "Pedersen, N. C. (2014). An update on feline infectious peritonitis: virology and immunopathogenesis. Vet. J. 201, 123\u2013132. doi: 10.1016/j.tvjl.2014.04.017",
            "crossref": "https://dx.doi.org/10.1016/j.tvjl.2014.04.017",
            "scite": "https://scite.ai/reports/10.1016/j.tvjl.2014.04.017"
        },
        {
            "id": "Pimentel_et+al_2009_a",
            "alt_id": "129",
            "entry": "Pimentel, T. A., Yan, Z., Jeffers, S. A., Holmes, K. V., Hodges, R. S., and Burkhard, P. (2009). Peptide nanoparticles as novel immunogens: design and analysis of a prototypic severe acute respiratory syndrome vaccine. Chem. Biol. Drug Des. 73, 53\u201361. doi: 10.1111/j.1747-0285.2008.00746.x",
            "crossref": "https://dx.doi.org/10.1111/j.1747-0285.2008.00746.x",
            "scite": "https://scite.ai/reports/10.1111/j.1747-0285.2008.00746.x",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1111/j.1747-0285.2008.00746.x"
        },
        {
            "id": "Poon_et+al_2005_a",
            "alt_id": "130",
            "entry": "Poon, L. L., Chu, D. K., Chan, K. H., Wong, O. K., Ellis, T. M., Leung, Y. H., et al. (2005). Identification of a novel coronavirus in bats. J. Virol. 79, 2001\u20132009. doi: 10.1128/jvi.79.4.2001-2009.2005",
            "crossref": "https://dx.doi.org/10.1128/jvi.79.4.2001-2009.2005",
            "scite": "https://scite.ai/reports/10.1128/jvi.79.4.2001-2009.2005",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/jvi.79.4.2001-2009.2005"
        },
        {
            "id": "Qiu_et+al_2005_a",
            "alt_id": "131",
            "entry": "Qiu, M., Shi, Y., Guo, Z., Chen, Z., He, R., Chen, R., et al. (2005). Antibody responses to individual proteins of SARS coronavirus and their neutralization activities. Microbes Infect. 7, 882\u2013889. doi: 10.1016/j.micinf.2005.02.006",
            "crossref": "https://dx.doi.org/10.1016/j.micinf.2005.02.006",
            "scite": "https://scite.ai/reports/10.1016/j.micinf.2005.02.006",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.micinf.2005.02.006"
        },
        {
            "id": "Raj_et+al_2013_a",
            "alt_id": "132",
            "entry": "Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H., Muller, M. A., Dijkman, R., et al. (2013). Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC. Nature 495, 251\u2013254. doi: 10.1038/nature12005",
            "crossref": "https://dx.doi.org/10.1038/nature12005",
            "scite": "https://scite.ai/reports/10.1038/nature12005",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/nature12005"
        },
        {
            "id": "Regamey_et+al_2008_a",
            "alt_id": "133",
            "entry": "Regamey, N., Kaiser, L., Roiha, H. L., Deffernez, C., Kuehni, C. E., Latzin, P., et al. (2008). Viral etiology of acute respiratory infections with cough in infancy A community-based birth cohort study. Pediatr. Infect. Dis. J. 27, 100\u2013105. doi: 10.1097/INF.0b013e31815922c8",
            "crossref": "https://dx.doi.org/10.1097/INF.0b013e31815922c8",
            "scite": "https://scite.ai/reports/10.1097/INF.0b013e31815922c8",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1097/INF.0b013e31815922c8"
        },
        {
            "id": "Reusken_et+al_2013_a",
            "alt_id": "134",
            "entry": "Reusken, C. B., Haagmans, B. L., Muller, M. A., Gutierrez, C., Godeke, G. J., Meyer, B., et al. (2013). Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect. Dis. 13, 859\u2013866. doi: 10.1016/s1473-3099(13)70164-6",
            "crossref": "https://dx.doi.org/10.1016/s1473-3099(13)70164-6",
            "scite": "https://scite.ai/reports/10.1016/s1473-3099(13)70164-6",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/s1473-3099%2813%2970164-6"
        },
        {
            "id": "Rota_et+al_2003_a",
            "alt_id": "135",
            "entry": "Rota, P. A., Oberste, M. S., Monroe, S. S., Nix, W. A., Campagnoli, R., Icenogle, J. P., et al. (2003). Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science 300, 1394\u20131399. doi: 10.1126/science. 1085952",
            "crossref": "https://dx.doi.org/10.1126/science.1085952",
            "scite": "https://scite.ai/reports/10.1126/science.1085952",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1126/science.1085952"
        },
        {
            "id": "Scobey_et+al_2013_a",
            "alt_id": "136",
            "entry": "Scobey, T., Yount, B. L., Sims, A. C., Donaldson, E. F., Agnihothram, S. S., Menachery, V. D., et al. (2013). Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc. Natl. Acad. Sci. U.S.A. 110, 16157\u201316162. doi: 10.1073/pnas.1311542110",
            "crossref": "https://dx.doi.org/10.1073/pnas.1311542110",
            "scite": "https://scite.ai/reports/10.1073/pnas.1311542110",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1073/pnas.1311542110"
        },
        {
            "id": "Severance_et+al_2008_a",
            "alt_id": "137",
            "entry": "Severance, E. G., Bossis, I., Dickerson, F. B., Stallings, C. R., Origoni, A. E., Sullens, A., et al. (2008). Development of a nucleocapsid-based human coronavirus immunoassay and estimates of individuals exposed to coronavirus in a US metropolitan population. Clin. Vaccine Immunol. 15, 1805\u20131810. doi: 10.1128/ cvi.00124-08",
            "crossref": "https://dx.doi.org/10.1128/cvi.00124-08",
            "scite": "https://scite.ai/reports/10.1128/cvi.00124-08",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/cvi.00124-08"
        },
        {
            "id": "Shao_et+al_2007_a",
            "alt_id": "138",
            "entry": "Shao, X., Guo, X., Esper, F., Weibel, C., and Kahn, J. S. (2007). Seroepidemiology of group I human coronaviruses in children. J. Clin. Virol. 40, 207\u2013213. doi: 10.1016/j.jcv.2007.08.007",
            "crossref": "https://dx.doi.org/10.1016/j.jcv.2007.08.007",
            "scite": "https://scite.ai/reports/10.1016/j.jcv.2007.08.007",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.jcv.2007.08.007"
        },
        {
            "id": "Snijder_et+al_2003_a",
            "alt_id": "139",
            "entry": "Snijder, E. J., Bredenbeek, P. J., Dobbe, J. C., Thiel, V., Ziebuhr, J., Poon, L. L., et al. (2003). Unique and conserved features of genome and proteome of SARScoronavirus, an early split-off from the coronavirus group 2 lineage. J. Mol. Biol. 331, 991\u20131004. doi: 10.1016/s0022-2836(03)00865-9",
            "crossref": "https://dx.doi.org/10.1016/s0022-2836(03)00865-9",
            "scite": "https://scite.ai/reports/10.1016/s0022-2836(03)00865-9",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/s0022-2836%2803%2900865-9"
        },
        {
            "id": "Snijder_et+al_2016_a",
            "alt_id": "140",
            "entry": "Snijder, E. J., Decroly, E., and Ziebuhr, J. (2016). The nonstructural proteins directing coronavirus RNA synthesis and processing. Adv. Virus Res. 96, 59\u2013 126. doi: 10.1016/bs.aivir.2016.08.008",
            "crossref": "https://dx.doi.org/10.1016/bs.aivir.2016.08.008",
            "scite": "https://scite.ai/reports/10.1016/bs.aivir.2016.08.008",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/bs.aivir.2016.08.008"
        },
        {
            "id": "Tai_et+al_2017_a",
            "alt_id": "141",
            "entry": "Tai, W., Wang, Y., Fett, C. A., Zhao, G., Li, F., Perlman, S., et al. (2017). Recombinant receptor-binding domains of multiple middle east respiratory syndrome coronaviruses (MERS-CoVs) induce cross-neutralizing antibodies against divergent human and camel MERS-CoVs and antibody escape mutants. J. Virol 91:e01651-16. doi: 10.1128/jvi.01651-16",
            "crossref": "https://dx.doi.org/10.1128/jvi.01651-16",
            "scite": "https://scite.ai/reports/10.1128/jvi.01651-16",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/jvi.01651-16"
        },
        {
            "id": "Tai_et+al_2016_b",
            "alt_id": "142",
            "entry": "Tai, W., Zhao, G., Sun, S., Guo, Y., Wang, Y., Tao, X., et al. (2016). A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology 499, 375\u2013382. doi: 10.1016/j.virol.2016.10.005",
            "crossref": "https://dx.doi.org/10.1016/j.virol.2016.10.005",
            "scite": "https://scite.ai/reports/10.1016/j.virol.2016.10.005",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.virol.2016.10.005"
        },
        {
            "id": "Tang_et+al_2015_a",
            "alt_id": "143",
            "entry": "Tang, J., Zhang, N., Tao, X., Zhao, G., Guo, Y., Tseng, C. T., et al. (2015). Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum. Vaccin. Immunother. 11, 1244\u20131250. doi: 10.1080/21645515.2015.1021527",
            "crossref": "https://dx.doi.org/10.1080/21645515.2015.1021527",
            "scite": "https://scite.ai/reports/10.1080/21645515.2015.1021527",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1080/21645515.2015.1021527"
        },
        {
            "id": "Tomar_et+al_2015_a",
            "alt_id": "144",
            "entry": "Tomar, S., Johnston, M. L., St John, S. E., Osswald, H. L., Nyalapatla, P. R., Paul, L. N., et al. (2015). Ligand-induced dimerization of Middle East respiratory syndrome (MERS) coronavirus nsp5 protease (3CLpro): implifications for nsp5 regulation and the development of antivirals. J. Biol. Chem. 290, 19403\u201319422. doi: 10.1074/jbc.M115.651463",
            "crossref": "https://dx.doi.org/10.1074/jbc.M115.651463",
            "scite": "https://scite.ai/reports/10.1074/jbc.M115.651463",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1074/jbc.M115.651463"
        },
        {
            "id": "Tortorici_et+al_2019_a",
            "alt_id": "145",
            "entry": "Tortorici, M. A., Walls, A. C., Lang, Y., Wang, C., Li, Z., Koerhuis, D., et al. (2019). Structural basis for human coronavirus attachment to sialic acid receptors. Nat. Struct. Mol. Biol. 26, 481\u2013489. doi: 10.1038/s41594-0190233-y Tu, C., Crameri, G., Kong, X., Chen, J., Sun, Y., Yu, M., et al. (2004). Antibodies to SARS coronavirus in civets. Emerg. Infect. Dis. 10, 2244\u20132248. doi: 10.3201/ eid1012.040520 Tyrrell, D. A., and Bynoe, M. L. (1965). Cultivation of a novel type of commoncold virus in organ cultures. Br. Med. J. 1, 1467\u20131470. doi: 10.1136/bmj.1.5448. 1467 Vabret, A., Mourez, T., Gouarin, S., Petitjean, J., and Freymuth, F. (2003). An outbreak of coronavirus OC43 respiratory infection in Normandy, France. Clin. Infect. Dis. 36, 985\u2013989. doi: 10.1086/374222",
            "crossref": "https://dx.doi.org/10.1038/s41594-0190233-y",
            "scite": "https://scite.ai/reports/10.1038/s41594-0190233-y",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/s41594-0190233-y"
        },
        {
            "id": "van_Boheemen_et+al_2012_a",
            "alt_id": "146",
            "entry": "van Boheemen, S., de Graaf, M., Lauber, C., Bestebroer, T. M., Raj, V. S., Zaki, A. M., et al. (2012). Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 3:e0047312. doi: 10.1128/mBio.00473-12",
            "crossref": "https://dx.doi.org/10.1128/mBio.00473-12",
            "scite": "https://scite.ai/reports/10.1128/mBio.00473-12"
        },
        {
            "id": "van_der_Hoek_et+al_2004_a",
            "alt_id": "147",
            "entry": "van der Hoek, L., Pyrc, K., Jebbink, M. F., Vermeulen-Oost, W., Berkhout, R. J., Wolthers, K. C., et al. (2004). Identification of a new human coronavirus. Nat. Med. 10, 368\u2013373. doi: 10.1038/nm1024",
            "crossref": "https://dx.doi.org/10.1038/nm1024",
            "scite": "https://scite.ai/reports/10.1038/nm1024",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/nm1024"
        },
        {
            "id": "Veit_et+al_2018_a",
            "alt_id": "148",
            "entry": "Veit, S., Jany, S., Fux, R., Sutter, G., and Volz, A. (2018). CD8+ T cells responding to the Middle East Respiratory Syndrome coronavirus nucleocapsid protein delivered by vaccinia virus MVA in mice. Viruses 10:E718. doi: 10.3390/ v10120718 Wang, C., Zheng, X., Gai, W., Zhao, Y., Wang, H., Wang, H., et al. (2017). MERSCoV virus-like particles produced in insect cells induce specific humoural and cellular imminity in rhesus macaques. Oncotarget 8, 12686\u201312694. doi: 10.18632/oncotarget.8475",
            "crossref": "https://dx.doi.org/10.3390/v10120718",
            "scite": "https://scite.ai/reports/10.3390/v10120718",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.3390/v10120718"
        },
        {
            "id": "Wang_et+al_2015_a",
            "alt_id": "149",
            "entry": "Wang, L., Shi, W., Joyce, M. G., Modjarrad, K., Zhang, Y., Leung, K., et al. (2015). Evaluation of candidate vaccine approaches for MERS-CoV. Nat. Commun. 6:7712. doi: 10.1038/ncomms8712",
            "crossref": "https://dx.doi.org/10.1038/ncomms8712",
            "scite": "https://scite.ai/reports/10.1038/ncomms8712",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/ncomms8712"
        },
        {
            "id": "Wang_et+al_2013_a",
            "alt_id": "150",
            "entry": "Wang, N., Shi, X., Jiang, L., Zhang, S., Wang, D., Tong, P., et al. (2013). Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res. 23, 986\u2013993. doi: 10.1038/cr. 2013.92 Wang, Y., Tai, W., Yang, J., Zhao, G., Sun, S., Tseng, C. K., et al. (2017). Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Hum. Vaccin. Immunother. 13, 1615\u20131624. doi: 10.1080/21645515. 2017.1296994 Wong, S. K., Li, W., Moore, M. J., Choe, H., and Farzan, M. (2004). A 193amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2. J. Biol. Chem. 279, 3197\u20133201. doi: 10.1074/ jbc.C300520200 Woo, P. C., Lau, S. K., Chu, C. M., Chan, K. H., Tsoi, H. W., Huang, Y., et al. (2005). Characterization and complete genome sequence of a novel coronavirus, coronavirus HKU1, from patients with pneumonia. J. Virol. 79, 884\u2013895. doi: 10.1128/jvi.79.2.884-895.2005",
            "crossref": "https://dx.doi.org/10.1038/cr.2013.92",
            "scite": "https://scite.ai/reports/10.1038/cr.2013.92",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/cr.2013.92"
        },
        {
            "id": "Woo_et+al_2009_a",
            "alt_id": "151",
            "entry": "Woo, P. C., Lau, S. K., Lam, C. S., Lai, K. K., Huang, Y., Lee, P., et al. (2009a). Comparative analysis of complete genome sequences of three avian coronaviruses reveals a novel group 3c coronavirus. J. Virol. 83, 908\u2013917. doi: 10.1128/jvi.01977-08",
            "crossref": "https://dx.doi.org/10.1128/jvi.01977-08",
            "scite": "https://scite.ai/reports/10.1128/jvi.01977-08",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/jvi.01977-08"
        },
        {
            "id": "Woo_et+al_2012_a",
            "alt_id": "152",
            "entry": "Woo, P. C., Lau, S. K., Lam, C. S., Lau, C. C., Tsang, A. K., Lau, J. H., et al. (2012). Discovery of seven novel mammalian and avian coronaviruses in the genus deltacoronavirus supports bat coronaviruses as the gene source of alphacoronavirus and betacoronavirus and avian coronaviruses as the gene source of gammacoronavirus and deltacoronavirus. J. Virol. 86, 3995\u20134008. doi: 10.1128/jvi.06540-11",
            "crossref": "https://dx.doi.org/10.1128/jvi.06540-11",
            "scite": "https://scite.ai/reports/10.1128/jvi.06540-11",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/jvi.06540-11"
        },
        {
            "id": "Woo_et+al_2014_a",
            "alt_id": "153",
            "entry": "Woo, P. C., Lau, S. K., Lam, C. S., Tsang, A. K., Hui, S. W., Fan, R. Y., et al. (2014). Discovery of a novel bottlenose dolphin coronavirus reveals a distinct species of marine mammal coronavirus in gammacoronavirus. J. Virol. 88, 1318\u20131331. doi: 10.1128/jvi.02351-13",
            "crossref": "https://dx.doi.org/10.1128/jvi.02351-13",
            "scite": "https://scite.ai/reports/10.1128/jvi.02351-13",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1128/jvi.02351-13"
        },
        {
            "id": "Woo_et+al_2009_b",
            "alt_id": "154",
            "entry": "Woo, P. C., Lau, S. K., Yip, C. C., Huang, Y., and Yuen, K. Y. (2009b). More and more coronaviruses: human coronavirus HKU1. Viruses 1, 57\u201371. doi: 10.3390/v1010057",
            "crossref": "https://dx.doi.org/10.3390/v1010057",
            "scite": "https://scite.ai/reports/10.3390/v1010057",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.3390/v1010057"
        },
        {
            "id": "Yang_et+al_2014_a",
            "alt_id": "155",
            "entry": "Yang, Y., Deng, Y., Wen, B., Wang, H., Meng, X., Lan, J., et al. (2014a). The amino acids 736-761 of the MERS-CoV spike protein induce neutralizing antibodies: implications for the development of vaccines and antiviral agents. Viral Immunol. 27, 543\u2013550. doi: 10.1089/vim.2014.0080",
            "crossref": "https://dx.doi.org/10.1089/vim.2014.0080",
            "scite": "https://scite.ai/reports/10.1089/vim.2014.0080",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1089/vim.2014.0080"
        },
        {
            "id": "Yang_et+al_2014_b",
            "alt_id": "156",
            "entry": "Yang, Y., Du, L., Liu, C., Wang, L., Ma, C., Tang, J., et al. (2014b). Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-tohuman transmission of MERS coronavirus. Proc. Natl. Acad. Sci. U.S.A. 111, 12516\u201312521. doi: 10.1073/pnas.1405889111",
            "crossref": "https://dx.doi.org/10.1073/pnas.1405889111",
            "scite": "https://scite.ai/reports/10.1073/pnas.1405889111",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1073/pnas.1405889111"
        },
        {
            "id": "Yang_et+al_2004_a",
            "alt_id": "157",
            "entry": "Yang, Z. Y., Kong, W. P., Huang, Y., Roberts, A., Murphy, B. R., Subbarao, K., et al. (2004). A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature 428, 561\u2013564. doi: 10.1038/nature02463",
            "crossref": "https://dx.doi.org/10.1038/nature02463",
            "scite": "https://scite.ai/reports/10.1038/nature02463",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/nature02463"
        },
        {
            "id": "Yuan_et+al_2017_a",
            "alt_id": "158",
            "entry": "Yuan, Y., Cao, D., Zhang, Y., Ma, J., Qi, J., Wang, Q., et al. (2017). CryoEM structures of MERS-CoV and SARS-CoV spike glycoproteins reveal the dynamic receptor binding domains. Nat. Commun. 8:15092. doi: 10.1038/ ncomms15092",
            "crossref": "https://dx.doi.org/10.1038/ncomms15092",
            "scite": "https://scite.ai/reports/10.1038/ncomms15092",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/ncomms15092"
        },
        {
            "id": "Zakhartchouk_et+al_2007_b",
            "alt_id": "159",
            "entry": "Zakhartchouk, A. N., Sharon, C., Satkunarajah, M., Auperin, T., Viswanathan, S., Mutwiri, G., et al. (2007). Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine. Vaccine 25, 136\u2013143. doi: 10.1016/j.vaccine.2006.06.084",
            "crossref": "https://dx.doi.org/10.1016/j.vaccine.2006.06.084",
            "scite": "https://scite.ai/reports/10.1016/j.vaccine.2006.06.084",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.vaccine.2006.06.084"
        },
        {
            "id": "Zaki_et+al_2012_a",
            "alt_id": "160",
            "entry": "Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D., and Fouchier, R. A. (2012). Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 367, 1814\u20131820. doi: 10.1056/NEJMoa1211721",
            "crossref": "https://dx.doi.org/10.1056/NEJMoa1211721",
            "scite": "https://scite.ai/reports/10.1056/NEJMoa1211721",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1056/NEJMoa1211721"
        },
        {
            "id": "Zeng_et+al_2004_a",
            "alt_id": "161",
            "entry": "Zeng, F., Chow, K. Y., Hon, C. C., Law, K. M., Yip, C. W., Chan, K. H., et al. (2004). Characterization of humoral responses in mice immunized with plasmid DNAs encoding SARS-CoV spike gene fragments. Biochem. Biophys. Res. Commun. 315, 1134\u20131139. doi: 10.1016/j.bbrc.2004.01.166",
            "crossref": "https://dx.doi.org/10.1016/j.bbrc.2004.01.166",
            "scite": "https://scite.ai/reports/10.1016/j.bbrc.2004.01.166",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.bbrc.2004.01.166"
        },
        {
            "id": "Zhang_et+al_2016_a",
            "alt_id": "162",
            "entry": "Zhang, N., Channappanavar, R., Ma, C., Wang, L., Tang, J., Garron, T., et al. (2016). Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell. Mol. Immunol. 13, 180\u2013190. doi: 10.1038/cmi.2015.03",
            "crossref": "https://dx.doi.org/10.1038/cmi.2015.03",
            "scite": "https://scite.ai/reports/10.1038/cmi.2015.03",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1038/cmi.2015.03"
        },
        {
            "id": "Zhang_et+al_2014_a",
            "alt_id": "163",
            "entry": "Zhang, N., Jiang, S., and Du, L. (2014). Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev. Vaccines 13, 761\u2013774. doi: 10.1586/14760584.2014.912134",
            "crossref": "https://dx.doi.org/10.1586/14760584.2014.912134",
            "scite": "https://scite.ai/reports/10.1586/14760584.2014.912134",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1586/14760584.2014.912134"
        },
        {
            "id": "Zhang_et+al_2015_a",
            "alt_id": "164",
            "entry": "Zhang, N., Tang, J., Lu, L., Jiang, S., and Du, L. (2015). Receptor-binding domainbased subunit vaccines against MERS-CoV. Virus Res. 202, 151\u2013159. doi: 10. 1016/j.virusres.2014.11.013",
            "crossref": "https://dx.doi.org/10.1016/j.virusres.2014.11.013",
            "scite": "https://scite.ai/reports/10.1016/j.virusres.2014.11.013",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.virusres.2014.11.013"
        },
        {
            "id": "Zhang_et+al_2020_a",
            "alt_id": "165",
            "entry": "Zhang, N., Wang, L., Deng, X., Liang, R., Su, M., He, C., et al. (2020). Recent advances in the detection of respiratory virus infection in humans. J. Med. Virol. [Epub ahead of print].",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zhang%2C%20N.%20Wang%2C%20L.%20Deng%2C%20X.%20Liang%2C%20R.%20Recent%20advances%20in%20the%20detection%20of%20respiratory%20virus%20infection%20in%20humans%202020",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Zhang%2C%20N.%20Wang%2C%20L.%20Deng%2C%20X.%20Liang%2C%20R.%20Recent%20advances%20in%20the%20detection%20of%20respiratory%20virus%20infection%20in%20humans%202020",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Zhang%2C%20N.%20Wang%2C%20L.%20Deng%2C%20X.%20Liang%2C%20R.%20Recent%20advances%20in%20the%20detection%20of%20respiratory%20virus%20infection%20in%20humans%202020"
        },
        {
            "id": "Zheng_et+al_2009_b",
            "alt_id": "166",
            "entry": "Zheng, N., Xia, R., Yang, C., Yin, B., Li, Y., Duan, C., et al. (2009). Boosted expression of the SARS-CoV nucleocapsid protein in tobacco and its immunogenicity in mice. Vaccine 27, 5001\u20135007. doi: 10.1016/j.vaccine.2009. 05.073",
            "crossref": "https://dx.doi.org/10.1016/j.vaccine.2009.05.073",
            "scite": "https://scite.ai/reports/10.1016/j.vaccine.2009.05.073",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/j.vaccine.2009.05.073"
        },
        {
            "id": "Zhong_et+al_2003_a",
            "alt_id": "167",
            "entry": "Zhong, N. S., Zheng, B. J., Li, Y. M., Poon, L. L., Xie, Z. H., Chan, K. H., et al. (2003). Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People\u2019s Republic of China, in February, 2003. Lancet 362, 1353\u20131358. doi: 10.1016/s0140-6736(03)14630-2",
            "crossref": "https://dx.doi.org/10.1016/s0140-6736(03)14630-2",
            "scite": "https://scite.ai/reports/10.1016/s0140-6736(03)14630-2",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1016/s0140-6736%2803%2914630-2"
        },
        {
            "id": "Zhou_et+al_2020_a",
            "alt_id": "168",
            "entry": "Zhou, P., Yang, X. L., Wang, X. G., Hu, B., Zhang, L., Zhang, W., et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature [Epub ahead of print].",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zhou%2C%20P.%20Yang%2C%20X.L.%20Wang%2C%20X.G.%20Hu%2C%20B.%20A%20pneumonia%20outbreak%20associated%20with%20a%20new%20coronavirus%20of%20probable%20bat%20origin%202020",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Zhou%2C%20P.%20Yang%2C%20X.L.%20Wang%2C%20X.G.%20Hu%2C%20B.%20A%20pneumonia%20outbreak%20associated%20with%20a%20new%20coronavirus%20of%20probable%20bat%20origin%202020",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Zhou%2C%20P.%20Yang%2C%20X.L.%20Wang%2C%20X.G.%20Hu%2C%20B.%20A%20pneumonia%20outbreak%20associated%20with%20a%20new%20coronavirus%20of%20probable%20bat%20origin%202020"
        },
        {
            "id": "Zhou_et+al_2018_a",
            "alt_id": "169",
            "entry": "Zhou, Y., Jiang, S., and Du, L. (2018). Prospects for a MERS-CoV spike vaccine. Expert Rev. Vaccines 17, 677\u2013686. doi: 10.1080/14760584.2018.150 6702",
            "crossref": "https://dx.doi.org/10.1080/14760584.2018.150",
            "scite": "https://scite.ai/reports/10.1080/14760584.2018.150",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.1080/14760584.2018.150"
        },
        {
            "id": "Zhou_et+al_2019_a",
            "alt_id": "170",
            "entry": "Zhou, Y., Yang, Y., Huang, J., Jiang, S., and Du, L. (2019). Advances in MERSCoV vaccines and therapeutics based on the receptor-binding domain. Viruses 11:E60. doi: 10.3390/v11010060",
            "crossref": "https://dx.doi.org/10.3390/v11010060",
            "scite": "https://scite.ai/reports/10.3390/v11010060"
        },
        {
            "id": "Zhu_et+al_2020_a",
            "alt_id": "171",
            "entry": "Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., et al. (2020). A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med. [Epub ahead of print].",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zhu%20N%20Zhang%20D%20Wang%20W%20Li%20X%20Yang%20B%20Song%20J%20et%20al%202020%20A%20novel%20coronavirus%20from%20patients%20with%20pneumonia%20in%20China%202019%20N%20Engl%20J%20Med%20Epub%20ahead%20of%20print"
        },
        {
            "id": "Zhu_et+al_2013_a",
            "alt_id": "172",
            "entry": "Zhu, X., Liu, Q., Du, L., Lu, L., and Jiang, S. (2013). Receptor-binding domain as a target for developing SARS vaccines. J. Thoracic Dis. 5, S142\u2013S148. doi: 10.3978/j.issn.2072-1439.2013.06.06",
            "crossref": "https://dx.doi.org/10.3978/j.issn.2072-1439.2013.06.06",
            "scite": "https://scite.ai/reports/10.3978/j.issn.2072-1439.2013.06.06",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=https%3A//dx.doi.org/10.3978/j.issn.2072-1439.2013.06.06"
        }
    ],
    "facts": [
        "Seven coronaviruses have been isolated from humans",
        "SARS-CoV infection in humans was first reported from China",
        "while MERS-CoV infection in humans was first reported from Saudi Arabia in June 2012",
        "a variety of vaccines have been developed against infections of SARS-CoV",
        "the current vaccine types to be developed against SARS-CoV",
        "These subunit vaccines are introduced on the basis of full-length",
        "this review will be helpful for rapid design and development of vaccines",
        "This review was written for the topic of Antivirals",
        "Coronaviruses belong to the subfamily Othocoronavirinae",
        "the Othocoronavirinae is comprised of four genera",
        "which belong to alpha-CoVs",
        "An RBD protein fragment containing MERSCoV S residues 377\u2013622 fused with the Fc tag of human IgG can induce MERS-CoV S1-",
        "MERS-CoV Subunit Vaccines Based on Non-RBD S Protein Fragments MERS vaccines targeting non-RBD regions",
        "that a MERS-CoV S1 protein formulated with Ribi or aluminum phosphate",
        "an RBD fragment corresponding to residues 377\u2013588 of S protein elicits the highest neutralizing antibodies"
    ],
    "claims": [
        "In this review, we have described the structure and function of key proteins of emerging human CoVs, overviewed the current vaccine types to be developed against SARS-CoV and MERS-CoV, and summarized recent advances in subunit vaccines against these two pathogenic human CoVs"
    ],
    "findings": [
        "In the serological surveillance on healthy adults, HCoV-229E, HCoV-NL63, and HCoV-OC43 demonstrated more than 90% seropositive with the immunological assay"
    ],
    "processes": [],
    "key_statements": [
        "According to the 10th Report on Virus Taxonomy from the International Committee on Taxonomy of Viruses (ICTV), the Othocoronavirinae is comprised of four genera, including alphacoronavirus, betacoronavirus, gammacoronavirus",
        "Among all CoVs identified so far, seven have the ability to infect humans, including human coronavirus 229E (HCoV-229E) and human coronavirus NL63 (HCoV-NL63), which belong to alpha-CoVs (Hamre and Procknow, 1966; <a class=\"ref-link\" id=\"cChiu_et+al_2005_a\" href=\"#rChiu_et+al_2005_a\">Chiu et al, 2005</a>), as well as human coronavirus OC43 (HCoV-OC43), human coronavirus HKU1 (HCoV-HKU1), severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and the newly emerged coronavirus (2019-nCoV), which are known to be beta-CoVs (<a class=\"ref-link\" id=\"cDrosten_et+al_2003_a\" href=\"#rDrosten_et+al_2003_a\">Drosten et al, 2003</a>; <a class=\"ref-link\" id=\"cKsiazek_et+al_2003_a\" href=\"#rKsiazek_et+al_2003_a\">Ksiazek et al, 2003</a>; Vabret et al, 2003; Woo et al, 2005; <a class=\"ref-link\" id=\"cZaki_et+al_2012_a\" href=\"#rZaki_et+al_2012_a\">Zaki et al, 2012</a>; <a class=\"ref-link\" id=\"cDu_et+al_2016_b\" href=\"#rDu_et+al_2016_b\">Du et al, 2016b</a>; <a class=\"ref-link\" id=\"cZhang_et+al_2020_a\" href=\"#rZhang_et+al_2020_a\">Zhang et al, 2020</a>; <a class=\"ref-link\" id=\"cZhu_et+al_2020_a\" href=\"#rZhu_et+al_2020_a\">Zhu et al, 2020</a>) (Figure 1)",
        "MERS-CoV Subunit Vaccines Based on Non-receptorbinding domain S Protein Fragments MERS vaccines targeting non-receptorbinding domain regions of S protein have been developed and investigated in mice and non-human primates",
        "MERS-CoV subunit vaccines containing different antigens or fragment lengths, those based on the receptorbinding domain, have apparently variable immunogenicity and/or protective efficacy, and a critical neutralizing domain that contains an receptorbinding domain fragment corresponding to residues 377\u2013588 of S protein elicits the highest neutralizing antibodies among several fragments tested (<a class=\"ref-link\" id=\"cMa_et+al_2014_b\" href=\"#rMa_et+al_2014_b\">Ma et al, 2014b</a>; <a class=\"ref-link\" id=\"cZhang_et+al_2015_a\" href=\"#rZhang_et+al_2015_a\">Zhang et al, 2015</a>)"
    ],
    "top_statements": [
        "Coronaviruses (CoVs) belong to the subfamily Othocoronavirinae, in the family Coronaviridae of the order Nidovirales",
        "According to the 10th Report on Virus Taxonomy from the International Committee on Taxonomy of Viruses (ICTV), the Othocoronavirinae is comprised of four genera, including alphacoronavirus, betacoronavirus, gammacoronavirus",
        "Among all CoVs identified so far, seven have the ability to infect humans, including human coronavirus 229E (HCoV-229E) and human coronavirus NL63 (HCoV-NL63), which belong to alpha-CoVs (Hamre and Procknow, 1966; <a class=\"ref-link\" id=\"cChiu_et+al_2005_a\" href=\"#rChiu_et+al_2005_a\">Chiu et al, 2005</a>), as well as human coronavirus OC43 (HCoV-OC43), human coronavirus HKU1 (HCoV-HKU1), severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome coronavirus (MERS-CoV), and the newly emerged coronavirus (2019-nCoV), which are known to be beta-CoVs (<a class=\"ref-link\" id=\"cDrosten_et+al_2003_a\" href=\"#rDrosten_et+al_2003_a\">Drosten et al, 2003</a>; <a class=\"ref-link\" id=\"cKsiazek_et+al_2003_a\" href=\"#rKsiazek_et+al_2003_a\">Ksiazek et al, 2003</a>; Vabret et al, 2003; Woo et al, 2005; <a class=\"ref-link\" id=\"cZaki_et+al_2012_a\" href=\"#rZaki_et+al_2012_a\">Zaki et al, 2012</a>; <a class=\"ref-link\" id=\"cDu_et+al_2016_b\" href=\"#rDu_et+al_2016_b\">Du et al, 2016b</a>; <a class=\"ref-link\" id=\"cZhang_et+al_2020_a\" href=\"#rZhang_et+al_2020_a\">Zhang et al, 2020</a>; <a class=\"ref-link\" id=\"cZhu_et+al_2020_a\" href=\"#rZhu_et+al_2020_a\">Zhu et al, 2020</a>) (Figure 1)",
        "MERS-CoV Subunit Vaccines Based on Non-receptorbinding domain S Protein Fragments MERS vaccines targeting non-receptorbinding domain regions of S protein have been developed and investigated in mice and non-human primates",
        "MERS-CoV subunit vaccines containing different antigens or fragment lengths, those based on the receptorbinding domain, have apparently variable immunogenicity and/or protective efficacy, and a critical neutralizing domain that contains an receptorbinding domain fragment corresponding to residues 377\u2013588 of S protein elicits the highest neutralizing antibodies among several fragments tested (<a class=\"ref-link\" id=\"cMa_et+al_2014_b\" href=\"#rMa_et+al_2014_b\">Ma et al, 2014b</a>; <a class=\"ref-link\" id=\"cZhang_et+al_2015_a\" href=\"#rZhang_et+al_2015_a\">Zhang et al, 2015</a>)"
    ],
    "headline": "Among all CoVs identified so far, seven have the ability to infect humans, including human coronavirus 229E and human coronavirus NL63, which belong to alpha-CoVs, as well as human coronavirus OC43, human coronavirus HKU1, severe acute respiratory syndrome coronavirus, Middle East respiratory syndrome coronavirus, and the newly emerged coronavirus, which are known to be beta-CoVs",
    "contexts": [],
    "abbreviations": {
        "RBD": "receptorbinding domain",
        "ICTV": "International Committee on Taxonomy of Viruses",
        "ORFs": "open reading frames",
        "NTD": "N-terminal domain",
        "CTD": "C-terminal domain",
        "RBDs": "receptor-binding domains",
        "ACE2": "angiotensin-converting enzyme 2",
        "RBM": "receptorbinding motif",
        "DPP4": "dipeptidyl peptidase 4",
        "VLPs": "viruslike particles",
        "ADE": "antibody-dependent enhancement",
        "Fc\u03b3RII": "Fc\u03b3 receptor II",
        "Fc": "fragment crystallizable",
        "CHO": "Chinese hamster ovary",
        "mAbs": "monoclonal antibodies",
        "HR1": "heptad repeat 1",
        "rRBD": "recombinant MERS-CoV RBD",
        "NHPs": "non-human primates",
        "TNF": "tumor necrosis factor",
        "rNTD": "recombinant MERS-CoV NTD protein",
        "MVA": "modified Vaccinia Ankara",
        "IL-4": "interleukin 4"
    }
}
